{"title": "PDF", "author": "PDF", "url": "ibdigital.uib.es/greenstone/sites/localsite/collect/medicinaBalear/index/assoc/AJHS_Med/icina_Ba/lear_202/1v36n3pd.dir/AJHS_Medicina_Balear_2021v36n3.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "www.medicinabalear.orgVOLUME 36  NUMBER 3 JULY - SEPTEMBER 2021\nMEDICINA BALEARACADEMIC  JOURNAL  \nOF HEALTH  SCIENCES\nPUBLICATION OF THE ROYAL ACADEMY OF MEDECINE OF THE BALEARIC ISLANDS\nDiagnostic Technology Assessment in Iran: A Grounded Theory Study\nEfecto del estado inflamatorio perioperatorio en el salvamento de extremidad de los pacientes \ncon isquemia cr\u00edtica sometidos a revascularizaci\u00f3n infrainguinal\nEffect of sesame oil extraction by traditional and cold press methods on total aflatoxin content\nValues of different index related to cardiovascular risk according the Findrisc test scores in caucasian\nInfluence of sociodemographic variables and tobacco consumption on the risk of nonalcoholic fatty liver disease and liver fibrosis\nResultados de la encuesta COVID-19 en alumnos, profesores y usuarios de la escuela universitaria ADEMA\nClostridium histolyticum collagenase (Xiapex\u00ae) in patients with peyronie disease. Expectations vs reality\nThe effect of Familact probiotic supplement in patients with diabetes\n(Evaluation of Blood Glucose Parameters, Lipid Profile)\nLa intervenci\u00f3n de los poderes p\u00fablicos frente a las pseudoterapias: posibilidades y l\u00edmites\nCyto-histological correlation in cervical cytology\nGenotypic and phenotypic assessment of antibiotic resistance of MRSA bacteria isolated from food stuffs\nAntibiotic resistance pattern of methicillin-resistant Staphylococcus aureus  isolates \nfrom powdered packaged medicinal plants and bottle herbal distillates\nEffect of estrogen and insulin sensitivity due to exercise training with dual intensities in female rats with estradiol valerate-induced PCOS\nEvaluation of risk factors, risk assessment and health-related quality of life in patients with dyslipidemia in Kempegowda \nInstitute of Medical Sciences (Kims) Hospital and Research Centre, Bangalore, India\nHelicobacter pylori  distribution in dental plaque specimens collected from individuals referred to dental clinics\nComparative study of clinical symptoms, laboratory and radiological findings of COVID-19 patients admitted to ICU ward \nwith internal ward of Forghani Hospital in Qom: a case series\nDirect instruction and inquiry-based method in teaching endodontics among preclinical dentistry students\nEnterotoxigenic profiles of Staphylococcus aureus  strains isolated from sweet samples\nPrescriptions analysis for various effects of polypharmacy in Kempegowda \nInstitute of Medical Sciences (Kims) Hospital and research centre, India\nEvaluation of arch bar fixation without surgical aid in jaw fracture treatment\nThe efficacy of Cognitive-behavior therapy based parenting for anxious children with cancer\nSeckel syndrome associated dental anomaly; case report\nInestabilidad cef\u00e1lica y derrame peric\u00e1rdicoAcademic Journal of Health Sciences Medicina Balear  is the organ of the Royal Academy of \nMedicine of the Balearic Island ,It was created in 1986 with the aim of following up the scientific \nconcerns and promoting the research spirit of health professionals in the Balearic Islands and with \nthe additional objective of projecting health issues of interest to society.\nCurrently Academic Journal of Health Sciences Medicina Balear  publishes in English, Spanish \nor Catalan original papers, review articles, letters to the editor and other writings of interest related \nto health sciences. The journal submits the originals to the anonymous review of at least two external \nexperts (peer review).\nThe scientific material published in AJHS Medicina Balear  is protected by copyright. AJHS \nMedicina Balear  is not responsible for the information and opinions of the authors.\nThis work-unless otherwise indicated in the text, photographs, or other illustrations-is licensed under \nthe Creative Commons NonCommercial-NoDerivativeWorks 3.0 Spain license.\nCreative Commons; http://creativecommons.org/licenses/by-nc-nd/3.0/es/. In addition, the general \npublic is authorized to reproduce, distribute and communicate the work provided that the authorship \nand the publishing entity are acknowledged and that no commercial use or derivative work is made.\nMedicina Balear is included in the Digital Library of the Balearic Islands, of the University of the \nBalearic Islands, and is included in the following databases: Emerging Sources Citation Index (ESCI), \nSherpa Romeo, Dulcinea, Latindex (cat\u00e0leg), Dialnet, \u00cdndice M\u00e9dico Espa\u00f1ol, DOAJ, Imbiomed, \nREDIB i Google Scholar.\nEDIT\nRoyal Academy of Medicine of the Balearic Islands\nCampaner, 4, baixos. 07003 Palma de Mallorca Tel. 971 72 12 30 Email: info@ramib.org  \nP\u00e0gina web: http://www.ramib.org\n \nDip\u00f2sit Legal: PM 486 - 95 \neISSN: 2255 - 0569\nDesign and layout\nIntelagencia Publicitat - www.intelagencia.es - intelagencia@intelagencia.es\nwww.ramib.org \nwww.medicinabalear.orgWith the collaboration Editor  A. Arturo L\u00f3pez Gonz\u00e1lez, RAMIB , \n  Reial Acad\u00e8mia de Medicina de les Illes Balears (RAMIB)\n EDITORIAL COUNCIL\n Assistant manager   Joan March Noguera, RAMIB\n Scientific editor  Marta Couce Matovelle, Case Western Reserve University\n Editorials consultings   Jos\u00e9 A. Guijarro Pastor, AEMET \u00b7 Jaume Rossell\u00f3 Mir, UIB\n Editor-in -chief   J. L. Olea Vallejo, RAMIB\n Vowels    Antoni Aguil\u00f3 Pons, Universitat de les Illes Balears  \u00b7 Antonia \nBarcel\u00f3 Bennassar, Hospital Son Espases  \u00b7 Bartolom\u00e9 \nBurguera Gonz\u00e1lez, Cleveland Clinic (Ohio)  \u00b7 Amador Calafat \nFar, Socidrogalcohol  \u00b7 Carlos Campillo Artero, Universitat \nPompeu Fabra  \u00b7 Valent\u00edn Esteban Buedo, Conselleria de \nSanitat, Generalitat Valenciana  \u00b7 Carmen Gonz\u00e1lez Bosch, \nUniversitat de Val\u00e8ncia  \u00b7 Miguel A. Limon Pons, Institut Menorqu\u00ed \nd\u2019Estudis  \u00b7 Jordi Mart\u00ednez Serra, Hospital Son Espases \u00b7  Virgili \nP\u00e1ez Cervi, Bibliosalut  \u00b7 Lucio Pallar\u00e9s Ferreres, Hospital \nSon Espases \u00b7 Ignacio Ricci Cabello, University of Oxford  \u00b7 \nGuillermo S\u00e1ez Tormo, Universitat de Val\u00e8ncia  \u00b7 Ma Te\u00f3fila \nVicente Herrero, IUNICS\n SCIENTIFIC  COUNCIL  \nM\u00aa Jos\u00e9 Anad\u00f3n Baselga ( Universidad Complutense de Madrid ), \nMiquel Cap\u00f3 Mart\u00ed ( Universidad Complutense de Madrid ), Antonio \nCoca Payeras ( Universitat de Barcelona ), James Drane ( Edinboro \nUniversity ), Leopoldo Forner Navarro ( Universitat de Val\u00e8ncia ), \nAlexandre Garc\u00eda-Mas, ( Universitat de les Illes Balears ), Antoni \nGelabert Mas ( Universitat Aut\u00f2noma de Barcelona ), Joan Grimalt \nObrador (Consell Superior d\u2019Investigacions Cient\u00edfiques, CSIC) , \nFederico Hawkins Carranza ( Universitat Complutense de Madrid ), \nJoan Carles March Cerd\u00e0 (Escuela Andaluza de Salud P\u00fablica, \nEASP ), Gabriel Mart\u00ed Amengual ( Universitat de Barcelona ), \nJasone Monasterio Aspiri ( Universitat Aut\u00f2noma de Barcelona ) \nRosa Pulgar Encinas ( Universidad de Granada ), Ciril Rozman \n(Universitat de Barcelona ), Joan Benejam Gual (Hospital de \nManacor), Joan Llobera C\u00e0naves ( Atenci\u00f3 Prim\u00e0ria - Mallorca ), \nJos\u00e9 Reyes Moreno ( Hospital de Inca ), Jos\u00e9 Mar\u00eda Vicens Colom \n(Cercle d\u2019Economia de Mallorca ), Carmen Tom\u00e1s-Valiente Lanuza \n(UIB), Antonio Pareja Bezares ( Conselleria de Salut ), Farhad \nSafarpoor Dehkordi ( Tehran University ), Anton Erkoreka Barrena \n(Director del Museo Vasco de Historia de la Medicina y de la \nCiencia ), Jos\u00e9 Ignacio Ram\u00edrez Manent ( Atenci\u00f3n Primaria de \nMallorca-Facultad de Medicina UIB ), Colwyn M. Jones ( European \nAssociation of Dental Public Health ), P\u00e5l Barkvoll ( Universitetet i \nOslo ), Teresa Szupiany-Janeczek ( Jagiellonian University Medical \nCollege Krakow ), Yarmukhamedov Bekhzod ( Tashkent University ).Three-monthly journal of the Royal Academic of Medicine \nof the Balearic IslandPREMIOS DE INVESTIGACI\u00d3N\nLa Fundaci\u00f3 Patronat Cient\u00edfic  convoca los Premios de Investigaci\u00f3n Mateu Orfila , Dami\u00e0 Carb\u00f3  y Metge Matas  con la \nfinalidad de premiar la trayectoria de la investigaci\u00f3n en Ciencias de la Salud  en nuestra comunidad.\nhttp://www.comib.com/wp-content/uploads/2021/02/01-Convocatoria-Premios-investigacio0n-2021-web.pdf\nPREMIO FUNDACI\u00d3 MUTUAL M\u00c8DICA  \nAL MEJOR PROYECTO DE TESIS DOCTORAL  \nEl premio tiene como finalidad facilitar a los m\u00e9dicos colegiados  en las Illes Balears la obtenci\u00f3n del t\u00edtulo de Doctor . Con el \npatrocinio de la Fundaci\u00f3 Mutual M\u00e9dica .\nhttp://www.comib.com/wp-content/uploads/2021/02/04-Convocatoria-mejor-proyecto-de-tesis-doctoral-2021-web.pdf\nBECAS FUNDACI\u00d3N BANCO SABADELL \nDE ROTACI\u00d3N EXTERNA PARA M\u00c9DICOS RESIDENTES  \nFacilitar a los m\u00e9dicos que realicen la residencia en hospitales de Balears la formaci\u00f3n , al menos durante un mes, en centros \nhospitalarios nacionales y extranjeros , en los dos \u00faltimos a\u00f1os de la residencia o al terminar la misma. Con la colaboraci\u00f3n \nde la Fundaci\u00f3 Banc Sabadell .\nhttp://www.comib.com/wp-content/uploads/2021/02/02-Convocatoria-Becas-Fundaci0-Banc-Sabadell-web-.pdf\nBECAS DE INNOVACI\u00d3N  \nTienen como objetivo facilitar a los m\u00e9dicos colegiados en las Illes Balears, excepto MIR, la formaci\u00f3n, durante al menos un mes, en \ncentros sanitarios nacionales y extranjeros en t\u00e9cnicas diagn\u00f3sticas o terap\u00e9uticas. \nhttp://www.comib.com/wp-content/uploads/2021/02/03-Convocatoria-Becas-de-Innovacion-2021-web.pdf\nCERTAMEN DE CASOS CL\u00cdNICOS PARA M\u00c9DICOS RESIDENTES\nPremios a los mejores casos cl\u00ednicos presentados por m\u00e9dicos residentes colegiados en Illes Balears de cualquier especialidad \nm\u00e9dica o quir\u00fargica .\nhttp://www.comib.com/wp-content/uploads/2021/02/05-Convocatoria-Certamen-de-casos-cliInicos-2021-web.pdf\nPREMIO CAMILO JOS\u00c9 CELA DE HUMANIDADES M\u00c9DICAS \nPremio literario de \u00e1mbito nacional destinado a honrar la especial relaci\u00f3n que tuvo el Nobel con los m\u00e9dicos  a lo largo de su vida.\nhttp://www.comib.com/wp-content/uploads/2021/02/06-Convocatoria-Premio-Camilo-Jose3-Cela-2021web.pdfPREMIOS Y BECAS 2021\nwww.comib.com/patronatcientificVOLUME 36  NUM. 3\nJULY - SEPTEMBER 2021 CONTENTS\nEDITORIAL \nA pending issue in occupational cancer: clinical-occupational history  9-10\nM\u00aa Te\u00f3fila Vicente Herrero\nORIGINALS ARTICLES \nDiagnostic Technology Assessment in Iran: A Grounded Theory Study  11-16\nSamira Abam, Fatemeh Dabbaghi, Ghahraman Mahmoodi     \nEffect of perioperative inflammatory status on limb salvage in critically ischemic 17-21 patients undergoing infrainguinal revascularization \nDavid Santiago Garc\u00eda Garc\u00eda, Krystell Daniela Escoto Theodoracopoulos, Gabriella Loria Rogers, \nOscar Antonio Merino Mairal, Ra\u00fal Lara Hern\u00e1ndez, Pascual Lozano Vilardell\nEffect of sesame oil extraction by traditional and cold press methods on total aflatoxin content   22-28\nNader Akbari, Masoud Sami, Zahra Esfandiari, Mohammad Javad Tarrahi\nValues of different index related to cardiovascular risk according the Findrisc test scores in caucasian  29-33  \nHector Orlando Patr\u00f3n Osorno, Rub\u00ed Zoe Manzanero Fern\u00e1ndez, Edmundo Alejandro Ke Aznar\nInfluence of sociodemographic variables and tobacco consumption on the risk of nonalcoholic  34-39fatty liver disease and liver fibrosis  \nLiliana Laird, Cristina N\u00fa\u00f1ez Fern\u00e1ndez, Mar\u00eda Gil Llin\u00e1s,  Rosa Gonz\u00e1lez Casquero\nResults of the COVID-19 survey on students, teachers and users of the ADEMA University School  40-44\nYolanda Perell\u00f3 Alonso, Dolores Llamas Canaves, Pedro Alomar Velasco, Hernan Jos\u00e9 Paublini Oliveira, Estefan\u00eda Garc\u00eda Ruiz  \nClostridium histolyticum collagenase (Xiapex\u00ae) in patients with peyronie disease.   45-51Expectations vs reality\nPedro \u00c1lvarez D\u00edaz, Yumaira Hern\u00e1ndez Mart\u00ednez, Antonio Servera Ruiz de Velasco, Mar\u00eda Reyes Garc\u00eda-Miralles Gravalos, Joan Mar\u00eda Benejam Gual\nThe effect of Familact probiotic supplement in patients with diabetes 52-63(Evaluation of Blood Glucose Parameters, Lipid Profile) \nSeyedeh Faezeh Miryousefiata, Fatemeh Alsadat Miryousefi Ata\nThe intervention of public authorities against pseudotherapies: possibilities and limits 64-71\nCarmen Tom\u00e1s-Valiente Lanuza\nCyto-histological correlation in cervical cytology  72-75\nJavier Cort\u00e9s Bordoy, Ana Forteza Valad\u00e9s\nGenotypic and phenotypic assessment of antibiotic resistance of MRSA bacteria  76-80isolated from food stuffs\nSeyyed Shahab Aldin Hosseini, Seyed Amirshayan Makkie, Bahareh Tavakoli-Far, Farhad Safarpoor Dehkordi\n Antibiotic resistance pattern of methicillin-resistant Staphylococcus aureus  isolates  81-87from powdered packaged medicinal plants and bottle herbal distillates\nMaedeh Rajabi, Zohreh Mashak, Roshanak Jazayeri, Bahareh Tavakoli-Far  Effect of estrogen and insulin sensitivity due to exercise training with dual intensities  88-92in female rats with estradiol valerate-induced PCOS\nMaryamosadat Miri, Foroozandeh Zaravar, Mohsen Davoodi\nEvaluation of risk factors, risk assessment and health-related quality of life in patients 93-98with dyslipidemia in Kempegowda Institute of Medical Sciences (Kims)  Hospital and Research Centre, Bangalore, India\nZahra Dehghanian\nHelicobacter pylori  distribution in dental plaque specimens collected 99-103from individuals referred to dental clinics \nAshkan Salehi\nComparative study of clinical symptoms, laboratory and radiological findings of COVID-19 patients  104-112admitted to ICU ward with internal ward of Forghani Hospital in Qom: a case series \nAbolfazl Mozafari, Foroozan Yarahmadi\nDirect instruction and inquiry-based method in teaching endodontics among preclinical dentistry students   113-116\nMaria Lourdes E. Cantor, Joseph M. Acosta\nEnterotoxigenic profiles of Staphylococcus aureus  strains isolated from sweet samples  117-121\nMohammadreza Mahmoodi Sadr, Amir Shakerian, Ebrahim Rahimi, Hasan Momtaz\n Prescriptions analysis for various effects of polypharmacy in Kempegowda Institute  122-125of Medical Sciences (Kims) Hospital and research centre, India\nShamimeh Fallah Ghorbani, Tejasvinii M, Kiran Nagaraju Evaluation of arch bar fixation without surgical aid in jaw fracture treatment  126-129\nFarnaz Dehabadi, Seyed Hadi Hosseini\nThe efficacy of Cognitive-behavior therapy based parenting for anxious children with cancer 130-135\nMehri Moradi, Shayan Alamdarifar, Masoud Besharati, Aliasghar Asgharnejad\nCASE REPORT \nSeckel syndrome associated dental anomaly; case report  136-139\nSoraya Bakhshani, Seyed Hossein Hosseini Zarch, Mahrokh Imani Moghadam, Atsa Pakfetrat\nInestabilidad cef\u00e1lica y derrame peric\u00e1rdico  140-144\nTom\u00e1s Javier Leal Rull\u00e1n, Marco Antonio Mart\u00ednez Ortega, Isabel Amengual Antich, Maria Dolors Ramis Estelrich, \nManuel del R\u00edo Vizoso, Elisa Torres del Pliego   www.bancamarch.es\u00bfQu\u00e9 profesional puede\ntener 45 a\u00f1os de edad y\n90 de experiencia?\nLa respuesta es Banca March\nLa experiencia de un profesional no est\u00e1 \n\u00fanicamente en su edad, sino tambi\u00e9n en la edad de \nla firma para la que trabaja.\nY 90 a\u00f1os de experiencia es lo que ofrecen los \nprofesionales de Banca March.\n90 a\u00f1os gestionando patrimonios y demostrando \nentre otras cosas, que la prudencia no est\u00e1 re\u00f1ida \ncon la rentabilidad.www.bancamarch.es\u00bfQu\u00e9 profesional puede\ntener 45 a\u00f1os de edad y\n90 de experiencia?\nLa respuesta es Banca March\nLa experiencia de un profesional no est\u00e1 \n\u00fanicamente en su edad, sino tambi\u00e9n en la edad de \nla firma para la que trabaja.\nY 90 a\u00f1os de experiencia es lo que ofrecen los \nprofesionales de Banca March.\n90 a\u00f1os gestionando patrimonios y demostrando \nentre otras cosas, que la prudencia no est\u00e1 re\u00f1ida \ncon la rentabilidad.VOLUMEN 36  NUM. 3\nJULIO - SEPTIEMBRE 2021 SUMARIO\nEDITORIAL \nUna asignatura pendiente en c\u00e1ncer ocupacional: la historia cl\u00ednico-laboral  9-10\nM\u00aa Te\u00f3fila Vicente Herrero\nORIGINALES \nEvaluaci\u00f3n de la tecnolog\u00eda diagn\u00f3stica en Ir\u00e1n: Un estudio de teor\u00eda fundamentada  11-16\nSamira Abam, Fatemeh Dabbaghi, Ghahraman Mahmoodi     \nEfecto del estado inflamatorio perioperatorio en el salvamento de extremidad 17-21 de los pacientes con isquemia cr\u00edtica sometidos a revascularizaci\u00f3n infrainguinal \nDavid Santiago Garc\u00eda Garc\u00eda, Krystell Daniela Escoto Theodoracopoulos, Gabriella Loria Rogers, \nOscar Antonio Merino Mairal, Ra\u00fal Lara Hern\u00e1ndez, Pascual Lozano Vilardell\nEfecto de la extracci\u00f3n de aceite de s\u00e9samo por m\u00e9todos tradicionales   22-28y de prensado en fr\u00edo sobre el contenido total de aflatoxinas \nNader Akbari, Masoud Sami, Zahra Esfandiari, Mohammad Javad Tarrahi\nValores de diferentes \u00edndices relacionados con riesgo cardiovascular 29-33  seg\u00fan las puntuaciones del test Findrisc en cauc\u00e1sicos \nHector Orlando Patr\u00f3n Osorno, Rub\u00ed Zoe Manzanero Fern\u00e1ndez, Edmundo Alejandro Ke Aznar\nInfluencia de las variables sociodemogr\u00e1ficas y del consumo de tabaco  34-39en el riesgo de padecer h\u00edgado graso no alcoh\u00f3lico y fibrosis hep\u00e1tica  \nLiliana Laird, Cristina N\u00fa\u00f1ez Fern\u00e1ndez, Mar\u00eda Gil Llin\u00e1s,  Rosa Gonz\u00e1lez Casquero\nResultados de la encuesta COVID-19 en alumnos, profesores y usuarios de la escuela universitaria ADEMA  40-44\nYolanda Perell\u00f3 Alonso, Dolores Llamas Canaves, Pedro Alomar Velasco, Hernan Jos\u00e9 Paublini Oliveira, Estefan\u00eda Garc\u00eda Ruiz  \nColagenasa clostridium histolyticum (xiapex\u00ae) en pacientes con enfermerdad peyronie.   45-51Expectativas vs realidad\nPedro \u00c1lvarez D\u00edaz, Yumaira Hern\u00e1ndez Mart\u00ednez, Antonio Servera Ruiz de Velasco, Mar\u00eda Reyes Garc\u00eda-Miralles Gravalos, Joan Mar\u00eda Benejam Gual\nEl efecto del suplemento probi\u00f3tico Familact en pacientes con diabetes 52-63(Evaluaci\u00f3n de glucosa en sangre y perfil lip\u00eddico)\nSeyedeh Faezeh Miryousefiata, Fatemeh Alsadat Miryousefi Ata\nLa intervenci\u00f3n de los poderes p\u00fablicos frente a las pseudoterapias: posibilidades y l\u00edmites 64-71\nCarmen Tom\u00e1s-Valiente Lanuza\nCorrelaci\u00f3n cito-histol\u00f3gica en la citolog\u00eda cervical  72-75\nJavier Cort\u00e9s Bordoy, Ana Forteza Valad\u00e9s\nEvaluaci\u00f3n genot\u00edpica y fenot\u00edpica de la resistencia a los antibi\u00f3ticos de bacterias MRSA  76-80aisladas de alimentos\nSeyyed Shahab Aldin Hosseini, Seyed Amirshayan Makkie, Bahareh Tavakoli-Far, Farhad Safarpoor Dehkordi\n Patr\u00f3n de resistencia a los antibi\u00f3ticos de los Staphylococcus aureus  aislados resistentes a la 81-87\nmeticilina procedentes de plantas medicinales envasadas en polvo y destilados de hierbas en botella\nMaedeh Rajabi, Zohreh Mashak, Roshanak Jazayeri, Bahareh Tavakoli-Far  Efecto de la sensibilidad a los estr\u00f3genos y la insulina debido al entrenamiento  88-92con ejercicios de intensidad dual en ratas hembras con SOP inducido por valerato de Estradiol\nMaryamosadat Miri, Foroozandeh Zaravar, Mohsen Davoodi\nEvaluaci\u00f3n de los factores de riesgo, valoraci\u00f3n del riesgo y calidad de vida relacionada 93-98con la salud en pacientes con dislipidemia en el Hospital y Centro de Investigaci\u00f3n  del Instituto Kempegowda de Ciencias M\u00e9dicas (Kims), Bangalore, India\nZahra Dehghanian\nDistribuci\u00f3n de Helicobacter pylori  en muestras de placa dental 99-103recolectadas de individuos remitidos a cl\u00ednicas dentales \nAshkan Salehi\nEstudio comparativo de s\u00edntomas cl\u00ednicos, hallazgos de laboratorio y radiol\u00f3gicos de pacientes  104-112\nCOVID-19 ingresados   en la sala de UCI con sala interna del Hospital Forghani en Qom: una serie de casos\nAbolfazl Mozafari, Foroozan Yarahmadi\nInstrucci\u00f3n directa y m\u00e9todo basado en la indagaci\u00f3n en la ense\u00f1anza  113-116de la endodoncia entre los estudiantes de odontolog\u00eda precl\u00ednica \nMaria Lourdes E. Cantor, Joseph M. Acosta\nPerfiles enterotoxig\u00e9nicos de cepas de Staphylococcus aureus  aisladas en muestras de dulces   117-121\nMohammadreza Mahmoodi Sadr, Amir Shakerian, Ebrahim Rahimi, Hasan Momtaz\n An\u00e1lisis de prescripciones para diversos efectos de la polifarmacia en el Hospital  122-125y centro de investigaci\u00f3n del Instituto de Ciencias M\u00e9dicas de Kempegowda (Kims), India\nShamimeh Fallah Ghorbani, Tejasvinii M, Kiran Nagaraju \nEvaluaci\u00f3n de la fijaci\u00f3n de barras de arco sin ayuda quir\u00fargica en el tratamiento de fracturas de mand\u00edbula  126-129\nFarnaz Dehabadi, Seyed Hadi Hosseini\nLa eficacia de la crianza basada en la terapia cognitivo-conductual para los ni\u00f1os ansiosos con c\u00e1ncer  130-135\nMehri Moradi, Shayan Alamdarifar, Masoud Besharati, Aliasghar Asgharnejad\nESTUDIO DE CASOS \nAnomal\u00eda dental asociada al s\u00edndrome de Seckel; reporte de un caso  136-139\nSoraya Bakhshani, Seyed Hossein Hosseini Zarch, Mahrokh Imani Moghadam, Atsa Pakfetrat\nCephalic instability and pericardial effusion  140-144\nTom\u00e1s Javier Leal Rull\u00e1n, Marco Antonio Mart\u00ednez Ortega, Isabel Amengual Antich, Maria Dolors Ramis Estelrich, \nManuel del R\u00edo Vizoso, Elisa Torres del Pliego   .com\nHaz algo grande por tu salud\nEn Asisa somos expertos en salud y sabemos \nque el sue\u00f1o es vital para el buen \nfuncionamiento de tu coraz\u00f3n, tu cerebro y \ntodo tu organismo.\nLos especialistas determinan que una \npersona adulta necesita entre 7 y 9 horas \ndiarias de sue\u00f1o para estar bien. \nSin embargo, se estima que el 80% de los \nespa\u00f1oles duermen menos de este tiempo, exponi\u00e9ndose a sufrir hipertensi\u00f3n, \ntaquicardia, depresi\u00f3n, p\u00e9rdida de \nmemoria, sobrepeso y diabetes, entre otros \nproblemas. Y como sabes, en Asisa solo nos \npreocupa tu salud. Por eso invertimos \ntodos nuestros recursos en cuidarte , \nincluido este anuncio en el que te \naconsejamos que duermas una hora m\u00e1s \ntodos los d\u00edas.\nAsisa Palma de Mallorca.\nC/ Pere Dezcallar i Net, 10\nasisa.e s 901 10 10 10Empresa Colaboradora:Nada m\u00e1s que tu salud\nNada menos que tu saludC\nM\nY\nCM\nMY\nCY\nCMY\nK170203 AF PG. PALMA DE MALLORCA generico A4.pdf   1   3/2/17   14:249\n2021/36 (3): 9-10.com\nHaz algo grande por tu salud\nEn Asisa somos expertos en salud y sabemos \nque el sue\u00f1o es vital para el buen \nfuncionamiento de tu coraz\u00f3n, tu cerebro y \ntodo tu organismo.\nLos especialistas determinan que una \npersona adulta necesita entre 7 y 9 horas \ndiarias de sue\u00f1o para estar bien. \nSin embargo, se estima que el 80% de los \nespa\u00f1oles duermen menos de este tiempo, exponi\u00e9ndose a sufrir hipertensi\u00f3n, \ntaquicardia, depresi\u00f3n, p\u00e9rdida de \nmemoria, sobrepeso y diabetes, entre otros \nproblemas. Y como sabes, en Asisa solo nos \npreocupa tu salud. Por eso invertimos \ntodos nuestros recursos en cuidarte , \nincluido este anuncio en el que te \naconsejamos que duermas una hora m\u00e1s \ntodos los d\u00edas.\nAsisa Palma de Mallorca.\nC/ Pere Dezcallar i Net, 10\nasisa.e s 901 10 10 10Empresa Colaboradora:Nada m\u00e1s que tu salud\nNada menos que tu saludC\nM\nY\nCM\nMY\nCY\nCMY\nK170203 AF PG. PALMA DE MALLORCA generico A4.pdf   1   3/2/17   14:24\neISSN 2255-0569\nEDITORIAL\nUna asignatura pendiente en c\u00e1ncer ocupacional: \nla historia cl\u00ednico-laboral\nA pending issue in occupational cancer: clinical-occupational history \nM\u00aa Te\u00f3fila Vicente Herrero   \nM\u00e9dico Especialista en Medicina del Trabajo\nLa notificaci\u00f3n del c\u00e1ncer laboral sigue siendo en el \nmomento actual la m\u00e1s baja dentro de las enfermedades \nprofesionales, tanto en Espa\u00f1a1, como en los pa\u00edses de \nnuestro entorno2. Esta tendencia no se ha visto modificada \ncon el paso de los a\u00f1os a pesar de los esfuerzos \nrealizados por las Organizaciones Internacionales m\u00e1s \nrepresentativas, como la Organizaci\u00f3n Mundial de la \nSalud3, y por los representantes de Salud P\u00fablica y \nSalud Laboral en nuestro pa\u00eds4.\nPara prevenir esta enfermedad en el entorno laboral, \ndesde 2016 y hasta 2020, la Comisi\u00f3n Europea ha ido  \nrevisando la principal herramienta legal para abordar el \nc\u00e1ncer laboral en Europa, la Directiva 2004/37/CE de \nagentes cancer\u00edgenos y mut\u00e1genos en el trabajo5.  \nSin duda, uno de los principales motivos de la \ninfradeclaraci\u00f3n es la complejidad a la hora de establecer \nuna relaci\u00f3n de causalidad entre la exposici\u00f3n a los \nfactores de riesgo laboral y el desarrollo de la neoplasia \nen una enfermedad multifactorial como el c\u00e1ncer,  \ndonde intervienen tanto aspectos personales como \nmedioambientales, h\u00e1bitos de vida y exposiciones \nlaborales.\nEl concepto de c\u00e1ncer ocupacional es m\u00e1s amplio \nque el de c\u00e1ncer como enfermedad profesional. No todos los c\u00e1nceres relacionados con el trabajo y con \nla presencia de agentes causales en el ambiente \nlaboral son considerados enfermedad profesional. \nExiste asociaci\u00f3n entre determinadas ocupaciones y la \npresencia de tipos de c\u00e1ncer concretos, pero no todos \nlos c\u00e1nceres con evidencia de exposici\u00f3n laboral a \nagentes cancer\u00edgenos se encuentran incluidos dentro \ndel listado de enfermedades profesionales6 y pueden \nser considerados como Enfermedad Profesional.\nLa aparici\u00f3n del c\u00e1ncer en la poblaci\u00f3n trabajadora \ndebe llevar a averiguar sus posibles causas laborales \npara actuar en prevenci\u00f3n, pero, al mismo tiempo, la \ndetecci\u00f3n de cualquier tipo de c\u00e1ncer fuera del \u00e1mbito \nlaboral debe inducir a incluir en la investigaci\u00f3n un \nestudio exhaustivo de exposiciones laborales de riesgo, \npartiendo de la base de que una misma persona puede \nhaber estado expuesta en su vida laboral a distintos \ncompuestos y en sectores laborales diversos, lo que \ndificulta todav\u00eda m\u00e1s poder establecer una relaci\u00f3n \ncausa-efecto y, con ello, actuar en prevenci\u00f3n.\nLa historia cl\u00ednico laboral se convierte en un instrumento \nclave para aunar la informaci\u00f3n cl\u00ednica con la ocupaci\u00f3n u \nocupaciones desarrolladas por el paciente-trabajador a lo \nlargo de su vida laboral y encontrar las posibles relaciones \ncon exposiciones en el lugar de trabajo que bien de \n10\n2021/36 (3): 9-10M\u00aa Te\u00f3fila Vicente   una asignatura pendiente en c\u00e1ncer ocupacional: la historia cl\u00ednico-laboral\nBibliograf\u00eda \n1. Enfermedades profesionales (CEPROSS). Disponible en: https://\nwww.seg-social.es/wps/portal/wss/internet/EstadisticasPresupuestos -\nEstudios/Estadisticas/EST231/2082 (consultado 4 de junio de 2021).\n2. Agencia europea para la Seguridad y Salud en el trabajo. C\u00e1ncer \nrelacionado con el trabajo. Disponible en: https://osha.europa.eu/es/\nthemes/work-related-diseases/work-related-cancer (consultado 4 de \njunio de 2021).\n3. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M, et al. Global \nCancer Observatory: Cancer Today. Lyon: Centro Internacional de \nInvestigaciones sobre el C\u00e1ncer; 2020. Disponible en: http://gco.irac.\nfr/today (consultado 4 de junio de 2021).\n4. Instituto Nacional de Seguridad y salud en el Trabajo. Ocupaci\u00f3n, actividad \necon\u00f3mica y mortalidad por c\u00e1ncer en Espa\u00f1a. Disponible en: https://www.\ninsst.es/documents/94886/599872/Mortalidad+cancer.pdf/2cdf1b22-\n82bb-4b2f-87ac-ea846d50080d (consultado 4 de junio de 2021).5. Directiva 2004/37/CE del Parlamento Europeo y del Consejo, de \n29 de abril de 2004, relativa a la protecci\u00f3n de los trabajadores contra \nlos riesgos relacionados con la exposici\u00f3n a agentes carcin\u00f3genos o \nmut\u00e1genos durante el trabajo (sexta Directiva espec\u00edfica con arreglo \nal apartado 1 del art\u00edculo 16 de la Directiva 89/391/CEE del Consejo) \n(Versi\u00f3n codificada) (Diario Oficial de la Uni\u00f3n Europea L 158 de 30 de \nabril de 2004).\n6. Real Decreto 1299/2006, de 10 de noviembre, por el que se aprueba \nel cuadro de enfermedades profesionales en el sistema de la Seguridad \nSocial y se establecen criterios para su notificaci\u00f3n y registro. Ministerio \nde Trabajo y Asuntos Sociales. Bolet\u00edn Oficial del estado n\u00fam. 302, de \n19 de diciembre de 2006 Referencia: BOE-A-2006-22169.forma independiente o bien, como es m\u00e1s frecuente, \nasociadas a otros factores son causa determinante, \ndesencadenante o agravante del proceso neopl\u00e1sico.\nSe trata de recabar informaci\u00f3n precisa, sistematizada \ny rigurosa que relacione tipos de c\u00e1ncer con  actividad \nlaboral, riesgos laborales y factores personales \ny sociodemogr\u00e1ficos, adem\u00e1s de los aspectos \npropiamente cl\u00ednicos, diagn\u00f3sticos, histol\u00f3gicos y \nterap\u00e9uticos.\nDe este modo, todos los implicados en el cuidado del \npaciente con c\u00e1ncer podremos  empezar a tener datos \nque se aproximen a la realidad, que permitan trabajar juntos a los sanitarios especialistas del \u00e1mbito laboral \ny extralaboral, mejorar las actuaciones preventivas y \nfacilitar la reintegraci\u00f3n social y laboral de la persona que \nha sufrido un c\u00e1ncer y vuelve al trabajo tras periodos \nde incapacidad, generalmente prolongada o muy \nprolongada.\nTrabajemos juntos en los aspectos formativos que \nrelacionan c\u00e1ncer y trabajo, en los procedimientos de \nnotificaci\u00f3n de las neoplasias relacionadas con el trabajo \ny en esa historia cl\u00ednico-laboral tan necesaria que ser\u00e1 la \npuerta de entrada a una colaboraci\u00f3n entre profesionales \nde distintas especialidades y que redundar\u00e1 en beneficio \nde todos.11\n2021/36 (3): 11-16ORIGINAL\nDiagnostic technology assessment in Iran: \nA grounded theory study \nEvaluaci\u00f3n de la tecnolog\u00eda diagn\u00f3stica en Ir\u00e1n: Un estudio de teor\u00eda fundamentada \nSamira Abam1      , Fatemeh Dabbaghi2      , Ghahraman Mahmoodi2      \n1. Ph.D Candidate of health services Administration, Sari Branch, Islamic Azad University, Sari, Iran\n2. Associated Professor, Hospital Administration Research Center, Sari Branch, Islamic Azad University, Sari, IraneISSN 2255-0569\nReceived:  15 - V - 2021\nAccepted:  22 - VI - 2021\ndoi: 10.3306/AJHS.2021.36.03.11Corresponding author\nFatemeh Dabbaghi \nHospital Administration Research Center, Sari Branch,\nIslamic Azad University, Sari, Iran \nE-mail: _dabbaghi@yahoo.comID ID ID\nAbstract  \nIntroduction:  Evaluation and selection of efficient medical equipment have always been among the concerns of health system \nmanagers.\nMethods:  The purpose of the present study was to present a model of diagnostic technology assessment in Iran based on a \nGrounded theory approach.The present qualitative Grounded Theory-based study was conducted in 2019. The participants in this \nstudy were medical equipment managers and health technology assessment experts working in university hospitals.\nResults:  The results showed that the Committee model is the most commonly used model of diagnostic technology assessment \nin Iran\u2019s university hospitals; it was also indicated that the organizational, economic, technological, clinical, and legal properties of \ndiagnostic technologies are considered important in the assessment process.\nConclusion: Medicines, Treatment, and Medical Equipment Committees in Iran\u2019s hospitals can create an appropriate platform for \ndiagnostic technology assessment, while the support and cooperation of managers play a decisive role in this process.\nKeywords:  Equipment and Supplies, Health, Ancillary Services Hospital.\nResumen\nIntroducci\u00f3n: La evaluaci\u00f3n y selecci\u00f3n de equipos m\u00e9dicos eficientes siempre han estado entre las preocupaciones de los \ngestores del sistema de salud.\nMetodolog\u00eda: El prop\u00f3sito del presente estudio fue presentar un modelo de evaluaci\u00f3n de la tecnolog\u00eda de diagn\u00f3stico en Ir\u00e1n \nbasado en un enfoque de la teor\u00eda fundamentada. El presente estudio cualitativo basado en la teor\u00eda fundamentada se llev\u00f3 a \ncabo en 2019. Los participantes en este estudio fueron gerentes de equipos m\u00e9dicos y expertos en evaluaci\u00f3n de tecnolog\u00eda de \nla salud que trabajan en hospitales universitarios.\nResultados: Los resultados mostraron que el modelo de Comit\u00e9 es el modelo m\u00e1s com\u00fanmente utilizado de evaluaci\u00f3n de tec -\nnolog\u00eda de diagn\u00f3stico en los hospitales universitarios de Ir\u00e1n; tambi\u00e9n se indic\u00f3 que las propiedades organizativas, econ\u00f3micas, \ntecnol\u00f3gicas, cl\u00ednicas y legales de las tecnolog\u00edas de diagn\u00f3stico se consideran importantes en el proceso de evaluaci\u00f3n.\nConclusiones: Los comit\u00e9s de medicamentos, tratamientos y equipos m\u00e9dicos de los hospitales iran\u00edes pueden crear una plata -\nforma adecuada para la evaluaci\u00f3n de las tecnolog\u00edas de diagn\u00f3stico, mientras que el apoyo y la cooperaci\u00f3n de los gestores \ndesempe\u00f1an un papel decisivo en este proceso.\nPalabras clave:  Equipos y suministros, salud, Servicios t\u00e9cnicos en salud.12\n2021/36 (3): 11-16Samira Abam et al.  \nIntroduction \nThe diversity of the equipment market and the increase \nof demands and expectations of physicians and patients \nfor the selection and application of new technologies \nhave led to an unbridled increase in the use of new \nhealth technologies in Iran1. Over the last few years, \nthe availability of a new generation of diagnostic and \ntherapeutic medical devices has caused a significant \nincrease in the use of such devices in Iranian hospitals, \nwhile hospitals\u2019 authorities are still looking forward to \nhaving more of these new devices in their hospitals2.\nThe results of studies in other countries show that \nhospitals and medical research centers spend about \n$500,000,000 to $1, 000,000,000 on medical \nequipment per year (plus 15-20% annual increase). \nIt can be said that medical equipment plays the most \nimportant role in the increase in health care spending in \ndifferent parts of the world3,4. In Iran, more than one-third \nof the total spending of various educational, medical, and \nhealth care centers is allocated to medical equipment5.\nTherefore, managers are always faced with decision-\nmaking situations concerning the selection of the \nmost appropriate technologies6. Due to the diversity of \nproducts and organizations\u2019 authority to select products \nbased on their needs, identifying factors affecting the \ndecision-making processes in a competitive environment \nand using scientific methods to select appropriate \nproducts and services are of particular importance in \nmedical settings7.\nHealth Technology Assessment (HTA) has emerged \nmainly in response to the increasing health care costs \nand to ensure the efficiency of resources used in health \nsystems8. Most studies on HTA have been conducted in \nhigh-income countries, and the HTA statuses in middle-\nincome and low-income countries remain unattended9 . \nIran\u2019s current Gross Domestic Product (GDP) has been \nestimated at $454.01 billion, making it a middle-income \ncountry based on the World Development Indicators \n(WDI)10.\n \nIn Iran, HTAs are performed at national level and there is \nno active HTA program at hospital level. Therefore, the \npresent study was executed to identify the parameters \nconsidered in Iranian University Hospitals (UHs) when \nassessing diagnostic medical equipment. This study also \npresents a model of HTA in Iranian UHs based on the \nGrounded Theory. Considering the limited resources of \nthe health system, the high cost of diagnostic medical \nequipment, and the effect of medical equipment on \nproper and timely treatment, the proposed model in \nthis study can play an effective role in the optimal and \nnondiscriminatory selection of scarce medical resources \nand lead to improved service quality. Methodology \nThis qualitative study was conducted based on a \nGrounded Theory approach. The data were collected \nthrough unstructured interviews; the statistical population \nof this study consisted of medical equipment managers \nand HTA experts working in Iranian UHs; the data \ncollection began in June 2019 and ended in August 2019. \nThe demographic characteristics of the participants are \npresented in table I . Data saturation was reached after \n15 interviews. \nThe participants were asked to describe the process of \nassessing diagnostic devices at hospitals where they \nwere working. They were also asked to specify what they \nusually consider when assessing diagnostic medical \ndevices? And what questions do they pose concerning \nthose devices?\nData analysis was a regular and continuous process of \ndata comparison, done in three stages of open coding, \naxial coding, and selective coding. In open coding , \nthe transcribed version of the interviews was read \nseveral times, the main themes were extracted and \nrecorded as codes; then, categories were developed \nby grouping similar codes. In axial coding , categories \nwere linked to their subcategories to provide more \naccurate explanations of the phenomenon. Moreover, \nthe primary categories, which were formed in the open \ncoding stage, were compared and similar categories \nwere placed on a common axis. Selective coding is the \nprocess of integrating and refining theme categorization; \ntherefore, the present study\u2019s researcher harmonized \nand arranged different categories to present and form \na theory. In the selective coding  stage, while integrating \nand purifying the categories, it was decided to have \na main theme; then, using the model paradigm, all \nthemes were linked to the main theme. Throughout \nthe study, methods were used to ensure the validity \nand reliability of the data. Four criteria have been \nproposed to ensure the trustworthiness of qualitative \nstudies: credibility, dependability, confirmability, \nand transferability. Making long contacts with the \nparticipants, providing them with information about \nthe project objectives to gain their trust throughout \nthe interviews, continuously reviewing the data, audio \nrecording each interview and transcribing it immediately \nafter it finished, and using its feedbacks in subsequent \ninterviews, the researchers tried to improve the study\u2019s \ncredibility. Data dependability was tested by asking the \nparticipants and observers to review the transcribed \ninterviews and express their corrective opinions. To \ntest the transferability of the study, the study findings \nwere sent to some medical equipment experts, who \ndid not participate in the current study, to compare \nthem with their own experiences. 13\n2021/36 (3): 11-16 Diagnostic Technology Assessment in Iran: A Grounded Theory Study\nResults \nThe results showed that, in line with the Ministry of Health \nand Medical Education instructions, the Medicines, \nTreatment, and Medical Equipment Committees have been \nformed in all Iranian UHs. In other words, the technology \nassessment of medical devices in Iranian UHs is performed \nvia the internal committee method. The results indicated \nthat five main properties are considered when assessing \nhealth technologies in Iranian UHs ( Table II ).\nStep 1. Open Coding\nClinical properties\nClinical properties are determined based on the results of \nscientific studies and evidence for the effectiveness and \nsafety of medical technologies. These properties also \ninvolve the impacts of technologies, such as their side \neffects and advantages in terms of safety and treatment. \nMoreover, meeting the needs of special patients, \nincluding those with viral infections such as AIDS, is \nconsidered here. \nEconomic properties\nThe economic value of the clinical effects of certain \ntechnology and its associated costs is determined through various types of economic analyses, such as \ncost-minimization analysis, cost-benefit analysis, etc. \nOrganizational properties\nOrganizational properties are related to health institutions\u2019 \noperational processes and infrastructures, such as \ninstitutional expertise, educational features, types of \nrelationships between work teams, workflow, potential \nbarriers, and meeting accountability and accreditation \nrequirements. \nTechnological Properties\nAssessing technological properties includes examining \na medical device in terms of mechanical and electrical \nsafety, proper application, required accessories, \nequipment, space, maintenance, and storage. \nLegal Properties\nLegal properties include regulations (laws, resolutions & \nenactments) and all legal requirements before and after \nthe application of a specific technology. \nAssessment Model\nThe method each hospital uses to obtain information and \nassess a specific diagnostic technology. Table I: Demographic Characteristics of the Participants.\nVariables  Frequency Percentage\nEducational Level (Academic Degree) Bachelor\u2019s Degree 3 20\n Masters\u2019 Degree 9 60\n Ph.D./Ph.D. Candidate 3 20\nOrganizational Status Medical Equipment Manager 13 86.7\n Master of HTA 2 13.3\nGender Female 9 60\n Male 6 40\nTable II: Main categories and themes of diagnostic technology assessment in Iranian UHs.\nNumber  Main categories Themes\n  Disease burden\n1 Clinical Alternative methods\n Properties Attending to clinical standards\n  Attending to the needs of specific groups of patients\n  Primary cost\n2 Economic Secondary cost\n Properties Utilization of available resources\n  Refund \n  Accreditation requirements\n3 Organizational Meeting the needs of special groups of patients \n Properties  in UHs (Education & Research Affairs) \n  Accountability requirements\n  Production feature\n4 Technological Properties Technical feature\n  Setup requirement \n  Medical Equipment Office\n5 Legal Department of Laboratory Affairs \n Properties Atomic Energy Organization\n  Etc.\n  Committee Model\n6 Asswessment Model Mini-HTA Model\n  no Model14\n2021/36 (3): 11-16Samira Abam et al.  \nStep 2: Axial Coding\nIn the present study, five main categories of clinical \nproperties, organizational properties, technological \nproperties, economic properties, and legal properties \nwere identified. Focusing on interviews, categories, \nthemes, and reminders, \u201cHTA characteristics in the \ndomain of diagnostic medical equipment\u201d was identified \nas the main variable in the selective coding step; this \nvariable related all categories and themes to each \nother. A brief explanation of each of those categories \nand themes will be presented in the following sections\nStep 3: Description of the Theorizing Stage \n(Selective Coding)\nAs mentioned, the goal of fundamental theorizing is to \nproduce a theory, not merely describing a phenomenon. \nTo turn analyses into a theory, categories must be \nadequately related to each other.\nThe Paradigmatic Model of Diagnostic Technology \nAssessment in Iran\u2019s Public Hospitals\nThis theory presents mechanisms through which the \ntarget population (decision-makers in the domain of \ndiagnostic medical equipment) identifies its needs and \nbetter assesses the diagnostic medical equipment; \non the other hand, hospitals allocate their resources \nefficiently and nondiscriminatory. A general model is \npresented to develop and extend the theory of diagnostic \ntechnology assessment (within hospitals affiliated with \nmedical sciences universities). \nDescription of the Paradigmatic Model\nHospitals are always faced with different kinds of \nrequests from doctors, nurses, and other medical staff \nfor applying diagnostic medical equipment and providing \npatients with better care. One of the most critical \ndecision-making situations that managers always face \nis selecting the most appropriate technologies. Limited \nresources, organizational limitations, and the country\u2019s \npolicies in the health domain are among the factors \ninvolved in these decision-making situations. Thus, it \nwould be appropriate to use methods that accurately \nand properly take into account the ambiguity of human \njudgment when deciding over such issues. \nIn the present study, the researchers sought to identify the \nmost important factors in the assessment of diagnostic \ntechnologies in Iranian UHs. The results of this study led \nto the formulation of useful and practical ideas for the \ncurrent condition of the country.  Considering the findings \nof the present study, the following theory was developed: When selecting a diagnostic technology, Medicines, \nTreatment, and Medical Equipment Committee is formed \nbased on the requirements of hospitals\u2019 accreditation \nrules, and the committee examines a technology from \ndifferent dimensions and finally makes a decision.\nOne of the most important issues in such decisions \nis the hospital\u2019s ability to provide \u201cprimary\u201d and \n\u201csecondary\u201d costs of diagnostic technology. In many \ncases, when a hospital is not \u201ceconomically\u201d capable \nto pay the costs of a certain technology, other \ndimensions of the technology will not be assessed. \n\u201cspecial needs patients\u201d, \u201calternative diagnostic \nmethods\u201d and \u201cclinical standards\u201d are also considered \nin decision-making situations; in fact,  clinical issues \nare of great importance in the decision making \nprocess.   Each hospital\u2019s grade is determined based \non the Ministry of Health and Medical Education\u2019s \naccreditation assessments, which has a direct impact \non hospitals\u2019 revenues. Therefore, medical equipment \nexperts and hospital managers usually consider this \nwhen selecting diagnostic technologies. In addition to \naccreditation requirements, due to the accountability \nrequirements, if regulatory institutions (e.g. the State \nInspectorate Organization, municipalities, provincial \ngovernments, Ministry of Health and Medical Education, \nMedical Council of the Islamic Republic of Iran, \nDepartment of Environment, etc.) have expectations \nfrom the hospitals, they usually try to purchase the \ndesired technologies. In other words, considering the \n\u201corganizational properties\u201d of a hospital is evident in \nevery decision. \nWhen deciding to purchase a medical device, its \n\u201ctechnological properties\u201d play vital roles in its \u201csetting \nup\u201d. The \u201cquality\u201d, organizations\u2019 capacity to provide \n\u201cafter-sales-services\u201d \u2026 are of great importance in \n\u201cbrand selection\u201d.\nFurthermore, compliance with the current \u201cregulations\u201d \nin the domain of medical equipment was among the \nmain features that were considered in the assessment of \ndiagnostic technologies in Iranian UHs.\nIt can be said that the issues considered in HTA \npractices in Iranian UHs depend on various factors, the \nmost important of which are \u201cclinical\u201d, \u201corganizational\u201d, \n\u201ctechnological\u201d, \u201ceconomic\u201d and \u201clegal\u201d properties. Taking \ninto account all of these properties in decision-making \nsituations will optimize hospitals\\ budget allocations; it \nalso helps provide doctors with the facilities they need to \nmeet the needs of the community and minimize possible \nhuman misjudgments.\nThe following figure ( Figure 1 ) is the basic conceptual \nmodel of HTA in Iranian UHs:15\n2021/36 (3): 11-16 Diagnostic Technology Assessment in Iran: A Grounded Theory Study\nDiscussion \nHospital- based HTA consists of specific hospital needs11. \nThis approach considers the local organizational \nconditions in which health technologies are used12. \nStudies have shown that many initiatives have emerged in the area of hospital-based HTA in the world13,14,15. In \n2008, the Health Technology Assessment International \n(HTAi) proposed four models of HTA at hospital level: \n1) Ambassador Model; 2) Mini-HTA Model; 3) Internal \nCommittee Model, and 4) HTA Unit Model16,17. The results \nof the present study showed that Iranian UHs use Internal \nCommittee and Mini HTA models of HTA; moreover, it \nwas indicated that clinical, organizational, economic, \ntechnological, and legal properties of medical devices \nare considered important factors in the assessment of \ndiagnostic medical technologies in Iranian UHs.\nResearch shows that clinical and economic aspects \nof medical devices are considered very important in \nhospital-based HTA18, which is in line with the presets \nstudy\u2019s findings. \nBesides, previous studies have reported that legal \nproperties had been considered in only 23% of their \nexamined hospital-based HTA documents19, while \nthose properties were quite widespread in the context \nof Iranian UHs.\nIn line with the present study\u2019s findings, the technological \nproperties of medical technologies have received \nconsiderable attention in previous studies, including the \none conducted in France20.Properties of HTA \nin medical \nequipment \ndomainClinical\nproperties\nOrganizational\nproperties\nEconomic\nproperties\nTechnological \nproperties\nLegal \npropertiesFigure 1: Basic conceptual model of HTA in Iranian UHs.\nReferences\n1. Marzban Sima, Marzban Ali, Rahmani Hojjat. Providing a model for \nmanaging the evaluation and use of medical equipment in the Iranian \nhealth system. Hospital. 1386; 7 (1 and 2): 18-22. URL: http://jhosp.\ntums.ac.ir/article- \u06f1\u06f1\u06f1\u06f1-\u06f1- fa.html\n2. Dehnavieh R, Hekmat SN, Ghasemi S, Mirshekari N. The volnerable \naspects of application of health technology assessment. International \njournal of technology assessment in health care. 2015; 31: 197-8.\n3. Abele J. Administration of medical electronics: A review of some \ncriteria basic to effective and economical management of medical \nelectronic equipment. . Biomedical Instrumentation & Technology \n:2017, 53-6.\n4. Ivelve I, Kneppo P , Bartak M. Multicriteria decision analysis: \nA multifaceted approach to medical equipment management. \nTechnological and Economic Development of Economy: 2014: \n576-89.\n5. Drummond MF, Schwartz JS, J\u00f6nsson B . Key principles for \nthe improved conduct of health technology assessments for \nresource allocation decisions. Int J Technol Assess Health Care. \n2008;24:244-58. \n6. Arab Zozani M, Bagheri Faradonbeh S, Jaafari Pooyan E. The Role \nOf Health Technology Assessment In Improving Healthcare Quality. \npayavard. 2015; 9 (4) :400-14\nURL: http://payavard.tums.ac.ir/article-1-5839-fa.html7. Lari A, Hajinabi K, Komeili A, Riahi L. The effective factors in the \ndecision making component of purchase management of Medical \nEquipment in hospitals affiliated to Tehran University of Medical Sciences. \njhosp. 2020; 18 (4) :87-95\nURL: http://jhosp.tums.ac.ir/article-1-6152-fa.html\n8. Banta D. The Development of Health Technology Assessment. Health \nPolicy 2003; 63(2): 121-32\n9. Gagnon MP . Hospital-based health technology assessment: \nDevelopments to date. Pharmacoeconomics. 14;32:819-24.\n10. The World Bank, Country Profile. 2018. Retrieved from http://\ndatabank.worldbank.org/data/Views/Reports/ReportWidgetCustom. \naspx?Report_Name=CountryProfile&Id=b450fd57&tbar=y&dd= \ny&inf=n&zm=n&country=IRN.\n11. Granados A. Health technology assessment and clinical decision \nmaking. International Journal of technology assessment in health care. \n1999; 15(03): 585-92.\n12. Pawson, Greenhalgh T, Harvey G, Walshe K. Realist review-a new \nmethod of systematic review designed for complex policy interventions. \nJournal of health services research & policy. 2005; 10(suppl 1): 21-34.\n13. Pawson, Greenhalgh T, Harvey G, Walshe K. Realist synthesis: \nan introduction. ESRC Research Methods Programme Manchester. \nUniversity of Manchester, 2004.\n16\n2021/36 (3): 11-16Samira Abam et al.   Diagnostic Technology Assessment in Iran: A Grounded Theory Study\n14. Battista RN. Expanding the scientific basis of health technology \nassessment: A research agenda for the next decade, International \nJournal of Technology Assessment in Health Care. 2006; 22(3): 275-80 \n15. Gagnon MP . Opportunities to Promote Efficiency in Hospital \nDecision-Making through the Use of Health Technology Assessment. \nCanadian Health Services Research Founclation. 2011.\n16. Hospital Based Health Technology Assessment Sub-Interest Group. \nHospital Based Health Technology Assessment World-Wide Survey; \nHealth Technology Assessment Internatinoal (HTAi); 2008.\n17. MajdzadehR,Jamshidi E.Hospital-based health technology \nassessment in Iran. International Journal of Technology Assessment in \nHealth Care 2017;33(4):529-33. doi:10.1017/S026646231700065418. Rahmani K, Rezayatmand R, Sadeghpour N, Nikaeen M, Arabi \nS, Molavi Taleghani Y. Policy-making for Rationing in the Healthcare \nSystem: A review to provide suggestions for Iran. Manage Strat Health \nSyst. 2018; 3 (3) :249-62\n19. Kidholm K, \u00d8lholm AM, Birk-Olsen M, Cicchetti A, Fure B, \nHalmesm\u00e4ki E, et al. Hospital Managers\u2019 Need for Information in \nDecision-Making: An Interview Study in Nine European Countries. Health \nPolicy 2015, 119, 1424-32. \n20. Martelli N, Devaux C, van den Brink H, Billaux M .Harmonizing health \ntechnology assessment practices in university hospitals: to what extent \nis the mini-hta model suitable in the french context? Published online by \nCambridge University Press: 2017 , pp. 307-1417\n2021/36 (3): 17-21ORIGINAL\nEfecto del estado inflamatorio perioperatorio en el \nsalvamento de extremidad de los pacientes con isquemia \ncr\u00edtica sometidos a revascularizaci\u00f3n infrainguinal\nEffect of perioperative inflammatory status on limb salvage in critically ischemic patients \nundergoing infrainguinal revascularization \nDavid Santiago Garc\u00eda Garc\u00eda, Krystell Daniela Escoto Theodoracopoulos, \nGabriella Loria Rogers, Oscar Antonio Merino Mairal, Ra\u00fal Lara Hern\u00e1ndez, \nPascual Lozano Vilardell\nHospital Universitari Son Espases. PalmaeISSN 2255-0569\nRecibido:  11 - IV - 2021\nAceptado:  2 - VI - 2021\ndoi: 10.3306/AJHS.2021.36.03.17Correspondencia\nDavid Santiago Garc\u00eda Garc\u00eda \nHospital Universitari Son Espases. Palma\nE-mail: davidsantiago.farciagarcia@ssib.esID\nResumen\nIntroducci\u00f3n: M\u00faltiples estudios han demostrado que la alteraci\u00f3n de diversos marcadores inflamatorios se relaciona con el \u00e9xito \ntras la revascularizaci\u00f3n en pacientes con isquemia cr\u00f3nica.\nEl objetivo  de este trabajo es evaluar la utilidad del \u00edndice plaqueta/linfocito (IPL) preoperatorio, \u00edndice neutr\u00f3filo/linfocito (INL) y \nde la Prote\u00edna C Reactiva-no ultrasensible (PCR) postoperatorios, como marcadores pron\u00f3sticos de curaci\u00f3n de lesi\u00f3n tr\u00f3fica y \nsalvamento de extremidad en pacientes con isquemia cr\u00edtica.\nMaterial y m\u00e9todos: Estudio retrospectivo, seguimiento de 24 meses. Se incluyen 261 pacientes con diagn\u00f3stico de isquemia \ncr\u00edtica tratados mediante revascularizaci\u00f3n. Los \u00edndices analizados fueron obtenidos a partir de anal\u00edtica sangu\u00ednea.\nResultados: La media de edad fue de 68 a\u00f1os. El 61% de los casos fueron tratados de forma endovascular. La tasa de super -\nvivencia fue del 93,5% y la tasa de salvamento de extremidad fue del 85%. De los marcadores analizados un valor de PCR post -\noperatorio > 3,03 mg/dl se asoci\u00f3 con un incremento en el riesgo de amputaci\u00f3n (p=0,024). El INL > 3,2 (p=0,51) y el IPL > 160 \n(p=0,6) mostraron relaci\u00f3n con la tasa de cicatrizaci\u00f3n  y el salvamento de extremidad. La diabetes mellitus (OR 2,22 IC95%1,13-\n4,36; p=0,019) con la amputaci\u00f3n mayor.\nConclusiones: El estado inflamatorio perioperatorio se relaciona con el \u00e9xito de la revascularizaci\u00f3n. La PCR no ultrasensible se \nasocia con un incremento de la tasa de amputaci\u00f3n. EL INL y el IPL son marcadores ampliamente disponibles que podr\u00edan estar \nrelacionados como marcadores pron\u00f3sticos, siendo necesario el desarrollo de estudios adicionales.\nPalabras clave:  Isquemia cr\u00edtica, inflamaci\u00f3n, salvamento de extremidad, revascularizaci\u00f3n, \u00edndice neutr\u00f3filo/linfocito, \u00edndice pla -\nqueta/linfocito, prote\u00edna C reactiva.\nAbstract  \nIntroduction:  multiple studies have shown that the alteration of several inflammatory markers is related to success after revascu -\nlarization in patients with chronic ischemia.\nThe aim  of this study is to evaluate the usefulness of preoperative platelet/lymphocyte index (PLI), neutrophil/lymphocyte index \n(NLI) and postoperative non-ultrasensitive C-reactive protein (CRP) as prognostic markers of trophic lesion healing and limb salvage \nin patients with critical ischemia.\nMaterial and methods:  retrospective study, 24-month follow-up. We included 261 patients with a diagnosis of critical ischemia \ntreated by revascularization. The indexes analyzed were obtained from blood tests. \nResults:  the mean age was 68 years. Sixty-one percent of the cases were treated endovascularly. The survival rate was 93.5% \nand the limb salvage rate was 85%. Of the markers analyzed a postoperative CRP value > 3.03 mg/dl was associated with an \nincreased risk of amputation (p=0.024). INL > 3.2 (p=0.51) and IPL > 160 (p=0.6) showed relationship with healing rate and limb \nsalvage. Diabetes mellitus (OR 2.22 CI95%1.13-4.36; p=0.019) with major amputation.\nConclusion: Perioperative inflammatory status is related to revascularization success. Non-ultrasensitive CRP is associated with \nincreased amputation rate. INL and IPL are widely available markers that could be related as prognostic markers, being necessary \nthe development of further studies.\nKeywords:  Critical ischemia, inflammation, limb salvage, revascularization, neutrophil/lymphocyte index, platelet/lymphocyte index, \nC-reactive protein.18\n2021/36 (3): 17-21David Santiago Garc\u00eda  et al.  \nIntroducci\u00f3n \nLa enfermedad arterial perif\u00e9rica (EAP) es una patolog\u00eda \nfrecuente y generalmente diagnosticada de forma \ntard\u00eda1. Si el abordaje de la EAP no se realiza de \nmanera oportuna la enfermedad progresa y una de las \nprincipales complicaciones asociadas es la isquemia \ncr\u00edtica de la extremidad (ICE)2. La ICE es una entidad \nasociada con una elevada mortalidad y alto riesgo \nde amputaci\u00f3n, que a pesar de las diversas t\u00e9cnicas \ndesarrolladas en las \u00faltimas d\u00e9cadas se mantiene en \ntasas elevadas3.\nLa EAP se define como una enfermedad inflamatoria, \nen la que diversos mediadores celulares (monocitos/\nmacr\u00f3fagos) y humorales (Prote\u00edna C Reactiva (PCR), \nInterleucinas(IL)) intervienen en el proceso de formaci\u00f3n y \nevoluci\u00f3n de la placa ateromatosa4. Se han relacionado \nmarcadores inflamatorios como la PCR ultrasensible o los \nniveles de IL-6 con el desarrollo de EAP y coronariopat\u00eda, \ndeterminando su uso como mecanismo pron\u00f3stico de \nevoluci\u00f3n de la enfermedad arterial5-7.\nLos leucocitos y en especial los neutr\u00f3filos juegan un \nrol importante en la aterog\u00e9nesis y aterotrombosis. \nEstudios previos han sugerido que la PCR1,8-10, el \nINL4,11-16, el IPL5,8,17,18, y el \u00edndice linfocito monocito \n(ILM)19 perioperatorios, se asocian con incremento en \nel riesgo de desarrollo de isquemia cr\u00edtica, mortalidad \ncardiovascular, y perdida de extremidad, en paciente \ncon EAP o coronariopat\u00eda.\nObjetivos \nDeterminar si la PCR, el INL, el IPL y el ILM en la admisi\u00f3n \no en las primeras horas del postoperatorio pueden \nser considerados como marcadores pron\u00f3sticos \nen pacientes con isquemia cr\u00edtica sometidos a \nrevascularizaci\u00f3n del sector infrainguinal.\nMateriales y M\u00e9todos \nSe desarroll\u00f3 un estudio retrospectivo en el que se \nincluyeron 261 pacientes sometidos a revascularizaci\u00f3n \nrealizada tanto de manera endovascular como mediante \ncirug\u00eda abierta, a nivel de sector femoro-popl\u00edteo o de \ntroncos distales por isquemia cr\u00edtica de miembros \ninferiores, admitidos entre enero del 2014 y diciembre \ndel 2015.\nEl objetivo primario analizado fue la amputaci\u00f3n \n(supervivencia de extremidad), como objetivos \nsecundarios se analizaron la curaci\u00f3n de lesiones tr\u00f3ficas \ny el control del dolor.Los datos cl\u00ednicos y demogr\u00e1ficos as\u00ed como los \ncorrespondientes al seguimiento se obtuvieron del registro \nm\u00e9dico de cada paciente. Comorbilidades como la \nhipertensi\u00f3n arterial y diabetes mellitus se documentaron, \nindependientemente del tratamiento administrado. La \ninsuficiencia renal cr\u00f3nica se defini\u00f3 como una filtraci\u00f3n \nglomerular menor de 60 ml/min calculada en base a la \nformula CKD-EPI. Se document\u00f3 de forma independiente \nel uso de aspirina, clopidogrel o estatinas.\nPara determinar los diferentes par\u00e1metros objeto del \nestudio se usaron los valores absolutos obtenidos de la \nanal\u00edtica sangu\u00ednea realizada a cada paciente en las 24 \nhoras previas y las 12 horas siguientes al procedimiento. \nEl c\u00e1lculo se efectu\u00f3 mediante la divisi\u00f3n del valor \nabsoluto de los neutr\u00f3filos entre el valor absoluto de los \nlinfocitos para calcular el INL, el valor absoluto de las \nplaquetas entre el valor absoluto de los linfocitos para \nel IPL y el valor absoluto de los linfocitos entre el valor \nabsoluto de los monocitos para el ILM.\nSe determin\u00f3 la tasa de salvamento de extremidad y de \nsupervivencia mediante el uso de curvas de Kaplan Meier.\nAn\u00e1lisis estad\u00edstico \nLas caracter\u00edsticas cl\u00ednicas de los sujetos de estudio \nfueron analizadas usando t\u00e9cnicas de estad\u00edstica \ndescriptiva. Los grupos fueron comparados usando test \nde chi-cuadrado para variables categ\u00f3ricas, test t de \nStudent para variables continuas con distribuci\u00f3n normal \ny test de U de Man Whitney para variables continuas con \ndistribuci\u00f3n no normal\nEl punto de corte \u00f3ptimo de los valores de INL, IPL, ILM, \nPCR se determin\u00f3 mediante la aplicaci\u00f3n de curvas de \ncaracter\u00edsticas receptor-operador (curvas ROC) y la \ndetecci\u00f3n de interacci\u00f3n autom\u00e1tica por Chi-cuadrado \n(CHAID), para determinar los posibles puntos de corte que \npod\u00edan discriminar entre amputaci\u00f3n o no amputaci\u00f3n.\nTras obtener los puntos de corte para cada una de las \nvariables analizadas, se desarrollo un modelo de regresi\u00f3n \nlog\u00edstica binario mediante el cual se calcularon los odds \nratio de cada factor, con sus correspondientes intervalos \nde confianza (IC) al 95% para los diferentes factores de \nriesgo. En todos los test se determin\u00f3 un valor de p < 0,05 \ncomo estad\u00edsticamente significativo. Todos los an\u00e1lisis \nestad\u00edsticos fueron realizados en el software R Studio 1.3.\nResultados \nUn total de 261 pacientes fueron incluidos en el an\u00e1lisis. \nLas caracter\u00edsticas de los pacientes se pueden observar \nen la tabla I .19\n2021/36 (3): 17-21Efecto del estado inflamatorio perioperatorio en el salvamento de extremidad de los pacientes con isquemia cr\u00edtica sometidos a revascularizaci\u00f3n infrainguinal\nLos puntos de corte significativos valorados mediante \nla aplicaci\u00f3n de la curva receptor-operador y el an\u00e1lisis \nCHAID de las diferentes razones se presentaron solo \ncuando la variable de resultado era la amputaci\u00f3n, y \nfueron: 3,2 para el INL postoperatorio (\u00e1rea bajo la curva \n0,65 IC 95% 0,54-0,78) ( Imagen 1 ), de 160 para el ILP \npreoperatorio(\u00e1rea bajo la curva 0,59 IC 95% 0,55-0,78) \n(Imagen 2 ), y de 3,03 para la PCR postoperatoria (\u00e1rea \nbajo la curva 0,65 IC 95% 0,61-0,75) ( Imagen 3 ).Con estos puntos de corte se realiz\u00f3 una regresi\u00f3n \nlog\u00edstica bivariante para evaluar los diversos marcadores \ncomo factores de riesgo independientes para amputaci\u00f3n. \nSe incluyeron en este an\u00e1lisis las siguientes variables: el \nsexo, la diabetes, la edad > 75 a\u00f1os, la historia de ictus, \nla insuficiencia renal cr\u00f3nica, el tabaquismo, el tipo de \nintervenci\u00f3n quir\u00fargica fueron incluidos. El valor de PCR \npostoperatoria > 3,03 mg/dl se asoci\u00f3 significativamente \ncon la necesidad de amputaci\u00f3n, OR 2,56 (IC95% 1,26-\n3,57 p 0,024). El INL con un OR 1.14 (IC95% 0,7-1,7 p \n0,058) y el IPL con un OR 1,6 (IC95% 0,9-2,89 p 0,06) no \nse asociaron de manera significativa con la necesidad de \namputaci\u00f3n durante el seguimiento, aunque demostraron \ntendencia a actuar como factores pron\u00f3sticos. De las \ncovariables incluidas en el estudio la diabetes mellitus con \nun OR 2,22 (IC95%1,13-4,36 p 0,019) se asocio con un \nmenos salvamento de la extremidad.\nAl desarrollar las curvas de supervivencias, la tasa de \nsupervivencia global de la serie fue del 93,5% ( Im\u00e1genes \n4 y 5). Cuando se valor\u00f3 la tasa de salvamento de la \nextremidad en base a los niveles de PCR, se encontraron \ndiferencia significativas, teniendo aquellos pacientes con \nPCR mas elevada mayor riesgo de p\u00e9rdida de extremidad.Tabla I: Datos demogr\u00e1ficos de la poblaci\u00f3n a estudio.\nEdad media: a\u00f1os +/- desviaci\u00f3n est\u00e1ndar  68,72 +/- 10,9\nSexo (masculino): n (%)  207 (79,3%)\nTabaquismo: n (%)  197 (75,5%)\nHipertensi\u00f3n arterial: n (%)  228 (87,4%)\nDiabetes mellitus: n (%) 178 (68,2%)\nEnfermedad renal cr\u00f3nica: n (%)  87 (33,3%)\nEnfermedad coronaria: n (%)  102 (39,1%)\nEnfermedad cerebro vascular: n (%)  32 (12,3%)\nDislipemia: n (%)  189 (72,4%)\nTipo de intervenci\u00f3n quir\u00fargica   \n   Endovascular: n (%) 158 (60,5%)\n   Convencional: n (%)  103 (39,5%)Sensibilidad\nSensibilidadImagen 5: Salvamento de Extremidad seg\u00fan valor de PCR.\nImagen 3\n100\n90\n80\n70\n60\n50\n40\n30\n20\n10\n01,1\n1\n0,9\n0,8\n0,7\n0,6\n0,5\n0,4\n0,3\n0,2\n0,1\n0\n0 12345678910111213141516171819202122232425262728 0,05 0,10,15 0,20,25 0,30,35 0,40,45\n1. Especificidad0,50,55 0,60,65 0,70,75 0,80,85 1 0,90,95PCR 3,03\nAUC 0,65 (0,61-0,75)\nSensibilidad 71%\nEspecificidad 63%Imagen 1: Curva ROC INL.Sensibilidad100\n90\n80\n70\n60\n50\n40\n30\n20\n10\n0\n00,05 0,10,15 0,20,25 0,30,35 0,40,45\n1. Especificidad0,50,55 0,60,65 0,70,75 0,80,85 0,9INL 3,2\nAUC 0,65 (0,51-0,78)\nSensibilidad 71%\nEspecificidad 57%SensibilidadImagen 2\n100\n90\n80\n70\n60\n50\n40\n30\n20\n10\n0\n00,05 0,10,15 0,20,25 0,30,35 0,40,45\n1. Especificidad0,50,55 0,60,65 0,70,75 0,80,85 0,9IPL 160\nAUC 0,59 (0,55-0,78)\nSensibilidad 68%\nEspecificidad 56%\nSeguimiento (meses)PCR>3,03 PCR<3,03Imagen 4: Curva de supervivencia global.Supervivencia acumulada\nSeguimiento (meses)1,0\n0,8\n0,6\n0,4\n0,2\n0,0\n,00 5,00 10,00 15,00 20,00 25,00 30,0020\n2021/36 (3): 17-21David Santiago Garc\u00eda  et al.  \nDiscusi\u00f3n \nEn este estudio se concluye que un valor de PCR \nmayor de 3,03 mg/dl en la anal\u00edtica postoperatoria se \nrelaciona con un riesgo incrementado de amputaci\u00f3n, \nesto ya que incluso tras ajustar para otros factores \nde riesgo conocidos como diabetes o consumo de \ntabaco, un valor de PCR mayor de 3,03 mg/dl se \nasocia con un incremento de 2,56 veces en el riesgo \nde amputaci\u00f3n mayor. La diabetes mellitus tambi\u00e9n se \npresenta como un factor pron\u00f3stico de amputaci\u00f3n tras \nrevascularizaci\u00f3n. Otros marcadores analizados como \nel INL o el IPL tambi\u00e9n se mostraron una tendencia a \nactuar como factores asociados con el salvamento de \nla extremidad, aunque las relaciones no presentaron \nsignificaci\u00f3n estad\u00edstica.\nLa inflamaci\u00f3n es un proceso fundamental en el desarrollo \ny evoluci\u00f3n de la patolog\u00eda ateroscler\u00f3tica, y los m\u00faltiples \nmediadores que intervienen en la misma pueden \nservir como marcadores pron\u00f3sticos de la evoluci\u00f3n \npostoperatoria de aquellos pacientes con ICE. De todos \nellos en nuestro estudio hemos analizado la influencia de \nla PCR y diversos mediadores de la inmunidad celular \nvalorados mediante los \u00edndices INL e IPL.\nLa PCR es un mediador inflamatorio de producci\u00f3n \nhep\u00e1tica y relacionado con el desarrollo de ICE20. Se ha \ndemostrado que act\u00faa como mediador en la acumulaci\u00f3n \nde l\u00edpidos a nivel de placa por parte de los macr\u00f3fagos \nmediante la activaci\u00f3n de receptores scavenger21. Si bien \nla evidencia existente hasta el momento ha relacionado \nniveles elevados de PCR con la progresi\u00f3n de la EAP \nhacia ICE, no existen hasta donde conocemos estudios \nque la relacionen como factor pron\u00f3stico del salvamento \nde la extremidad tras revascularizaci\u00f3n a nivel de sector \nfemoro-popl\u00edteo y de troncos distales, tomando en \ncuenta la necesidad de intervenciones endovasculares \no de cirug\u00eda abierta. \nLos leucocitos en general juegan un rol importante en \nel desarrollo de lesiones ateroscler\u00f3ticas, especialmente \nen la deposici\u00f3n lip\u00eddica en la placa, y las plaquetas se \nhallan en relaci\u00f3n directa con el proceso inestabilidad y \nrotura de la placa3. El INL y el IPL se obtienen a partir de \nlas concentraciones absolutas de neutr\u00f3filos, linfocitos \ny plaquetas todos estos valores f\u00e1cilmente obtenidos \nmediante una anal\u00edtica sangu\u00ednea.\nDesde el punto de vista fisiopatol\u00f3gico los neutr\u00f3filos \nmedian la respuesta inflamatoria por mecanismos como \nla liberaci\u00f3n de metabolitos del \u00e1cido araquid\u00f3nico, \nmientras que la linfopenia reactiva refleja la producci\u00f3n \nde cortisol inducida como respuesta al estr\u00e9s, y tambi\u00e9n \npor la activaci\u00f3n de mecanismos de apoptosis a nivel \nde placa ateromatosa12. Los linfocitos tambi\u00e9n se han \nasociado con el desarrollo de circulaci\u00f3n colateral por medio de la IL-16 en modelos murinos16. Es por ello que \nla relaci\u00f3n entre neutr\u00f3filos y linfocitos en una muestra \nde sangre perif\u00e9rica puede darnos una idea del estado \nproinflamatorio en los pacientes afectados de ICE, lo que \nsirve como un marcador indirecto de la severidad de la \nenfermedad ateroscler\u00f3tica.\nAdem\u00e1s las plaquetas tambi\u00e9n se relacionan con el \ngrado de respuesta inflamatoria sist\u00e9mica y la presencia \nde trombocitosis se ha reportado como un marcador \npron\u00f3stico adverso en pacientes con enfermedad \narterial perif\u00e9rica17. La fase proinflamatoria asociada con \nla liberaci\u00f3n de IL-1, IL-3 e IL 6 incrementa la cantidad de \nplaquetas circulantes16. Por lo tanto si tenemos en cuenta \nla linfopenia reactiva de los pacientes con aterosclerosis, \nla relaci\u00f3n entre plaquetas y linfocitos puede ser de \nutilidad para la valoraci\u00f3n del estado inflamatorio a nivel \nendoluminal y, como tal de la evoluci\u00f3n de la enfermedad \ntras la aplicaci\u00f3n de una medida terap\u00e9utica.\nConclusi\u00f3n \nLos resultados de este estudio se\u00f1alan que el estado \ninflamatorio en el perioperatorio de los pacientes con \nisquemia cr\u00edtica que son sometidos a revascularizaci\u00f3n \npuede ser un factor pron\u00f3stico de salvamento de \nextremidad. En nuestro estudio la PCR postoperatoria \nelevada > 3,03 mg/dl se asoci\u00f3 con una mayor \nfrecuencia de amputaci\u00f3n.\nOtros marcadores del estado inflamatorio del paciente \npueden ser de utilidad debido a que son f\u00e1cilmente \nobtenidos a partir de la anal\u00edtica sangu\u00ednea, y aunque \nno han presentado resultados estad\u00edsticamente \nsignificativos, se requieren estudios encaminados a \nanalizar su rol como marcadores con mayor tama\u00f1o \nmuestral o estratificados en base al tipo de intervenci\u00f3n \npara dilucidar su posible utilidad.21\n2021/36 (3): 17-21Efecto del estado inflamatorio perioperatorio en el salvamento de extremidad de los pacientes con isquemia cr\u00edtica sometidos a revascularizaci\u00f3n infrainguinal\nBibliograf\u00eda\n1. Fowkes FGR, Aboyans V, Fowkes FJI, McDermott MM, Sampson \nUKA, Criqui MH. Peripheral artery disease: epidemiology and global \nperspectives. Nature Reviews Cardiology. 2016;14(3):156-70, Doi: \n10.1038/nrcardio.2016.179. \n2. Olin JW, Sealove BA. Peripheral Artery Disease: Current Insight Into the \nDisease and Its Diagnosis and Management. Mayo Clinic Proceedings. \n2010;85(7):678, Doi: 10.4065/MCP .2010.0133. \n \n3. Novo S, Coppola G, Milio G. Critical Limb Ischemia: Definition and \nNatural History. Current Drug Target -Cardiovascular & Hematological \nDisorders. 2004;4(3):219\u201325, Doi: 10.2174/1568006043335989. \n4. Ross R. Atherosclerosis \u2014 An Inflammatory Disease. New \nEngland Journal of Medicine. 1999;340(2):115-26, Doi: 10.1056/\nNEJM199901143400207. \n \n5. Ridker PM, Stampfer MJ, Rifai N. Novel Risk Factors for Systemic \nAtherosclerosis. JAMA. 2001;285(19):2481, Doi: 10.1001/\njama.285.19.2481. \n \n6. Amrock SM, Weitzman M. Multiple biomarkers for mortality \nprediction in peripheral arterial disease. Vascular Medicine. 2016, Doi: \n10.1177/1358863X15621797. \n \n7. Montgomery JE, Brown JR. Metabolic biomarkers for predicting \ncardiovascular disease. Vascular health and risk management. 2013, \nDoi: 10.2147/VHRM.S30378. \n8. DeSart K, O\u2019Malley K, Schmit B, Lopez M-C, Moldawer L, Baker H, et \nal. Systemic inflammation as a predictor of clinical outcomes after lower \nextremity angioplasty/stenting. Journal of vascular surgery. 2015, Doi: \n10.1016/j.jvs.2015.04.399. \n \n9. Harris SK, Roos MG, Landry GJ. Statin use in patients with peripheral \narterial disease. Journal of Vascular Surgery. 2016;64(6):1881\u20138, Doi: \n10.1016/j.jvs.2016.08.094. \n \n10. Ridker PM, Cushman M, Stampfer MJ, Tracy RP , Hennekens CH. \nPlasma Concentration of C-Reactive Protein and Risk of Developing \nPeripheral Vascular Disease. Circulation. 1998;97(5):425-8. \n \n11. Luo H, Yuan D, Yang H, Yukui M, Huang B, Yang Y, et al. Post-\ntreatment neutrophil-lymphocyte ratio independently predicts amputation \nin critical limb ischemia without operation. Clinics (Sao Paulo). 2015, Doi: \n10.6061/clinics/2015(04)09. \n \n12.Gary T, Pichler M, Belaj K, Hafner F, Gerger A, Froehlich H, et al. \nNeutrophil-to-Lymphocyte Ratio and Its Association with Critical Limb \nIschemia in PAOD Patients. PLoS ONE. 2013, Doi: 10.1371/journal.\npone.0056745. 13. Chan C, Puckridge P , Ullah S, Delaney C, Spark JI. Neutrophil-\nlymphocyte ratio as a prognostic marker of outcome in infrapopliteal \npercutaneous interventions for critical limb ischemia. Journal of Vascular \nSurgery. 2014, Doi: 10.1016/j.jvs.2014.03.277. \n \n14. Arbel Y, Finkelstein A, Halkin A, Birati EY, Revivo M, Zuzut \nM, et al. Neutrophil/lymphocyte ratio is related to the severity of \ncoronary artery disease and clinical outcome in patients undergoing \nangiography. Atherosclerosis. 2012;225(2):456-60, Doi: 10.1016/j.\natherosclerosis.2012.09.009. \n \n15. Erturk M, Cakmak HA, Surgit O, Celik O, Aksu HU, Akgul O, et al. \nThe predictive value of elevated neutrophil to lymphocyte ratio for long-\nterm cardiovascular mortality in peripheral arterial occlusive disease. \nJournal of Cardiology. 2014, Doi: 10.1016/j.jjcc.2014.02.019. \n \n16. Tasoglu I, Sert D, Colak N, Uzun A, Songur M, Ecevit A. Neutrophil-\nlymphocyte ratio and the platelet-lymphocyte ratio predict the limb survival \nin critical limb ischemia. Clinical and applied thrombosis/hemostasis: \nofficial journal of the International Academy of Clinical and Applied \nThrombosis/Hemostasis. 2014, Doi: 10.1177/1076029613475474. \n \n17. Gary T, Pichler M, Belaj K, Hafner F, Gerger A, Froehlich H, et al. \nPlatelet-to-Lymphocyte Ratio: A Novel Marker for Critical Limb Ischemia \nin Peripheral Arterial Occlusive Disease Patients. PLoS ONE. 2013, Doi: \n10.1371/journal.pone.0067688. \n18. Joviliano EE, Piccinato CE, Dellalibera-Joviliano R, Moriya T, \u00c9vora \nPRB. Inflammatory markers and restenosis in peripheral percutaneous \nangioplasty with intravascular stenting: Current concepts. Annals of \nvascular surgery. 2011, Doi: 10.1016/j.avsg.2011.02.026. \n \n19.Gary T, Pichler M, Belaj K, Eller P , Hafner F, Gerger A, et al. \nLymphocyte-to-monocyte ratio: A novel marker for critical limb ischemia \nin PAOD patients. International Journal of Clinical Practice. 2014, Doi: \n10.1111/ijcp.12495. \n20. Nakazawa KR, Wengerter SP , Power JR, Lookstein RA, Tadros RO, \nTing W, et al. Preoperative inflammatory status as a predictor of primary \npatency after femoropopliteal stent implantation. Journal of Vascular \nSurgery. 2017;66(1):151-9, Doi: 10.1016/j.jvs.2017.01.031. \n \n21. Tousoulis D, Oikonomou E, Economou EK, Crea F, Kaski JC. \nInflammatory cytokines in atherosclerosis: current therapeutic \napproaches. European Heart Journal. 2016;37(22):1723-32, Doi: \n10.1093/eurheartj/ehv759. 22\n2021/36 (3): 22-28ORIGINAL\nEffect of sesame oil extraction by traditional \nand cold press methods on total aflatoxin content\nEfecto de la extracci\u00f3n de aceite de s\u00e9samo por m\u00e9todos tradicionales \ny de prensado en fr\u00edo sobre el contenido total de aflatoxinas \nNader Akbari1      , Masoud Sami2      , Zahra Esfandiari3      , Mohammad Javad Tarrahi4\n1. MSc Student, Department of Food Science and Technology, School of Nutrition and Food Science, Student Research \nCommittee, Isfahan University of Medical Sciences, Isfahan, Iran   2. Associate Professor, Food Security Research Center, Department \nof Food Science and Technology, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran    \n3. Assistant Professor, Food Security Research Center, Department of Food Science and Technology, School of Nutrition and \nFood Science, Isfahan University of Medical Sciences, Isfahan, Iran   4.Associate Professor, Department of Epidemiology and \nBiostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, IraneISSN 2255-0569\nReceived:  9 - IV - 2021\nAccepted:  5 - V - 2021\ndoi: 10.3306/AJHS.2021.36.03.22Corresponding author\nMasoud Sami  \nDepartment of Food science and Technology, School of Nutrition \nand Food Science, Isfahan University of Medical Sciences, \nIsfahan, Iran. Postal code: 8174673461\nE-mail: Masoud_sami@nutr.mui.ac.irID ID ID ID\nAbstract  \nBackground:  Aflatoxin contamination is an undesirable issue in the oil industry. Methods of extraction have efficient effects on the \naflatoxin contents of achieved oil. \nAim: The present survey was performed to assess the effects of traditional and cold press extraction methods on the aflatoxin \ncontents of sesame oil. \nMethods: A total of 17 crude sesame, 17 unfiltered oil, and 17 filtered oil samples were collected from different steps of oil \nproduction by cold press. Additionally, a total of 9 crude sesame, 9 unfiltered oil, and 9 filtered oil samples were collected from \ndifferent steps of oil production by the traditional method. All samples were tested for aflatoxins B1, B2, G1, and G2 . Aflatoxin content \nwas determined by high-performance liquid chromatography. \nResults:  Dehulling reduced total aflatoxin as 79.79%. Traditional and cold press procedures caused 8.2% and 70.22% transferring \nof total aflatoxin from crude sesame to achieved oil, respectively. \nConclusion:  Traditional method was more effective than cold press in decreasing aflatoxin contents of achieved sesame oil.\nKeywords:  Sesame, oil extraction, traditional method, cold press, aflatoxin content.\nResumen\nAntecedentes:  La contaminaci\u00f3n por aflatoxinas es un problema indeseable en la industria del aceite. Los m\u00e9todos de extracci\u00f3n \ntienen efectos eficaces sobre el contenido de aflatoxinas del aceite obtenido. \nObjetivo:  El presente estudio se realiz\u00f3 para evaluar los efectos de los m\u00e9todos de extracci\u00f3n tradicionales y de prensado en fr\u00edo \nsobre el contenido de aflatoxinas del aceite de s\u00e9samo. \nMetodolog\u00eda:  Se recogieron un total de 17 muestras de aceite crudo de s\u00e9samo, 17 de aceite sin filtrar y 17 de aceite filtrado, \nprocedentes de diferentes etapas de la producci\u00f3n de aceite por prensado en fr\u00edo. Adem\u00e1s, se recogieron un total de 9 muestras \nde s\u00e9samo crudo, 9 de aceite sin filtrar y 9 de aceite filtrado de diferentes etapas de la producci\u00f3n de aceite por el m\u00e9todo \ntradicional. Todas las muestras fueron analizadas para detectar aflatoxinas B1, B2, G1 y G2 . El contenido de aflatoxinas se determin\u00f3 \nmediante cromatograf\u00eda l\u00edquida de alto rendimiento. \nResultados: El descascarillado redujo el total de aflatoxinas en un 79,79%. Los procedimientos tradicional y de prensado en fr\u00edo \nprovocaron una transferencia del 8,2% y del 70,22% del total de aflatoxinas del s\u00e9samo crudo al aceite obtenido, respectivamente. \nConclusiones: El m\u00e9todo tradicional fue m\u00e1s eficaz que el prensado en fr\u00edo para reducir el contenido de aflatoxinas en el aceite \nde s\u00e9samo obtenido.\nPalabras clave:  S\u00e9samo, extracci\u00f3n de aceite, m\u00e9todo tradicional, prensado en fr\u00edo, contenido de aflatoxinas.23\n2021/36 (3): 22-28 Effect of sesame oil extraction by traditional and cold press methods on total aflatoxin content\nIntroduction  \nFood security is one of the most critical challenges in the \npresent century1-5. Edible oil is among the most commonly \nused food products playing a crucial factor in human \nhealth. Vegetable oils have an essential role in health \nstatus. Impurities and contamination of vegetable oils may \nvary based on the materials, weather, soil, harvesting, \nstorage and processing. Also different oil extraction \nmethods including organic solvent, water (traditional) \nand press effect on the transferring contamination from \nmaterials to the final product. Given consumers\u2019 concerns \nabout chemicals used in food products, oil extraction by \nwater and press has been much-paid attention. Sesame \n(Sesamum indicum L.) is an oilseed cultivated in tropical \nand temperate regions. Sesame oil is known as the \nqueen of oilseeds due to its high-quality oil6. Sesame oil \nis one of the most widely used products as 4756000 t \nsesame oil was produced in 2013 worldwide7. This kind \nof oil is extracted by traditional, cold press, and solvent \nmethods. Diagram of sesame oil exaction by traditional \nand cold press methods are shown in figure 1 .\nWater flotation is a traditional method in Iran and Sudan \nfor the extraction of sesame oil. Sesame seed is heated \nto 110\u00b0C for 10 min and milled. Enough boiling water \nis then added to suspend the ground seed on stirring. \nThe mixture is boiled with stirring for 15 min. After \ncooling, the upper oil layer is separated off and dried by \nheating. The oil recovery from 0.5 kg seed is 108 ml, \nequivalent to an oil extraction efficiency of 41%8. Cold press is a popular method of sesame oil extraction in \nIran where no chemicals, solvent or additives are used, \nand it is produced in the presence of customers in some \nshops9. However, the product\u2019s safety is not assessed \nin Iran and aflatoxin is produced under improper storage \nconditions. Sesame oil contamination with aflatoxin has \nbeen reported in China, Sudan, and Senegal10.\nMaterials for edible oil production are often stored under \nsuch conditions for weeks that promote the growth \nof moulds producing mycotoxin aflatoxins such as \nAspergillus flavus , A. parasiticus  and A. nomius  naturally \noccurring in foods. Among 18 known aflatoxins, B1, B2, G1 \nand G2 are classified in group A of carcinogenic factors by \nInternational Agency for Research on Cancer (IARC)11,12. \nGiven the harmful effects of aflatoxins on public health, \nmost studies on mycotoxins are presently concentrated \non aflatoxin13. Furthermore, aflatoxin is continuously \nmonitored in most products by health monitoring \nsystems. Thus, the various national and international \nstandard for the permitted limit of aflatoxin in food \nproducts has been developed14-17. Aflatoxin produced \nin oilseeds may be transferred to the final oil product. \nHowever, the concentration of these contaminants can \nbe reduced through the processing method (extraction \nand purification). Traditional and cold press extraction \nare the two most widely used extraction techniques in \nIran. This study aimed to examine the effect of different \nprocesses in sesame oil extraction using traditional and \ncold press methods on total aflatoxin content.\nMaterials and methods  \nSampling\nSufficient amount of sesame seeds were collected from \nsesame oil extraction shops in Isfahan, Iran. Sesame oil \nwas extracted by traditional method including washing, \ndehulling, roasting (110\u00baC, 10 min) and oil extraction \nsteps. The collected sesame seeds were processed \nby the traditional oil extraction method. In addition to 9 \nsamples of raw sesame seeds, 9 samples were collected \nfrom each of the stages of washing, peeling, roasting and \noil production. Moreover, 17 raw sesame seeds samples \nwere collected from 17 cold press extraction shops in \nIsfahan, Iran. First, aflatoxin content in the raw seeds was \ndetermined, then the aflatoxin levels of the extracted oil \nsamples were measured, and finally aflatoxin content \nof the filtered oil was determined. For a complementary \nassessment, 19 filtered oil samples obtained by the cold \npress extraction were collected, the aflatoxin content was \ndetermined, and the results were reported. \nThe amounts of aflatoxins B1, B2, G1 and G2 in the \nsamples were measured according to Iranian national \nstandard No. 6872 (ISIRI, 2004). This analysis included \nthree steps of purification, detection and determination. \nThe toxins were purified by using immunoaffinity columns. Figure 1: Diagram of sesame oil exaction by traditional and cold press methods.\nSesame seeds\nCleaning\nWashed and dehulled\nRoast (110\u00baC, 10min)\nMilling\nStirring in hot water\nSesame oil extraction \nby traditonial methodSeparation of oil by\ngravitation or centrifugationSesame \npasteOil extraction \nwith expeller\nUnfiltered\nsesame oil\nFiltered\nsesame oil\n(Sesame oil extraction\nby cold press method)24\n2021/36 (3): 22-28Nader Akbari et al.  \nThey were detected by Kobra cell and determined by use \nof florescence detector at 365 nm excitation wavelength \nand 435nm emission wavelength. The procedure was \nvalidated via spiking with different levels of aflatoxins B1, \nB2, G1, and G2 and then efficacy parameters such as \nlinearity, accuracy, precision and limit of detection (LOD) \nwere measured. The validity of method was confirmed \nand it was used for our purpose.\nCalibration and standard curve drawing\nTo draw the calibration curve, 1 mg of each aflatoxin pure \npowder was dissolved in 5 ml toluene: acetonitrile (90: \n10) and a standard solution (200 \u00b5g/ml) was prepared. \nAfter dilution, four standard solutions were obtained from \nthe secondary standard solution and injected into High-\nPerformance Liquid Chromatography (HPLC). To prepare \nmobile phase solvent, water: acetonitrile: methanol \n(6:2:3) were mixed, and 300 \u00b5L 4M nitric acid and 120 \nmg potassium bromide were added per L mobile phase. \nThe samples were extracted with 200 mL 80% methanol \nand 5 g salt. The mixture was filtered and added to 130 \nmL water to obtain 150 mL diluted extract.\nAflatoxin measurement\nThe samples were purified using immunoaffinity columns \n(IAC) with antibodies against aflatoxins B1, B2, G1, and \nG2 and a vacuum Manifold system. The first 70 mL of \nthe solution passed through the column. Afterwards, \nthe column was washed with double distilled water. \nThe column was dried, and aflatoxins B1, B2, G1 and \nG2 were removed with 1500 \u00b5L distilled water as 100 \nML were injected into HPLC. To examine the accuracy \nand precision of the applied method, a control sample \nwas spiked with aflatoxin B1 and was analyzed with the \ntest samples. A calibration curve was drawn every day \nusing 4 standards, and then the samples were injected, \nand aflatoxin content was determined. Principles of the \nprevious survey were applied19.\nRecovery\nTo calculate the recovery, a certain amount of \nstandard solution of aflatoxin was added to control the \ncontaminated sample then was injected into HPLC and \naflatoxin content was calculated by the following relation:\nR= (CSample spike \u2013 CSample)*100/Cspike \n \nWhere R is recovery value, and C sample spike is aflatoxin \nconcentration in the contaminated sample. \nLOD and LOQ \nThe detection limit (LOD) and limit of quantitation (LOQ) \nwere used to calculate the method\u2019s sensitivity. LOD \nis the lowest concentration in a detectable matrix but \ncannot be measured precisely, and LOQ is the lowest \nconcentration that is detectable and measurable \nprecisely. These parameters were calculated by using \nthe calibration curve. To do so, calibration gradient (a) and standard deviation of \nindependent variable regression (Sb) were put in LOD=3* \nSb/a equation and LOQ=10* Sb/a and LOD and LOQ \nwere calculated. \nStatistical analysis \nData were analyzed by SPSS software version 20 \n(Chicago, IL, version, SPSS Inc). Mean, and standard \ndeviation was presented in frequency distribution tables. \nTotal aflatoxin mean was compared to International and \nnational standard by one-sample t-test20-22. Aflatoxin \nmean in different steps of oil extraction was compared by \nWilcoxon signed ranks test.\nResults  \nStandard curve  \nAflatoxins B1, B2, G1 and G2 were analyzed by four \nstandard solutions at 1, 3, 5 and 7 ppm. An example of \nchromatograms is shown in figure 2. As illustrated in the \nfigure, the peak is in a proper form with a retention time \nof about 4 min.\nFigure 2: Chromatogram using 1ppm by HPLC.\nFigure 3: Calibration curve of Aflatoxin B.\n1,6\n1,4\n1,2\n1\n0,8\n0 2 4 6 8 10 12 14 16min\n60\n50\n40\n30\n20\n10\n00 2 4 6 8Calibration curve\nDistrict\ny=8.1555 x -2,5693\nR2 = 0,998LinearArea\nConcentrations25\n2021/36 (3): 22-28 Effect of sesame oil extraction by traditional and cold press methods on total aflatoxin content\nCalibration curve  \nThe calibration curve of aflatoxin is shown in figure 3 . \nThe calibration curve results revealed a linear relationship \nbetween different concentrations of aflatoxin B1, B2, G1 \nand G2 and area under the curve with the correlation \ncoefficient (r) of all calibration curves being > 0.998.\nResults of recovery \nResults of validation by spiking sesame and its oil with \naflatoxins B1, B2, G1 and G2 were studied. The amounts \nof spiking of aflatoxins B1, B2, G1 and G2 in examined \nsamples were 1, 1, 1, and 1 ppb, respectively. The \namounts of aflatoxins B1, B2, G1 and G2 in examined \nsamples were 133, 1.099, 1.155, and 1.127 ppb, \nrespectively. Additionally, the recovery rates of aflatoxins \nB1, B2, G1 and G2 in examined samples were 133%, \n109.9%, 155.5% and 112.7%, respectively. \nResults of LOD and LOQ \nThe lowest LOQ for aflatoxins B1 and G1 was<0.5, and \naflatoxins B2 and G2 were <0/1. The lowest LOD for B1 \nand G1 was<0/16, and B2 and G2 was <0.03, being the \nlowest LOD. \nResults of aflatoxin measurement in oil \nextracted by cold press \nMinimum, maximum and mean contents of four aflatoxins \nB1, B2, G1 and G2 are displayed in table I . In the present \nstudy, 25 samples showed 69.4% aflatoxin contamination \nwith the mean value being 1.337\u00b1 0.329 ppb. Total \naflatoxin content in all samples ranges < LOQ to 3.1 ppb. \nComparison of the result to Iranian national standard for total aflatoxin (15 ppb) suggest that it is lower than the \nspecified amount. Mean aflatoxin B1 contamination was \n0.437\u00b10.33. Aflatoxin B1 contamination was found in \n27.8% of the samples. Aflatoxin B2 contamination in the \nsamples was 0.106\u00b10.033 ppb. There was no aflatoxin \nG1 and G2 in the samples. In the present study, total \naflatoxin, B1 and B2 contents were 1.337\u00b10.329 ppb, \n0.473\u00b1 0.426 ppb and 0.33\u00b10.106, respectively. G1 \nand G2 content was zero. Only one sample showed B1 \ncontent higher than the amount permitted by EU (2 ppb).  \nEffect of cold press method \non aflatoxin content in the extracted sesame oil\nMaximum, minimum, mean and standard deviation of \nfour aflatoxins B1, B2, G1, and G2 in different steps of \noil extraction by cold press are presented in table II . \nThe mean of total aflatoxin in crude sesame, extracted \noil and filtered oil was 1.88\u00b11.15 ppb, 1.32\u00b10.32 ppb \nand 1.21\u00b1 0.032 ppb, respectively. Mean aflatoxin \nB1 contents in crude sesame, oil, and filtered oil were \n1.31\u00b10.865 ppb, 0.421\u00b10.34 ppb, and 0.192\u00b10.23 \nppb, respectively. Mean aflatoxin B2 in crude sesame \nand oil was 0.224\u00b10.31 ppb and 0.107\u00b10.032 ppb, \nrespectively. Aflatoxin B2 in filtered oil was < LOQ. No \naflatoxins G1 and G2 were found in the samples. Total \naflatoxin, B1 and B2 in oil samples extracted by cold press \nwere 63.5, 48.68, and 12.06, respectively. These toxins \nshowed 8.33, 54.39 and 10% significant decrease in \nfiltered oil, respectively. As shown in the table, extraction \nsteps and filtration reduced total aflatoxin, B1 and B2, \nas cold press method resulted in 35.63%, 77.80% and \n59.83% decrease in total aflatoxin, B1 and B2.\nTable I: Max., Min., Mean, and SD of four aflatoxins B1, B2, G1 and G2 in sesame oil produced by cold press.\nAflatoxin type Min Max Mean\u00b1SD Contaminated oil Non-contaminated oils\nB1 < LOQ* 2.3 0.473\u00b10.426 69.4 25 30.6 11\nB2 < LOQ 0.2 0.106\u00b10.033 27.8 10 72.2 26\nG1 < LOQ < LOQ < LOQ 0 0 0 0\nG2 < LOQ < LOQ < LOQ 0 0 0 0\nTotal aflatoxin  < LOQ 3.1 1.337\u00b10.329 69.4 25 30.6 11\n*LOQ: limit of quantitation (B1, G1= 0.5 ppb   B2, G2= 0.1 ppb)\nTable II: Max., Min., Mean, and SD of four aflatoxins B1, B2, G1 and G2 in different steps of oil production by cold press.\nSample Type Sample number Aflatoxin type Min Max Mean\u00b1SD\n  B1 < LOQ* 4.57 0.865\u00b11.31\n  B2 < LOQ 1.35 0.224\u00b10.31\nCrude Sesame  17 G1 < LOQ < LOQ < LOQ\n  G2 < LOQ < LOQ < LOQ\n  Total <1/2 5.67 1.88\u00b11.15\n  B1 < LOQ 1.04 0.421\u00b10.34\n  B2 < LOQ 0.19 0.107\u00b10.032\nUnfiltered Oil  17 G1 < LOQ < LOQ < LOQ\n  G2 < LOQ < LOQ < LOQ\n  Total <1/2 1.75 1.32\u00b10.15\n  B1 < LOQ 0.63 0.192\u00b10.23\n  B\u00b2 < LOQ < LOQ < LOQ\nFiltered Oil  17 G1 < LOQ < LOQ < LOQ\n  G2 < LOQ < LOQ < LOQ\n  Total <1/2 1.33 1.21\u00b10.032\n*LOQ: Limit Of Quantitation (B1, G1= 0.5 ppb   B2, G2= 0.1 ppb.26\n2021/36 (3): 22-28Nader Akbari et al.  \nEffect of traditional water method \non aflatoxin content in the extracted sesame oil\nMaximum, minimum, mean and standard deviation of four \naflatoxins B1, B2, G1 and G2 in different steps of the oil \nextraction by traditional method are presented in table III . \nMean total aflatoxin in crude sesame, dehulled sesame, \nroasted sesame, and oil was 17.46\u00b113.35, 3.53\u00b12.17, \n2.86\u00b11.33 and 1.43\u00b10.628 ppb, respectively. Mean \naflatoxin B1 in crude sesame, dehulled sesame, roasted \nsesame and oil was 16.1\u00b112.946, 2.71\u00b12.04, 2.07\u00b11.26 \nand 0.36\u00b10.74 ppb, respectively, and mean aflatoxin B2 \nwas 0.77\u00b10.605, 0.21\u00b10.135, 0.18\u00b10.09 and 0.11 \n\u00b10.48 ppb, respectively. No G1 and G2 were found in \nthe samples. Dehulling resulted in 79.79%, 86.95% and \n72.72% in total aflatoxin, B1 and B2, respectively. However \nroasting at 110\u00baC had no significant (p>0.05) effect on \naflatoxin decrease. Traditional (water) method resulted in \n91.80%, 97.76%, and 85.71% decrease in total aflatoxin, \nB1 and B\u00b2, respectively. Comparative results of total \naflatoxin, B1 and B2 measurement in different steps of oil \nextraction by traditional method.\nEffect of cold press and traditional method \non aflatoxin content in the extracted sesame oil\nThe method of edible oil extraction may affect aflatoxin \ndecrease depending on the type of oil, extraction and \npurification methods. There were no studies on the \neffect of the sesame oil extraction process, so studies \non similar oilseeds were used. Filtration resulted in 8.33, \n54.39 and 100% decrease in total aflatoxin, B1 and B2 \nin sesame oil produced by the cold press method. Cold \npress and filtration decreased total aflatoxin, B1 and B2. \nDiscussion  \nAflatoxin contamination is an undesirable issue in the oil \nindustry. Consumption of oil contained diverse aflatoxin levels caused severe health-related complications, \nincluding cancer, neoplasia, mutations, hepatic toxicities, \nrenal failure, abortion and even fetal malformation23. \nThus, it is essential to control the aflatoxin content of \nedible oils. The oil extraction stage from seeds is one \nof the most significant steps in controlling aflatoxin in \nachieved oils10. Several reports disclosed that the oil \nextraction method caused significant effects on the \naflatoxin contents of oils10,24. \nThe present survey was performed to assess sesame oil \nextraction by traditional and cold press methods on total \naflatoxin contents of achieved oil. The present research \nfindings disclosed that the traditional method of sesame \noil extraction was more effective in reducing aflatoxin \ncontents than the cold-press technique. One of the main \nreasons for the high aflatoxin contamination in sesame \noil samples may be attributed to unhygienic conditions \nof the sesame oil extraction in producing units. Thus, \ngood hygiene, safety and supervision in the sesame oil-\nproducing units may be crucial to decrease the aflatoxin \ncontent of sesame oil. Additionally, using high-quality \nsesame is another way to decrease the risk of aflatoxin \nresidues in achieved oil. Aflatoxin content found in the \npresent investigation was within the range permitted by \nthe Iranian national standard. However, regarding the daily \nconsumption of contaminated sesame oil, this aflatoxin \ncontent may have some health threats to the consumers. \nIn a study conducted in Sudan, aflatoxins B1, B2, G1, and \nG2 contents were measured, and the amount of G1 and \nG2 at present study were inconsistent with their findings, \nwith our found amounts being lower25. A study on aflatoxin \ncontent in edible oils (sesame, peanut, and cottonseed) \nusing HPLC was found that aflatoxin content in all samples \nwas within the permitted limit26.In contrast to our results, \nno aflatoxin B2 was found in samples. Elzupir et al. (2010)27 \ndetermined aflatoxin content in edible oils (unpurified \nsesame oil, cottonseed oil and peanut oil) by HPLC. In \nTable III: Max., Min., Mean, and SD of four aflatoxins B1, B2, G1 and G2 in different steps of oil production by the traditional method.\nSample Type Sample number Aflatoxin type Min (ppb) Max (ppb) Mean\u00b1SD  (ppb)\n  B1 1.8 40.5 16.1\u00b112.94\n  B2 0.1 1.9 0.77\u00b10.605\nCrude Sesame  9 G1 < LOQ* < LOQ < LOQ\n  G2 < LOQ < LOQ < LOQ\n  Total 2.4 41.9 17.46\u00b113.35\n  B1 0.65 6.4 2.71\u00b12.04\nWashed   B2 < LOQ 0.5 0.21\u00b10.135\nand dehulled  9 G1 < LOQ < LOQ < LOQ\nsesame   G2 < LOQ < LOQ < LOQ\n  Total 1.38 7.3 3.53\u00b12.17\n  B1 0.5 4 2.07\u00b11.26\nRoasted   B\u00b2 < LOQ 0.4 0.18\u00b10.09\nsesame  9 G1 < LOQ < LOQ < LOQ\n  G2 < LOQ < LOQ < LOQ\n  Total 1.2 4.8 2.86\u00b11.33\n  B1 < LOQ 2.3 0.36\u00b10.74\n  B2 < LOQ 0.2 0.11\u00b10.048\nOil 9 G1 < LOQ < LOQ < LOQ\n  G2 < LOQ < LOQ < LOQ\n  Total 1.2 3.1 1.43\u00b10.628\n*LOQ: Limit Of Quantitation (B1, G1= 0.5 ppb   B2, G2= 0.1 ppb)    27\n2021/36 (3): 22-28  Effect of sesame oil extraction by traditional and cold press methods on total aflatoxin content\ncontrast to our results, total aflatoxin in all sesame oil was \nabove the level specified by FDA (20 \u00b5g/kg). In their study, \naflatoxins G1 and G2 were found in all samples, while in \nour study, no G1 and G2 were observed in the samples25. \nAsadi et al. (2011)28 measured aflatoxin content in 182 \nsesame samples in Iran. 18/1% of the samples showed \nB1 contamination. Also, 8 samples had aflatoxin B2, and \none sample had G1 and G2. Abalaka (1984)29 studied \naflatoxins in purified and unpurified peanut oil and found \nthat purified oil had no aflatoxins.\nA study on aflatoxin content in peanut was conducted \nin India, and it was found that the cold-press method \nresulted in 85% decrease in total aflatoxin10. Our \nresults are not consistent with the results of the study \nmentioned above. In the present study, washing and \ndehulling decreased total aflatoxin, B1 and B2 significantly, \nwhile roasting at 90-100\u00baC had no significant effect on \naflatoxin. Aflatoxin is resistant to heating as it is degraded \nat 237-306\u00baC30. Jalili (2016)30 studied the effect of \nroasting at different temperatures on aflatoxin content in \npeanut and concluded that roasting at 150\u00baC resulted in \n60.8-79 decrease in B1 and G1 and roasting at 140\u00baC \nresulted in 5.8-64.58 decrease in B1 and G1 and roasting \nat 100\u00baC for 30\u00baC did not affect aflatoxin decrease. \nOur finding was consistent with their results. Arzandeh \nand Jinap (2011)31 examined the effect of roasting on \naflatoxin content in peanut. The results showed that \nroasting at 90-150\u00baC resulted in 78.4, 57.3, 73.9 and \n25.2% decrease in B1, B2, G1, and G2. In another study, \nHussain et al. (2011)32 studied peanut roasting at 150\u00baC for 120 min and observed a noticeable decrease (95%) \nin aflatoxin content. Our results are not in agreement with \ntheir finding. The roasting procedure also had significant \neffects on the aflatoxin degradation among the Nigerian \npeanut seeds33. One of the limitation of our study was the \nlack of similar national or international studies on sesame \noil extraction by water (traditional) and cold press. \nConclusion  \nIn the present study, the traditional method was more \neffective than the cold press in decreasing aflatoxin. \nOne of the main reasons for high aflatoxin contamination \nin sesame oil samples is inappropriate materials storage \nconditions in sesame oil extraction. Thus proper hygiene, \nsafety and supervision are of great importance. In the \npresent study, aflatoxin content was within the Iranian \nnational standard range; however, high contamination in \nthe samples may pose severe threats to human health.\nAcknowledgements    \nThis research was supported by the Research Council \nof Isfahan University of Medical Sciences, Isfahan, \nIran. The authors would like to thank the Food Security \nResearch Center staff, Department of Food Science \nand Technology, School of Nutrition and Food Science, \nIsfahan University of Medical Sciences, Isfahan, Iran, for \ntheir laboratory supports.\nReferences \n1. Dehkordi FS, Valizadeh Y, Birgani TA, Dehkordi KG. Prevalence \nstudy of Brucella melitensis and Brucella abortus in cow\u2019s milk using \ndot enzyme linked immuno sorbent assay and duplex polymerase chain \nreaction. Journal of Pure and Applied Microbiology. 2014;8(2):1065-9.\n2. Abdolmaleki Z, Mashak Z, Dehkordi FS. Phenotypic and genotypic \ncharacterization of antibiotic resistance in the methicillin-resistant \nStaphylococcus aureus strains isolated from hospital cockroaches. \nAntimicrobial Resistance & Infection Control. 2019;8(1):1-4.\n3. Ranjbar R, Farsani FY, Dehkordi FS. Phenotypic analysis of antibiotic \nresistance and genotypic study of the vacA, cagA, iceA, oipA and babA \ngenotypes of the Helicobacter pylori strains isolated from raw milk. \nAntimicrobial Resistance & Infection Control. 2018;7(1):1-4.\n4. Dehkordi FS. Prevalence study of Bovine viral diarrhea virus by \nevaluation of antigen capture ELISA and RT-PCR assay in Bovine, Ovine, \nCaprine, Buffalo and Camel aborted fetuses in Iran. AMB Express. \n2011;1(1):1-6.\n5. Dehkordi FS, Haghighi N, Momtaz H, Rafsanjani MS, Momeni M. \nConventional vs real-time PCR for detection of bovine herpes virus type \n1 in aborted bovine, buffalo and camel foetuses. Bulgarian Journal of \nVeterinary Medicine. 2013;16(2).6. Supriya P , Bhat KV. Genome-wide identification of genes, transcription \nfactors and transposable elements in sesame (Sesamum indicum L.). Int \nJ Curr Microbiol App Sci. 2018;7(2):2362-6. \n7. Mart\u00ednez ML, Bord\u00f3n MG, Lallana RL, Ribotta PD, Maestri DM. \nOptimization of sesame oil extraction by screw-pressing at low \ntemperature. Food and Bioprocess Technology. 2017;10(6):1113-21. \n8. Warra AA. Sesame (sesamum indicum l.) seed oil methods of \nextraction and its prospects in cosmetic industry: a review. Bayero \nJournal of Pure and Applied Sciences. 2011;4(2):164-8. \n9. Hosseini S, Esteri S, Meet V. Evaluation of the effect of the method \nof extracting sesame oil on fatty acid profile, antioxidant capacity and its \noxidative stability. Journal of Innovation in Food Science and Technology, \n2019; 11(1). \n10. Bordin K, Sawada MM, da Costa Rodrigues CE, da Fonseca CR, \nOliveira CA. Incidence of aflatoxins in oil seeds and possible transfer to \noil: a review. Food Engineering Reviews. 2014;6(1-2):20-8. \n11. Mohammad-Hasani F, Mirlohi M, Mosharraf L, Hasanzade A. \nOccurrence of aflatoxins in wheat flour specified for sangak bread and \nits reduction through fermentation and baking. Quality Assurance and \nSafety of Crops & Foods. 2016;8(4):501-7. 28\n2021/36 (3): 22-28Nader Akbari et al.  Effect of sesame oil extraction by traditional and cold press methods on total aflatoxin content\n12. Dehkordi FS, Momtaz H, Doosti A. Application of Real-Time PCR for \ndetection of Aspergillus species in aborted ruminant foetuses. Bulgarian \nJournal of Veterinary Medicine. 2012;15(1):30-6.\n13. Dehghani S, Sami M, Mirlohi M. The contamination of \u201cGaz\u201d to \naflatoxin residue in Isfahan city, Iran. Journal of Isfahan Medical School. \n2016;33(363):2167-71. \n14. Cheraghali AM, Yazdanpanah H, Doraki N, Abouhossain G, Hassibi \nM, Ali-Abadi S, Aliakbarpoor M, Amirahmadi M, Askarian A, Fallah N, \nHashemi T. Incidence of aflatoxins in Iran pistachio nuts. Food and \nChemical Toxicology. 2007;45(5):812-6. \n15. Dini A, Khazaeli P , Roohbakhsh A, Madadlou A, Pourenamdari M, \nSetoodeh L, Askarian A, Doraki N, Farrokhi H, Moradi H, Khodadadi E. \nAflatoxin contamination level in Iran\u2019s pistachio nut during years 2009\u2013\n2011. Food Control. 2013;30(2):540-4.\n16. Jahanmard E, Azarani F, Sharifi M, Esfandiari Z. Aflatoxin in pistachio \nnuts used as ingredients in Gaz sweets produced in Isfahan, Iran. Food \nAdditives & Contaminants: Part B. 2014;7(1):70-3. \n17. Pour RS, Rasti M, Zighamian H, Garmakhani AD. Occurrence of \naflatoxins in pistachio nuts in Esfahan Province of Iran. Journal of Food \nSafety. 2010;30(2):330-40. \n18. ISIRI. Food stuffs, determination of aflatoxins by HPLC and clean up \nby IAC. National standard of Institute of Standard and Industrial Research \nof the Islamic Republic of Iran, 2004.\n19. Nayebpoor F, Momeni M, Dehkordi FS. Incidence of ochratoxin A in \nraw and salted dried fruits using high performance liquid chromatography. \nAmerican Eurosian Journal of Toxicological Science. 2013;5:1-6.\n20. Dehkordi FS, Saberian S, Momtaz H. Detection and segregation \nof Brucella abortus and Brucella melitensis in Aborted Bovine, Ovine, \nCaprine, Buffaloes and Camelid Fetuses by application of conventional \nand real-time polymerase chain reaction. The Thai Journal of Veterinary \nMedicine. 2012;42(1):13.\n21. Nejat S, Momtaz H, Yadegari M, Nejat S, Safarpour Dehkordi F, \nKhamesipour F. Seasonal, geographical, age and breed distributions of \nequine viral arteritis in Iran. Kafkas Univ Vet Fak Derg. 2015;21(1):111-6.\n22. Ranjbar R, Seif A, Safarpoor Dehkordi F. Prevalence of antibiotic \nresistance and distribution of virulence factors in the shiga toxigenic Escherichia coli recovered from hospital food. Jundishapur Journal of \nMicrobiology. 2019;12(5).\n23. Sarma UP , Bhetaria PJ, Devi P , Varma A. Aflatoxins: implications on \nhealth. Indian Journal of Clinical Biochemistry. 2017;32(2):124-33. \n24. Sinha KK. Prevention of aflatoxin production in some cereals and \noil-seeds by natural plant constituents. Irish journal of food science and \ntechnology. 1990:109-20. \n25. Idris YM, Hassan SA, Mariod AA. Physicochemical characteristics \nand aflatoxin levels in two types of Sudanese sesame oil. Journal of the \nAmerican Oil Chemists\u2019 Society. 2013;90(7):989-98. \n26. Idris YM, Mariod AA, Elnour IA, Mohamed AA. Determination of \naflatoxin levels in Sudanese edible oils. Food and Chemical Toxicology. \n2010;48(8-9):2539-41. \n27. Elzupir AO, Suliman MA, Ibrahim IA, Fadul MH, Elhussein AM. \nAflatoxins levels in vegetable oils in Khartoum State, Sudan. Mycotoxin \nResearch. 2010 May;26(2):69-73. \n28. Asadi M, Beheshti HR, Feizy J. A survey of aflatoxins in sesame in \nIran. Mycotoxin Research. 2011;27(4):259. \n29. Abalaka JA. Aflatoxin distribution in edible oil-extracting plants and \nin poultry feedmills. Food and chemical toxicology. 1984;22(6):461-3. \n30. Jalili M. A review on aflatoxins reduction in food. Iranian Journal of \nHealth, Safety and Environment. 2016;3(1):445-59. \n31. Arzandeh S, Jinap S. Effect of initial aflatoxin concentration, heating \ntime and roasting temperature on aflatoxin reduction in contaminated \npeanuts and process optimisation using response surface modelling. \nInternational journal of food science & technology. 2011;46(3):485-91. \n32. Ali J, Hussain A, Ullah S. Studies on contamination level of \naflatoxins in Pakistani rice. Journal of the Chemical Society of Pakistan. \n2011;33(6):481. \n33. Ogunsanwo BM, Faboya OO, Idowu OR, Lawal OS, Bankole SA. \nEffect of roasting on the aflatoxin contents of Nigerian peanut seeds. \nAfrican Journal of Biotechnology. 2004;3(9):451-5. 29\n2021/36 (3): 29-33ORIGINAL\nValues of different index related to cardiovascular risk \naccording the Findrisc test scores in caucasian\nValores de diferentes \u00edndices relacionados con riesgo cardiovascular \nseg\u00fan las puntuaciones del test Findrisc en cauc\u00e1sicos\nHector Orlando Patr\u00f3n Osorno1      , Rub\u00ed Zoe Manzanero Fern\u00e1ndez2      , \nEdmundo Alejandro Ke Aznar1      \n1. Secretary of Health. Universidad Autonoma de Campeche. Mexico\n2. Previs Gesti\u00f3n de Riesgos S.L.U. Palma. Balearic Islands. SpaineISSN 2255-0569\nReceived:  25 - IV - 2021\nAccepted:  2 - V - 2021\ndoi: 10.3306/AJHS.2021.36.03.29Corresponding author\nZoe Manzanero  \nPrevis Gestion de Riesgos S.L.U.\nGremi de Sabaters, 68, 1\u00aa, 07009 Palma, Balearic Islands\nE-mail: rzmanzan@gmail.comID ID\nID\nAbstract  \nIntroduction:  Diabetes is a very prevalent disease and therefore it is very important to have tools to assess the risk of suffering \nfrom it.\nMethods:  A descriptive and cross-sectional study was carried out on 59,042 workers from different productive sectors. The \nrelationship between different scales of overweight, obesity and cardiovascular risk such as waist circumference, waist to height \nratio, body shape index, visceral adiposity index, conicity index, hypertriglyceridemic waist and Cholindex with the Findrisk type 2 \ndiabetes risk scale was evaluated.\nResults:  A worsening in the mean values of the different scales analyzed is observed as the value of the Findrisk test increases \nin both sexes. An increase in the prevalence of altered values of these same scales is also observed as the values of the Findrisk \ntest increase and equally in both sexes.\nConclusion: As expected, the Findrisk test is directly related to the different scales of overweight, obesity and cardiovascular risk \nanalyzed.\nKeywords:  Cardiovascular diseases, diabetes, obesity, abdominal obesity, Finrisk test.\nResumen\nAntecedentes: La Diabetes es una enfermedad prevalente y por lo mismo es muy importante tener las herramientas para evaluar \nel riesgo de sufrirla.\nMaterial y m\u00e9todos: Se realiz\u00f3 un estudio descriptivo y transversal en 59,042 trabajadores de diferentes sectores productivos.  \nSe evalu\u00f3 la relaci\u00f3n entre diferentes escalas de sobrepeso, obesidad y riesgo cardiovascular como circunferencia de la cintura, \n\u00edndice cintura/altura, \u00edndice de forma corporal, \u00edndice de adiposidad visceral, \u00edndice de conicidad, cintura hipertrigliceridemica y \ncholindex con la escala findrisk de riesgo de diabetes tipo 2.\nResultados: Se observ\u00f3 un empeoramiento de los valores medios en las diferentes escalas analizadas  cuando los valores del \ntest findrisk aumentaban en ambos sexos. Se observ\u00f3 tambi\u00e9n un incremento en la prevalencia de valores alterados en estas \nmismas escalas cuando los valores del Findrisk test se incrementaban, igualmente en ambos sexos.\nConclusiones: El test Finrisk  se relaciona directamente con las escalas de sobrepeso, obesidad y riesgo cardiovascular analizadas.\nPalabras clave:  Enfermedades cardiovasculares, diabetes mellitus, obesidad, obesidad abdominal, test de Finrisk.30\n2021/36 (3): 29-33Hector Orlando Patr\u00f3n et al.  \nIntroduction  \nCardiovascular diseases (CVD) cause great morbidity \nand mortality both in the developed and undeveloped \ncountries. In recent years 80 percent of deaths from \nCVD have occurred in countries with medium or low \nincome, and the number is growing1. The cardiovascular \nrisk (CVR) is defined as the likelihood of an event in a \ngiven period, usually 10 years, for its determination \ngenerally scales are based on cohort studies are used. \nDetermining the CVR it is based on clinical guidelines that \naddress cardiovascular prevention. \nIn the occurrence of CVD is influenced by different factors \nsuch as tobacco consumption, obesity, dyslipidemia \nand diabetes. The risk of diabetes can be determined \nwith different scales among which we highlight the \nFINDRISC (FINnish Diabetes RIsk Score) questionnaire \nfor being perhaps the most widely used. FINDRISC has \nbeen successfully implemented as a practical screening \ninstrument to assess diabetes risk and to detect \nundiagnosed type 2 diabetes in European populations2-4. \nHowever it has also become evident that it is not universally \napplicable among all ethnic groups and populations5,6.\nThere are many indexes that help predict CVD from \nclassic Body Mass Index (BMI), waist circumference and \nwaist to height ratio to the most recent Body Adiposity \nIndex (BAI)7,8. There are other indices that could perhaps \nbe useful in predicting these CVD among which are the \nBody Shape Index (ABSI) at some authors they have \nlinked to an increased risk of cardiovascular mortality9, \nthe Visceral Adiposity Index (VAI) which has been linked \nwith visceral fat levels10, type 2 diabetes11 and coronary \nartery disease12, Cholindex which has been linked \nwith coronary artery disease13, the Conicity Index (CI)) \nwhich has been linked with high coronary risk14 and \nHypertriglyceridemic waist (HTGW) has been associated \nwith type 2 diabetes15, coronary artery disease16 and \neven acute myocardial infarction17.\nAn analysis of the scientific literature shows that previous \nindexes have not been used too much in cardiovascular \nprevention but perhaps can provide valuable information \non the assessment of CVR.\nFor all these reasons, and trying to improve cardiovascular \nprevention, this study presents the main objective is to \ndetermine what relationship exists between FINDRISC \ntest values and the values of these indices.\nMaterials and Methods  \nSubjects and Study Protocol\nA cross-sectional study with Caucasians adult workers \nwas performed. All subjects were from different productive \nsectors. Participants in the study were systematic selected during their work health periodic examination between \nJanuary and December 2019. Every day each worker \nwas assigned a number and half of the examined workers \nwere randomly selected using a random number table. \nThus, from a total population of 130,487 workers, 65,200 \nof them were invited to participate in the study. 3,869 They \ndo not have any parameter necessary to calculate any of \nthe scales. 533 refused to participate and 1,756 they are \nexcluded to be diabetic and not being able to perform \nthe FINDRISC test, being the final number of participants \n59,042 (see flowchart in figure 1 ), with 25,510 women \n(43.2%) and 33,532 men (56.8%). The mean of age of \nparticipants in the study was 39.7 years (SD\u00b110.30).\nThe following inclusion criteria were considered: age \nbetween 18 and 70 (working age population), no \ndiabetic, agreement to participate in the study and to be \ngainfully employed. Subjects who did not meet any of \nthe inclusion criteria and those who refused to participate \nwere excluded from the study.\nMeasurements and Calculations\nAll anthropometric measurements were made in the \nmorning, after an overnight fast, at the same time (9 \na.m.), and according to the recommendations of the \nInternational Standards for Anthropometric Assessment \n(ISAK)18. Furthermore, all measurements were performed \nby well trained technicians or researchers to minimize \ncoefficients of variation. Each measurement was made \nthree times and the average value was calculated. Weight \nand height were determined according to recommended \ntechniques mentioned above. Body weight was \nmeasured to the nearest 0.1 kg using an electronic scale \n(Seca 700 scale, Secagmbh, Hamburg). Height was \nmeasured to the nearest 0.5 cm using a stadiometer \n(Seca 220 (CM) Telescopic Height Rod for Column \nScales, Secagmbh, Hamburg). BMI was calculated as \nweight (kg) divided by height (m) squared (kg/m\u00b2). Criteria Figure 1: Flowchart of participants. \n65,200 workers \nstart the study\n533 did not accept \nto participate1,756 were \ndiabetic3,869 did not have \nany variable \nto calculate risk \nof diabetes type 2\n59,042 workers\nfinally entered \nthe study31\n2021/36 (3): 29-33 Values of different indices related to cardiovascular risk according the Findrisc test scores in caucasians\nto define overweight were the ones of the World Health \nOrganization (WHO)19 which considers obesity when BMI \n\u2265 30 kg/m\u00b2. Abdominal waist was measured using a \nflexible steel tape (Lufkin Executive Thinline W 606). The \nplane of the tape was perpendicular to the long axis of \nthe body and parallel to the floor. Waist circumference \nwas measured at the level of the umbilicus and superior \niliac crest. The measurement was made at the end of a \nnormal expiration while the subject stood upright, with \nfeet together and arms hanging freely at the sides. Waist \ncircumference (WC) was measured using a tapeline at \nthe level midway between the lateral lower rib margin and \niliac crest. Waist-to-height ratio (WtHR) was calculated by \ndividing WC by height in cm.\nVenous blood samples were taken from the antecubital \nvein with suitable vacutainers without anticoagulant \nto obtain serum. Blood samples were taken following \na 12 h overnight fast. Participants were seated at rest \nfor at least 15 minutes before blood samples were \ntaken. Serum was obtained after centrifugation (15 min, \n1,000 g, 4\u00b0C) of blood samples. Serum was stored \nat -20\u00b0C and analysis were performed within 3 days. \nConcentrations of glucose, cholesterol and triglycerides \nwere measured in serum by standard procedures used \nin clinical biochemistry laboratory using a clinical system \nBeckman Coulter SYNCHRON CX\u00ae9 PRO (Beckman \nCoulter, Brea, CA, USA).\nBlood pressure was determined after a resting period \nof 10 minutes in the supine position using an automatic \nand calibrated sphygmomanometer OMRON M3 \n(OMRON Healthcare Europe, Spain). As indicated for \nthe anthropometrical measures, blood pressure was \nmeasured three times with a one-minute gap between \neach measurement and an average value was calculated.\nFINDRISC questionnaire value 8 items: age, BMI, waist \ncircumference, physical activity, dietary consumption of \nfruits, vegetables, and berries, Use of antihypertensive \nmedication, previously measured high blood glucose and \nfamily history of diabetes. The maximum achievable score \nis 26. Less than 7 points is considered low risk, 7-11 \npoint slightly elevated risk, 11-14 points moderate risk, \n15-20 points high risk and 21-26 points very high risk.\n \nReal Body shape index (ABSI)9 was calculated using the \nequation: \n- Waist circumference (cm)/BMI2/3 weight1/2 (kg)\nTheoretical ABSI is set based on sex and age. The ratio \nbetween real and theoretical ABSI is called ABSI relative \nrisk (ABSI RR). ABSI RR <1 is considered abnormal.\nConicity index(CI)14 was calculated using the equation:\n- Waist circumference (m)/ (0,109 \u221a weight (kg)/height (m))\nThe cut-off to consider high CI were 1.18 for women and \n1.25 for men.Visceral Adiposity Index (VAI)20 was calculated using the \nequations: \nWomen (Waist circumference /(39.68+(1.89 BMI)) x \n(triglycerides/1.03) x (1.31/HDL-C)\nMen (Waist circumference /(36.58+ (1.89 BMI)) x \n(triglycerides /0.81) x (1.52/HDL-C)\nThe cut-off to consider optimal VAI were < 30 years \n(\u22652.52) 30-42 years (\u2265 2.23) 43-51 years (\u22651.92) 52-65 \nyears (\u2265 1.93) \u2265 66 years (\u2265 2.00)\nCholindex13  was calculated using the equations:\n- LDLC-HDL-C (if triglycerides <400 mg/dl) or LDL-C-\nHDL-C+TG/5 (if triglycerides \u2265 400 mg/dl)\nThe cut-off to consider high Cholindex was 80 mg/dl\nWe believe that there are Hypertriglyceridemic waist \n(HTGW)15 when:\n-Waist circumference \u2265 88cm in women and \u2265102 cm in \nmen and triglycerides \u2265 150 mg/dl.\nStatistical Analyses\nAll the data were tested for their normal distribution \n(Kolmogorov-Smirnov test). Results are expressed as \nmeans and standard deviations (SD) and, when required, \nin percentages. Student t test for unpaired data was used \nto evaluate differences in anthropometric and biochemical \ncharacteristics between genders. Chi-square test was \nused for the difference of proportions. The existence \nof significant bivariate correlations between parameters \nsuch as ABSI, CI, VAI and Cholindex and FINDRISC \nquestionnaire was ascertained by determining Pearson \nor Spearman correlation coefficients.\nStatistical analysis was carried out using IBM SPSS \nStatistics 27.0 software (SPSS/IBM, Chicago, IL, USA). \nSignificance was accepted at p<0.05.\nEthical considerations and aspects\nThe study was approved by the Institutional Review \nBoard of the Region. All procedures were performed in \naccordance with the ethical standards of the institutional \nresearch committee and with the 2013 Declaration of \nHelsinki. All patients signed written informed consent \ndocuments prior to participation in the study.\nResults  \nAge and anthropometrical and clinical characteristics of \nthe participants in the study as a whole and categorized \nby gender are shown in table I . Significant differences \nbetween men and women were found in all parameters \nanalyzed with higher values of age, anthropometric \ncharacteristics (height, weight, body mass index, waist \ncircumference, and waist to height ratio), systolic and \ndiastolic blood pressure, total cholesterol, high-density \nlipoprotein cholesterol, low-density lipoprotein cholesterol \nand triglycerides in men.32\n2021/36 (3): 29-33Hector Orlando Patr\u00f3n et al.  \nTable I: Anthropometric, clinical and analytical characteristics of participants in \nthe study.\n  Women Man Total  \nCharacteristics1 (n=25,510) (n=33,532) (n=59,042) value1 \nAge (years)  39.30 \u00b1 10.10 40.01 \u00b1 10.35 39.70 \u00b1 10.25 <0.0001\nWeight (kg) 161.32 \u00b1 6.51 173.94 \u00b1 7.04 168.49 \u00b1 9.25 <0.0001\nHeight (cm) 64.87 \u00b1 12.94 81.06 \u00b1 13.75 74.06 \u00b1 15.62 <0.0001\nBMI (kg/m\u00b2) 24.94 \u00b1 4.84 26.78 \u00b1 4.16 25.98 \u00b1 4.56 <0.0001\nWaist (cm)  75.24 \u00b1 9.66 88.37 \u00b1 9.54 82.69 \u00b1 11.59 <0.0001\ncircumference\nWtHR  0.47 \u00b1 0.06 0.51 \u00b1 0.06 0.49 \u00b1 0.06 <0.0001\nSystolic BP 114.36 \u00b1 14.94 124.91 \u00b1 15.36 120.35 \u00b1 16.06 <0.0001\n(mmHg)  \nDyastolic BP  70.29 \u00b1 10.34 75.77 \u00b1 10.74 73.40 \u00b1 10.91 <0.0001\n(mmHg) \nCholesterol  192.78 \u00b1 36.39 196.74 \u00b1 38.63 195.03 \u00b1 37.73 <0.0001\n(mg/dl) \nHDL-C (mg/dl) 55.03 \u00b1 9.17 50.68 \u00b1 7.53 52.56 \u00b1 8.56 <0.0001\nLDL-C (mg/dl)  120.39 \u00b1 36.92 121.82 \u00b1 37.18 121.20 \u00b1 37.07 <0.0001\nTriglycerides 86.98 \u00b1 43.77 123.24 \u00b1 85.76 107.58 \u00b1 72.99 <0.0001\n(mg/dl)\nBMI, Body mass index. WtHR, waist-to-height-ratio. Systolic BP , Systolic blood \npressure. Dyastolic BP , Diastolic blood pressure.\nHDL-C, high-density lipoprotein cholesterol. LDL-C, low-density lipoprotein \ncholesterol.\n1 data are expressed as means \u00b1 standard deviation.\nStatistical significance was estimated by independent t-test\nTable II: Mean values of the different indices as FINDRISC test.\n   ABSI  CI  VAI  Cholindex  \n    n2 Mean (SD) p value1 Mean (SD) p value1 Mean (SD) p value1  Mean (SD) p value1\nWomen  Low 19057 0.090 (0.080) <0.0001 1.08 (0.08) <0.0001 2.14 (1.09) <0.0001 60.75 (40.78) <0.0001\n  Slightly raised 4777 0.091 (0.012)   1.14 (0.14)   3.01 (1.94)   77.08 (41.26)  \n  Moderate 1017 0.088 (0.011)   1.12 (0.13)  3.33 (2.10)   84.26 (40.31)  \n  Hight 643 0.088 (0.012)   1.15 (0.14)   4.15 (2.83)   88.81 (41.27)  \n  Very hight 16 0.084 (0.090)   1.11 (0.11)  6.06 (3.74)   99.66 (45.81)  \nMen Low 22465 0.094 (0.070)   1.17 (0.07)   2.53 (1.63)   66.36 (39.56)  \n  Slightly raised 8117 0.094 (0.090)   1.23 (0.11)   4.48 (3.96)   84.35 (43.70)  \n  Moderate 1856 0.093 (0.080)   1.24 (0.10)   5.17 (4.26)   89.74 (44.86)  \n  Hight 960 0.093 (0.090)   1.25 (0.11)   6.28 (5.67)   90.37 (49.95)  \n  Very hight 134 0.092 (0.080)   1.25 (0.10)   7.14 (5.56)   99.63 (46.40)  \nABSI, Body shape index. CI, Conicity index.  1 Statistical significance was estimated by independent t-test   2 Number of participants in the study.\nTable III: Cataloging the various indices according on the value of FINDRISC test by gender. VAI, Visceral Adiposity Index. HTGW, Hypertriglyceridemic waist. ABSI, \nBody Shape Index.\n      Women         Men      \n  Low Slightly Moderate High Very high Low Slightly Moderate High Very high p value\n  raised     raised\nHigh VAI   37.7 66.0 74.6 84.9 93.8 48.7 79.6 86.3 88.2 94.0 <0.0001\nNormal VAI  62.3 34.0 25.4 15.1 6.3 51.3 20.4 13.7 11.8 6.0  \nHTGW absence  99.9 90.1 85.1 71.2 43.8 98.3 76.6 67.6 57.2 44.0 <0.0001\nHTGW presence  0.1 9.9 14.9 28.8 56.3 1.7 23.4 32.4 42.8 56.0  \nABSI Relative Riskaltered  89.9 76.7 85.3 81.0 100.0 82.8 74.2 81.6 76.3 84.3 <0.0001\nNormal ABSI RelativeRisk  10.1 23.3 14.7 19.0 0.0 17.2 25.8 18.4 23.8 15.7  \nHigh Conicity index  11.2 35.1 28.0 39.5 37.5 14.5 41.0 47.7 48.6 48.5 <0.0001\nNormal Conicity index  88.8 64.9 72.0 60.5 62.5 85.5 59.0 52.3 51.4 51.5  \nHigh Cholindex  31.0 46.8 51.4 60.2 75.0 34.9 51.9 57.5 54.4 68.7 <0.0001\nNormal Cholindex  69.0 53.2 48.6 39.8 25.0 65.1 48.1 42.5 45.6 31.3  The mean values for the different indices according \nFINDRISC questionnaire are shown in table II . The ABSI, \nVAI and Cholindex values in women are worsening in \nparallel with FINDRISC test values, the same applies to \nmen. The Conicity index values behave differently in men \nand women, in men also they are getting worse with \nincreasing the value of the FINDRISC test, however in \nwomen no clear relationship with the test was observed.\nThe prevalence of normal and altered values of the \ndifferent indices according FINDRISC questionnaire \nvalues are shown in table III . In women, the prevalence of high VAI, HTGW and high Cholindex is increasing in \nparallel with the increase in the value of the FINDRISC \ntest, in men we can observe the same with high VAI, \nHTGW, high CI and high Cholindex. ABSI altered shows \nno clear relationship with the FINDRISC questionnaire \nvalues in women and men. In women this relationship \nwas not seen with the high CI.\nThe correlations between parameters such as ABSI, CI, \nVAI and Cholindex and FINDRISC questionnaire was \n-0.087 ABSI, 0.242 CI, 0.398 VAI and, 0.329 Cholindex, \np-value <0.01.\nDiscussion  \nDespite the evident relationship between overweight and \nobesity with the onset of diabetes, we have not found in \nthe literature consulted, and in the different databases, \nany study that establishes relationships between any \ntype 2 diabetes risk scale, whether Findrisk or other, with \nscales that assess overweight and obesity such as those \nassessed in this study.\nAlthough there are a large number of studies that analyze the \nFindrisk test, almost none relate it to this type of scales. We \nfound two studies carried out in the Spanish population22,23 \nthat related the values of this test with cardiovascular risk \nscales such as atherogenic indices, metabolic syndrome, \nREGICOR, SCORE, heart age and vascular age.\nThe strengths of the study include the large sample size, \nalmost 60,000 workers, and the fact that for the first time 33\n2021/36 (3): 29-33 Values of different indices related to cardiovascular risk according the Findrisc test scores in caucasians\na type 2 diabetes risk scale such as the Findrisk is related \nto other scales related to overweight and cardiovascular \nrisk such as the body shape index, visceral adiposity \nindex, conicity index and Cholindex, which makes this \nstudy a future reference for further research.\nThe limitations of this study are that it was carried out in \na specific region and in a working population, so that the \nresults cannot be extrapolated to the general population \nand to other regions.Authorship contributions   \nPATR\u00d3N O, HECTOR.: conception, study design, data \ncollection and drafting of the original version of the manuscript. \nKE A. EDMUNDO: study conception, data collection and \nanalysis, and critical revision of the paper. \nMANZANERO F. ZOE: conception and design of the study, \nanalysis of the data, critical revision of the manuscript and writing \nof the final version of the manuscript. All authors approved the \nfinal version of the manuscript.\nReferences \n1. Leeder S. A race against time: the challenge of cardiovascular disease \nin developing economies. Columbia University, New York. 2004.\n2. Saaristo T, Peltonen M, Keinanen-Kiukaanniemi S, Vanhala M, Saltevo \nJ, Niskanen L, Oksa H, Korpi-Hy\u00f6v\u00e4lti E, Tuomilehto J. FIN-D2D Study \nGroup. National type 2 diabetes prevention programme in Finland: FIN-\nD2D. Int J Circumpolar Health. 2007;66:101-12\n3. Soriguer F, Valdes S, Tapia MJ, Esteva I, Ruiz de Adana MS, Almaraz \nMC, et al. Validation of the FINDRISC (FINnish Diabetes RIsk SCore) \nfor prediction of the risk of type 2 diabetes in a population of southern \nSpain. Pizarra Study. Med Clin (Barc) 2012;138:371-6.\n4. Tankova T, Chakarova N, Atanassova I, Dakovska L. Evaluation of \nthe Finnish Diabetes Risk Score as a screening tool for impaired fasting \nglucose, impaired glucose tolerance and undetected diabetes. Diabetes \nRes Clin Pract. 2011;92:46-52.\n5. Makrilakis K, Liatis S, Grammatikou S, Perrea D, Stathi C, Tsiligros P , \nKatsilambros N. Validation of the Finnish diabetes risk score (FINDRISC) \nquestionnaire for screening for undiagnosed type 2 diabetes, \ndysglycaemia and the metabolic syndrome in Greece. Diabetes Metab. \n2011;37:144-51\n6. Hippisley-Cox J, Coupland C, Robson J, Sheikh A, Brindle P . \nPredicting risk of type 2 diabetes in England and Wales: prospective \nderivation and validation of QDScore. BMJ. 2009;338:b880.\n7. L\u00f3pez-Gonz\u00e1lez AA, Cespedes ML, Vicente T, Tomas M, Bennasar-\nVeny M, Tauler P , et al. Body adiposity index utilization in a Spanish \nMediterranean population: comparison with the body mass index. PLoS \nOne. 2102;7(4):e35281\n8. Bennasar-Veny M, Lopez-Gonzalez AA, Tauler P , Cespedes ML, \nVicente-Herrero T, Ya\u00f1ez A, et al. Body adiposity index and cardiovascular \nhealth risk factors in Caucasians: a comparison with the body mass \nindex. PLoS One. 2013;8(5):e63999.\n9. Krakauer NY, Krakauer JC. A new Body Shape Index predicts mortality \nhazard independently of Body Mass Index. Plos One. 2012;7(7):e39504\n10. Mohammadreza B, Farzad H, Davoud K, Fereidoun A. \nPrognostic significance of the Complex \u201cVisceral Adiposity Index\u201d vs \nsimple anthropometric measures: Tehran lipid and glucose study. \nCardiovascDiabetol. 2012;11:20\n11. Al-Daghri NM, Al-Attas OS, Wani K, Alnaamil AM, Sabico S, Al-\nAjlan A, et al. Sensitivity of various indices in identifying cardiometabolic \ndisease in Arab adults. CardiovascDiabetol. 2015;14:101Patil VC, \nParale GP , Kulkarni PM, Patil HV. Relation of anthropometric variables to \ncoronary artery disease risk factors. Indian Journal of Endocrinology and \nMetabolism. 2011; 15(1):31-7.12. Akpinar O, Bozkurt A, Acart\u00fcrk E, Seydaoglu G. A new \nindex (CHOLINDEX) in detecting coronary artery disease risk. \nAnadoluKardiyolDerg. 2013; 13:315-9.\n13. Gondin-Pitanga FJ, Lessa I. Anthropometricindexes of obesity as \nan instrument of screening for high coronary risk in adults in the city of \nSalvador-Bahia. ArquivosBrasileiros de Cardiologia. 2005;85(1):26-31\n14. Amini M, Esmaillzadeh A, Sadeghi M, Mehvarifar N, Amini M, Zare \nM. The association of hypertriglyceridemic waist phenotype with type 2 \ndiabetes mellitus among individuals with first relative history of diabetes. \nJRMS. 2011; 16(2):156-64.\n15. Arsenault BJ, Lemieux I, Despres JP , Wareham NJ, Kastelein JJP , \nKhaw KT, et al. The hypertriglyceridemic-waist phenotype and the risk \nof coronary artery disease: results from the EPIC-Norfolk Prospective \nPopulation Study. CMAJ. 2010;182(13):1427-32\n16. Egeland GM, Igland J, Nygard O, Sulo G, Tell GS. Hypertriglyceridemic-\nwaist phenotype is a usefull global assessment tool for predicting acute \nmyocardial infarction. J Cardiovasc Dis Diagn. 2015;3:4\n17. Bioelectrical impedance analysis in body composition measurement: \nNational Institutes of Health Technology Assessment Conference \nStatement. Am J  ClinNutr. 1996;64:524S-532S.\n18. Organization WH.  Obesity: preventing and managing the global \nepidemic. Report of a WHO Consultation. 2000. Ginebra:WHO\n19. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri \nM, et al. Visceral Adiposity Index. A reliable indicator of visceral function \nassociated with cardiometabolic risk. Diabetes Care. 2010; 33(4):920-2\n20. Amato MC, Giordano C, Pitrone M, Galluzzo A. Cut-off points of the \nvisceral adiposity index (VAI) identifying a visceral adipose dysfunction \nassociated with cardiometabolic risk in a Caucasian Sicilian population. \nLipids in Health and Disease. 2011; 10:183-90.\n21. L\u00f3pez-Gonz\u00e1lez AA, Garcia-Agudo S, Tom\u00e1s-Salv\u00e1 M, Vicente-\nHerrero MT, Queimadelos-Carmona M, Guijarro-Tom\u00e1s F. Test \nFindrisc: relaci\u00f3n con par\u00e1metros y escalas de riesgo cardiovascular \nen poblaci\u00f3n mediterr\u00e1nea Espa\u00f1ola. Rev Med InstMex Seguro Soc. \n2017;55(3):309-16\n22. Ram\u00edrez I\u00f1iguez de la Torre MV , Vicente-Herrero MT , L\u00f3pez-\nGonz\u00e1lez AA , Capdevila L. S\u00edndrome metab\u00f3lico y diabetes tipo 2. \nEstimaci\u00f3n de riesgo en trabajadores aparentemente sanos. Medicina \nBalear 2020; 35 (2): 34-4034\n2021/36 (3): 34-39ORIGINAL\nInfluence of sociodemographic variables and tobacco \nconsumption on the risk of nonalcoholic fatty liver disease \nand liver fibrosis\nInfluencia de las variables sociodemogr\u00e1ficas y del consumo de tabaco \nen el riesgo de padecer h\u00edgado graso no alcoh\u00f3lico y fibrosis hep\u00e1tica\nLiliana Laird1, Cristina N\u00fa\u00f1ez Fern\u00e1ndez2      ,  Mar\u00eda Gil Llin\u00e1s3,\nRosa Gonz\u00e1lez Casquero3, Irene del Roc\u00edo Campos Gonz\u00e1lez3    \n1. Aesthetica Edinburgh. Scotland   2. Cl\u00ednica Aureo. Palma. Balearic Islands. Spain   \n3. Occupational Health Service of Balearic Health ServiceeISSN 2255-0569\nReceived:  1 - V - 2021\nAccepted:  23 - V - 2021\ndoi: 10.3306/AJHS.2021.36.03.34Corresponding author\nLiliana Laird  \nAesthetica Edinburgh \n3A-4B Randolph Place Edinburgh EH3 7TQ Scotland\nE-mail: enquiries@aestheticaedimburgh.comID\nAbstract  \nIntroduction:  Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver disease in the Western world. Although it is \nnormal to have a certain amount of fat in the liver, when it exceeds 10% it becomes a health problem. It is not usually a serious \ndisease, unless it is accompanied by steatohepatitis (inflammation of the liver caused by the presence of fat), which can develop \ninto cirrhosis and/or liver cancer.\nMethods:  A descriptive and cross-sectional study was carried out in 9,550 users of the Scottish National Health System in which \nthe influence of sociodemographic variables such as age, sex and educational level and tobacco consumption on the prevalence \nof non-alcoholic fatty liver disease and liver fibrosis determined with different scales was assessed. \nResults:  The prevalence of high risk of NAFLD and liver fibrosis determined by risk scales is influenced by sex (more prevalent in \nmen), age (increasing with age), educational level (higher prevalence in people with less education) and tobacco use (somewhat \nmore prevalent in smokers, although only with the hepatic steatosis index).\nConclusions: The high-risk values in the NAFLD and hepatic fibrosis scales are influenced by sociodemographic variables and \nonly in some cases by tobacco consumption.\nKeywords:  Fatty liver, liver fibrosis, tobacco.\nResumen\nIntroducci\u00f3n: El h\u00edgado graso no alcoh\u00f3lico (NAFLD) es la principal causa de enfermedad hep\u00e1tica en el mundo occidental. \nAunque es normal tener una cantidad determinada de grasa en el h\u00edgado, cuando \u00e9sta supera el 10% se convierte en un problema \nde salud. No suele ser una enfermedad grave, a no ser que se acompa\u00f1e de esteatohepatitis (inflamaci\u00f3n del h\u00edgado causado por \nla presencia de grasa), lo que puede evolucionar en cirrosis y/o c\u00e1ncer hep\u00e1tico.\nMaterial y m\u00e9todos: Se realiz\u00f3 un estudio descriptivo y transversal en 9,550 usuarios del Sistema Nacional de Salud de Escocia \nen los que se valor\u00f3 la influencia de variables sociodemogr\u00e1ficas como edad, sexo y nivel de estudios y, el consumo de tabaco \nen la prevalencia de H\u00edgado graso no alcoh\u00f3lico y fibrosis hep\u00e1tica determinados con diferentes escalas.\nResultados: La prevalencia de alto riesgo de NAFLD y fibrosis hep\u00e1tica determinada mediante escalas de riesgo se ve influenciada \npor el sexo (m\u00e1s prevalente en hombres), edad (va increment\u00e1ndose con la edad), nivel de estudios (mayor prevalencia en las \npersonas con menores estudios) y consumo de tabaco (algo m\u00e1s prevalente en los fumadores aunque s\u00f3lo con el hepatic \nsteatosis index).\nConclusiones: Los valores de alto riesgo en las escalas de NAFLD y fibrosis hep\u00e1tica se ven influidos por las variables \nsociodemogr\u00e1ficas y solo en algunos casos por el consumo de tabaco.\nPalabras clave:  H\u00edgado graso, fibrosis hep\u00e1tica, tabaco.35\n2021/36 (3): 34-39 Influence of sociodemographic variables and tobacco consumption on the risk of nonalcoholic fatty liver disease and liver fibrosis\nIntroduction  \nThe main and defining characteristic of non-alcoholic fatty \nliver disease (NAFLD) is the accumulation of free fatty \nacids and triglycerides in the hepatocytes, specifically in \nthe cytoplasm, mainly in the form of large fat vacuoles, \nin individuals who do not consume alcohol excessively \n(\u2264 3 standard drinking unit/day in men and \u2264 2 standard \ndrinking unit/day in women) and do not present other liver \ndiseases1. Although in most cases it follows a benign \ncourse, a small percentage of patients may develop non-\nalcoholic steatohepatitis (NASH), characterized by the \nappearance of hydropic degeneration of the hepatocytes \nand lobular inflammation with or without perisinusoidal \nfibrosis, which can progress to cirrhosis and hepatocellular \ncarcinoma, leading to death due to liver disease2.\nNAFLD is currently considered the leading cause of \nliver disease in the Western world, with an estimated \nprevalence of 20-30% according to the criteria used in \ndifferent studies3-5.\nThe causal factors of NAFLD can be divided into primary \nfactors, which are the most important, and are related to the \ndifferent components of the metabolic syndrome such as \nobesity, type 2 diabetes and dyslipidemia6-9. NAFLD could \nbe considered the hepatic component of the metabolic \nsyndrome. Insulin resistance would be the determining \nalteration of steatosis and this in turn would be responsible \nfor inflammatory disorders (IL-6, TNF \u03b1), oxidative stress, \nmitochondrial dysfunction, NASH and fibrosis10-14. \nSecondary factors are less frequent, and are related to \nthe consumption of drugs (corticosteroids, estrogens, \namiodarone, tamoxifen), bariatric surgery, parenteral \nnutrition, congenital metabolic diseases and other toxins6,7. \nIn clinical practice, many patients with NAFLD present \nobesity, type 2 diabetes or dyslipidemia as a causal factor, \nand the association of various factors is frequent.\nBlood tests (elevated liver enzymes ALT and AST), \ndiagnostic imaging (ultrasound, CT and MRI) and even \nliver biopsy are used to diagnose NAFLD. There are also \nseveral scales that assess the risk of NAFLD as we will \nsee below.\nThe aim of this work is to know how different \nsociodemographic variables such as age, sex, \neducational level and tobacco consumption affect the \nrisk of NAFLD and liver fibrosis.\nMethods  \nRetrospective, cross-sectional study in a sample of 9668 \nusers of the National Health Service  between January \n2018 and June 2020. 78 did not agree to participate in \nthe study and 40 lacked some of the variables necessary \nto calculate the fatty liver or liver fibrosis scales. The total number of participants who entered the study was 9550. \n(see Flow chart in figure 1 ).\nInclusion criteria\n- Age between 18 and 70 years.\n- Agree to participate in the study by giving up data for \nepidemiological purposes.\nSociodemographic variables such as age and sex, \nlevel of education (primary, secondary and university) \nand tobacco consumption were collected, being \nconsidered smokers when they had regularly consumed \nat least 1 cigarette/day (or its equivalent in other types of \nconsumption) in the last month, or had quit less than 1 \nyear ago.  \nFatty liver and hepatic fibrosis risk scales\n- Lipid accumulation product (LAP)15 \n\u00b7 Men: (waist circumference (cm) \u2013 65) x (trigycerides \n(mMol)).\n\u00b7 Women: (waist circumference (cm) \u2013 58) x \n(trigycerides (mMol))\n- Fatty liver index (FLI)16 \nA person is considered to be at high risk when the FLI \nvalue is equal to or greater than 60\n- Hepatic steatosis index (HSI)17 \nHSI = 8 x ALT/AST + BMI (+ 2 if type 2 diabetes yes, \n+ 2 if female)\n- Zhejian University index (ZJU)18\nBMI + FPG mmol L + TG mmol L+ 3 ALT/AST + 2 if \nfemaleFigure 1: Participant flow chart. \n9.668 patients \nstart the study\n9.550 (246,061 men \nand 6.085 women) \nfinally entered \nthe study40 did not have any \nvariable to calculate \nNAFLD or liver \nfibrosis scales\n78 did not accept \nto participate\nFLI = (e0.953*log  (triglycerides ) + 0.139*BMI + 0.718*log  (GGT) + 0.053*waist circumference  \n- 15.745) / (1 + e0.953*log  (triglycerides ) + 0.139*BMI + 0.718*log  (GGT) + 0.053*waist \ncircumference  - 15.745) x 10036\n2021/36 (3): 34-39Liliana Laird et al.  \n- Fatty liver disease index (FLD)19\nBMI + TG + 3 \u00d7 (ALT/AST) + 2 \u00d7 Hyperglycemia \n(presence= 1; absence = 0)\nValues <28.0 or >37.0 excluded the possibility of NAFLD\n- Framingham steatosis index20\nFSI = \u20137.981 + 0.011x age \u2013 0.146 x sex (female = \n1, male = 0) + 0.173 x BMI + 0.007 x TG + 0.593 x \nhypertension (yes = 1, no = 0) + 0.789 x diabetes (yes = \n1, no = 0) + 1.1 x ALT/AST ratio \u2265 1.33 (yes = 1, no = 0).\n- Bard scoring system (BSS)21\nBMI \u2265 28 = 1 point, AST/ALT \u2265 0.8 = 2 points, type 2 \ndiabetes mellitus = 1 point.\nCut off for high risk 2 points\nStatistical analysis\nA descriptive analysis of the categorical variables was \nperformed and the frequency and distribution of the \nresponses were calculated for each of them. The mean \nand standard deviation were calculated for quantitative \nvariables, and the percentage for qualitative variables. \nA bivariate association analysis was performed using \nthe \u03c72 test (with a correction with Fisher\u2019s exact test, \nwhen conditions required it) and a Student\u2019s t test for \nindependent samples. For the multivariate analysis, \nbinary logistic regression was used with the Wald \nmethod, with calculation of the Odds ratio, and the \nHosmer-Lemeshow goodness-of-fit test was performed. Statistical analysis was performed with the SPSS 27.0 \nprogram, and a p value of <0.05 was considered \nstatistically significant.\nEthical considerations and aspects\nThe study was approved by the Clinical Research Ethics \nCommittee. The procedures were performed following \nthe ethical standards of the institutional research \ncommittee and with the 2013 Declaration of Helsinki. \nAll patients signed written informed consent documents \nbefore participating in the study.\nResults  \nThe mean age of the patients included in our study \nwas slightly over 47 years. Most of them had primary \neducation. Women smoked more than men. The clinical \nand analytical variables are more unfavorable in men, the \ndifferences being statistically significant in most cases as \ncan be seen in table I .\nThe mean values of all fatty liver and liver fibrosis scales \nanalyzed in this study are higher in men. An increase in the \nvalues of all scales is observed as the age of the patients \nincreases. People with a university education are those \nwith the most favorable values in all scales. Smokers \nhave lower values than non-smokers. In all cases, the \ndifferences observed were statistically significant. The \ncomplete data can be found in table II .\nTable I: Sociodemographic, anthropometric, clinical and analytical  characteristics of the sample.\n  Men Women Total  \n  n=6085 n=3465 n=9550  \n  Mean (SD) Mean (SD) Mean (SD) p-value\nAge (years)  47.55 (8.32) 46,97 (7.92) 47.34 (8.19) 0.001\nHeight (cm)  174.94 (6.65) 161.90 (6.19) 170.21 (9.02) <0.0001\nWeight (kg)  83.61 (14.52) 67.47 (13.07) 77.75 (16.02) <0.0001\nBody mass index (kg/m\u00b2)  27.29 (4.31) 25.75 (4.85) 26.73 (4.58) <0.0001\nWaist circumference (cm)  84.84 (7.93) 73.25 (8.52) 80.63 (9.87) <0.0001\nWaist to height ratio  0.49 (0.04) 0.45 (0.05) 0.47 (0.05) <0.0001\nSystolic blood pressure (mmHg)  128.07 (15.93) 117.69 (16.33) 124.30 (16.83) <0.0001\nDiastolic blood pressure (mmHg)  78.83 (11.05) 73.22 (10.85) 76.79 (11.30) <0.0001\nTotal cholesterol (mg/dL)  201.90 (36.33) 199.90 (34.13) 201.17 (35.55) 0.008\nHDL-cholesterol (mg/dL)  52.61 (8.98) 57.77 (9.75) 54.48 (9.60) <0.0001\nLDL-cholesterol (mg/dL)  122.97 (34.38) 122.79 (32.77) 122.90 (33.80) 0.809\nTriglycerides (mg/dL)  133.18 (77.00) 96.93 (48.27) 120.03 (70.19) <0.0001\nGlucose (mg/dL)  95.05 (24.19) 88.47 (17.98) 92.66 (22.36) <0.0001\nALT (U/L)  28.79 (14.65) 19.40 (9.51) 25.39 (13.78) <0.0001\nAST (U/L)  24.12 (9.52) 18.54 (7.00) 22.10 (9.09) <0.0001\nGGT (U/L)  34.22 (26.38) 20.11 (15.00) 29.10 (23.89) <0.0001\n  Percentage Percentage Percentage p-value\n18-39 years  18.32 17.63 18.07 <0.0001\n40-49 years  39.43 46.24 41.90 \n50-69 years  42.25 36.13 40.03 \nPrimary school  69.09 51.95 62.87 <0.0001\nSecondary school  21.74 37.23 27.36 \nUniversity  9.17 10.82 9.77 \nNon-smokers  72.62 68.69 71.19 <0.0001\nSmokers  27.38 31.31 28.81  37\n2021/36 (3): 34-39 Influence of sociodemographic variables and tobacco consumption on the risk of nonalcoholic fatty liver disease and liver fibrosis\nThe prevalence of high-risk values of all the scales, both \nof nonalcoholic fatty liver disease and liver fibrosis, is \nmuch higher in men. An increase in prevalence is also \nobserved parallel to the increase in age. As with the mean \nvalues, the most disadvantaged group in the prevalence \nof high-risk scales is the group with the lowest level of \neducation. Non-smokers have a higher prevalence in all \nthe high-risk scales. In all cases the differences show \nstatistical significance. The complete data can be found \nin table III .\nIn the multivariate analysis using binary logistic regression, \nage 50 years or older, male sex, non-university \neducation, and tobacco consumption were established \nas covariates. Age over 50 years and male sex were \nthe variables that most increased the risk of presenting \nnonalcoholic fatty liver disease or liver fibrosis. Tobacco \nconsumption increases the risk exclusively with hepatic steatosis index. All the data from the multivariate analysis \nare presented in table IV .\nDiscussion  \nMale sex is the variable that most increases the risk \nof presenting NAFLD in all the scales assessed in this \nstudy. Age is another variable that also increases the risk \nin all the scales. Low socioeconomic level increases the \nrisk of NAFLD in all except the Fatty liver disease index.  \nTobacco consumption only influences NAFLD when \nassessed with the hepatic steatosis index.\nThe increase in the prevalence of NAFLD with age \nobtained in our work has also been observed in other \nstudies consulted; thus, in 550 Japanese studies22 it \nwas seen that both NAFLD and liver fibrosis diagnosed \nTable II: Mean values of different fatty liver and liver fibrosis scales according to sociodemographic variables and tobacco consumption.\nFLI: Fatty liver index, HSI: Hepatic steatosis index, ZJU: Zhejian University index, FLD: Fatty  liver disease, FSI: Framingham steatosis index, LAP: Lipid accumulation \nproducto, BSS: Bard scoring system.\nIn all cases the differences are statistically significant.    FLI HSI ZJU FLD FSI LAP BSS\n  n Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)\nMen 6085 39.74 (24.93) 37.43 (6.56) 37.77 (5.56) 32.59 (5.18) 0.23 (0.19) 31.16 (25.41) 1.38 (1.06)\nWomen  3465 18.35 (20.68) 36.52 (6.27) 36.99 (5.62) 30.11 (5.35) 0.15 (0.16) 17.86 (16.58) 0.82 (0.89)\n18-39 years  1726 29.40 (26.56) 36.80 (6.83) 36.90 (5.81) 31.26 (5.72) 0.16 (0.17) 24.77 (24.26) 0.71 (0.89)\n40-49 years  4001 29.73 (25.09) 36.82 (6.26) 37.08 (5.29) 31.31 (5.22) 0.18 (0.17) 24.64 (22.69) 0.74 (0.88)\n50-70 years  3823 35.47 (25.37) 37.51 (6.45) 38.17 (5.70) 32.24 (5.30) 0.24 (0.20) 28.82 (23.79) 1.84 (0.88)\nPrimary school  6004 34.47 (26.09) 37.37 (6.62) 37.87 (5.82) 32.15 (5.50) 0.22 (0.19) 28.03 (24.23) 1.26 (1.03)\nSecondary school  2613 27.35 (24.09) 36.73 (6.26) 36.88 (5.16) 30.92 (5.09) 0.17 (0.16) 23.32 (22.07) 1.01 (1.00)\nUniversity  933 28.87 (24.72) 36.33 (5.94) 36.72 (5.06) 30.87 (5.00) 0.18 (0.17) 23.90 (21.44) 1.08 (1.06)\nNon-smokers  6799 32.50 (25.69) 37.16 (6.40) 37.56 (5.57) 31.78 (5.34) 0.20 (0.19) 26.79 (23.69) 1.19 (1.04)\nSmokers  2751 30.67 (25.45) 36.94 (6.64) 37.30 (5.65) 31.46 (5.46) 0.19 (0.18) 25.20 (22.99) 1.13 (1.03)\nTable III: Prevalence of high risk of different fatty liver and liver fibrosis scales according to sociodemographic variables and tobacco consumption.\nFLI: Fatty liver index, HSI: Hepatic steatosis index, ZJU: Zhejian University index, FLD: Fatty  liver disease, FSI: Framingham steatosis index, LAP: Lipid accumulation \nproducto, BSS: Bard scoring system.\nIn all cases the differences are statistically significant.     FLI high risk HSI high risk ZJU high risk FLD high risk LAP high risk BSS high risk\n  n Percentage Percentage Percentage Percentage Percentage Percentage\nMen 6085 22.96 54.49 42.55 65.06 36.11 41.59\nWomen  3465 7.04 47.22 36.25 48.66 22.42 20.81\n18-39 years  1726 15.16 42.35 34.59 53.94 27.11 18.13\n40-49 years  4001 15.30 49.41 38.17 58.14 27.94 18.87\n50-70 years  3823 19.62 56.08 45.02 62.46 36.31 57.13\nPrimary school  6004 19.47 53.51 42.85 60.03 33.73 36.91\nSecondary school  2613 12.94 49.67 35,82 57.90 27.02 28.93\nUniversity  933 14.36 47.37 36.01 56.59 26.05 30.01\nNon-smokers  6799 17.59 52.67 40.67 59.76 31.73 34.53\nSmokers  2751 16,18 49,84 39.26 57.51 29.70 32.86\nTable IV: Multivariate binary logistic regression analysis.\n    50-70 years   Male   Non university   Smokers  \n  OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value\nFLI high risk  1.26 (1.13-1.40) <0.0001 3.88 (3.36-4.48) <0.0001 1.23 (1.01-1.49) 0.042  ns\nHSI high risk  1.31 (1.20-1.43) <0.0001 1.31 (1.20-1.43) <0.0001 1.21 (1.06-1.39) 0.006 1.10 (1.01-1.19) 0.026\nZJU high risk  1.37 (1.26-1.49) <0.0001 1.28 (1.17-1.39) <0.0001 1.22 (1.06-1.40) 0.007  ns\nFLD high risk  1.22 (1.12-1.33) <0.0001 1.94 (1.79-2.12) <0.0001  ns  ns\nLAP high risk  1.45 (1.33-1.58) <0.0001 1.91 (1.74-2.11) <0.0001 1.30 (1.12-1.52) 0.001  ns\nBSS high risk  6.01 (5.46-6.61) <0.0001 2.86 (2.57-3.17) <0.0001 1.29 (1.10-1.53) 0.002   ns38\n2021/36 (3): 34-39Liliana Laird et al.  \nby biopsy were more frequent in older persons, which \nled to the conclusion that age is strongly associated with \nthe development and progression of NAFLD. Something \nsimilar was observed in a study of 522 Indian diabetics23.              \n \nIn our research, males have a higher risk of developing \nNAFLD and hepatic fibrosis, these data are similar to those \nfound in the Chinese population24 where the OR were \n3.48 (similar to those found by us with FLI). In this study \nthe diagnosis was made with ultrasound. However, other \nauthors have found a higher prevalence in women23 and \nothers have found no differences between the sexes25.\nOur data indicate that the prevalence of NAFLD is higher in \npeople with lower socioeconomic status, and these data \ncoincide with those found by other authors. In a study carried \nout in a Chinese population26 it was found that people with \na low socioeconomic level were 2.19 times more at risk \nthan those with a higher standard of living. An investigation \nin 5272 Koreans27 assessing the relationship between \nsocial status and muscle strength with the occurrence \nof NAFLD showed that both low socioeconomic status \nand decreased muscle strength were independently and \nsynergistically associated with an increased risk of NAFLD \nin older persons. One study compared the prevalence of \nNAFLD in 21 countries28 with different economic status \nand concluded that prevalence correlated positively with \nthe per capita income of individuals, such that countries \nwith higher economic status tend to have a higher \nprevalence of NAFLD. A study in young people under 21 \nyears of age showed that NAFLD appeared earlier in the more economically disadvantaged group but there was no \ndifference in severity29. \nWe have only found a relationship between smoking and \nNAFLD when assessed with HSI, finding an increased \nprevalence among smokers. Two Korean studies also \nfound a positive relationship, one in almost 200,000 \npeople where current smoking levels, pack-years \nand urinary cotinine levels were positively associated \nwith the risk of developing NAFLD, suggesting that \nsmoking contributed to the development of NAFLD30. \nThe other Korean study in 160 862 persons31 with \nsimilar methodology concluded that cotinine-verified \ncurrent smoking and self-reported current smoking were \nindependent risk factors for NAFLD. A study in 8580 \nChinese32 over 40 years of age assessed the effect of \npassive and active smoking on NAFLD determined by \nultrasound and liver enzymes and observed that passive \nsmoking and heavy active smoking were associated with \nincreased prevalence. \nThe strengths of this study include the large sample size, \nalmost 10,000 people, and the large number of scales \nthat evaluate fatty liver and liver fibrosis, a total of 7 scales. \nAs limitations we would highlight the lack of objective \ndiagnostic methods for the diagnosis of NAFLD.\nConflicts of interest  \nThe authors declare no conflicts of interest.\nReferences \n1. Angulo P . Nonalcoholic fatty liver disease. N Engl J Med 2002; \n346:1221-31\n2. Vernon G, Baranova A, Younossi ZM. Systematic review: the \nepidemiology and natural history of non-alcoholic fatty liver disease and \nnon-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011 \nAug;34(3):274-85. \n3. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, \net al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic \nsteatohepatitis among a largely middle-aged population utilizing \nultrasound and liver biopsy: a prospective study. Gastroenterology. 2011 \nJan;140(1):124-31.\n4. Caballer\u00eda L, Pera G, Auladell MA, Tor\u00e1n P , Mu\u00f1oz L, Miranda D, et \nal. Prevalence and factors associated with the presence of nonalcoholic \nfatty liver disease in an adult population in Spain. Eur J Gastroenterol \nHepatol. 2010 Jan;22(1):24-32.\n5. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-\nalcoholic fatty liver disease. Dig Dis. 2010;28(1):155-61.\n6. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et \nal. The diagnosis and management of non-alcoholic fatty liver disease: \npractice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American \nGastroenterological Association. Hepatology. 2012 Jun;55(6):2005-23. \n7. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: \nnatural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic \naccuracy of non-invasive tests for liver disease severity. Ann Med. 2011 \nDec;43(8):617-49\n8. Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with \nnonalcoholic fatty liver disease. Semin Liver Dis. 2012 Feb;32(1):22-9. \n9. Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an \nemerging threat to obese and diabetic individuals. Ann N Y Acad Sci. \n2013 Apr;1281(1):106-22.\n10. Day CP . Non-alcoholic fatty liver disease: a massive problem. Clin \nMed (Lond). 2011 Apr;11(2):176-8\n11. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of \nnonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid \nmetabolites. Hepatology. 2010 Aug;52(2):774-88\n12. Browning JD, Horton JD. Molecular mediators of hepatic steatosis \nand liver injury. J Clin Invest. 2004 Jul;114(2):147-5239\n2021/36 (3): 34-39 Influence of sociodemographic variables and tobacco consumption on the risk of nonalcoholic fatty liver disease and liver fibrosis\n13. Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in \nNASH: Which is the best target to treat? J Hepatol. 2006 Feb;44(2):253-61.\n14. Jornayvaz FR, Shulman GI. Diacylglycerol activation of protein kinase \nC\u03b5 and hepatic insulin resistance. Cell Metab. 2012 May 2;15(5):574-84. \n15. Chiang JK, Koo M. Lipid accumulation product: a simple and \naccurate index for predicting metabolic syndrome in Taiwanese people \naged 50 and over. BMC Cardiovasc Disord. 2012; 12:78\n16. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, \nCastiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate \npredictor of hepatic steatosis in the general population. BMC \nGastroenterol. 2006; 6:33.\n17. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic \nsteatosis index: a simple screening tool reflecting nonalcoholic fatty liver \ndisease. Dig Liver Dis. 2010 ;42(7):503-8.\n18. Wang J, Xu C, Xun Y, Lu Z,Shi J, Yu Ch, et al. ZJU index: a novel \nmodel for predicting nonalcoholic fatty liver disease in a Chinese \npopulation. Sci Rep 2015;5:16494.\n19. Fuyan S, Jing L, Wenjun C, Zhijun T, Weijing M, Suzhen W, et al. \nFatty liver disease index: a simple screening tool to facilitate diagnosis \nof nonalcoholic fatty liver disease in the Chinese population. Dig Dis Sci. \n2013;58(11):3326-34.\n20. Long MT, Pedley A, Colantonio LD, Massaro JM, Hoffmann U, \nMuntner P , Fox CS. Development and Validation of the Framingham \nSteatosis Index to Identify Persons With Hepatic Steatosis. Clin \nGastroenterol Hepatol. 2016 Aug;14(8):1172-1180.\n21. Raszeja-Wyszomirska J, Szymanik B, \u0141awniczak M, Kajor M, \nChwist A, Milkiewicz P , et al. Validation of the BARD scoring system \nin Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC \nGastroenterol. 2010 Jun 28;10:67.\n22. Shima T, Seki K, Umemura A, Ogawa R, Horimoto R, Oya H, et \nal. Influence of lifestyle-related diseases and age on the development \nand progression of non-alcoholic fatty liver disease. Hepatol Res. 2015 \nMay;45(5):548-59.23. Kalra S, Vithalani M, Gulati G, Kulkarni CM, Kadam Y, Pallivathukkal \nJ, et al. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) \nin type 2 diabetes patients in India (SPRINT). J Assoc Physicians India. \n2013 Jul;61(7):448-53. \n24. Hu X-Y, Li Y, Li L-Q, Zheng Y, Lu J-H, Huang S-Cet al. Risk factors \nand biomarkers of non-alcoholic fatty liver disease: an observational \ncross-sectional population survey. BMJ Open 2018;8:e019974\n25. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of \nnon-alcoholic fatty liver disease. Dig Dis 2010;28:155-61. (art 9 ref 3)\n26. Jia G, Li X, Wang L, Li Q, Yang L, Li N, Di F. Relationship of \nsocioeconomic status and non-alcoholic fatty liver disease in patients \nwith type 2 diabetes mellitus. Zhonghua Gan Zang Bing Za Zhi. 2015 \nOct;23(10):760-4.\n27. Cho J, Lee I, Park DH, Kwak HB, Min K. Relationships between \nSocioeconomic Status, Handgrip Strength, and NonAlcoholic Fatty Liver \nDisease in Middle-Aged Adults. Int. J. Environ. Res. Public Health 2021; \n18: 1892.\n28. Zhu JZ, Dai YN, Wang YM, Zhou QY, Yu CH, Li YM. Prevalence \nof Nonalcoholic Fatty Liver Disease and Economy. Dig Dis Sci. 2015 \nNov;60(11):3194-202. \n29. Orkin S, Brokamp C, Yodoshi T, Trout AT, Liu C, Meryum S, et al. \nCommunity Socioeconomic Deprivation and Nonalcoholic Fatty Liver \nDisease Severity. J Pediatr Gastroenterol Nutr. 2020 Mar;70(3):364-70.\n30. Jung HS, Chang Y, Kwon MJ, Sung E, Yun KE, Cho YK, Shin H, Ryu \nS. Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort \nStudy. Am J Gastroenterol. 2019 Mar;114(3):453-63.\n31. Kim NH, Jung YS, Hong HP , Park JH, Kim HJ, Park DI, et al. \nAssociation between cotinine-verified smoking status and risk of \nnonalcoholic fatty liver disease. Liver Int. 2018 Aug;38(8):1487-94.\n32. Liu Y, Dai M, Bi Y, Xu M, Xu Y, Li M, Wang T, Huang F, Xu B, Zhang \nJ, Li X, Wang W, Ning G. Active smoking, passive smoking, and risk of \nnonalcoholic fatty liver disease (NAFLD): a population-based study in \nChina. J Epidemiol. 2013;23(2):115-21.40\n2021/36 (3): 40-44ORIGINAL\nResultados de la encuesta COVID-19 en alumnos, profesores \ny usuarios de la escuela universitaria ADEMA\nResults of the COVID-19 survey on students, teachers and users \nof the ADEMA University School\nYolanda Perell\u00f3 Alonso      , Dolores Llamas Canaves      , Pedro Alomar Velasco      , \nHernan Jos\u00e9 Paublini Oliveira      , Estefan\u00eda Garc\u00eda Ruiz      \nADEMA Escuela UniversitariaeISSN 2255-0569\nRecibido:  8 - IV - 2021\nAceptado:  15 - V - 2021\ndoi: 10.3306/AJHS.2021.36.03.40Correspondencia\nYolanda Perell\u00f3 Alonso   \nADEMA Escuela Universitaria \nGremi de Passamaners 11 2\u00ba 07009 Palma\nE-mail: y.perello@eua.edu.esID ID ID\nID\nResumen\nIntroducci\u00f3n: El SARS-Cov-2 es el coronavirus responsable de la pandemia que ha asolado el mundo desde finales del a\u00f1o \n2019, teniendo su origen en Wuhan. El cuadro cl\u00ednico incluye multitud de s\u00edntomas aunque los m\u00e1s frecuentes son fiebre, tos \nseca y dificultad para respirar, y tiene como complicaciones principales la neumon\u00eda, el s\u00edndrome respiratorio agudo o la sepsis.\nMaterial y m\u00e9todos: Se realiz\u00f3 una encuesta en 1296 usuarios (profesores, alumnos y pacientes de la cl\u00ednica odontol\u00f3gica) de la \nEscuela Universitaria ADEMA a los que se les pregunt\u00f3 sobre s\u00edntomas compatibles con la COVID en las dos semanas anteriores, \nsobre situaciones de riesgo de contagio y sobre el conocimiento del protocolo elaborado por el centro educativo.\nResultados: M\u00e1s del 99% de los encuestados no han tenido s\u00edntomas compatibles con una infecci\u00f3n por SARS-CoV-2 en \nlas dos semanas anteriores a completar la encuesta. Un porcentaje similar han cumplido con las normas establecidas por las \nautoridades sanitarias en lo referente al uso de mascarillas y no han estado en contacto o conviviendo con personas sospechosas \no diagnosticadas de la COVID. Menos del 1% est\u00e1n esperando los resultados de pruebas diagn\u00f3sticas y el 40,9% de los \nencuestados confirman que han le\u00eddo el protocolo elaborado por ADEMA para la pandemia.\nConclusiones: El n\u00famero de usuarios de la Escuela Universitaria ADEMA que han presentado s\u00edntomas o han estado expuestos \na situaciones de riesgo es muy bajo, inferior al 1%, mientras que el porcentaje de los que confirman haber le\u00eddo los protocolos \nelaborados para esta pandemia es muy bajo, de apenas un 40%.\nPalabras clave:  COVID-19, s\u00edndrome respiratorio agudo grave, encuestas epidemiol\u00f3gicas. \nSummary  \nIntroduction:  SARS-Cov-2 is the coronavirus responsible for the pandemic that has ravaged the world since the end of 2019, \nhaving its origin in Wuhan. The clinical picture includes a multitude of symptoms although the most frequent are fever, dry cough \nand shortness of breath, and has as main complications pneumonia, acute respiratory syndrome or sepsis.\nMaterial and methods:  A survey was made of 1296 users (teachers, students and patients of the dental clinic) of the ADEMA \nUniversity School who were asked about symptoms compatible with COVID in the previous two weeks, about situations of risk of \ncontagion and about knowledge of the protocol drawn up by the educational center. \nResults:  More than 99% of respondents had not had symptoms compatible with SARS-CoV-2 infection in the two weeks prior to \ncompleting the survey. A similar percentage have complied with the rules established by the health authorities regarding the use \nof masks and have not been in contact or living with persons suspected or diagnosed with COVID. Less than 1% are awaiting \ndiagnostic test results and 40.9% of respondents confirm that they have read the protocol developed by ADEMA for the pandemic.\nConclusions: The number of ADEMA University School users who have presented symptoms or have been exposed to risk \nsituations is very low, less than 1%, while the percentage of those who confirm having read the protocols elaborated for this \npandemic is very low, barely 40%.\nKeywords:  COVID-19, Severe acute respiratory s\u00edndrome, health surveys.41\n2021/36 (3): 40-44 Resultados de la encuesta COVID-19 en alumnos, profesores y usuarios de la escuela universitaria ADEMA\nIntroducci\u00f3n  \nLa COVID-19 es una pandemia ocasionada por el virus \nSARS-CoV-21. El primer caso apareci\u00f3 en diciembre de \n2019 en la ciudad de Wuhan2, al presentar un grupo \nde personas un tipo de neumon\u00eda desconocida. La \nmayor\u00eda de los individuos afectados ten\u00edan relaci\u00f3n con \ntrabajadores del Mercado Mayorista de Mariscos del \nSur de China de Wuhan3. La Organizaci\u00f3n Mundial de \nla Salud (OMS) la reconoci\u00f3 como pandemia el 11 de \nmarzo de 20204.\nEl virus se transmite esencialmente por peque\u00f1as gotas \nde saliva (microgotas de Fl\u00fcgge), que se emiten al hablar, \nestornudar, toser o espirar5-7 y tambi\u00e9n est\u00e1 documentada \nla transmisi\u00f3n por aerosoles (< 5\u03bcm). Su per\u00edodo de \nincubaci\u00f3n suele ser de cinco d\u00edas, pero puede variar de \ndos d\u00edas a dos semanas8,9. Los s\u00edntomas m\u00e1s comunes \nson fiebre, tos seca y dificultad para respirar8 mientras \nque las complicaciones pueden incluir la neumon\u00eda, el \ns\u00edndrome respiratorio agudo o la sepsis10-12. \nLas medidas de prevenci\u00f3n incluyen el lavado de manos, \nla desinfecci\u00f3n de superficies, cubrirse la boca al toser, \nel distanciamiento f\u00edsico entre las personas y el uso \nde mascarillas , adem\u00e1s del confinamiento domiciliario \ny el seguimiento para las personas sospechosas de \nestar infectadas6,13. La edad es un factor de riesgo (ser \nmayor de 65 a\u00f1os) y tambi\u00e9n lo son la presencia de \nenfermedades cr\u00f3nicas como la diabetes, cardiopat\u00edas, \nenfermedades respiratorias, inmunodeficiencias o  \nhipertensi\u00f3n arterial.\nLa pandemia ha tenido un gran impacto \nsocioecon\u00f3mico14, se han cerrado centros educativos \nen m\u00e1s de 124 pa\u00edses lo que ha afectado a m\u00e1s \nde 2200 millones de estudiantes15. Un tercio de la \npoblaci\u00f3n mundial est\u00e1 confinada existiendo importantes \nrestricciones a la libre circulaci\u00f3n16, lo que ha provocado \nuna dram\u00e1tica reducci\u00f3n de la actividad econ\u00f3mica17 \ny un incremento paralelo del desempleo18. Uno de los \npocos efectos positivos de la pandemia ha sido que \nla reducci\u00f3n de los viajes y el cierre de numerosas \nempresas ha provocado un importante descenso en la \ncontaminaci\u00f3n atmosf\u00e9rica19,20.\nA 1 de abril de 2021 se hab\u00edan contabilizado m\u00e1s de \n130,2 millones de casos en 255 pa\u00edses y 2.840.729 de \nfallecidos. En octubre de 2020, la OMS estimaba que \nal menos un 10 % de la poblaci\u00f3n mundial  se hab\u00eda \ncontagiado, debido al gran subregistro de casos a nivel \nmundial21,22.\nEl objetivo de este estudio es conocer la prevalencia de \ns\u00edntomas sospechosos de COVID y el conocimiento de \nla obligatoriedad de comunicarlos entre los usuarios de \nla Escuela Universitaria ADEMA .Metodolog\u00eda  \nSe realiz\u00f3 un estudio descriptivo y transversal en 1.346 \nusuarios (profesores, alumnos y pacientes de la cl\u00ednica \nodontol\u00f3gica) de la Escuela Universitaria ADEMA en el \nperiodo septiembre 2020 y enero 2021, de ellos 50 no \nse incluyeron (29 por no aceptar la cesi\u00f3n de los datos \ny 21 por no responder a todas las preguntas) por lo que \nfinalmente entraron en el estudio 1296 personas. (ver \nflujograma en la figura 1 ).\nSe elabor\u00f3 un cuestionario no validado de 12 preguntas, \nlas cinco primeras valoraban la presencia de s\u00edntomas \nde la COVID (fiebre, tos, otros s\u00edntomas respiratorios, \ndiarrea, cansancio o malestar general), las \u00faltimas ocho  \npreguntas se centraban en situaciones de riesgo o en \nla realizaci\u00f3n de pruebas diagn\u00f3sticas. La encuesta la \nrealiz\u00f3 personal sanitario entrenado.\nAn\u00e1lisis estad\u00edstico\nSe realiza un an\u00e1lisis descriptivo de las variables \ncateg\u00f3ricas, calculando la frecuencia y distribuci\u00f3n de \nrespuestas de cada una de ellas. Para las variables \ncualitativas se calcula el porcentaje. El an\u00e1lisis estad\u00edstico \nse realiza con el programa SPSS 27.0 siendo el nivel de \nsignificaci\u00f3n estad\u00edstica aceptado de 0,05. \nConsideraciones y aspectos \u00e9ticos\nTodos los procedimientos se realizaron de acuerdo con \nlas normas \u00e9ticas del comit\u00e9 de investigaci\u00f3n institucional \ny con la Declaraci\u00f3n de Helsinki de 2013. Todos los \npacientes firmaron documentos de consentimiento \ninformados por escrito antes de participar en el estudio. Figura 1: Diagrama de flujo de los participantes en el estudio. \n1296 personas \nparticipan \nfinalmente \nen el estudio\n29 no aceptaron \nceder los datos1346 personas \niniciaron el estudio\n21 no hab\u00edan \nrespondido \na todas \nlas preguntas42\n2021/36 (3): 40-44Yolanda Perell\u00f3 et al.  \nResultados  \nLa inmensa mayor\u00eda de los encuestados (m\u00e1s del \n99%) no han presentado s\u00edntomas compatibles con \nuna infecci\u00f3n con la COVID-19 en los d\u00edas o semanas \nanteriores a la realizaci\u00f3n de la encuesta. Tambi\u00e9n \nla gran mayor\u00eda de los encuestados no han estado \nexpuestos a situaciones de riesgo de esta pandemia. Casi ninguno de los encuestados (menos del 1%) est\u00e1n \nesperando el resultado de pruebas diagn\u00f3sticas para la \nCOVID. Pr\u00e1cticamente todos los encuestados conocen \nla obligaci\u00f3n de comunicar cualquier cambio que pueda \nestar relacionado cola COVID, mientras que s\u00f3lo un \n40,9% conocen el protocolo de la Escuela Universitaria \nADEMA frente a la pandemia. Todos los datos se \npresentan en las figuras 2a , 2b y 2c.\nFigura 2a: Resultados del cuestionario. Figura 2b: Resultados del cuestionario. \n\u00bfPresenta o ha presentado fiebre en los \u00faltimos 4 d\u00edas previos? \u00bfPresenta o ha presentado p\u00e9rdida de olfato o del sentido del gusto en \nlos 14 d\u00edas previos?\n\u00bfPresenta o ha presentado diarrea o signo digestivo \nen los 14 d\u00edas previos?Si se ha realizado alg\u00fan tipo de test y este ha dado positivo\n\u00bfPresenta o ha presentado tos o cualquier otro signo respiratorio \nen los 14 d\u00edas previos?\u00bfHa estado en contacto o conviviendo con alguien sospechoso \no confirmado de COVID-19?\n\u00bfPresenta o ha presentado cansancio, malestar general en los 14 \nd\u00edas previos?Est\u00e1 esperando el resultado de alg\u00fan test de COVID-19No No\nNo No\nNo No\nNo No99,8% 99,7%\n99,5% 99,5%\n99,4% 97,2%\n99%99,8%S\u00ed S\u00ed\nS\u00ed S\u00ed\nS\u00ed S\u00ed\nS\u00ed S\u00ed43\n2021/36 (3): 40-44 Resultados de la encuesta COVID-19 en alumnos, profesores y usuarios de la escuela universitaria ADEMA\nDiscusi\u00f3n\nLos resultados de nuestro estudio ponen de manifiesto \nque la pr\u00e1ctica totalidad de las personas encuestadas \nno presentaban s\u00edntomas sospechosos de infecci\u00f3n por \nSARS-CoV-2 en ninguna de sus modalidades cl\u00ednicas, \nya que m\u00e1s del 99% de ellos eran asintom\u00e1ticos. Un \nporcentaje similar no recordaban haber tenido contactos \ncon personas sospechosas de sufrir la enfermedad. Del \nmismo modo un porcentaje tambi\u00e9n muy elevado cumpl\u00eda \ncon las normas de seguridad en lo referente al uso de \nmascarillas y distancia de seguridad. Un dato a destacar \nes que poco m\u00e1s del 40% hab\u00edan le\u00eddo los protocolos \nelaborados por la Escuela Universitaria ADEMA.\nNo hemos encontrado en la literatura encuestas similares \nrealizadas en centros educativos pero si dos actividades \nrealizadas en poblaci\u00f3n general. La primera de ellas la \nrealiz\u00f3 Madrid Salud en 39799 personas, la mayor\u00eda de \nla Comunidad de Madrid. A diferencia de lo observado \nen nuestro estudio solo el 61% no ha tenido s\u00edntomas y \npiensa que no se ha contagiado y el 6% no sabe si se \nha contagiado, pero ha guardado cuarentena por haber \nestado en contacto con personas contagiadas23. El \nsegundo estudio se realiz\u00f3 en el Gobierno de Colima, en \nM\u00e9xico, con el objetivo de cotejar la tasa de confirmaci\u00f3n \nde personas infectadas con coronavirus identificando a \nlos contagiados activos que no hab\u00edan sido detectados y as\u00ed evitar que se expanda el n\u00famero de contagios. \nLa estrategia denominada Dapecode (Detecci\u00f3n \nAcelerada de Personas Contagiadas No Detectadas) \npermiti\u00f3 localizar al 15% de personas, que en uno o m\u00e1s \nmiembros de la familia, resultaron positivos al Covid-19. \nEst\u00e1s cifras son tambi\u00e9n muy superiores a las obtenidas \npor nosotros.\nComo fortalezas del estudio destacaremos el elevado \ntama\u00f1o muestral y que es la primera encuesta de estas \ncaracter\u00edsticas en el \u00e1mbito educativo. Como limitaciones \nque no se han podido estratificar los resultados por \nsexo, grupos de edad o colectivo al que pertenec\u00edan \n(profesores, alumnos o usuarios de la cl\u00ednica).\nConflicto de intereses\nLos autores no declaran conflicto de intereses.\nContribuci\u00f3n de los autores\nDise\u00f1o del estudio: YP , recogida de datos YP , PA, an\u00e1lisis \nestad\u00edstico HP   metodolog\u00eda D, PA, HP , redacci\u00f3n del \nmanuscrito YP revisi\u00f3n del manuscrito PA, HP ,D.Figura 2c: Resultados del cuestionario. \n\u00bfSe han realizado salidas o encuentros sin mantener \nlas distancias de seguridad?\u00bfHa habido encuentros con gran n\u00famero de personas y sin mascarilla?\nHe le\u00eddo el protocolo que ADEMA Escuela Universitaria ha establecido y \ntiene colgado en la plataforma virtualTengo conociemiento o la obligaci\u00f3n de informar si se produce \nalguna variaci\u00f3n en los datos que he aportado en la presente \nencuesta\nNo 99,3%S\u00edNo 97,8%S\u00ed\nNo 99,6%S\u00ed\nNo59,1%\nS\u00ed\n40,9%44\n2021/36 (3): 40-44Yolanda Perell\u00f3 et al.  Resultados de la encuesta COVID-19 en alumnos, profesores y usuarios de la escuela universitaria ADEMA\nBibliograf\u00eda     \n1. Enfermedad por coronavirus, COVID-19. Centro de Coordinaci\u00f3n \nde Alertas y Emergencias Sanitaria. 4 de abril de 2020. Disponible \nen; https://www.mscbs.gob.es/profesionales/saludpublica/ccayes/\nalertasactual/ncov-china/documentos/20200404_itcoronavirus.pdf\n2. Huang Ch, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of \npatients infected with 2019 novel coronavirus in Wuhan, China.  Lancet \n2020;395(10223):497-506.  \n3. Nuevo coronavirus - China\u00bb. Organizaci\u00f3n Mundial de la Salud \n(OMS). Disponible en: http://www.who.int/csr/don/12-january-2020-\nnovel-coronavirus-china/es/\n4. Alocuci\u00f3n de apertura del Director General de la OMS en la rueda \nde prensa sobre la COVID-19 celebrada el 11 de marzo de 2020. \nOrganizaci\u00f3n Mundial de la Salud. Disponible en: http://www.who.int/\nes/director-general/speeches/detail/who-director-general-s-opening-\nremarks-at-the-media-briefing-on-covid-19---11-march-2020\n5. Carl Fl\u00fcgge y las gotas de saliva que se expulsan al hablar. Disponible \nen: http://alef.mx/ carl- fl\u00fcgge-y-las- gotas-de-saliva-que-se-expulsan-\nal-hablar/\n6. Saltar A: Q&A on coronaviruses. World Health Organization. Disponible \nen: http://www.who.int/news-room/q-a-detail/q-a-coronaviruses\n7. Coronavirus Disease 2019 (COVID-19) - Transmission\u00bb. Centers for \nDisease Control and Prevention. Disponible en: http://www.cdc.gov/\ncoronavirus/2019-ncov/prepare/transmission.html\n8. Saltar A: Symptoms of Novel Coronavirus (2019-nCoV)\u00bb. US Centers \nfor Disease Control and Prevention. Disponible en: http://www.cdc.gov/\ncoronavirus/2019-ncov/about/symptoms.html\n9. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis \nof coronavirus disease (COVID-19) outbreak. J Autoimmun \n2020;109:102433.\n10. Coronavirus Disease 2019 (COVID-19). Centers for Disease Control \nand Prevention. Disponible en: http://www.cdc.gov/coronavirus/2019-\nncov/hcp/clinical-guidance-management-patients.html\n11. La sepsis causa la mayor\u00eda de las muertes por coronavirus\u00bb. El Mundo \n(Espa\u00f1a). 24 de marzo de 2020. Disponible en: http://www.elmundo.es/\nciencia-y-salud/salud/2020/03/24/5e6cb95afdddffba6b8b45ab.html\n12. Coronavirus: los supervivientes conservan ARN del virus hasta 20 \nd\u00edas. Redacci\u00f3n M\u00e9dica. 10 de marzo de 2020. Disponible en: http://\nwww.redaccionmedica.com/secciones/sanidad-hoy/coronavirus-\nsupervivientes-conservan-ARN-del-virus-hasta-20-d\u00edas-2123\n13. Recomendaciones de la OMS respecto al coronavirus. Disponible en: \nhttp://www.who.int/es/emergencies/diseases/novel-coronavirus-2019/\nadvice-for-public/q-a-coronaviruses14. Here Comes the Coronavirus Pandemic: Now, after many fire drills, \nthe world may be facing a real fire. Editorial. The New York Times. 29 de \nfebrero de 2020. Disponible en: http://www.nytimes.com/2020/02/29/\nopinion/sunday/corona-virus-usa.html\n15. COVID-19 Educational Disruption and Response. UNESCO. 20 de \nmarzo de 2020. Disponible en: http://e..unesco.org/themes/education-\nemergencies/coronavirus-school-closures\n16. Un tercio de la poblaci\u00f3n mundial, confinada por coronavirus. \nEl Peri\u00f3dico de Extremadura. Disponible en: http://www.\nelperiodicoextremadura.com/noticias/sociedad/tercio-poblacion-\nmundial-confinada-coronavirus_1225789.html\n17. El FMI alerta que el covid-19 llevar\u00e1 al mundo a una recesi\u00f3n como \nla de 1930. Heraldo de Arag\u00f3n. Disponible en: http://www.heraldo.es/\nnoticias/economia/2020/04/14/e-fmi-alerta-que-el-covid-19-llevar\u00e1-al-\nmundo-a-una-recesion-como-la-de-1930-1369570.html\n18. El COVID-19 podr\u00eda cobrarse casi 25 millones de empleos en el \nmundo, afirma la OIT. Organizaci\u00f3n Internacional del Trabajo. 18 de \nmarzo de 2020. Disponible en: http://www.ilo.org/global/about-the-ilo/\nnewsroom/news/wcms_738766/lang--es/index.htm\n19. Watts J, Kommenda N. Coronavirus pandemic leading to huge drop \nin air pollution. The Guardian. 2020. ISSN 0261-3077. \n20. Analysis: Coronavirus temporarily reduced China's CO2 emissions \nby a quarter. Carbon Brief. 19 de febrero de 2020. Disponible en: http://\nwww.carbonbrief.org/analysis-coronavirus-has-temporarily-reduced-\nchinas-co2-emissions-by-a-quarter\n21. El Pa\u00eds 5 de octubre de 2020. La OMS estima que el 10% de \nla poblaci\u00f3n mundial se ha contagiado de covid, 22 veces m\u00e1s que \nlos casos diagnosticados. Disponible en: http://www.elpais.com/\nsociedad/2020/10/05/la-OMS-estima-que-el-10-de-la-poblacion-\nmundial-se-ha-contagiado-de-covid-22-veces-mas-que-los-casos-\ndiagnosticados.html\n22. COVID-19 Virtual Press conference transcript - 12 October 2020. \nwww.who.int.\n23. Encuesta sobre el Impacto de la pandemia de COVID - 19 y el \nconfinamiento en la salud de la poblaci\u00f3n. Disponible en: www.\nmadrid.es/unidadescentralizadas/salud/gestionevaluacionycalidad/\npublicaciones/ficheros/avance_de_resultados_encuestacovid_19_\nmadridsalud.pdf \n24. Con encuestas telef\u00f3nicas, gobierno de Colima busca detectar \ncasos de Covid-19. Disponible en: https://www.milenio.com/estados/\ncolima-buscan-detectar-casos-covid-19-encuestas-telefonicas45\n2021/36 (3): 45-51ORIGINAL\nClostridium histolyticum collagenase (Xiapex\u00ae) in patients \nwith peyronie disease. Expectations vs reality\nColagenasa clostridium histolyticum (xiapex\u00ae) en pacientes \ncon enfermerdad peyronie. Expectativas vs realidad\nPedro \u00c1lvarez D\u00edaz      , Yumaira Hern\u00e1ndez Mart\u00ednez, \nAntonio Servera Ruiz de Velasco      ,  Mar\u00eda Reyes Garc\u00eda-Miralles Gravalos, \nJoan Mar\u00eda Benejam Gual\nUrology Department. Manacor Hospital.eISSN 2255-0569\nRecibido:  7 - V - 2021\nAceptado:  18 - VI - 2021\ndoi: 10.3306/AJHS.2021.36.03.45Corresponding author\nPedro \u00c1lvarez D\u00edaz   \nUrology Department. Manacor Hospital \nCarretera Manacor Alcudia, s/n, 07500 Manacor. \nBalearic Islands. Spain\nE-mail: palvarez@hmanacor.org\nAbstract  \nIntroduction:  Peyronie's disease conditions the deformity of the penis. Its etiology and effective treatment to prevent surgery have \nnot been determined. The approval of Xiapex\u00ae, collagenase from Clostridium histolyticum, generated great expectations.\nJustification and objectives:  Drug of recent use in Europe that requires multicenter studies to support its application. The aim is \nto collect the clinical results obtained from the implantation of Xiapex\u00ae.\nMaterial and methods:  A study of 24 patients treated with Xiapex\u00ae between 2017 and 2020 was carried out. Previous data was \ncollected in consultation and information on the results by telephone questionnaire.\nResults:  The initial deviation was 61.4 degrees with a dorsal direction in 59%. 77% of the patients completed the 4 cycles. 41% \nreported having improved and would recommend the use of Xiapex\u00ae. 95% improved penile pain.\nDiscussion:  Numerous studies have been published on Xiapex\u00ae. Many focus on modifying the treatment scheme proposed by \nthe manufacturer, either by reducing the number of cycles or by the use of vacuum or traction devices. It is known that it is a disease \nwith an important psychological profile, so it is necessary to consider the assessment of subjective results.\nConclusions: New studies are needed to collect and assess the real ability to modify the course of the disease with Xiapex\u00ae. It is \nnecessary to insist on clear and concise inclusion and exclusion criteria, as well as a treatment scheme that achieves reproducible results.\nKeywords:  Peyronie, colagenasa, Xiapex, Clostridium, Histlyticum, curvature. \nResumen\nIntroducci\u00f3n: La Enfermedad de Peyronie condiciona la deformidad del pene. No se ha determinado su etiolog\u00eda ni tratamiento \neficaz que evite la cirug\u00eda. La aprobaci\u00f3n de Xiapex\u00ae, colagenasa de Clostridium histolyticum, gener\u00f3 grandes expectativas.\nJustificaci\u00f3n y objetivos: F\u00e1rmaco de reciente uso en Europa que precisa de estudios multic\u00e9ntricos que avalen su aplicaci\u00f3n. \nSe busca recoger los resultados cl\u00ednicos obtenidos de la implantaci\u00f3n de Xiapex\u00ae.\nMaterial y m\u00e9todos: Se ha realizado un estudio de 24 pacientes tratados con Xiapex\u00ae entre 2017 y 2020. Los datos previos se \nrecogieron en consulta y la informaci\u00f3n sobre los resultados mediante cuestionario telef\u00f3nico.\nResultados: La desviaci\u00f3n inicial fue de 61,4 grados con direcci\u00f3n dorsal en el 59%. El 77% de los pacientes completaron los 4 \nciclos. El 41% refer\u00eda haber mejorado y recomendar\u00eda el uso de Xiapex\u00ae. Un 95% mejor\u00f3 del dolor peneano.\nDISCUSI\u00d3N: Han sido publicados numerosos estudios sobre Xiapex\u00ae. Muchos se centran en la modificaci\u00f3n del esquema de \ntratamiento propuesto por el fabricante, bien por la disminuci\u00f3n del n\u00famero de ciclos o bien por el uso de dispositivos de vac\u00edo o \ntracci\u00f3n. Se sabe que se trata de una enfermedad con un importante perfil psicol\u00f3gico por lo que hay que considerar la valoraci\u00f3n \nde los resultados subjetivos.\nConclusiones: Quedan muchos estudios por realizar que recojan y valoren la capacidad real de modificaci\u00f3n del curso de la \nenfermedad con Xiapex\u00ae. Es necesario insistir en unos criterios de inclusi\u00f3n y exclusi\u00f3n claros y concisos, as\u00ed como un esquema \nde tratamiento que consiga resultados reproductibles.\nPalabras clave:  Peyronie, colagenasa, Xiapex, Clostridium, Histlyticum, curvatura. ID\nID\nID46\n2021/36 (3): 45-51Pedro \u00c1lvarez et al.  \nIntroduction\nPeyronie's disease is a disorder that causes the deformity \nof the penis, mainly, causing its curvature. However, it \ncan lead to other results such as shortening, narrowing... \nIn addition, it can associate other disorders or alterations \nsuch as erectile dysfunction.\nIts etiology is not clearly defined and there are several \ntheories for its justification. The most accepted, explains \nthat it occurs as a result of a healing process that gives \nrise to the appearance of fibrotic plaques in the tunica \nalbuginea of the penis. ( Figure 1 ).\nThe disease occurs in two phases. A first acute phase, \nwhich associates pain and in which penile curvature \nappears, followed by another chronic phase, which does \nnot usually associate pain, in which the fibrotic plaque \nand curvature tend to stabilize.\nFor many years, urology has sought medical treatments \nthat improve the patient's symptoms, penile curvature \nand deformity. However, good clinical results have not \nbeen achieved.\nThe European Medicines Agency approved in 2014 \nthe use of collagenase from Clostridium histolyticum \nintraplaca (Xiapex\u00ae) for the treatment of adult men with \nPeyronie's disease, with a palpable plaque and curvature \ndeformity of the penis of at least 30 degrees when start \ntreatment.\nAs a last resort, surgical treatment continues. It is the \none that achieves the greatest penile correction. The \nmost used involve the plication of the tunica albuginea, \nthe excision of the fibrous plaque, the application of \nincisions in them and, even, the implantation of penile \nprostheses to solve, in turn, the usually coexisting erectile \ndysfunction. Justification and objectives\nThe arrival of Xiapex\u00ae was a motivation for urology, \nespecially for andrological urologists who for many years \nhad seen how patients who came to their consultations \nwith this disorder could only offer not completely effective \nmedical treatment or surgical treatment with the derived \ncomplications.\nTreatment with collagenase from Clostridium histolyticum \nwas already known for its use for Dupuytren's disease \nwith palpable plaque. It is a disorder that results from a \nfibrotic process in the palmar fascia of unknown origin \nthat causes progressive closure of the hand due to \nretraction of the superficial palmar aponeurosis. \nThe drug is composed of two collagenase enzymes \nwhose coexpression and isolation is obtained from \nthe anaerobic fermentation of a strain of the bacterium \nClostridium histolyticum selected for its phenotypic \ncharacteristics. These collagenases, called AUX-I and \nAUX-II, are representative of the two main classes of \ncollagenases produced by the germ.\nCollagenases are proteinases that hydrolyze collagen, \neffectively cleave interstitial collagen such as that present \nin penile fibrotic plaques. Injection of Xiapex\u00ae into a \nPeyronie's plate can cause enzymatic rupture of the \nplate. After plaque rupture, penile curvature deformity and \npatient discomfort from Peyronie's disease are reduced.\nMaking a review of the current bibliography, there are no \nworks that assess the application of this novel treatment \nin our closest environment. For this reason, we consider \nit essential to carry out a study that analyzes the clinical \nresults obtained after the implantation of treatment with \nXiapex\u00ae. The elements necessary to consider if the \ntreatment with the collagenase injection has met the \nexpectations generated after its approval for use will be \nevidenced or, on the contrary, if we find another non-\nsurgical treatment whose efficacy is not always objective. \n \nMaterials and methods\nThis is a prospective study on patients who were \ncandidates for treatment with Xiapex\u00ae. 24 patients \nwere selected to undergo treatment with Clostridium \nhistolyticum Xiapex\u00ae collagenase between January \n2017 and March 2020. Of the total number of patients \nundergoing treatment, 2 of them refused to participate in \nthe present study.\nInitial clinical data and characteristics were collected \nin the consultation before initiating treatment with \nClostridium histolyticum collagenase. The results \nrelated to the response to treatment were collected by \ntelephone call to the patients since, in the context of a \nFigure 1: Image taken from https://www.mens-app.es/enfermedad-de-peyronie/. 47\n2021/36 (3): 45-51\n Clostridium histolyticum collagenase (xiapex\u00ae) in patients with peyronie disease. Expectations vs reality\nCOVID-19 pandemic, it was not possible to proceed to \nthe appointment of the patients at the hospital center for \nthe measurement and collection of results. \nInitially, variables related to clinical aspects were \nanalyzed, such as age at the onset of symptoms and at \nthe beginning of treatment, risk factors (Diabetes Mellitus, \narterial hypertension and vascular diseases) and if they \nhad received previous medical treatment and what it had \nbeen. Likewise, variables related to the characteristics of \nthe penis deformity were obtained, such as the angle \nof curvature, its direction, the length and width of the \nplate and, finally, whether they presented penile pain \nassociated with the erection.\nRegarding the information on the result of the treatment, \ncollected through individualized telephone calls to the \ntreated patients, questions were asked about general \nsatisfaction with the treatment, reduction of the angle of \ncurvature, modification of penile length, penile pain, if they \nwould repeat the treatment and if would recommend it.\nThe application of the treatment was carried out \nfollowing the indications that appear in the \"Product \nSheet\", respecting the inclusion criteria: palpable plaque \nand curvature deformity of at least 30 degrees at the \nbeginning of the treatment and less than 90 degrees. \nPatients with ventral deformity, \"hourglass\" or calcified \nplaque were excluded.\nThe complete treatment consists of applying 4 cycles. \nEach of them consists of 2 injections of the drug and an \nin-office penis modeling process. It should be between \n1 to 3 days between the first injection and the second. \nModeling is done 1 to 3 days after the second injection. \nThe cycles should be approximately 6 weeks apart. In \nthe time that elapses between one cycle and the next, \nthe patient must perform penis modeling activities on a \ndaily basis. (See figure 2 , 3)\nPenis modeling is a manual procedure that helps reduce \ncurvature deformity and straighten the shaft of the penis. In \naddition to this in-office penis modeling procedure, patients \nwere instructed to perform penis modeling at home.\nIt can be administered up to a total of 4 treatment cycles, \nthat is, 8 injections and 4 modeling procedures. A smaller \nnumber of cycles may be applied if the urology physician \nso indicates, if the patient refuses to continue with the \ntreatment or, as indicated in the Technical Data Sheet, if \nthe angle of the curvature after the first, second or third \ncycle is less 15 degree. (See figure 4 ).\nResults\nThe treatment was applied in 22 male patients whose \nmean age was 59.3 years (range 39-73 years). Regarding Figure 2: Image taken from  \"Gu\u00eda para el m\u00e9dico en el tratamiento de la \nEnfermedad de Peyronie con Xiapex\".\nFigure 3: Image taken from \"Gu\u00eda para el m\u00e9dico en el tratamiento de la Enfermedad \nde Peyronie con Xiapex\".\nFigure 4: Modeling process. Image taken from https://tratamientopeyronie.com/\nfase-cronica/tratamiento-no-invasivo-inyectable/\n48\n2021/36 (3): 45-51Pedro \u00c1lvarez et al.  \ncardiovascular risk factors, 18,2% had Diabetes Mellitus \n(DM) and 27.3% had Arterial Hypertension (HT).\n40.9% of the patients had previously received treatment \nwith Auxin\u00ae, a drug that is used orally whose components \nare Vitamin A and E. In 4 of the patients who had received \nthis treatment, other drugs such as Tamoxifen (3 cases) \nand Verapamil (1 case). \nThe time elapsed between the onset of symptoms related \nto Peyronie's disease and the start of treatment with \nXiapex\u00ae was, on average, 1.2 years (range 0-3 years).\nRegarding the clinical characteristics of the disease, the \nmean penile curvature angle was 61.4 degrees with a \ndorsal direction in 59.1% of the cases; in only 1 case \nthere was curvature towards purely right laterality, the rest \nbeing to the left laterality. (See figure 5 ).\nThe mean length of the fibrotic plaque was 2.3 cm (range \n0.5-4 cm) and the mean width was 1.2 cm (range 0.5-\n2.5 cm). 27.3% of the patients had pain before starting \ntreatment.\nIn 77.27% of the patients, 4 treatment cycles were \napplied, that is, 8 injections of Xiapex\u00ae. In two cases, \ntreatment could not be continued because patients \ndid not continue to attend check-ups. In 1 case it was \nsuspended due to not obtaining results and in another \ndue to the appearance of another additional fibrotic \nplaque. Finally, treatment could not be continued in 1 \ncase due to the European shortage of Xiapex\u00ae.\nThe evaluation of the results was carried out by means \nof a telephone call to the patients. 40.91% of them (9 \npatients) reported improvement after completing the \ntreatment, and 31.82% (7 cases) indicated that they had \nperceived a decrease in the angle of penile curvature.\nIt is curious that 3 of the patients who claimed to have \nimproved after treatment reported not having improved \nin the angle of curvature. This leads us to think that the \nimprovement to which they referred was related to the disappearance of pain and the stabilization of the process, \nas well as to their overall psychological satisfaction.\nOn the other hand, one patient reported having noticed a \ndecrease in the angle of curvature but, nevertheless, he \nconsidered that this fact alone did not improve his initial \nclinical situation.\nRegarding penile pain, especially related to erection, \n95.45% of the patients answered that it had disappeared. \nOne of the main problems of penile curvature correction is \npenile shortening, 50% (11 cases) of the patients reported \nthis fact. Finally, 40.91% of the patients would recommend \nXiapex\u00ae treatment to other patients. (See figure 6 ).\nAs adverse reactions, only mention 1 case that presented \nsevere but self-limited hematoma that did not require \nsurgical drainage. \nDiscussion\nPeyronie's disease has been studied for more than 260 \nyears since Fran\u00e7ois de la Peyronie described it in 1743. \nDespite this, epidemiological data that are currently \navailable are limited. According to Chung et al1. the \ndisease presents a prevalence rate between 0.4-20.3%, \nwith a higher prevalence among patients with Diabetes \nMellitus and erectile dysfunction. As can be seen, the \nrange provided in the different studies is still very wide. \nIn the USA, Stuntz et al2. (2016) carried out a survey in \nwhich 0.7% confirmed cases were determined compared \nto 11% of probable cases, which suggests that it is an \nunderdiagnosed disease. \nThe age of onset of the disease is usually between 50-\n60 years, although more and more cases are reported in \nyounger patients. In our study, the mean age coincides \nwith that usually referred to, however, it can be stated that \nthere are cases of younger patients, such as a 39-year-\nold patient who participated in the study.\nThe most commonly associated risk factors are diabetes, \nhigh blood pressure and vascular diseases, as can be \nseen in the results obtained in the present study.Figure 5. Direction angle curvature.Figure 6. Main variables taken from the telephone questionnaire (%).\nLEFT\n36,4%DORSAL\n59,1%RIGHT\n4,5%\nSatisfaction \nwith treatmentCurvature angle\ndecrease40,9131,8295,45\n40,91\nPenile pain\ndisappearenceRecommend\ntreatment49\n2021/36 (3): 45-51 Clostridium histolyticum collagenase (xiapex\u00ae) in patients with peyronie disease. Expectations vs reality\nIn general, the first symptom usually referred to is penile \ndeformity (52-94%) followed by penile pain (20-70%), \nas described in their study by Pryor3 and Ralph4. The \nappearance of fibrotic plaques is reported as an initial \nsymptom in 39% of patients with a dorsal deviation as \nthe most frequent; as in the current study where it was \npresent in 59% of the cases. \nIt is a disease with an important psychological affectation. \nValidated questionnaires and multiple studies, as reported \nby Nelson et al5, show that around 50% of patients with \nPeyronie's disease have moderate or severe depression.\nClassically, the management of the disease was based \non the choice of surgical treatment over conservative \ntreatment. Regarding the conservative, the studies \nare often contradictory and with very unsuccessful \nresults. They mainly consisted of oral treatments such \nas pentoxifylline, vitamin E, tamoxifen, procarbazine, \npotassium paraminobenzoate (POTABA), among others.\nOne of the most used had been potassium para-\naminobenzoate (POTABA); It is a drug with an anti-\ninflammatory and fibrinolytic effect due to the activation of \nmonoamine oxidase. It was the only oral drug approved by \nthe American drug agency for Peyronie's disease based \non studies that concluded that, although it does not \nreduce penile curvature, it could prevent its progression.\nAnother option was colchicine, which could be given in \ncombination with vitamin E. Colchicine is an alkaloid that \ninhibits the formation of microtubules and the secretion of \ncollagen by fibroblasts. The second is an antioxidant with \nan effect on tissue regeneration. It was claimed that they \ncould reduce pain, the size of the plaque and, in some \ncases, the degree of curvature.\nAlthough, in routine medical practice a very insignificant \neffect was evidenced with these drugs. Even in the \nabsence of adverse events, it was found that treatment \nwith these could delay the approach to the disease in a \nmore effective way.\nTreatment with Xiapex\u00ae for all this was a before and after, \nit was not just another treatment option, it was the only \nnon-surgical option that initially offered very promising \nresults. Many centers, after being approved in Europe \nand despite the high economic cost involved, began \nto apply it to be able to offer patients with Peyronie's \ndisease what was supposed to be an effective and non-\nsurgical treatment. \nThe approval of this drug came after the IMPRESS I \nand II clinical trials. These are randomized, double-blind, \nplacebo-controlled trials. Overall, a mean improvement \nin curvature of 34% was demonstrated compared to \n18.2% in the placebo group. It was established that the \ngreatest probability of improvement in curvature was in plaques curved between 30 and 60\u00ba, longer duration of \nthe disease and absence of calcification. However, it is \ncurious that 18.2% improved in the placebo arm. \nOne of the most controversial aspects has been the \nreference to the number of cycles. Many groups have \nstudied the influence of the number of cycles on the \nresults obtained. Anaissie et al6 in a retrospective review \nof 77 patients treated between April 2014 and March \n2016 concludes that the therapeutic benefit decreases \nfrom the third cycle, not finding significant differences \nfrom this in the results obtained. In the same study, the \nresearchers wanted to find predictive response factors, \nfinding that only the response that the patient presents \nafter the first cycle can serve to predict the final response. \nThey consider that the 4-cycle protocol proposed in the \nproduct sheet is not being applied in most of the centers \ndue to its high cost and difficulty in compliance with care. \nIn most centers, alternative protocols are applied with \nfewer injections and adding traction mechanisms.\nIn the present study, the number of cycles indicated in \nthe product sheet has been maintained. Although in \nsome cases no significant improvement was observed \nafter the application of the injections, the initial idea was \nmaintained in order to be able to homogenize results and \nmake a more objective comparison. Two patients who \ndecided not to continue applying the treatment should \nbe highlighted.\nAs mentioned above, in the period that elapses between \ncycle and cycle, penile modeling must be applied. This fact \nhas also been questioned or valued in different studies. \nZiegelmann et al7 conducted a study in which 51 patients \nwho completed the 4 cycles of collagenase treatments \nwere analyzed and were divided into 2 groups: 35 patients \nunderwent mechanical traction modeling and the rest \nwithout said device. No statistically significant differences \nwere found in curvature reduction or penetration ability. \nDifferences were reported, although with no degree of \nsignificance, in penis length, being + 0.4cm on average \nin the group that used the traction device. In the study by \nRaphl et al4 include 2 groups in which a vacuum device is \nused with the difference that, in one of them, in addition, \nclassical modeling is performed. It reports that there are \nno significant differences in the reduction of the angle \nof curvature. On the contrary, Fern\u00e1ndez-Pascual et al8 \ncarry out a study in which they include 50 patients who \nundergo aggressive modeling and traction device and 94 \npatients to whom only aggressive modeling is applied. It \nconcludes that the former achieve a 36% improvement in \ncurvature compared to 28% for the latter. He adds that, \nin the first group, there is an increase in adverse effects \nsuch as ecchymosis, bruising and pain. \nAnother aspect to take into account is the overall \nsatisfaction of the patient. In a study led by Ziegelmann \net al9 from the Mayo Clinic in Minnesota analyzed in 69 50\n2021/36 (3): 45-51Pedro \u00c1lvarez et al.  \npatients treated with Xiapex\u00ae, among other things, the \ndegree of subjective improvement. They conclude that \npatients reported a sensation of improvement in curvature \nwith each cycle of collagenase injections. This study can \nbe considered as the first to prospectively assess patient \nsatisfaction not only with objective data but also subjective \ndata provided by themselves with significant improvement \nin the ability to restore penetrative intercourse.\nIn the present study, up to 40% of the patients considered \nthe treatment satisfactory, regardless of the reduction in \nthe angle of curvature. Therefore, it must be valued that \nthe assessment of this disease must be global, both \nin clinical objective aspects and in the patient's own \nexperience. The implication of the psychological sphere \ncannot be forgotten and the evolution of the patient must \nalso be considered in this area.\nIn relation to this issue, the study carried out by Anaissie et \nal10 derives from the same conclusion. It also addresses \nthe satisfaction of the partners, collecting a satisfaction of \nthe patient and the partner of 67% and 71%, respectively. \nIt establishes significant predictive factors of partner \nsatisfaction such as previous sexual intercourse, the \nimprovement in the ability to maintain relationships with \nthe treatment and the absence of hypoesthesia in the \nglans after it. It therefore assumes that the injection of \nXiapex\u00ae in patients with Peyronie's disease achieves a \nsignificant benefit for the sexual health of the couples.\nWith regard to safety problems and adverse effects, \naccording to various studies, patients undergoing \ncollagenase injections experience at least a mild or \nmoderate reaction localized to the penis. Most frequently, \naccording to Carson et al11, is the appearance of \nhematoma (50.2%), penile pain (33.5%), inflammation \n(28.9%) and pain at the injection site (24.1%).\nThe analyzed patients presented mild reactions that were \nnot specifically reported except for 1 case that presented \npenile hematoma and associated pain. In any case, they \nwere all resolved spontaneously. \nAnalyzing the results globally, it can be considered that in \nour center the results were lower than those expected or \nthose reflected in the literature. A possible cause could be \na defect in the form in the application of the treatment but, \nprobably, this should not be the main reason for this as it \nis a relatively simple technique, which does not require a \nlong learning curve and has been carried out scrupulously \nfollowing the indications given by the manufacturer.\nHowever, the scientific method requires criticism and \nassessment of possible biases that may have occurred. \nThe main one would be the low number of patients \nundergoing treatment. It is a generalized bias, already \ncommented and pointed out in the vast majority of studies \nas in many of those previously referenced. Although this fact is understandable since it is a disease that, although \nit has a higher prevalence than what is really known, as \npreviously indicated, the number of patients who consult \nfor it is lower than the one who actually suffers from it in \nthe population. \nAnother aspect that can skew the sample is the \nappropriate selection of patients. Although the inclusion \ncriteria specified by the manufacturer have been followed, \nvarious studies have observed how there are factors \nthat could influence the patient's response to treatment. \nThese would be: plaque length, its calcification, long \nevolution time, among others. Although the mean time \nfrom the onset of symptoms to the use of treatment is 1 \nyear, it could be, as supported by various studies, that the \napplication in the acute phase, at the onset of symptoms, \ncould favor the patient's response. The use of Doppler \nultrasound should also be considered for an expanded \nstudy of the characteristics of the fibrosis plaque and to \nconfirm the absence of calcification in the plaque.\nFinally, another bias to be pointed out is the lack of validity \nof the questionnaire made to the patients to analyze the \nresults obtained. This would have been more objective \nif the pertinent measurements and analyzes could \nhave been carried out in a medical consultation with an \nadequate anamnesis and examination of the patients. \nThese aspects have also been valued in other works. \nM\u00fcller and Mulhall12 in a study based on another 26 \npublished in the last 15 years on Peyronie's disease \nconclude that most of the published trials have lacked a \ncontrol group and only a few have had any randomization, \nwhich constitutes a relevance bias. Even a consensus \nconference is considered necessary to share and \nestablish guidelines for the definition, adequate duration \nof treatment and follow-up. \nIt can be considered that there are two aspects related \nto the treatment of the disease through the injection of \ncollagenase that need further analysis and study. On the \none hand, the placebo effect that the treatment has; As \nreflected in the studies that led to the approval of the \ndrug, approximately 20% of those who were treated \nwith placebo in the clinical trial presented significant \nimprovement in the disease. This fact reveals an \nimportant psychological component in the disease, \nmentioned above, and, therefore, a questioning of \nthe results collected in all the studies that address the \ntreatment of Peyronie's disease. On the other hand, \nthe fact that since December 31, 2019 the drug has \nbeen out of circulation in Europe is of special importance \nand significance. According to the American laboratory \nthat produces it, it has decided to withdraw it from all \nover Europe for strictly economic reasons. Producing \nthis drug is very expensive and the price in Europe is \nlower than in the US, being already high in our continent, \nassuming an outlay of between \u20ac 5000-7000 for 4 51\n2021/36 (3): 45-51 Clostridium histolyticum collagenase (xiapex\u00ae) in patients with peyronie disease. Expectations vs reality\ncomplete treatment cycles per patient. All of this can \nlead to questioning that it could be about more than \nprice. Currently, there are drugs for benign diseases that \ninvolve a large financial outlay and that, nevertheless, \nremain available. Therefore, it can be deduced that \nthe results initially reported in the studies cannot be \nextrapolated to those that most urologists assess in the \npatients they treat.\nOther questionable considerations are the large number \nof studies that modify the initial protocol proposed by \nthe manufacturer; some add traction or vacuum devices \ninstead of the described modeling and others question \nthe number of cycles. All this casts doubt on the very \nfavorable result of the treatment of Peyronie's disease \nwith Xiapex\u00ae collected in the literature.\nFinally, as shown in most studies, the expectations \ncreated during the treatment approach to the patient \ntake on special relevance in relation to the results that \nthey assess. A clash between expectation versus reality \nthat can further lead to frustration and psychological \nworsening of patients must be avoided. \nIt is important to know the difficulty that currently exists to \npresent studies that start a path against the current, but it \nis a moral obligation to inform the scientific community of \nthe results obtained in this study, with all the biases and \nobjections mentioned, to collaborate in favor of medicine \nbeing able to continue advancing, and giving a reference \nto those centers that, like our case, the results obtained \nhave not been as expected.Conclusions\nIt can be concluded that treatment with Clostridium \nhistolyticum collagenase is a safe and established \ntreatment for Peyronie's disease. It seems that the \nevidence leads to think that it can affect the progression \nof the disease in the active phase, although there is \nan important placebo effect. It should also be taken \ninto account that it is essential to associate a traction \nor modeling effect, intense and persistent over time, for \nwhich additional devices can be used.\nThe scientific evidence regarding the use of Xiapex\u00ae is \nextensive but variable, so it can be deduced that they are \nnot easily reproducible.\nThere are multiple studies that report modified protocols, \nbut they have a small number of patients and are largely \nuncontrolled. The results obtained are highly variable and \ndepend on the selection criteria of the patients and multiple \nother predisposing factors that have not been fully clarified. \nTherefore, patients should be counseled on the efficacy of \ncollagenase and the high cost of treatment. New clinical \ntrials, with a better design, would be necessary to provide \nthe drug with objective and reproducible results.\nThe withdrawal by the pharmaceutical company of the \ndrug in Europe represents a burden to be able to advance \nin favor of greater scientific evidence and to achieve a non-\nsurgical solution for patients affected by Peyronie's disease. \nWe will have to wait for new studies, mainly from the US, \nto value the effectiveness of the product and demand, if \nnecessary, its redistribution throughout our continent.\nBibliography\n1. Chung E, Gillman M, Rushton D, Love C, Katz D. Prevalence of penile \ncurvature: a population-based cross-sectional study in metropolitan and \nrural cities in Australia. BJU Int. 2018 Nov;122 Suppl 5:42-49. \n2. Stuntz M, Perlaky A, des Vignes F, Kyriakides T, Glass D. The Prevalence \nof Peyronie's Disease in the United States: A Population-Based Study. \nPLoS One. 2016 Feb 23;11(2):e0150157. \n3. Pryor JP , Ralph DJ. Clinical presentations of Peyronie's disease. Int J \nImpot Res. 2002 Oct;14(5):414-7. \n4. Ralph DJ, Abdel Raheem A, Liu G. Treatment of Peyronie's Disease With \nCollagenase Clostridium histolyticum and Vacuum Therapy: A Randomized, \nOpen-Label Pilot Study. J Sex Med. 2017 Nov;14(11):1430-1437. \n5. Nelson CJ, Diblasio C, Kendirci M, Hellstrom W, Guhring P , Mulhall JP . \nThe chronology of depression and distress in men with Peyronie's disease. \nJ Sex Med. 2008 Aug;5(8):1985-90.\n6. Anaissie J, Yafi FA, DeLay KJ, Traore EJ, Sikka SC, Hellstrom WJG. \nImpact of Number of Cycles of Collagenase Clostridium Histolyticum \non Outcomes in Patients With Peyronie's Disease. Urology. 2017 \nFeb;100:125-130. \n7. Ziegelmann MJ, Viers BR, Montgomery BD, Avant RA, Savage JB, \nTrost LW. Clinical Experience With Penile Traction Therapy Among Men Undergoing Collagenase Clostridium histolyticum for Peyronie Disease. \nUrology. 2017 Jun;104:102-109.\n8. Fern\u00e1ndez-Pascual E, Gonz\u00e1lez-Garc\u00eda FJ, Angulo J, Cerezo E, \nQuintana LM, Turo J, Mart\u00ednez-Ballesteros C, Carballido J, Mart\u00ednez-\nSalamanca JI. Optimizing collagenase Clostridium histolyticum therapy \nfor Peyronie's disease using a novel approach with percutaneous needle \ntunnelling. BJU Int. 2019 Dec;124(6):1055-1062.\n9. Ziegelmann MJ, Viers BR, McAlvany KL, Bailey GC, Savage JB, Trost \nLW. Restoration of Penile Function and Patient Satisfaction with Intralesional \nCollagenase Clostridium Histolyticum Injection for Peyronie's Disease. J \nUrol. 2016 Apr;195(4 Pt 1):1051-6. \n10. Anaissie J, Yafi FA, Traore EJ, Sikka SC, Hellstrom WJ. Survey of patient \nand partner satisfaction following collagenase Clostridium histolyticum \ntreatment for Peyronie's disease. Andrology. 2017 Mar;5(2):274-277. \n11. Carson CC 3rd, Sadeghi-Nejad H, Tursi JP , Smith TM, Kaufman GJ, \nGilbert K, Honig SC. Analysis of the clinical safety of intralesional injection \nof collagenase Clostridium histolyticum (CCH) for adults with Peyronie's \ndisease (PD). BJU Int. 2015 Nov;116(5):815-22. \n12. M\u00fcller A, Mulhall JP . Peyronie's disease intervention trials: methodological \nchallenges and issues. J Sex Med. 2009 Mar;6(3):848-61. 52\n2021/36 (3): 52-63ORIGINAL\nThe effect of Familact probiotic supplement \nin patients with diabetes\n(Evaluation of Blood Glucose Parameters, Lipid Profile) \nEl efecto del suplemento probi\u00f3tico Familact en pacientes con diabetes\n(Evaluaci\u00f3n de glucosa en sangre y perfil lip\u00eddico)\nSeyedeh Faezeh Miryousefiata1      , Fatemeh Alsadat Miryousefi Ata2      \n1. Faculty of Biochemistry, Islamic Azad University Science and Research Branch,Tehran,Iran.\n2. General Practitioner, School of Medical sciences, Tehran Branch, Islamic Azad University, Tehran, IraneISSN 2255-0569\nReceived:  3 - V - 2021\nAccepted:  2 - VI - 2021\ndoi: 10.3306/AJHS.2021.36.03.52Corresponding author\nSeyedeh Faezeh Miryousefiata   \nFaculty of Biochemistry, Islamic Azad University Science \nand Research Branch,Tehran,Iran    \nE-mail: faezeh.ataee@yahoo.com\nAbstract  \nDue to the increasing prevalence of this disease, the present study was performed to investigate the effect of pure probiotic supplement \nFamilact on fasting blood glucose and insulin indices and lipid profile of patients with type 2 diabetes. This double-blind randomized \ncontrolled clinical trial was performed on 60 patients with type 2 diabetes. The subjects in the Moore intervention group received 7 \nprobiotic capsules containing 7 strains of a mixture of Lametobacillus and Bifidobacterium, at a dose of 1010 CFU, and the placebo group \nreceived 4 placebo capsules containing magnesium stearate daily for 6 weeks. Dietary intake, anthropometric indices including weight, \nbody mass index, waist circumference, waist circumference and hip circumference, along with biochemical indices including fasting blood \nsugar, fasting blood insulin and lipid profile were measured and evaluated at the beginning and end of the study. Statistical analysis was \nperformed using SPSS software using chi-square test, t-test and analysis of variance. Finally, it was observed that the mean fasting blood \nsugar in the probiotic group was significantly lower than before the intervention (P = 0.001). Also, at the end of the study, the amount of \nHDL cholesterol in the probiotic group was significantly increased compared to the amount before the intervention (P = 0.006), but this \nincrease was not significant in comparison between groups. Minor and intragroup increases in blood insulin and cholesterol, decrease in \nLDL cholesterol and insulin and triglyceride resistance were also not significant.\nKeywords:  Probiotics, type 2 diabetes, fasting blood sugar, insulin, lactobacillus. \nResumen\nDebido a la creciente prevalencia de esta enfermedad, el presente estudio se realiz\u00f3 para investigar el efecto del suplemento \nprobi\u00f3tico puro Familact en los \u00edndices de glucosa e insulina en sangre en ayunas y en el perfil lip\u00eddico de los pacientes con \ndiabetes de tipo 2. Este ensayo cl\u00ednico controlado y aleatorizado a doble ciego se realiz\u00f3 en 60 pacientes con diabetes de tipo \n2. Los sujetos del grupo de intervenci\u00f3n Moore recibieron 7 c\u00e1psulas de probi\u00f3ticos que conten\u00edan 7 cepas de una mezcla de \nLametobacillus y Bifidobacterium, a una dosis de 1010 UFC, y el grupo de placebo recibi\u00f3 4 c\u00e1psulas de placebo con estearato \nde magnesio al d\u00eda durante 6 semanas. Al principio y al final del estudio se midieron y evaluaron la ingesta diet\u00e9tica, los \u00edndices \nantropom\u00e9tricos, como el peso, el \u00edndice de masa corporal, el per\u00edmetro de la cintura y el per\u00edmetro de la cadera, y los \u00edndices \nbioqu\u00edmicos, como la glucemia en ayunas, la insulina en ayunas y el perfil lip\u00eddico. El an\u00e1lisis estad\u00edstico se realiz\u00f3 con el programa \ninform\u00e1tico SPSS mediante la prueba de chi-cuadrado, la prueba t y el an\u00e1lisis de la varianza. Se observ\u00f3 que la media de az\u00facar \nen sangre en ayunas en el grupo probi\u00f3tico era significativamente menor que antes de la intervenci\u00f3n (p= 0.001). Asimismo, al \nfinal del estudio, la cantidad de colesterol HDL en el grupo probi\u00f3tico aument\u00f3 significativamente en comparaci\u00f3n con la cantidad \nanterior a la intervenci\u00f3n (P = 0.006), pero este aumento no fue significativo en la comparaci\u00f3n entre grupos. Tampoco fueron \nsignificativos los aumentos menores e intragrupo de la insulina y el colesterol en sangre, la disminuci\u00f3n del colesterol LDL y la \nresistencia a la insulina y los triglic\u00e9ridos. \nPalabras clave:  Probi\u00f3ticos, diabetes de tipo 2, glucemia en ayunas, insulina, lactobacillus. ID ID53\n2021/36 (3): 52-63 The effect of Familact probiotic supplement in patients with diabetes\nIntroduction \nToday, diabetes is one of the most common diseases \nin the world, affecting half of the world's population. \nTreatment for diabetes varies depending on the type1-3. \nIn type 1 diabetes, the main treatment is based on insulin \nintake as the most important chemical drug, while in \ntype 2 diabetes, due to environmental factors, the main \nand various treatments, including drug and chemical \ntreatments, lifestyle changes (increased physical activity, \nreduced stress) 4-6. And smoking cessation) and diet \nchanges and natural remedies. Therefore, in type 2 \ndiabetes, today, most efforts are made to reduce the \nnumber of chemical drugs used in this disease by using \nlifestyle changes and natural remedies, including herbal \nremedies and other natural substances7-10.\nEven prevented the disease. Because doctors are \nincreasingly emphasizing the diagnosis of latent \ndiabetes as a way to prevent type 2 diabetes, as well \nas its complications, including cardiovascular, eye and \nkidney problems11-13. For this reason, in this study, the \neffect of probiotics as a natural substance that can have \ntherapeutic or preventive properties on type 2 diabetes \nis investigated. Therefore, in this project, in order to \ninvestigate the possibility of prescribing probiotics \nas a dietary supplement to help treat or reduce the \ncomplications of diabetes along with diet and medication \nand in the next stage, its use in the production of probiotic \ndairy and non-dairy products, its effect on patients with \ntype 2 diabetes will be discussed. research questions:\n1. Is the mean and difference of mean lipid profile (plasma \nconcentration of HDL-C, LDL-C, Total Cholesterol, \nTG) between the two groups of patients with type 2 \ndiabetes receiving probiotics and placebo, before and \nafter the intervention and in each Are the two groups \ndifferent before and after the intervention?\n2. Are the mean and mean differences in fasting plasma \nglucose levels between the two groups of patients \nwith type 2 diabetes receiving probiotics and placebo, \nbefore and after the intervention, and in each of the \ntwo groups, before and after the intervention?\n3. Is the mean and mean difference in plasma insulin \nlevels between the two groups of patients with type 2 \ndiabetes receiving probiotics and placebo, before and \nafter the intervention, and in each of the two groups, \nbefore and after the intervention?\nResearch Hypotheses  \n1. Mean and difference of mean lipid profile levels (plasma \nconcentrations of HDL-C, LDL-C, Total Cholesterol, \nTG), between two groups of patients with type 2 \ndiabetes receiving probiotics and placebo, before and \nafter the intervention and in each It differs from the two \ngroups.2. Mean and difference of mean fasting plasma glucose \nlevels between the two groups of patients with type 2 \ndiabetes receiving probiotics and placebo, before and \nafter the intervention and in each of the two groups, \nbefore and after the intervention.\n3. Mean and difference of mean plasma insulin level \nbetween the two groups of patients with type 2 \ndiabetes receiving probiotics and placebo, before and \nafter the intervention and in each of the two groups, \nbefore and after the intervention. Mean and difference \nof mean level of insulin resistance index (HOMA-\nIR) between the two groups of patients with type 2 \ndiabetes receiving probiotics and placebo, before and \nafter the intervention and in each of the two groups, \nbefore and after the intervention. Mean and difference \nof mean level of anthropometric indices (weight, \nbody mass index, abdomen circumference and hip \ncircumference) between two groups of patients with \ntype 2 diabetes receiving probiotics and placebo, \nbefore and after the intervention and in each of the two \ngroups, before is different from after the intervention.\nA review of Studies  \nDespite the wide range of animal studies around the \nworld, most of the studies conducted in Iran to measure \nthe effect of probiotics on blood parameters of people \nwith type 2 diabetes have been human studies14-18. \n \nHowever, these studies make up the bulk of human \nstudies available worldwide. The first human study \nconducted in Iran was conducted in Shiraz in 2010 by \nMs. Mazloum et al in their study, they examined the effect \nof daily intervention on a number of probiotic capsules \ncontaining 1,500 mg of L. bacteria. acidophilus L. \nbulgaricus, L. bifidum, and L. casei or placebo capsules, \ncontaining 1000 mg of magnesium stearate, in 40 \ndiabetic patients (20 in the intervention group and 20 in \nthe placebo group), for 6 weeks they paid. Finally, despite \na significant reduction in waist circumference of the \nintervention samples compared to the placebo group, no \nsignificant changes were observed in the patients' blood \nsugar, blood insulin and other blood factors19-22.\nIt should be noted that after measuring the quality of \nhuman articles through the Jadad scale, this study did \nnot obtain a sufficient and desirable score in terms of the \nquality of clinical studies23.\nMs. Ijtihad et al. they intervened. Unlike Mazlum et al, they \nwere able to report a significant reduction in fasting blood \nsugar levels as well as glycosylated hemoglobin in patients. \nBut they did not see a significant difference in blood insulin \nlevels and insulin resistance at the end of their study24-28.\nIn several animal studies, the effect of probiotics on the \ncontrol of fasting blood sugar has been found to have 54\n2021/36 (3): 52-63Seyedeh Faezeh Miryousefiata et al.  \na significant effect on lowering fasting blood sugar in \nvarious ways29-31.\nMost of the strains used were Lactobacillus and \nBifidobacterium. The intervention period of these studies \nvaried from 3 to 8 weeks, except for two studies that \nHsieh et al32 and Andersson et al33 respectively. Finished \nat 14 and 18 weeks. The results of this study showed \nsignificant and positive effects on lowering blood sugar in \ndiabetic rats without any side effects. It is also noteworthy \nthat these significant effects were seen from the sixth \nweek of the study until the end of the intervention period.\nThe results of a study by Honda et al in 201234 showed \nthat the use of Lactobacilus GG strain in diabetic rats in \n2 stages of 3 and 6 weeks, separately and in daily doses \nof y% and 0.5%, respectively. 0% of the solution enriched \nwith the mentioned bacteria causes a significant decrease \nin the levels of Nasha blood sugar, 5-hour blood sugar and \nglycosylated hemoglobin, while the use of Lactobacillus \nBulgricus strain during these two stages showed a \nsignificant result in none of the indicators. This study \nshowed that Lactobacilus GG was more potent than L. \nBulgaricus and had a greater effect on intestinal metabolic \nactivity. In a 2013 study, Huang et al examined the effect \nof Lactobacillus Plantarum on four distinct groups. These \n4 groups included the control group, the group receiving \nLactobacillus Plantarum pure and at a daily dose of 108 \nCFU, the group receiving fermented vegetables and the \ngroup receiving a mixture of Lactobacillus Plantarum and \nfermented vegetables. They found that the intervention \nof these substances separately for 8 weeks significantly \nreduced blood sugar and significantly increased blood \ninsulin in diabetic rats35.\nIn fact, this study showed that probiotics can play a \npositive role in glycemic control even without the presence \nof prebiotics as a carrier and adjuvant effect. In a study, \nTomaro et al found that high doses of L. fermentum \n(1010 CFU) significantly decreased blood sugar levels \nin diabetic and hypercholesterolemic mice only 11 days \nafter the start of the intervention, which remained at the \nend of 8 weeks of intervention. Remaining and even \nat the end of this period, fasting blood sugar levels of \ndiabetic rats showed a significant decrease. \nHowever, they did not report significant changes in \nblood insulin levels, insulin resistance, and glycosylated \nhemoglobin36.\nOn the other hand, Hsieh et al in a study conducted \nin 2013, stated that the daily intervention of high dose \nof L. reuteri (109 2 CFU) for 14 weeks increases the \nbeneficial intestinal flora of Bifidobacteria (Lactobacilli) and \nLactobacilli) and reduces harmful bacteria. It becomes the \ngastrointestinal tract (Clostridia) and therefore can have \nbeneficial effects on controlling blood sugar in diabetics. \nAt the end of their intervention period, they observed a significant decrease in fasting blood sugar, glycosylated \nhemoglobin, 5-hour blood sugar and insulin resistance, \nas well as a significant increase in blood insulin levels \nin diabetic mice receiving probiotics compared to the \nhealthy or placebo group37.  \nAlsalami et al. Also stated that daily intervention of a \nmixture of L. acidophilus, L. rhamnosus and B. lactis at a \ndose of 75 mg / kg body weight in mice for only 3 days \nhad significant hypoglycemic effects, especially in early-\nstage diabetes develops in diabetic rats and decreases \nserum glucose sub-graph (AUC)38. In this study, they \nshowed that probiotic intervention after administration \nof glycilazide (a hypoglycemic drug) increased the \nbioavailability of this drug in mice with type 1 diabetes \ncompared to non-diabetic mice.\nResearch Method   \nIn the simple random method of this study, the Balanced \nBlock method is also used to reduce possible errors. In \nfact, in this method, patients are divided into m groups \nand in each group, they are randomly selected so that \nthey are randomly assigned to treatment A and B and \nfinally each group is randomly selected. This method \nassigns the same treatment to each group.\nResearch Community   \nWith inclusion and exclusion criteria Patients with type 2 \ndiabetes referred to Metabolism Research Center who \nwere willing to cooperate were invited to study. Main \ncriteria for inclusion in the study and sample selection: \nPatients whose blood sugar is defined according to \nWHO or ADA index (non-insulin dependent diabetes due \nto non-response of the body to secretory insulin and \noften due to obesity and inactivity) and less It takes 15 \nyears for them to develop diabetes and they will be in \nthe age range of 25 to 65 years. Selected individuals, in \naddition to taking medications prescribed by a physician, \nshould be at a controlled level in terms of blood sugar \nand lipids, and during the study can use these drugs \nwithout changing the previous dosage39.\nSelected individuals should not use hormone replacement \ntherapy or vitamin supplements. Also, people who smoke \nand drink alcohol or who have chronic kidney, liver, lung, \nand chronic or acute inflammatory diseases (especially \nacute pancreatitis and endocarditis), heart valve disease, \nshort bowel syndrome, and allergies. People with low \nimmune systems (autoimmune) and pregnant and \nlactating women were removed from the list of eligible \npeople. (These conditions were confirmed by the clinical \nconsultant in the case of the subjects). 55\n2021/36 (3): 52-63 The effect of Familact probiotic supplement in patients with diabetes\nExclusion Criteria   \nPeople who become allergic to probiotic or placebo \ncapsules during the study, or become pregnant during \nthe study, or develop one of the above-mentioned \ndiseases, or have to change the dosage of medications, \nwill be excluded from the study. Also, people who took \nless than 10% of probiotic capsules or placebo were \nexcluded from the study.\nSampling method and sample size: Specifications of \nthe studied samples (entry and exit criteria) along with \nsampling method and sample size.\nDetermining the sample size and how to calculate it \n(Sample Size):  Considering \u03b1 error of 0.05 and 80% \npower and considering Total Cholesterol = 0.25 = mmol \n/ yr, standard deviation of 2.5 and variance of 6.25, and \nconsidering drop of 32 samples per drop in each group \nand in total 64 people were studied. The sample size is \ncalculated based on the above assumptions and using \nSTATA software and considering the equal volume in \neach of the groups. Formula 1, the desired formula in \ncalculating the sample size.\nZ1-\u03b1/2 =96/1         95% \u03b4 = 2.5\nZ1-\u03b2 = 84/0          80% \u00b5-1 \u00b52 =2\nSampling   \nAfter approval by the Medical Ethics Committee and \ndetermination of 64 patients (32 in each group) participants \nwho were willing to cooperate and signed the informed \nconsent, using the Balanced Block method (division of \nindividuals into equal groups) with the same size, random \nselection of individuals in each group to receive capsule \nor placebo treatment) were included in the study and \nwere divided into one of two intervention groups (probiotic \ncapsule recipient) and placebo (placebo recipient). Data \nwere collected through interviews, anthropometrics, and \nbiochemical tests. \nData Collection Tools   \nThe questionnaire used in collecting and evaluating \nthe food consumed by the participants was a 24-\nhour feed questionnaire as well as a food frequency questionnaire (FFQ) and a questionnaire to measure their \nphysical activity, each before and after the intervention \nby the facilitator and separately for each participant was \ncompleted. After collecting the food information of the \nparticipants, the average information in the mentioned \nquestionnaires was converted into home units in terms \nof grams and entered into the Nutritionist 4 software \nto calculate the calories consumed micronutrients and \nmacronutrients. \nThen, the information obtained from this software \nalong with other information and findings were entered \ninto EndNote software version 16 for final analysis of \ninformation. To measure the weight before and after the \nintervention of each participant from a digital scale with an \naccuracy of 1.0 kg. The German model \"Ska\" was used. \nAlso, to measure their height, a portable height gauge with \nan accuracy of 0.1 cm (Ska model, made in Germany) \nwas used. The size of their breasts, abdomen and hips \nwere also measured using a plastic meter before and \nafter the intervention. For the intervention capsules, the \nstrains used per gram of Familact supplement capsules \nare as follows:\n\u00b7 Lactobasillus casaei 2\u00d7108 cfu/g\n\u00b7 Lactobasillus Acidofilus 2\u00d7108 cfu/g\n\u00b7 Lactobasillus Bulgarigus 2\u00d7109 cfu/g\n\u00b7 Lactobasillus rhamnosus 3\u00d7108 cfu/g\n\u00b7 Bifidobacterium Breve 2\u00d7108 cfu/g\n\u00b7 Bifidobacterium Longum 1\u00d7109 cfu/g\n\u00b7 Streptococus Thermophilus 3\u00d7108 cfu/g\nThe total dose for each of the 7 strains is 1010 CFU per. \nCapsule. Patients' venous blood samples at the beginning \nand end of the study, which were taken at a rate of 5 \ncc each time for 10 hours of fasting, were poured into \n1 ml microtubes and stored in a freezer at -70 \u00b0 C until \nthe experiments. Serum glucose, total cholesterol and \ntriglyceride levels were measured by calorimetric method \n(based on enzymatic method (Glucose Kit, Pars Azmoun \nCompany, USA-France), Alcyon Iran) and autoanalyzer 300 \n(HDL and LDL cholesterol concentration using Photometric \nmethod, Pars Azmoun Company, USA-France and Alcyon \nIran) and autoanalyzer (300 were measured).\nTable I: Summary of application descriptions.\nName of equipment Consumption or Required\nor materials non-Consumption number\nFamilact probiotic supplement Consumption 210\nPlacebo capsules Consumption 150\nsingle-use glove Consumption 100\nMicrotube 1.5 cc Consumption 25\n5 ml blood collection syringe Consumption 140\nInsulin Kit Consumption 1\nGlucose kit and lipid profile Consumption y\nBlue sampler head Consumption 3\nYellow sampler head Consumption 3000\nDisposable test tube Consumption 280\nMicro tube Consumption 3\nMicro tube Consumption 1000\nSmall packet milk Consumption 14456\n2021/36 (3): 52-63Seyedeh Faezeh Miryousefiata et al.  \nData Analysis Method    \nNumerical indicators and frequency tables were used \nto display the data, so that the data is shown as an \naverage (standard deviation) for quantitative variables \nand as a frequency (percentage) for qualitative \nvariables. In general, SPSS software version 16 was \nused for data analysis. The normality of data distribution \nwas assessed using Kolmogorov-Smirnov test. Chi-\nsquare test and Fisher's exact test were used to \nanalyze the qualitative data. T test and paired T test \nwere used to compare quantitative traits. Analysis of \nvariance with repetitive data was used to investigate \nthe trend of quantitative trait changes between the two \ngroups by controlling confounders. Significant level was \nconsidered P <0.05 in all cases.Place and Time of Study\nThe sampling of this project started, from patients with \ntype 2 diabetes, and having the conditions for inclusion \nin the study mentioned in the proposal, was performed \nfrom Taleghani Hospital. On Saturday, Tuesday, and \nWednesday, patients were referred to Taleghani Hospital \nin Tehran, Velenjak St., Yemen St. \nTherefore, the facilitator was present at the hospital on the \nmentioned days and talked orally with the patients about \nthe free probiotic supplement intervention plan and its \npossible benefits in reducing the complications of diabetes. \nSome people participated in the project voluntarily. \nPatients referred to clinic department, on Sundays, \nTable II: Basic information of individuals.\n*P  Medicine  Probiotic group\nP=0/020  61,3\u00b1 5,2  57/3\u00b17/5  Age (years)\nP=0/438 Woman( n=14) 46%/7 Woman( n=13) 43%/3 man / Woman \n man( n=16) 53%/3 man( n=17) 56%/7 (percentage and number)\nP=0/612  154/4 \u00b19/08  164/89 \u00b19/29  Height (Sunni meters)\nP=0/697  5/8 \u00b12/8  6/16 \u00b13/05  Period of diabetes (year)\nP=0/712 7% 5% Physical activity\n 47% 45% (percentage)\n 46% 50% Top \u00b7 medium \u00b7 Low\nP=0/186 41%/7 44%/7 Medications received (percentage) \u00b7\n 53%/3 51%/3 Matt Fermin \u00b7 Glybine glamide \u00b7\n 5% 4% Other medicines\nTable III: Comparison of the effect of probiotics on biochemical parameters before and after the intervention in the groups.\n P=0/610  P=0/910  147/0\u00b136/3  146/8\u00b135/1  P=0/001  132/7\u00b133/6  146/5\u00b14/3 Fasting blood sugar (mg /dl)\n P=0/811  P=0/713  153/8\u00b138/5  155/1\u00b133/9  P=0/510  151/4\u00b135/ y  149/3\u00b136/3  Total cholesterol (mg/dl)\n P=0/521  P=0/423  153/8\u00b138/5  151/1\u00b133/9  P=0/100  135/3\u00b161/3  141/8\u00b162/3  Triglyceride (mg/dl)\n P=0/823  P=0/832  44/5\u00b16/9  44/6\u00b16/0  P=0/006  46/3\u00b110/8  44/y\u00b111/7  HDL cholesterol (mg/dl)\n P=0/715  P=0/810  81/9\u00b136/0  82/5\u00b131/1 P=0/812  77/5\u00b131/ y  79/4\u00b139/ y  LDL cholesterol (mg/dl)\n P=0/412  P=0/931  10/5\u00b15/0  10/5\u00b15/6  P=0/913  10/5\u00b15/1  10/3\u00b16/5  Fasting insulin \u03bcU/ml\n P=0/410  P=0/641  3/7\u00b11/8  3/6\u00b11/7  P=0/112  3/3\u00b11/6  3/7\u00b12/7 Insulin resistance (/U/ml/mg/dl)The value \nof P\nbetween\ngroups \u2020Intragrou\np P value*After the\ninterventionPlacebo group Probiotic group\nAfter the\ninterventionBefore\ninterventionBefore\ninterventionVariables Intragroup\nP value*\nHDL: High Density of Lipoprotein\nLDL: Low Density of Lipoprotein\n*Comparison within the group at the end of the intervention, the value of P is less than 0.05. (Fasting blood glucose unit is mg / dL.) The mean fasting blood glucose \nbefore intervention in the probiotic group was 146.5 43 43.6 mg / dL and after the intervention in this group was 33.6, reached 132.7 mg / dL. While the mean of this \nindex before and after the intervention in the placebo group was 146.8 35 35.1 and 147 36 36.3 mg / dl, respectively. \nBased on analysis of variance, comparing the mean blood sugar after the intervention, it was found that the mean of this index decreased in the probiotic group \ncompared to the placebo group, but this decrease did not reach a significant level (P = 0.1). \nIn contrast, the intragroup comparison showed that this decrease reached a significant level after the probiotic intervention compared to before the intervention in the \nintervention group. Also, the mean HDL cholesterol before the intervention in the probiotic group was 44.1 1 1.1 mg / dl and the mean in this group after the intervention \nreached 46.29 mg/dl. \nWhile the mean of this index before and after the intervention in the placebo group was 44.6 0 0.6 and 45.4 9 6.9 mg / dl, respectively. Based on analysis of variance, \ncomparing the mean HDL cholesterol after the intervention, it was found that the mean of this index increased in the probiotic group compared to the placebo group, \nbut this increase did not reach a significant level (P = 0.4). In contrast, the intragroup comparison showed that this increase reached a significant level after the probiotic \nintervention compared to before the intervention in the intervention group. \n*Comparison within the group at the end of the intervention, the value of P is less than 0.05. (The unit of fasting blood sugar is milligrams per deciliter.) Comparison \nbetween group and intragroup other biochemical parameters showed that blood insulin levels and insulin resistance in the probiotic group compared to the placebo \ngroup did not change significantly. Also, in relation to lipid profile levels, no significant intragroup and intergroup changes were reported for total cholesterol, triglyceride \nand LDL cholesterol indices. \nRegarding anthropometric variables, weight, waist circumference and body mass index in both groups decreased slightly compared to the initial value, which did not \nreach a significant level. Also, changes in waist circumference and hip circumference did not change significantly. (All values are P <0.05).57\n2021/36 (3): 52-63 The effect of Familact probiotic supplement in patients with diabetes\nMondays, and sometimes Tuesdays. The day before \neach patient was referred, I reminded them by phone \nof the date of the test. The number of patients referred \nper day varied from 2 to 5 (due to limited admission \nconditions). The duration of intervention was 6 weeks for \neach patient.\nThe difference between groups at the beginning of the \nstudy was significant in terms of P <0.05. Numbers \nare expressed as \"standard deviation mean\" and \n\"percentage\". Measurement of basal food intake (before \nintervention) including energy intake, micronutrients and \nmacronutrients in the intervention subjects, which was \nmeasured by N4 software, showed that there was no \nsignificant difference between the energy intake of \nindividuals before the intervention. This comparison also \nshowed that there was no significant difference between \nmicronutrients and macronutrients, except for sodium, \nvitamin D, vitamin E, and PUFA, sodium and selenium \nintake (P <0.05). \nTherefore, to compare the mean of the variables after the \nintervention, the distorting effect of age nodes, sodium, \nselenium, vitamin D and vitamin E intake and PUFA intake \nwere adjusted. After comparing the diets of patients \nbefore and after the intervention, it was shown that there \nwas no significant difference between energy intake, and \nall macronutrients and micronutrients (P <0.05). Table III  \nlists the information related to the analysis of food intake \nof individuals before and after the intervention.\nDiscussion\nThe effect of probiotics on fasting blood sugar \nThe present experimental study showed that the \nintervention of probiotics without changing the diet or \napplying a special diet in individuals, can significantly \nreduce fasting blood sugar (FPG) in the probiotic group, \nwhile this reduction in comparison between the probiotic \ngroup and the placebo group Did not reach a significant \nlevel. Positive effects of probiotics on the control and \nimprovement of FPG were seen in many animal studies. \nIn several animal studies that examined only fasting blood \nsugar, significant effects on FPG reduction were observed \nwithin the intervention group and between the placebo \nand intervention groups. However, there are many \ndifferences between the study method and the groups \ntested in these studies. In fact, this effect was significant in \nthe probiotic intervention group compared to the diabetic \nand non-diabetic groups receiving placebo40, the fat-rich \ndiet group41, Huang et al  or fructose42, (used to cause \ndiabetes), the group receiving a diet rich in fermented \nvegetables43, and the group receiving skim milk44, has \nbeen seen. In the present study, from 7 different strains \nincluding 3 species of Lactobacillus (Lactobasillus casaei, \nLactobasillus acidophilus, Lactobasillus Bulgarigus, \nLactobasillus rhamnosus), 2 strains of Bifidobacterium (Bifidobacterium Brev, Bifidobacterium longum) and 10 \nstrains of Cocene 1 Each. Capsule was used. In all of \nthese animal studies, a class of the same bacteria called \nLactobacillus was used. \nHowever, different species such as L. reuteri GMNL-\n, L. plantarum, L. fermentum, Lactococcus lactis, L. \nrhamnosus GG and L. bulgaricus have been used \nin each study; In only two studies, a mixture of L. \nfermentum, L. acidophilus and Bifidobaterium lactis or \na mixture of Lactobacillus casei and Lactococcus lactis \nbiovar diacetylactis was used. The dose of probiotics \nintervened in these studies varies from 108 to 1010 CFU \nper gram of body weight or ml of gavage per sample \nper day. The time of intervention also varied from 3 to 8 \nweeks, except for a study conducted by Hsieh et al at 14 \nweeks44, and Andersson et al at 20 weeks45.\nIn the study of Honda et al., 2 intervention sessions \nwere performed separately; They believed that the \neffect of probiotics on diabetes control was not due to \ncellular components and immune factors, but to the type \nof bacterial strain and its ability to be active in the gut. \nIn conclusion, in this study, they examined the effect \ndifference between L.GG and L. bulgaricus for 6 weeks \nand at a daily dose of 0.5% and also the effect difference \nbetween active L. GG and L. ggar heated for 3 weeks \nand at a daily dose of 2%, and found that only active L. \nGG significantly reduced blood sugar in both groups46.\nIn general, animal studies show that Lactobacillus strain \nintervention can have positive effects on lowering blood \nsugar in diabetic animals; Also, although in these studies \nthe minimum daily dose of 108 CFU was reported in \neach mouse and the minimum duration of intervention \nwas 3 weeks, it is not possible to determine the effects \nof the effective dose and period of intervention and the \neffect of different species. \nHowever, the results of the present study also showed \na significant decrease in the probiotic group before and \nafter the intervention, although this reduction was not \nsignificant compared to the placebo group. In contrast, \nvery few human studies are correct. Similar to the present \nstudy, among the 4 human studies that examined the \neffect of probiotics on FPG, y the study reported a \nsignificant difference in FPG levels and Andreasen et \nal. As well as the oppressed and colleagues could not \nachieve significant results47.  \nIjtihad and his colleagues in Tabriz used enriched yogurt \nwith a daily dose of 300 g and 106 \u00d7 600 CFU per gram \nof L. acidophilus La and B. lactis Bb strains for 6 weeks \nand a significant reduction in group comparison. And \nreported between groups48.  \nWhile Asemi et al in Kashan, similar to the present study, \nused capsules containing seven strains of bacteria (L. 58\n2021/36 (3): 52-63Seyedeh Faezeh Miryousefiata et al.  \nacidophilus, L. casei, L. rhamnosus, L. Bulgaricus, B. \nbreve, B. longum and Streptococcus thermophilus) with \nthis difference. The dose and duration of the present \nstudy was 1010 CFU per day for 6 weeks, but in their \nstudy, one capsule containing 14 10 109 CFU per day \nfor 8 weeks49.\nThe important point in Asemi et al study is that the level of \nFPG in the placebo group has increased, while the level \nof this index in the probiotic group after the intervention \nwas equal to its value before the intervention and had a \nvery small increase and their study showed that Probiotic \nintervention significantly prevented fasting blood glucose \ncompared with the placebo group, and they did not \nreport any FPG-lowering effects in their study. \nHowever, the present study reported a significant \ndecrease in the probiotic group after the intervention of \npure probiotic capsules, so the result of the present study \nis more important and more indicative of the therapeutic \nand prophylactic effects of probiotics. \nIn general, in previous studies, significant differences \nwere found in the improvement of FPG levels in both \nhigh-dose interventions of several probiotic strains and \ninterventions with lower doses of 2 bacterial strains at 6 \nand 8 weeks, respectively; From these results, it can be \ninferred that the duration of effective intervention, which \nis approved and effective by the FDA up to 8 weeks50. \nIt is more important depending on the type of strain or \ntheir dose, because Andreasen et al. Intervened with L. \nacidophilus at a daily dose of 1010 CFU per tablet but for \nonly 4 weeks and did not achieve significant results. Also, \nMazlum and his colleagues, who used L. acidophilus, L. \nlongum, L. bifidum and L. casei strains in a daily dose \nof 1500 mg in their study in Shiraz, did not report any \ndecrease in fasting blood sugar in patients.\nHonda and colleagues stated that preventing glucose \nuptake into the intestine through probiotic intervention \nis the main mechanism of 2-hour hypoglycemia and \nthat the anti-diabetic effect of probiotics is due to this \nmechanism. The main mechanism of this finding was \nthe reduction of hepatic glycogen storage and the \nchanges in the 2K-dependent osteocalcin pathway by \nB. fragilis. In fact, they found that osteocalcin levels were \nsignificantly and positively correlated with B. fragilis levels \nin diabetic rats60; Osteocalcin is a protein dependent on \nvitamin 2K51, and B. fragilis is one of the major bacteria \nproducing vitamin K52.\nOn the other hand, it has been shown that vitamin \nK together with osteocalcin can play an important \nrole in improving the state of diabetes in humans, so \nthis mechanism may indicate the cause of 2-hour \nhypoglycemia in diabetic rats.Effect of probiotics on lipid profile\nThe present study also showed that probiotic intervention \ncould lead to a significant increase in HDL levels in the \nintervention group, although this increase was not \nsignificant compared to the placebo group. In this regard, \n5 animal studies also reported a significant increase in \nHDL and intragroup and HDL levels. Among these \nstudies, El-khamisi et al stated that the mixed intervention \nof L.acidophilus and B. lactis has a better and more \nfavorable effect on increasing the level of HDL than the \nintervention of each species alone. \nThey used a daily gavage dose of 108 CFU for 6 weeks. \nIn their 3 studies, Yadav et al. Used a probiotic mixture \ncalled \"Dahi\" which includes 3 species of Lactobacillus \nin similar doses (73 8 108 CFU per day) but in different \nintervention periods of 8 weeks, 6 weeks and 4 weeks \nand in each Three studies showed a significant increase \nin HDL levels in diabetic rats compared to the control \ngroup at the end of the intervention, although they did not \nshow any significant increase within the group. \nVery few human studies have examined the effect of \nprobiotics on HDL levels. Out of 3 human studies that \nhave evaluated the effect of probiotics on HDL index \nso far, 2 studies reported a significant increase in the \nlevel of this index. Asemi et al in Kashan, who tested \nsupplements containing probiotic strains, stated that HDL \nlevels in the intervention group increased significantly \ncompared to the placebo group after 8 weeks of 108-\nday daily intervention of bacteria. Similar to this study, the \npresent study also evaluated the net supplementation \nof probiotic-like strains, with the difference that the \ninterventional dose was higher at about 1010 CFU but for \na shorter period of time (due to the absence of possible \ncomplications from the high dose of the intervention) and \nat about 6 weeks and only a significant increase within \nthe group was reported. It is possible that increasing the \ntime intervened will affect the outcome of the work. \nIn Another study conducted by Ijtihad et al. In Tabriz and \nMohammad Shahi et al in Ahvaz, probiotic-enriched \nyogurt was used at a daily dose of 300 mg for 6 and 8 \nweeks of intervention. Out of these 2 studies, which had \nthe same working method and only different intervention \ntime, only Mohammad Shahi et al were able to report \na significant increase after the intervention period in \nthe probiotic group compared to the initial values in \nthis group, which is similar to the present study. From \nthese results, it can be inferred again that increasing the \nintervention period if lower doses can be used can have \na positive effect on improving the results. \nHowever, due to the limited human results in this field, \nmore clinical studies are needed. Regarding other \nlipid profile indices, the present study did not achieve \nsignificant results at TG, LDL-C, and TC levels. In fact, a 59\n2021/36 (3): 52-63 The effect of Familact probiotic supplement in patients with diabetes\nvery small decrease was observed in TG and LDL levels, \nbut did not reach a significant level.\nStudies have also reported contradictory effects in this \nregard. Studies that achieved significant results often \nused high doses or longer intervention periods. For \nexample, Hsieh et al. [53], and Huang et al. [4], after \n14 and 8 weeks of intervention, respectively, had a \nsignificant reduction in the total cholesterol of the group \nreceiving 10 10 2 daily CFU probiotics. For each mouse \nof L. reuteri GMNL5, and the group receiving daily \nreceived one ml containing 109 \u00d7 1 CFU probiotic per \nmouse of L. plantarum K10. These studies also reported \na significant decrease in LDL and TG levels. However, \na study by Andersson et al. On diabetic mice using a \ndaily probiotic dose of about 40 g/kg body weight of L. \nplantarum DSM showed only a significant reduction in \nTC levels despite high doses. And their high intervention \ntime did not report a decrease in other lipid parameters. \nOn the other hand, in human studies conducted in this \nfield, which is limited to 3 studies, different results have \nbeen expressed. Unlike the present study, Asemi et al \nwho used probiotic capsules (mentioned above) were \nalso able to report a significant decrease in LDL levels, \nalthough they did not report a significant change in TC \nlevels similar to the present study?\nOn the other hand, Mohammad Shahi et al as well as \nijtihad et al. could not mention a significant change in \nLDL level after the intervention of yogurt enriched with \nprobiotics. In the meantime, only Ijtihad et al. Mentioned \na significant decrease in TC level both at the intra-group \nand inter-group level. Many mechanisms have been \nsuggested in these animal studies due to the reduction \nof probiotics on the lipid profile. Adherence of bacterial \ncell wall to cholesterol in the gastrointestinal tract, \ndeconjugation of bile ducts, and production of short-\nchain fatty acids are important in these studies. However, \nthis work needs more research.\nEffect of Probiotics on Insulin \nIn the present study, no significant change in blood \ninsulin levels was reported in diabetics. However, two \nanimal studies measuring serum insulin alone reported \nboth significant reductions in blood insulin levels after \nintervention with probiotics20. While 4 animal studies \nachieved significant results in reducing the level of this \nindex11, These significant results (at serum and blood \nplasma insulin levels) in the intervention with high doses \nof probiotics (daily 108, 109, 1010 CFU 50, per mouse, 1 \nmg or 2% of probiotics to for each mouse) was obtained \nin the medium duration (6, 8 69, and 9 weeks) or long \n(14 weeks). \nLactobacillus species were used in all significant studies, \nexcept for two studies in which a mixture of Lactobacillus and Bifidobacterium was used in one and Lactococcus \nin the other. The effect of probiotic reduction on blood \ninsulin is debatable in human studies. Because among \nhuman studies, 3 studies examined the effect of \nprobiotics on plasma insulin index and serum insulin \nand only Asemi et al despite the high intervention of \nseveral species of bacteria (L. acidophilus, L. casei, \nL. rhamnosus L. bulgaricus, Bifidobacterium breve, B. \nlongum, Streptococcus thermophilus) for a long time (8 \nweeks)9, or Andreasen et al. by intervening a bacterial \nspecies (L. acidophilus) for a short time (4 weeks), were \nable to increase Report significance at the level of this \nfactor only in their intragroup comparison7, and similar to \nthe present study, no significant intergroup results were \nreported in all three studies. Most of the reported results \non the effect of probiotics on plasma insulin are based \non animal studies, and since there are few reports from \nhuman studies, more human studies are needed to \nbetter conclude on the effect of probiotics on insulin in \ndiabetic specimens.\nThe role of probiotics in insulin resistance (IR) Chronic \nhyperglycemia in diabetics is usually due to long-term \ninsulin resistance and is one of the most important \npathophysiological factors in type 2 diabetes18. \nThe present study could not report a significant change \nin the level of this index after 6 weeks of intervention of \na mixture of beneficial bacteria. In this regard, despite \nthe similarity of the results of other studies, some \nanimal studies mentioned a significant change. Two \nstudies reported a significant effect on improving insulin \nresistance22, In these two studies, approximately equal \ndoses of L. reuteri (109 2 F CFU per mouse) and L. \nplantarum (109 \u00d7 1 CFU per mouse) were used for \n14 and 8 weeks of intervention, respectively. However, \nTomaro et al did not achieve significant results with \nthe intervention of L. fermentum NCIMB at a daily \ngavage dose of 1010 CFU per mouse for 8 weeks in \nhyperlipidemic and hyperglycemic mice27. \nTanida et al. Also used the method of injection of \nLactobacillus casei Shirota at a dose of 108 \u00d7 1 CFU \nfor less than 150 minutes before blood insulin test, and \ndid not achieve significant results32. Human studies \ndid not show significant results along with the present \nstudy. Ijtihad et al. (2012) and Asemi et al evaluated \ninsulin resistance using the HOMA-IR method, but did \nnot observe any significant change in the level of this \nfactor. Andreasen et al in their study also intervened with \nL. acidophilus NCFM at high dose (1010 CFU) for only \n4 weeks, and also examined the insulin resistance index \nby measuring HOMA-IR2, but as a result No significance \nwas reached at the level of this index33. Despite these \nresults, these studies suggest that proinflammatory \nfactors and hyperlipidemia play an important role in \nregulating insulin resistance and are themselves affected \nby probiotic intervention; Therefore, the use of probiotics 60\n2021/36 (3): 52-63Seyedeh Faezeh Miryousefiata et al.  \nin interventions can have important effects on improving \ninsulin resistance. The number of studies in this field is \nvery limited and contradictory, so that human studies \nhave not achieved significant results and among animal \nstudies, only 2 studies using Lactobacillus strain for a \nlong time were able to achieve the desired and significant \nresults, using different subspecies. Bacteria and in \ndifferent doses may be the reason for the different results. \nTherefore, due to the limited amount of animal and \nespecially human information available, we need to \nconduct this group of studies with more accurate \nmethods to obtain better results.\nEffect of probiotics on body weight \nand food intake  \nThe present study showed that receiving probiotics \nwithout changing the diet had no effect on weight loss \nafter the intervention period. Most studies in this regard \nhave been animal. Twenty animal studies9-16, and only \ntwo human studies to date have examined changes in \nbody weight of the test specimens22-28, of which only 12 \nanimal studies reported food intake along with weight \nchanges. Although the present study did not report a \nsignificant change in the weight change process, but \na slight weight loss trend was observed in the subjects \nafter the intervention period. \nContrary to the present study, some studies have \nsuggested that probiotic intervention increases the \nweight of diabetic specimens. Four studies more \naccurately stated that probiotics-maintained body weight \nin the samples and resulted in a continuous weight loss \nprocess induced by streptozotocin3-6, or alloxan4, high \nfat diet (HFD)9, or high fructose diet (HFrD)2. This weight \ngain was demonstrated in the study of Marraza et al \nwith the intervention of L. rhamnosus CRL along with \nsoy milk. They found that soy milk intervention improved \nand increased the weight lost in streptozotocin-induced \ndiabetic mice, and increased this amount with the \nintervention of L. rhamnosus CRL. \nThey stated that giving streptozotocin to mice caused \nDNA damage, protein loss, and hypoinsulinemia, which \nin turn prevented carbohydrates from being consumed \nas energy in the mice and ultimately reduced their weight. \nOn the other hand, the intervention of soy milk \nand probiotics, due to having micronutrients and \nmacronutrients, proteins and salts, as well as isoflavone \naglycone, leads to increasing and compensating for their \nlost weight. Marraza et al did not correlate this weight \ngain with energy intake because, similar to the present \nstudy, they did not observe a significant change in rat \nfood intake47. Matsuzaki et al also reported a significant \nincrease in weight after L. casei intervention compared \nto the control group in alloxan-induced diabetic rats and stated that probiotic intervention prevented the alloxan-\ninduced weight loss process, which had an effect in the \nhigher dose L. casei (0.1% daily) is more sensitive than \nlower dose (0.05% daily)42.\nBejar et al39, as well as Davari et al16, initially observed \nweight loss in diabetic mice, while after intervention L. \nplantarum TN52, and A mixture of L. acidophilus and B. \nlactis, L. fermentum46, prevented continued weight loss \nand significant weight gain was seen in the probiotic \ngroup compared to the control group. Andersson et al. \nStated that L. plantarum DSM intervention after HFD diet \nincreased lean mass in the probiotic and HFD group \ncompared to the control group (HFD recipient), which \nin turn led to greater glucose excretion and ultimately \nlower sugar. Samples and their body weight gain. They \nalso cited another reason for weight gain as increased \ncolonization due to L. plantarum DSM intervention, which \nleads to increased adipose tissue and improved functional \nmucosa of the gastrointestinal tract of mice. They stated \nthat this significant increase in the weight of the samples \nwas not due to the increase in energy intake5. While \nHuang et al attributed the weight loss and prevention of \nweight gain to the HFFrD diet by L. plantarum intervention \nand its association with probiotics, bacterial polypidemic \nproperties, or changes in adiponectin ad leptin levels in \nthe mice1. \nZhang et al who studied the preventive and therapeutic \neffect of L. casei Zhang on type 2 diabetes in two different \ngroups, observed that L. casei Zhang caused significant \nweight loss only. In the L. group, it was preventive \ncompared to the control group, and had no effect on \nthe L. treatment group. They attributed the weight loss \nto its association with the glucagon-like peptide (GLP-2) \nand said that the intervention of this bacterium reduced \nthe effect of GLP-2 and reduced the absorption of \ncarbohydrates and fats in mice and their body weight. \nThey are also reduced3. \nIn another experiment after the intervention of Lactobacillus \ncasei, Matsuzaki and colleagues reported weight loss \nand prevention of continued weight gain in samples of \nmice with non-insulin dependent diabetes, and even \ndeclared this effect to be dose-dependent and stated \nthat the rate of reduction Weight in the higher dose group \n(2 mg per day) was higher than in the lower dose group \n(0.05%). However, Matsuzaki and colleagues reported \nno change in the dietary intake of the samples, and \ntherefore the main cause of weight loss was unknown \nand probably due to a change in their immune system \nafter probiotic intervention. Among the 12 animal studies \nthat examined changes in energy intake36-42, all studies \nsimilar to the present study, except for two studies3- 9, \nreported no significant change in changes in this index. \nIn fact, only Bejar et al 40, and Yun et al 10, both \nobserved a significant decrease in food intake of the 61\n2021/36 (3): 52-63 The effect of Familact probiotic supplement in patients with diabetes\nprobiotic group compared to the control group after the \nintervention. In contrast, very few human studies have \nbeen done in this regard. So, that only Asemi et al7 and \nIjtihad et al9, measured the amount of weight changes \nand similar to the present study, both no group and \nintergroup changes in the weight of the samples after \nthe intervention Announced. Therefore, more studies are \nneeded in this field.\nConclusion   \nOverall, the present study stated that the intervention of a \ndietary supplement containing a pure mixture of probiotics \nfor 6 weeks can lead to a decrease in fasting blood sugar in \npeople with type 2 diabetes and also significantly improve \ntheir good cholesterol (HDL) cholesterol levels. Increase, \nso that other lipid parameters, especially total cholesterol \nin patients, do not change. However, it can be argued \nthat both of these effects may prevent the progression of \ndiabetes and its complications, such as insulin resistance \nand hyperglycemia, or prevent other comorbidities such \nas cardiovascular disease, hyperlipidemia, or heart \nattack and stroke. Be. Past animal studies have shown \nthat safe and high-dose intervention in these strains over a relatively long and effective period of time can \nhave beneficial effects on improving fasting blood sugar \nlevels, lipid profiles, blood insulin, and even lowering the \nlevel of proinflammatory markers. Increased levels of \nantioxidant markers in diabetic patients. As mentioned, \nthe type of probiotic intervention is very effective in \nchanging the results because the present study used \na probiotic dietary supplement, while some human \nstudies used probiotic carriers that have macronutrients \nand micronutrients such as carbohydrates, protein \nand calcium. They are interfering agents and have a \ndistinct role in lowering blood sugar or other biochemical \nparameters, even without probiotics. Therefore, the use \nof probiotic supplements as adjunctive therapy will be \ndiscussed separately from the consumption of probiotic \ncarriers. However, other existing studies have shown \nthat it does not significantly affect the blood counts of \ndiabetes, although there may be an error in the method \nof their research or a difference in these methods has \nbeen used by the user. These supplements are used in \nsome diseases such as autoimmune diseases including \nthyroid disease, type 1 diabetes, allergies and especially \ngastrointestinal diseases such as short bowel syndrome, \nor other diseases such as acute pancreatitis, chronic \nkidney and liver disease, heart valve disease. 62\n2021/36 (3): 76 -83 2021/36 (3): 76 -83Seyedeh Faezeh Miryousefiata et al.  \nReferences\n1. Al-Salami H, Butt G, Fawcett JP , Tucker IG, Golocorbin-Kon S, Mikov \nM. Probiotic treatment reduces blood glucose levels and increases \nsystemic absorption of gliclazide in diabetic rats. Eur J Drug Metab \nPharmacokinet. 2008. Apr-Jun;33(2):101-6.\n2. Al-Salami H,  ButtG, TuckerI, Golocorbin-Kon S, Mikov M . Probiotics \ndecreased the bioavailability of the bile acid analog, monoketocholic \nacid, when coadministered with gliclazide, in healthy but not diabetic \nrats. European Journal of Drug Metabolism and Pharmacokinetics. \n2012.37(2): 99-108.\n3. AnderssonU, Branning C, Ahrne S, Molin G, Alenfall J, Onning G, \net al.  Probiotics lower plasma glucose in the high-fat fed C57BL/6J \nmouse. Benef Microbes . 2010. 1(2): 189-96.\n4. Andresean V, Baumgart DC. Role of probiotics in the treatment of  \nirritable bowel syndrome: potential mechanisms and current clinical  \nevidence. international journal of probiotics and prebiotics.2007. 1:  8.\n5. Asemi Z, Khorrami-Rad A, Alizadeh S, Shakeri H, Esmaillzadeh A . \nEffects of synbiotic food consumption on metabolic status of diabetic \npatients: a double-blind randomized cross-over controlled clinical trial. \nClin Nutr.2014. 33(2): 198-203.\n6. Asemi Z, Samimi M, Tabassi Z, Naghibi Rad M, Rahimi Foroushani \nA, Khorammian H, et al. Effect of daily consumption of probiotic yoghurt \non insulin resistance in pregnant women: A randomized controlled trial. \nEuropean Journal of Clinical Nutrition.2013. 67(1): 71-4.\n7. Semi Z, Zare Z, Shakeri H,  Sabihi S, Esmaillzadeh A. Effect of \nmultispecies probiotic supplements on metabolic profiles, hs-CRP , \nand oxidative stress in patients with type 2 diabetes. Ann Nutr Metab \n.2013.63(1-2): 1-9.\n8. Ashar M,  Prajapati J. B. Verification of hypocholesterolemic effect of \nfermented milk on human subjects with different cholesterol levels. Folia \nMicrobiol (Praha) .2000.45(3): 263-8.\n9. Besselink MG, Buskens E. Probiotic prophylaxis in predicted severe \nacute pancreatitis: a randomised, double-blind, placebo-controlled trial. \nLancet .2008. 371 9613: 8.\n10. Davari S, Talaei S, Alaei H , Salami M . Probiotics treatment improves \ndiabetes-induced impairment of synaptic activity and cognitive function: \nbehavioral and electrophysiological proofs for microbiome-gut-brain \naxis. Neuroscience.2013. 240: 287-96.\n11. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-\nJafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in \ntype 2 diabetic patients. Nutrition. 2012 May;28(5):539-43. \n12. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-\nJafarabadi M, Mofid V, Akbarian-Moghari A. Effect of probiotic yogurt \ncontaining Lactobacillus acidophilus and Bifidobacterium lactis on lipid \nprofile in individuals with type 2 diabetes mellitus. J Dairy Sci. 2011 \nJul;94(7):3288-94. \n13. FAO/WHO . Health and Nutritional Properties of Probiotics in Food \nincluding Powder Milk with Live Lactic Acid Bacteria, Report of a Joint \nFAO/WHO Expert Consultation on Evaluation of Health and Nutritional \nProperties of Probiotics in Food Including Powder Milk with Live Lactic \nAcid Bacteria.\"2001.\n14. Fran\u00e7ois-Joseph F. Biographie Universelle des Musiciens et \nBibliographie G\u00e9n\u00e9rale de la Musique ' Tome 1 (Second ed.). Paris: \nFirmin Didot Fr\u00e8res ' 2010.5.15. GroverS, M. Rashmi H, Srivastava A, Batish V. Probiotics for human \nhealth -new innovations and emerging trends. Gut Pathog .2012. 4(1): 15.\n16. Honda K, Moto M, Uchida N,  Hashizume N.  Anti-diabetic effects of \nlactic acid bacteria in normal and type 2 diabetic mice. J Clin Biochem \nNutr .2012.51(2): 96-101.\n17. Hove KD, Br\u00f8ns C, F\u00e6rch K, Lund SS, Rossing P , Vaag A. Effects \nof 12 weeks of treatment with fermented milk on blood pressure, \nglucose metabolism and markers of cardiovascular risk in patients with \ntype 2 diabetes: a randomised double-blind placebo-controlled study. \nEur J Endocrinol. 2015 Jan;172(1):11-20. \n18. Hsieh FC, Lee CL, Chai CY, Chen WT, Lu YC, Wu CS. Oral \nadministration of Lactobacillus reuteri GMNL-263 improves insulin \nresistance and ameliorates hepatic steatosis in high fructose-fed rats. \nNutr Metab (Lond). 2013 Apr 17;10(1):35\n19. Huang Y, Korivi M, Tsai C, Yang J, Tsai Y. Supplementation of \nLactobacillus plantarum K68 and Fruit-Vegetable Ferment along with High \nFat-Fructose Diet Attenuates Metabolic Syndrome in Rats with Insulin \nResistance. Evid Based Complement Alternat Med 2013. 943020.\n20. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, \nGavaghan DJ, McQuay HJ. Assessing the quality of reports of \nrandomized clinical trials: is blinding necessary? Control Clin Trials. \n1996 Feb;17(1):1-12.\n21. Raziani Y, Raziani S, Investigating the Predictors of Overweight and \nObesity in Children. Int. J. Adv. Stu. Hum. Soc. Sci., 2020, 9(4), 262-80.  \n22. Torabi Z. Status of Health Literacy and Consumer Health Behaviors. \nInt. J. Adv. Stu. Hum. Soc. Sci., 2021, 10(2), 68-76.\n23. Haddadi M. Employing Women in the Fields of Entrepreneurship \nand Green Management as the Wheel of Society's Progress.  Int. J. \nAdv. Stu. Hum. Soc. Sci., 2020, 9(3), 172-7.  \n24. Lu Y, Yin L, Chang W, Huang J. Effect of Lactobacillus reuteri GMNL-\n263 treatment on renal fibrosis in diabetic rats. Journal of Bioscience \nand Bioengineering.2010. 110(6): 709-15.\n25. Mahan L, Stump S, Reymond J. Krause's food and nutriton care \nprocess, chapter 31, Medical Nutrition Therapy for Diabetes Mellitus \nand Hypoglycemia of Nondiabetic Origin.2012.\n26. Maioli M, Pes G, Sanna M, Cherchi S, Dettori M, Manca E, et \nal.  Sourdough-leavened bread improves postprandial glucose and \ninsulin plasma levels in subjects with impaired glucose tolerance. Acta \nDiabetol .2008.45(2): 91-6.\n27. Manirarora J, Parnell S, Hu Y,   Kosiewicz M, Alard P . NOD dendritic \ncells stimulated with Lactobacilli preferentially produce IL-10 versus IL-\n12 and decrease diabetes incidence. Clin Dev Immunol 2011: 630187.\n28. Marazza J, LeBlanc J, de Giori G, Garro M. Soymilk fermented \nwith Lactobacillus rhamnosus CRL981 ameliorates hyperglycemia, lipid \nprofiles and increases antioxidant enzyme activities in diabetic mice. \nJournal of Functional Foods.2013.\n29. Mathers J, Fernandez F, Hill M, McCarthy P , Shearer M, Oxley A . \n\"Dietary modification of potential vitamin K supply from enteric bacterial \nmenaquinones in rats.\" Br J Nutr .1990.63(3): 639-52.\n30. Matsuzaki T, Nagata Y, Kado S, Uchida K, Hashimoto S , Yokokura \nT. Effect of oral administration of Lactobacillus casei on alloxan-induced \ndiabetes in mice. APMIS .1997.105(8): 637-42.63\n2021/36 (3): 76 -83 2021/36 (3): 76 -83 The effect of Familact probiotic supplement in patients with diabetes\n31. Matsuzaki T, Nagata Y, Kado S, Uchida K, Kato I, Hashimoto S, et al. \nPrevention of onset in an insulin-dependent diabetes mellitus model, NOD \nmice, by oral feeding of Lactobacillus casei. APMIS .1997.105(8): 643-9.\n32. Matsuzaki T, Yamazaki R, Hashimoto S, Yokokura T . Antidiabetic \neffects of an oral administration of Lactobacillus casei in a non-insulin-\ndependent diabetes mellitus (NIDDM) model using KK-A(y) mice. \nEndocrine Journal .1997.44(3): 357-65.\n33. MazloomZ, Yousefinejad A, Dabaghmanaesh M. Effect of probiotics \non lipid profile, glycemic control, insulin action, oxidative stress, and \ninflammatory markers in patients with type 2 diabetes: A clinical trial. \nIranian Journal of Medical Sciences .2013.38(1): 38-43.\n34. Mohamadshahi M, Veissi M, Haidari F, Shahbazian H, Kaydani GA, \nMohammadi F. Effects of probiotic yogurt consumption on inflammatory \nbiomarkers in patients with type 2 diabetes. Bioimpacts. 2014;4(2):83-8. \n35. Moroti C, Souza Magri L, de Rezende Costa M, Cavallini D, Sivieri \nK.  Effect of the consumption of a new symbiotic shake on glycemia and \ncholesterol levels in elderly people with type 2 diabetes mellitus. Lipids \nHealth Dis.2012. 11: 29.\n36. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, \nRudensky B, et al. Toll-like receptor 9 signaling mediates the anti-\ninflammatory effects of probiotics in murine experimental colitis. \nGastroenterology. 2004 Feb;126(2):520-8. \n37. Rijkers GT, de Vos WM, Brummer RJ, Morelli L, Corthier G, Marteau \nP . Health benefits and health claims of probiotics: bridging science and \nmarketing. Br J Nutr. 2011 Nov;106(9):1291-6.\n38. Roberfroid M.  Prebiotics and probiotics: are they functional \nfoods? Am J Clin Nutr 71(6 Suppl): 1682S-1687S; discussion \n.2000.1688S-1690S.\n39. Roselino MN, Pauly-Silveira ND, Cavallini DC, Celiberto LS, Pinto \nRA, Vendramini RC, Rossi EA. A potential synbiotic product improves \nthe lipid profile of diabetic rats. Lipids Health Dis. 2012 Sep 11;11:114. \n40. Kosmulski M. Skeptical comment about double-blind trials. J Altern \nComplement Med. 2010 Apr;16(4):339. \n41. Smedman A, Gustafsson I, Berglund L, Vessby B. Pentadecanoic \nacid in serum as a marker for intake of milk fat: relations between intake \nof milk fat and metabolic risk factors. The American Journal of Clinical \nNutrition .1999.69(1): 22-9.\n42. Tabuchi M, Ozaki M, Tamura A, Yamada N, Ishida T, Hosoda M, \nHosono A. Antidiabetic effect of Lactobacillus GG in streptozotocin-\ninduced diabetic rats. Biosci Biotechnol Biochem. 2003 Jun;67(6):1421-4. 43. Tanida M, Imanishi K, Akashi H, Kurata Y, Chonan O, Naito E, et al. \nInjection of Lactobacillus casei strain Shirota affects autonomic nerve \nactivities in a tissue-specific manner, and regulates glucose and lipid \nmetabolism in rats. J Diabetes Investig. 2014 Mar 23;5(2):153-61.\n44. Tomaro-Duchesneau C, Saha S, Malhotra M, Jones ML, Labb\u00e9 A, \nRodes L, Kahouli I, Prakash S. Effect of orally administered L. fermentum \nNCIMB 5221 on markers of metabolic syndrome: an in vivo analysis \nusing ZDF rats. Appl Microbiol Biotechnol. 2014 Jan;98(1):115-26. \n45. Yadav H, Jain S, Sinha P . Effect of skim milk and dahi (yogurt) on \nblood glucose, insulin, and lipid profile in rats fed with high fructose diet. \nJ Med Food. 2006.9(3): 328-35.\n46. Yadav H, Jain S, Sinha P . Antidiabetic effect of probiotic dahi \ncontaining Lactobacillus acidophilus and Lactobacillus casei in high \nfructose fed rats. Nutrition .2007.23(1): 62-8.\n47. Yadav H, Jain S, Sinha P . Oral administration of dahi containing \nprobiotic Lactobacillus acidophilus and Lactobacillus casei delayed \nthe progression of streptozotocin-induced diabetes in rats. J Dairy Res \n.2008.75(2): 189-95.\n48. Yoshida M, Jacques PF, Meigs JB, Saltzman E, Shea MK, \nGundberg C, Dawson-Hughes B, Dallal G, Booth SL. Effect of vitamin \nK supplementation on insulin resistance in older men and women. \nDiabetes Care. 2008 Nov;31(11):2092-6. \n49. Yun S, Park H , Kang J . Effect of Lactobacillus gasseri BNR17 \non blood glucose levels and body weight in a mouse model of type 2 \ndiabetes. J Appl Microbiol .2009.107(5): 1681-6.\n50. Zarfeshani A, Khaza'ai H, Mohd Ali R, Hambali Z, Wahle K, Mutalib \nM. Effect of Lactobacillus casei on the Production of Pro-Inflammatory \nMarkers in Streptozotocin-Induced Diabetic Rats. Probiotics and \nAntimicrobial Proteins .2011.3(3-4): 168-74.\n51. Zhang Y, Guo X, Guo J, He Q, Li H, Song Y, Zhang H. Lactobacillus \ncasei reduces susceptibility to type 2 diabetes via microbiota-mediated \nbody chloride ion influx. Sci Rep. 2014 Jul 18;4:5654. \n52. Mohammadkhani Orouji F, Investigating the Relationship between \nEmotional Intelligence and Social Causes of Job Development in \nWorking Children and Normal Children. Int. J. Adv. Stu. Hum. Soc. Sci., \n2021, 10(1), 1-6.\n53. Zhang Y, Wang L, Zhang J, Li Y, He Q, Li H, et al. Probiotic \nLactobacillus casei Zhang ameliorates high-fructose-induced \nimpaired glucose tolerance in hyperinsulinemia rats. Eur J Nutr. 2014 \nFeb;53(1):221-32.64\n2021/36 (3): 64-71ORIGINAL\nLa intervenci\u00f3n de los poderes p\u00fablicos frente a las \npseudoterapias: posibilidades y l\u00edmites\nThe intervention of public authorities against pseudotherapies: possibilities and limits\nCarmen Tom\u00e1s-Valiente Lanuza      \nProfesora Titular Derecho penal. Facultad de Derecho Universidad de las Islas Baleares\n eISSN 2255-0569\nRecibido:  12 - V - 2021\nAceptado:  22 - V - 2021\ndoi: 10.3306/AJHS.2021.36.03.64Correspondencia\nCarmen Tom\u00e1s-Valiente Lanuza   \nFacultad de Derecho \nUniversidad de las Islas Baleares\nc/ Valldemossa km. 7.5, Palma 07122    \nE-mail: carmen.tomas-valiente@uib.es\nResumen\nEl desaf\u00edo para la salud p\u00fablica planteado por la proliferaci\u00f3n de las pseudoterapias legitima e incluso exige la intervenci\u00f3n de \nlos poderes p\u00fablicos en este contexto. Tras una caracterizaci\u00f3n inicial en la que se destaca la variedad y muy diversos grados \nde peligrosidad de este tipo de pr\u00e1cticas, as\u00ed como los distintos instrumentos para intentar atajar sus efectos (entre ellos, una \nnormativa administrativa quiz\u00e1s desaprovechada), se hace hincapi\u00e9 en los l\u00edmites que constri\u00f1en la intervenci\u00f3n estatal, relativos a \nlos derechos fundamentales de los ciudadanos que las adoptan y los de quienes las defienden y difunden. Dentro ya del campo \nsancionador, se analiza con mayor detalle el juego del Derecho penal en este contexto, a trav\u00e9s de figuras como la estafa, el \ninstrusimo, la publicidad enga\u00f1osa o los delitos contra la salud p\u00fablica relacionados con los medicamentos no autorizados. \nPalabras clave:  Pseudoterapias, intrusismo, estafa, salud p\u00fablica, libertad de expresi\u00f3n, publicidad enga\u00f1osa. \nAbstract  \nThe recent proliferation of pseudotherapies undoubtedly poses a challenge to public health which not only legitimizes but even requires \npublic action in this field. After an initial characterization of this phenomenon, which highlights the variety and very different degrees of \ndangerousness entailed by this type of practices, this paper goes over the various legal instruments which enable a better control by \nthe state, not loosing sight, on the other hand, of constitutional constrains on state intervention imposed by the fundamental rights of \nthe citizens who decide to adopt them and the freedom of speech of those who defend and disseminate them. Within the sanctioning \nfield, the paper analyzes the role of criminal law in this context throught criminal offenses such as fraud, professional intrusion, misleading \npublicity or drug-related crimes against public health.\nKeywords:  Pseudotherapies, professional intrusion, public health, freedom of speech, misleading publicity.ID65\n2021/36 (3): 64-71 La intervenci\u00f3n de los poderes p\u00fablicos frente a las pseudoterapias: posibilidades y l\u00edmites\n1. Sobre la importancia de la terminolog\u00eda en la construcci\u00f3n del discurso sobre el tema, con un recorrido sobre su utilizaci\u00f3n en la esfera de las \npol\u00edticas p\u00fablicas en los \u00faltimos a\u00f1os en Espa\u00f1a, LOPERA PAREJA, \u00abEl debate pol\u00edtico sobre las terapias alternativas y complementarias en Espa\u00f1a \nen la interfaz entre ciencia, pol\u00edtica y sociedad (1979-2018)\u00bb, Perspectivas de la Comunicaci\u00f3n 2019, Vol 12, N\u00ba 2, pp. 155-193.\n2. 20181108 Plan Protecci\u00f3n frente pseudoterapias VF\n3. Plan Nacional 2018, p. 3.\n4. La imbricaci\u00f3n de la falsa informaci\u00f3n con el aspecto conspirativo las hace especialmente dif\u00edciles de contrarrestar, puesto que como muy \nbien explican SUNSTEIN y VERMEULE (\"Conspiracy Theories\", University of Chicago Public Law & Legal Theory Working Paper No. 199, 2008) \nlas teor\u00edas conspirativas son en esencia autoconfirmatorias (los intentos de desmontarlas por los poderes p\u00fablicos son percibidos y presentados \nprecisamente como una persecuci\u00f3n y por ende la confirmaci\u00f3n de su acierto). \n5. \u00abPreying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed \u2018\u2018Stem Cell Treatments\u2019\u2019 for COVID-19\u00bb, Cell \nStem Cell 26, June 4, 2020.\n6. La presentaci\u00f3n como tratamiento del trastorno autista resulta especialmente peligrosa, en la medida en que los quienes lleguen a ingerirlo no \nser\u00e1n personas competentes (por m\u00e1s que mal informadas), sino a menudo menores a los que les ser\u00e1 suministrado por sus progenitores.\n7. Skyler B. Johnson, Henry S. Park, Cary P . Gross, James B. Yu,  \u201cUse of Alternative Medicine for Cancer and Its Impact on Survival\u201d, JNCI J Natl \nCancer Inst (2018) 110(1): djx145.\n8. As\u00ed, la carta firmada por medio centenar de cient\u00edficos Contra las pseudociencias y las artes m\u00e1gicas , EL PA\u00cdS 14-2-2015.Introducci\u00f3n. \nLa multiplicidad de planos de la \nintervenci\u00f3n estatal sobre un grupo \nheterog\u00e9no de pr\u00e1cticas.   \nEn los \u00faltimos a\u00f1os, los poderes p\u00fablicos de distintos \npa\u00edses vienen intensificando su intervenci\u00f3n para hacer \nfrente a la creciente difusi\u00f3n y pr\u00e1ctica de las hasta hace \nno mucho tiempo conocidas como \u201cterapias alternativas \ny complementarias\u201d, que \u2013en una mutaci\u00f3n cargada de \nsignificado por la connotaci\u00f3n mucho m\u00e1s peyorativa de \nla nueva terminolog\u00eda\u2013, en la actualidad han pasado a \ndesignarse con mayor frecuencia como \u201cpseudoterapias\u201d1. \nEn lo que a Espa\u00f1a se refiere, las intenciones m\u00e1s \nrecientes de avanzar en esta l\u00ednea por parte del Gobierno \nse plasmaron en el a\u00f1o 2018 en un Plan para la Protecci\u00f3n \nde la Salud frente a las Pseudoterapias de los Ministerios \nde Sanidad, Consumo y Bienestar Social, y Ministerio \nde Ciencia, Innovaci\u00f3n y Universidades2, en el que se \ntrazaban una serie de l\u00edneas de actuaci\u00f3n y modificaciones \nnormativas que \u2013presumiblemente por los nuevos tiempos \nimpuestos por la pandemia\u2013 no han podido todav\u00eda \nllevarse a t\u00e9rmino en su totalidad.\nHablar de pseudoterapias \u2013asumida su definici\u00f3n como \n\u201csustancia, producto, actividad o servicio con pretendida \nfinalidad sanitaria que no tenga soporte en el conocimiento \ncient\u00edfico ni evidencia cient\u00edfica que avale su eficacia y su \nseguridad\u201d3 \u2013 supone, para empezar, referirse a un grupo \nnumeroso y muy heterog\u00e9neo de pr\u00e1cticas, que no deben \nser tratadas sin m\u00e1s como un todo indistinto. La diversidad \nes notable en todos sus aspectos: su origen ideol\u00f3gico \n(las hay totalmente desprovistas de tal componente frente \na algunas en las que este s\u00ed parece con claridad, como las \nllamadas \u201cterapias de conversi\u00f3n\u201d de la orientaci\u00f3n sexual, \no aquellas otras, m\u00e1s pr\u00f3ximas las teor\u00edas conspirativas, \ncargadas de un confuso tinte supuestamente contestatario \ncontra la alizanza del \u201cpoder\u201d, la ciencia convencional y \nla industria farmac\u00e9utica4 (notas que permean al menos \nuna parte del movimiento antivacunas). La diversidad es \ntambi\u00e9n notable por lo que se refiere a su apariencia de \nseriedad cient\u00edfica (encontramos desde el curanderismo \nm\u00e1s elemental a otras revestidas de solvencia cient\u00edfica y tecnol\u00f3gica, como las recientes ofertas por empresas \nnorteamericanas de costosos tratamientos preventivos \ny curativos del Covid con c\u00e9lulas madre5), o, en fin, y \nesto es lo m\u00e1s relevante, en lo que ata\u00f1e a su grado de \npeligrosidad para la salud. En relaci\u00f3n con este \u00faltimo \nfactor, que es el que aqu\u00ed m\u00e1s nos interesa, existe un \namplio rango de propuestas, del mismo modo que \u2013\nen el plano m\u00e1s general de las \u201cpseudociencias\u201d\u2013 poco \ntienen que ver en cuanto a su da\u00f1osidad, por ejemplo, \nel creacionismo y las doctrinas negacionistas del cambio \nclim\u00e1tico, estas s\u00ed extremadamente peligrosas para la \nsupervivencia del planeta. Pseudoterapias directamente \ninocuas por m\u00e1s que de eficacia no (o cuando menos no \ntodav\u00eda) cient\u00edficamente validada, que adem\u00e1s conviven \nsin problema con la terapia convencional, coexisten con \notras claramente peligrosas per se en tanto promueven el \nconsumo de productos con consecuencias adversas para \nla salud, sea porque disminuyen los efectos terap\u00e9uticos \ndel tratamiento convencional, sea por su propia toxicidad \n(as\u00ed, el caso reciente del MMS, el preparado de clorito \ns\u00f3dico conocido como Suplemento Mineral Milagroso, \nque se presenta como medicamento curativo del trastorno \nautista y muchas otras dolencias)6; a ello se a\u00f1ade, como \nfactor de peligrosidad especialmente relevante, la cuesti\u00f3n \nde si, con independencia del contenido de la pr\u00e1ctica en s\u00ed \nmisma, se induce al abandono de la terapia cient\u00edficamente \ncontrastada (como ocurre con algunas de las dirigidas \na pacientes oncol\u00f3gicos). Que la implantaci\u00f3n firme de \npr\u00e1cticas de este \u00fatimo tipo \u2013como sucede en Estados \nUnidos\u2013 pueden generar un verdadero problema de salud \np\u00fablica lo evidencian cada vez m\u00e1s estudios cient\u00edficos \ncomparativos de los \u00edndices de supervivencia de pacientes \noncol\u00f3gicos que recurren a unos u otros medios para \nafrontar su enfermedad7.\nEn el concreto caso espa\u00f1ol, la implicaci\u00f3n de los \npoderes p\u00fablicos en esta materia no solo se legitima por \nel deber de tutela de la salud p\u00fablica que el art. 43 de \nla Constituci\u00f3n de 1978 les asigna, sino que enlaza con \nla creciente implicaci\u00f3n de numerosos colectivos \u2013de \nprofesionales m\u00e9dicos, de pacientes o en defensa de los \nintereses de estos, de cient\u00edficos8, etc.\u2013 que insisten en \ndemandar una actuaci\u00f3n m\u00e1s en\u00e9rgica al Estado en la 66\n2021/36 (3): 64-71Carmen Tom\u00e1s-Valiente Lanuza  \nprotecci\u00f3n de la salud de los ciudadanos, especialmente \nde quienes, en situaci\u00f3n de especial vulnerabilidad \npor padecer una enfermedad seria, pueden ser m\u00e1s \npropensos a esperanzarse con cualquier promesa de \ncuraci\u00f3n. Tambi\u00e9n en el tratamiento del tema por parte \nde los medios de comunicaci\u00f3n, que en tantas ocasiones \nse han prestado a jugar el papel de difusores de este \ntipo de pr\u00e1cticas (a trav\u00e9s de entrevistas, reportajes, o \nsimplemente acogiendo publicidad), puede empezar \na detectarse un cierto cambio de actitud en los \u00faltimos \ntiempos, m\u00e1s acorde con su papel de pieza capital en la \nconformaci\u00f3n de una opini\u00f3n p\u00fablica informada9. \nLas iniciativas planteadas por el Plan para la Protecci\u00f3n de \nla Salud frente a las Pseudoterapias de 2018 no han podido \ntodav\u00eda concretarse en el proyectado nuevo Real Decreto \nde Protecci\u00f3n de la Salud frente a las Pseudoterapias. En \nestas p\u00e1ginas haremos alusi\u00f3n a algunas de las medidas \npropuestas, pero tambi\u00e9n a los instrumentos normativos \ncon los que ya cuenta nuestro ordenamiento, que \nabarcan por cierto una escala de intensidad muy diversa. \nDe mayor a menor, como veremos, pueden entrar aqu\u00ed \nen juego figuras delictivas como la publicidad enga\u00f1osa, \nla estafa o el intrusismo; por otro lado, en un sector tan \nintervenido por el Derecho Administrativo como es el \nsanitario se cuenta como es l\u00f3gico con una regulaci\u00f3n \ndetallada de la fabricaci\u00f3n, publicidad y venta de \nmedicamentos10, e incluso con una regulaci\u00f3n espec\u00edfica \nperfectamente aplicable a las pseudoterapias (el Real \nDecreto 1907/1997, sobre publicaci\u00f3n y promoci\u00f3n \ncomercial de productos, actividades o servicios con \npretendida finalidad sanitaria) que probablemente podr\u00eda \nser m\u00e1s utilizada en nuestro contexto de lo que lo ha \nsido hasta el momento, y que permite el ejercicio de la \npotestad sancionadora de la Administraci\u00f3n. M\u00e1s all\u00e1 de \neste aspecto puramente sancionatorio, a los poderes \np\u00fablicos les cabe tambi\u00e9n por supuesto actuaciones m\u00e1s \nsencillas, como denegar solicitudes de uso de locales \ne infraestructuras de titularidad p\u00fablica (por ejemplo, \nmunicipales) para celebrar encuentros en los que vayan \na difundirse este tipo de terapias, prohibir expresamente su pr\u00e1ctica en centros sanitarios p\u00fablicos11, no prestarles \ncobertura dot\u00e1ndolas de revestimiento cient\u00edfico (aspecto \nen el que cobra especial importancia el papel de las \nUniversidades)12, o liderar campa\u00f1as informativas en la \nred dirigidas al conjunto de los ciudanos13.\nLos l\u00edmites infranqueables \na la intervenci\u00f3n tuitiva del Estado\nAl margen de la concreta modalidad de intervenci\u00f3n \nestatal en juego, la misma se topa necesariamente con \nuna serie de l\u00edmites impuestos por nuestro propio marco \nconstitucional en tanto derivados del respeto a los derechos \nfundamentales, sean los de los enfermos convencidos de \nlos efectos curativos de una pseudoterapia, sean los de \nquienes la defienden o difunden. El primero de tales l\u00edmites \n\u2013que ni siquiera para preservar su salud o incluso su vida \npuede el Estado imponer una actuaci\u00f3n terap\u00e9utica a un \nciudadano, tampoco en el supuesto de que su rechazo a la \nterapia basada en la evidencia se asiente en informaciones \nfalsas- hace tiempo que ha sido asumido con claridad \npor nuestro ordenamiento jur\u00eddico y asimilado por los \nprofesionales; el segundo \u2013el juego en este contexto del \nderecho fundamental a la libertad de expresi\u00f3n- pertenece \nigualmente al n\u00facleo de nuestro sistema jur\u00eddico, pero sus \ncontornos pueden resultar m\u00e1s complejos.\n1. La especial peligrosidad de las pseutoterapias (o al \nmenos de aquellas que conducen al rechazo por el \npaciente de las terapias basadas en la evidencia en casos \nde dolencias graves) se relaciona estrechamente con la \nimposibilidad jur\u00eddica de imponer una terapia convencional \nal ciudadano que libremente la rechaza. Lo que convierte \nestos casos en especialmente complicados y frustrantes \npara el profesional que en primera instancia ha atendido \nal paciente es el hecho de que no  pueda hablarse en \npuridad de un \u201crechazo informado\u201d, en la medida en \nque la negativa se basa en asunciones falsas sobre \ndatos relevantes para su elecci\u00f3n, relativas a la aptitud \ncurativa de otros cursos de acci\u00f3n preferidos por \u00e9l (la \n9. Numerosos trabajos recientes dan cuenta del papel de los medios en este \u00e1mbito. Entre otros, CORTI\u00d1AS-ROVIRA/MOYA-ARRABAL, \u201cLa falsa-\nci\u00e8ncia (pseudoci\u00e8ncia) als mitjans de comunicaci\u00f3. Estudi de les estrat\u00e8gies discursives d\u2019inserci\u00f3 social a la premsa espanyola (2011-2016)\u201d, \nCommunication Papers \u2013Media Literacy & Gender Studies\u2013  Vol.7 - No13 (2018), pp. 129-144.\n10. Real Decreto 1416/1994, de 25 de junio, por el que se regula la publicidad de los medicamentos de uso humano, o el Real Decreto Legislativo \n1/2015, de 24 de julio, por el que se aprueba el texto refundido de la Ley de garant\u00edas y uso racional de los medicamentos y productos sanitarios.\n11. Por ejemplo, Instrucci\u00f3n 22/2017 de la Conselleria de Salut de la Generalitat Valenciana, que en los centros sanitarios de titularidad p\u00fablica de \nla Comunidad Valencia no autoriza la publicidad, promoci\u00f3n, presencia o pr\u00e1ctica de cualquier actividad no oficialmente reconocida e incluye una \nlista ejemplificativa de las en aquel momento consideradas como pseudociencias por el Ministerio.\n12. Comunicado de la Conferencia de Rectores de las Universidades Espa\u00f1olas de febrero de 2021, https://www.crue.org/2021/02/comunicado-\ncontra-pseudoterapias/\n13. En el marco del ya citado Plan para la Protecci\u00f3n de la Salud frente a las Pseudoterapias, de noviembre de 2018, el Gobierno ha creado \nla p\u00e1gina www.conprueba.es, en la que entre otras iniciativas se van publicando los informes emitidos por la Red Espa\u00f1ola de Agencias de \nTecnolog\u00edas Sanitarias y Prestaciones del SNS (RedETS) sobre concretas t\u00e9cnicas. En febrero de 2021, por ejemplo, se han publicado las \nconclusiones sobe las pr\u00e1cticas conocidas como magnetoterapia est\u00e1tica, la dieta macrobi\u00f3tica, el masaje tailand\u00e9s y la sanaci\u00f3n espiritual activa, \ntodas las cuales han sido consideradas pseudoterapias. Cuesti\u00f3n distinta, como se\u00f1ala PIGGLIUCI, (\u201cHow to behave virtuously in an irrational \nworld\u201d, Disputatio. Philosophical Research Bulletin , Vol. 9, No. 13, Jun. 2020, pp. 4 y ss.  acudiendo a la tr\u00edada aristot\u00e9lica, es la importancia \npersuasiva que, m\u00e1s all\u00e1 de la presentaci\u00f3n de la evidencia o l\u00f3gica (logos), despliegan el factor autoridad (ser percibido como fuente fiable, ethos) \ny, sobre todo, el de la conexi\u00f3n emocional con el destinatario del mensaje (pathos), un aspecto explotado por los difusores de las pseudoterapias \ny que las campa\u00f1as informativas dirigidas a la generalidad de los ciudadanos no deben desatender.67\n2021/36 (3): 64-71 La intervenci\u00f3n de los poderes p\u00fablicos frente a las pseudoterapias: posibilidades y l\u00edmites\nimposici\u00f3n de manos, el MMS, la magnetoterapia est\u00e1tica \no cualesquiera otros). A diferencia del ya cl\u00e1sico supuesto \ndel Testigo de Jehov\u00e1 (que conoce perfectamente la \nnecesidad de la transfusi\u00f3n y el riesgo que su negativa \na consentirla puede comportar), en los supuestos que \nnos ocupan cabe cuando menos poner en duda si el \npaciente, a la hora de prestar o negar su consentimiento \ninformado, ha aprehendido realmente  las consecuencias \nde su opci\u00f3n, y si su decisi\u00f3n de rechazar el tratamiento \nindicado por la lex artis  hubiera sido la misma de haber \nsabido que la milagrosa terapia no era tal (que no es as\u00ed \nlo evidencia la frecuencia con la que pacientes ya muy \ngraves terminan acudiendo a la Medicina convencional \nuna vez comprobada la ineficacia de la terapia enga\u00f1osa). \nCon todo y con ello, incluso aun trat\u00e1ndose de decisiones \nno verdaderamente \u201cinformadas\u201d, el grado de invasividad \nde los derechos fundamentales que la imposici\u00f3n de \nun tratamiento comporta obliga a respetar la decisi\u00f3n \ndel paciente tambi\u00e9n en estos casos14. Solo cuando se \nencuentra en juego la salud de terceros puede plantearse \nalg\u00fan tipo de compulsi\u00f3n, que incluso aqu\u00ed suele encontrar \nl\u00edmites: por ejemplo, cuando se propugna la vacunaci\u00f3n \nobligatoria (por motivos no ya de salud individual sino \np\u00fablica) no se trata de autorizar su administraci\u00f3n coercitiva \nal ciudadano, sino de terminar induci\u00e9ndole a consentir \na trav\u00e9s de la amenaza de sanciones pecuniarias (como \nrecientemente ha dispuesto, de modo excepcional en un \ncontexto general de voluntariedad de la vacuna contra el \nCOVID-19, la Ley 8/2021 de la Comunidad Aut\u00f3noma de \nGalicia, por cierto recurrida ante el Tribunal Constitucional \npor el Gobierno espa\u00f1ol)15.\n2. Desde un punto de vista jur\u00eddico, resulta esencial \ndiferenciar la mera difusi\u00f3n  de ideas, creencias o \nconstrucciones te\u00f3ricas de la efectiva pr\u00e1ctica de la \nactividad  como servicio; en un terreno intermedio entre \nambas se sit\u00faa, por su parte, la publicidad  de dicha \nactividad comercial. Por lo que se refiere al primer \nestadio \u2013y me limito ahora a las construcciones m\u00e1s \nclaramente falsas y peligrosas dentro de la amplia escala \na la que antes me refer\u00eda- plantearnos las posibilidades \nde intervenci\u00f3n estatal suscita una controversia de \nimportante calado jur\u00eddico, con un componente de \nlegitimidad o l\u00edmites (c\u00f3mo controlar la difusi\u00f3n de \ninformaciones objetivamente falsas y peligrosas para bienes jur\u00eddicos relevantes sin invadir la esfera de \nlos derechos fundamentales de quien las emite) y \nun segundo componente, este ya de orden f\u00e1ctico,  \nrelativo a las posibilidades reales de ejercer un control \nde contenidos en esta nueva era tecnol\u00f3gica en la que \nla informaci\u00f3n ha dejado de difundirse a trav\u00e9s de los \nmedios cl\u00e1sicos de comunicaci\u00f3n de masas para pasar \na transmitirse en gran parte a trav\u00e9s de las redes sociales \ny en general, de internet.\nQue la mera difusi\u00f3n de este tipo de construcciones \n(previa a su efectiva pr\u00e1ctica pero tambi\u00e9n incluso a \nsu oferta o publicidad) entra\u00f1a ya un riesgo para la \nsalud p\u00fablica parece claro: es la consulta de blogs, \np\u00e1ginas web, canales de Youtube, etc. en los que se \nponderan las ventajas de unas determinadas terapias \nfrente a la medicina convencional lo que convence y \nmotiva a personas enfermas a acudir a determinados \nservicios. Puede tambi\u00e9n sostenerse, por otra parte, \nque la difusi\u00f3n de esta informaci\u00f3n falsa queda excluida \ndel amparo del derecho fundamental a \u201ccomunicar o \nrecibir libremente informaci\u00f3n\u201d, que el art. 20.1.d de \nla Constituci\u00f3n Espa\u00f1ola condiciona a que se trate de \ninformaci\u00f3n \u201cveraz\u201d. Sin embargo, aun siendo cierto lo \nanterior, la posibilidad de prohibir (con sanciones penales \no administrativas) la mera difusi\u00f3n o circulaci\u00f3n de este \ntipo de construcciones o teor\u00edas se enfrenta a enormes \ndificultades. La primera de ellas es que en este contexto \nresulta muy complejo delimitar la mera informaci\u00f3n (falsa) \nde la expresi\u00f3n y difusi\u00f3n de \u201clos pensamientos, ideas y \nopiniones mediante la palabra, el escrito o cualquier otro \nmedio de reproducci\u00f3n\u201d, que s\u00ed se encuentra protegido \ncomo derecho fundamental por el art. 20.1a CE \u2013\nespecialmente, aunque no solo, cuando revista un sesgo \nideol\u00f3gico, por absurdo o rechazable que pueda parecer \n(\u201cla medicina convencional aliada con la gran industria \nfarmac\u00e9utica solo persigue el lucro en detrimento de \nla salud de los ciudadanos; por eso solo la medicina \nnatural garantiza \u2026.\u201d)\u2013; un derecho que seg\u00fan el texto \nconstitucional, no puede restringirse \u201cmediante ning\u00fan tipo \nde censura previa\u201d, y que seg\u00fan el Tribunal Constitucional \nacoge sin duda tambi\u00e9n las ideas m\u00e1s molestas o \nrechazables16. En el caso de celebraci\u00f3n de encuentros, \ncongresos, etc., se halla en juego, adem\u00e1s, el derecho \nfundamental de reuni\u00f3n del art. 21 CE, cuyo ejercicio \n14. En este mismo sentido se pronuncia dese hace ya d\u00e9cadas la doctrina claramente dominante; as\u00ed, p. ej., BROCK, Life and Death, Philosophical \nessays in biomedical ethics  Cambridge University Press, Cambridge, Mass., 1993, p. 80; ENGELHARDT, Los fundamentos de la Bio\u00e9tica , Paid\u00f3s, \nBarcelon/Buenos Aires/M\u00e9jico, 1995, p. 330, o  HAKSAR, Equality, Liberty and Perfectionism , Oxford University Press, New York, 1979, p. 240.\n15. Por supuesto, desde el punto de vista jur\u00eddico existe una importante diferencia entre la negativa a la propia vacunaci\u00f3n y la que afecta \ndirectamente a personas incompetentes para decidir por s\u00ed mismas, cuando es la persona que ha de prestar el consentimiento por representaci\u00f3n \n(padre de un menor, tutor de una persona judicialmente  incapacitada) la que se niega a otorgarlo. A este respecto, el Tribunal Europeo de Derechos \nHumanos ha considerado compatible con el Convenio de Europeo de Derechos Humanos las sanciones y restricciones de derechos derivadas \ndel incumplimiento del deber de vacunar a los hijos (puede consultarse el resumen de esta reciente jurisprudencia en el apunte de CLIMENT \nDURAN, https://idibe.org/tribuna/tedh-avala-las-sanciones-restricciones-derechos-derivadas-del-incumplimiento-del-deber-vacunar-los-hijos/.\n16. El mismo derecho fundamental ampara, por descontado, la cr\u00edtica acerva a las pseudoterapias peligrosas; de ah\u00ed que los tribunales hayan \ndesestimado todas las demandas civiles de protecci\u00f3n del derecho al honor interpuestas en los \u00faltimos a\u00f1os contra distintas voces cr\u00edticas \u2013\nperiodistas y comunicadores cient\u00edficos, directivos de la Asociaci\u00f3n para Proteger a los Enfermos de Terapias Pseudocient\u00edficas (APETP) o el propio \nMinistro de Ciencia- por personas o asociaciones \u2013Asamblea Nacional de Homeopat\u00eda (ANH), la Asociaci\u00f3n de los Profesionales y Aut\u00f3nomos de \nlas Terapias Naturales (COFENAT), la Fundaci\u00f3n de Terapias Naturales (FTN) o la Fundaci\u00f3n Sald y Naturaleza (FSN)\u2013 que las defienden o ejercen. \nPuede verse, por ejemplo, la STS 57/2020, de 4 de febrero, que desestima una demanda contra el Ministro de Ciencia.68\n2021/36 (3): 64-71Carmen Tom\u00e1s-Valiente Lanuza  \n\u201cno necesitar\u00e1 autorizaci\u00f3n previa\u201d. As\u00ed pues, iniciativas \nque en los \u00faltimos a\u00f1os pretenden de la Administraci\u00f3n \nla prohibici\u00f3n de la celebraci\u00f3n de encuentros de este \ntipo est\u00e1n destinadas al fracaso17; cosa distinta es que \nse dirijan a los organizadores advertencias de posibles \nsanciones administrativas (que como despu\u00e9s veremos \npodr\u00edan ser incluso penales) para el caso de que en el \ncurso de dichas actividades se incurriera en concretas \nconductas prohibidas, como la publicidad enga\u00f1osa.\nEs precisamente en ese campo fronterizo entre la mera \ndifusi\u00f3n de las ideas y la promoci\u00f3n y publicidad de \nproductos y m\u00e9todos pretendidamente sanitarios donde se \nsit\u00faa el Real Decreto de 1997 antes citado y tambi\u00e9n algunas \nde las l\u00edneas de actuaci\u00f3n del Plan de 2018 que pretende \nreformarlo, en concreto para \u201cincluir en la regulaci\u00f3n los \nactos o encuentros \u201d y \u201cla utilizaci\u00f3n de internet o redes \nsociales \u201d cuando unos u otra \u201cconlleven la publicaci\u00f3n o \npromoci\u00f3n comercial de productos, actividades o servicios \ncon pretendida finalidad sanitaria\u201d. Como con toda raz\u00f3n \napunta \u00c1lvarez Rubio18, no termina de entenderse, en \nrealidad, qu\u00e9 novedad aportar\u00eda la reforma apuntada, pues \nlo cierto es que las prohibiciones del RD 1907/1996 se \nformulan con car\u00e1cter general y por tanto ya abarcan tanto \nla promoci\u00f3n o publicidad realizada en actos o encuentros \ncomo la que tiene lugar a trav\u00e9s de internet o en redes; \ncosa distinta es que cualquier actuaci\u00f3n en este \u00faltimo \ncaso enfrenta enormes dificultades desde el punto de vista \npr\u00e1ctico19. En los \u00faltimos a\u00f1os, de hecho, la Generalitat \nde Catalunya ha hecho uso de esta normativa en varias \nocasiones para multar a los organizadores de encuentros \nen los que se ha promocionado el consumo del MSS20.\nResponsabilidades penales\nEl C\u00f3digo penal no contempla expresamente, como delito \nen s\u00ed mismo, la publicidad o la pr\u00e1ctica de pseudoterapias, \npor peligrosas que estas puedan resultar para la salud. \nEllo no es \u00f3bice, sin embargo, para que en ciertos casos \npuedan resultar aplicables determinadas figuras delictivas: \nel intrusismo, la estafa, la publicidad de medicamentos y \nla publicidad enga\u00f1osa; mayores dificultades plantea en \ncambio la aplicaci\u00f3n de las lesiones o el homicidio.\nRepasaremos brevemente las dificultades de encaje \nque a menudo se plantean y el modo en que las han \nabordado los tribunales. 1. Estafa.  El delito de estafa del art. 248 del CP , que \nen cualquier caso \u00fanicamente atiende a una dimensi\u00f3n \nparcial del problema (la protecci\u00f3n del patrimonio), ha sido \naplicado en ocasiones a las pr\u00e1cticas que nos ocupan, si \nbien su encaje no est\u00e1 exento de dificultades. \nEn primer lugar, la propia idea de \u201cenga\u00f1o\u201d requiere la \nconciencia de la falsedad de lo que se afirma, un elemento \nmuy evidente en algunos casos pero no tanto en otros. \nEn segundo t\u00e9rmino, dado que la estafa se define como \nutilizar \u201cenga\u00f1o bastante para producir error en otro, \ninduci\u00e9ndolo a realizar un acto de disposici\u00f3n en perjuicio \npropio o ajeno\u201d, el delito no puede aplicarse (seg\u00fan una \ninterpretaci\u00f3n muy consolidada) si tal concatenaci\u00f3n de \nsus factores no se produce en el orden descrito; la estafa \nrequiere un enga\u00f1o que produzca un error y que como \nconsecuencia de este se lleve a cabo la disposici\u00f3n \npatrimonial, de tal manera que los supuestos conocidos \ncomo de \u201cerror preexistente\u201d \u2013cuando el luego perjudicado \ndemanda un servicio ya previamente convencido de sus \nventajas- no dar\u00e1n lugar al delito (como ocurre, por ejemplo, \ncon quien previamente persuadido de las facultades de un \nechador de cartas o del sanador por imanes, acude a \u00e9l y \nle paga por su servicio). A pesar de esta dificultad inicial, \ns\u00ed es posible sancionar por estafa cuando en momentos \nposteriores el sujeto \u201ca\u00f1ade\u201d elementos enga\u00f1osos m\u00e1s \nall\u00e1 del inicial convencimiento err\u00f3neo de la v\u00edctima, que \nconsiguen el pago de cantidades m\u00e1s all\u00e1 de las iniciales21. \nLa tercera dificultad de aplicaci\u00f3n de la estafa en estos \ncontextos tiene que ver con el elemento del enga\u00f1o \n\u201cbastante\u201d, que durante al menos unos a\u00f1os hab\u00eda sido \ninterpretado por el Tribunal Supremo en el sentido de excluir \nla estafa en los enga\u00f1os muy burdos o extremadamente \nelementales (en los que se dar\u00eda una cierta vulneraci\u00f3n \ndel deber de autoprotecci\u00f3n del propio enga\u00f1ado), \nque no satisfar\u00edan as\u00ed el requisito de ser \u201cobjetivamente \nbastantes\u201d. Con todo, el propio Tribunal ha ido matizando \nenormemente esta idea, que \u00e9l mismo reconoce \nque no puede servir para excluir la protecci\u00f3n de las \npersonas m\u00e1s cr\u00e9dulas por raz\u00f3n de su edad, formaci\u00f3n \ncultural, o circunstancias que las hacen especialmente \nvulnerables, elementos todos ellos que han de incluirse \nen el par\u00e1metro de la valoraci\u00f3n del car\u00e1cter bastante del \nenga\u00f1o. De ah\u00ed que (incluso siendo enga\u00f1os muy burdos) \nsuela condenarse en casos pr\u00f3ximos a los que aqu\u00ed \nnos interesan (propiamente esoterismo con supuestos \n17. https://www.lavanguardia.com/politica/20180111/434219528876/el-colegio-de-medicos-de-barcelona-pide-prohibir-congreso-contra-oncologos.html\n18. \u201cProblemas (y paradojas) actuales de la regulaci\u00f3n publicitaria en el \u00e1mbito sanitario\u201d, LEX N\u00b0 26 - A\u00d1O XVIII - 2020-II, pp. 177-204, pp. 190-191. \n19. De hecho, el art. 4 del RD 1907/1996 contiene prohibiciones que se ajustan perfectamente a determinadas pseudoterapias. As\u00ed, \u201cqueda \nprohibida cualquier clase de publicidad o promoci\u00f3n directa o indirecta, masiva o individualizada, de productos, materiales, sustancias, energ\u00edas \no m\u00e9todos con pretendida finalidad sanitaria\u201d, entre otros casos, cuando \u201cse destinen a la prevenci\u00f3n, tratamiento o curaci\u00f3n de enfermedades \ntransmisibles, c\u00e1ncer y otras enfermedades tumorales, insomnio, diabetes y otras enfermedades del metabolismo\u201d, o cuando \u201catribuyan car\u00e1cter \nsuperfluo o pretenda sustituir la utilidad de los medicamentos o productos sanitarios legalmente reconocidos\u201d. Lo mismo sucede con la Ley \nde Competencia Desleal,  cuyo art. 23.3, reputa como desleal, por enga\u00f1oso, \u201cproclamar, falsamente, que un bien o servicio puede curar \nenfermedades, disfunciones o malformaciones\u201d.\n20. https://www.lavanguardia.com/local/lleida/20181026/452557092851/salud-sanciona-josep-pamies-pseudociencia.html:   https://elpais.\ncom/sociedad/2018/10/22/actualidad/1540229352_723272.html\n21. Ver el razonamiento en tal sentido, por ejemplo, en la STS 407/2005 de 23 de marzo.69\n2021/36 (3): 64-71 La intervenci\u00f3n de los poderes p\u00fablicos frente a las pseudoterapias: posibilidades y l\u00edmites\nfines curativos de enfermedades)22 y que solo se haya \nabsuelto en supuestos de v\u00edctimas con cierta formaci\u00f3n \ncultural23 (e incluso aqu\u00ed resulta muy discutible, puesto que \nla especial vulnerabilidad derivada del deseo o incluso la \ndesesperaci\u00f3n por recobrar la salud tambi\u00e9n debe ser \ntomada en consideraci\u00f3n; de hecho, el propio TS as\u00ed \nlo hace en otras sentencias en las que se condena por \nestafa en enga\u00f1os burdos a pesar de que los enfermos \nno necesariamente presentan un muy bajo nivel cultural). \nJunto a ello se sit\u00faan condenas por estafa en pr\u00e1cticas \nm\u00e1s claramente catalogables como pseudoterapias, \nrevestidas de una p\u00e1tina de cierta mayor credibilidad24. Ha \nde apuntarse, en cualquier caso, que los supuestos que \nllegan a los tribunales suelen caracterizarse por un perjuicio \npatrimonial elevado y son, en todo caso, puntuales.\n2. Publicidad enga\u00f1osa.  Si la estafa s\u00f3lo puede entrar en \njuego cuando la pr\u00e1ctica enga\u00f1osa en cuesti\u00f3n ha tenido \nlugar y ha producido un efectivo perjuicio patrimonial, el \ndelito de publicidad enga\u00f1osa puede aplicarse a lo que \npodr\u00edamos considerar el \u201cestadio previo\u201d a la estafa. El art. \n282 Cp sanciona con una pena de prisi\u00f3n de seis meses \na un a\u00f1o o multa de 12 a 24 meses a los \u201cfabricantes \no comerciantes que, en sus ofertas o publicidad de \nproductos o servicios, hagan alegaciones falsas o \nmanifiesten caracter\u00edsticas inciertas sobre los mismos, de \nmodo que puedan causar un perjuicio grave y manifiesto a \nlos consumidores, sin perjuicio de la pena que corresponda \naplicar por la comisi\u00f3n de otros delitos\u201d. Se trata en cualquier \ncaso un delito orientado a la protecci\u00f3n gen\u00e9rica de los \nconsumidores y sus intereses como tales, y no a la tutela \nde la salud p\u00fablica. De hecho, ha sido muy escasamente \naplicado en el contexto de las pseudoterapias (quiz\u00e1s, entre \notros factores, por la dificultad de encuadrar a quienes las \npractican en el t\u00e9rmino legal de \u201ccomerciantes\u201d), aunque \ns\u00ed existe alguna sentencia25. Quiz\u00e1s una modificaci\u00f3n \ndel precepto o la introducci\u00f3n de un subtipo espec\u00edfico \nconcebido expresamente para las pseudoterapias \nenga\u00f1osas m\u00e1s peligrosas (en t\u00e9rminos similares a los \ndel ya citado Real Decreto 1907/1997, sobre publicaci\u00f3n y promoci\u00f3n comercial de productos, actividades o \nservicios con pretendida finalidad sanitaria) podr\u00eda resultar \nun instrumento adecuado para la intervenci\u00f3n penal, pues \ncarece de sentido que se tipifiquen como merecedoras de \nsanci\u00f3n penal conductas enga\u00f1osas aptas para poner en \npeligro los intereses (patrimoniales) de los consumidores \ny no se haga lo propio con la publicidad de pr\u00e1cticas \nfraudulentas peligrosas para un bien jur\u00eddico de primer \nrango como es la salud.\n3. Intrusismo.  Esta figura delictiva del art. 403 CP \ns\u00ed ha sido ocasionalmente aplicada a la pr\u00e1ctica de \npseudoterapias, las m\u00e1s de las veces en concurso de \ndelitos con la estafa (convivencia posible en la medida \nen que cada uno de los delitos protege un bien jur\u00eddico \ndistinto y por tanto sanciona una dimensi\u00f3n diferente de \nla conducta)26. El encaje bajo el intrusismo, definido (en \nla modalidad que aqu\u00ed nos interesa) como ejercer \u201cactos \npropios de una profesi\u00f3n sin poseer el correspondiente \nt\u00edtulo acad\u00e9mico expedido o reconocido en Espa\u00f1a de \nacuerdo con la legislaci\u00f3n vigente\u201d, solo resulta posible, \nempero, si efectivamente se realizan dichos actos propios \nde la profesi\u00f3n, reservados por ello a quienes acreditan la \nformaci\u00f3n acad\u00e9mica requerida. El n\u00facleo de la cuesti\u00f3n \nreside, por tanto, en clarificar cu\u00e1les son exactamente \ntales actos en el caso del ejercicio de la medicina (la \njurisprudencia los agrupa en \u201cprofilaxis\u201d, \u201cdiagn\u00f3stico\u201d \ny \u201ctratamiento\u201d de la enfermedad), y en perfilar de qu\u00e9 \nmodo han de llevarse a cabo para que la conducta pueda \nconsiderarse intrusiva; en este \u00faltimo sentido, suele \nconsiderarse que si se emplea un cauce completamente \najeno a lo cient\u00edfico (diagnosticar mediante adivinaci\u00f3n, \nrevisi\u00f3n de la dentadura o empleo de imanes, o tratar \na trav\u00e9s de la meditaci\u00f3n, el masaje o la imposici\u00f3n de \nmanos, por ejemplo) no podr\u00e1 decirse que se practica \nun acto propio  de la profesi\u00f3n27. De ah\u00ed que los actos \ndel curanderismo m\u00e1s burdo (cercanos al esoterismo o \nla brujer\u00eda) no perfeccionen el delito, como tampoco lo \nhacen per se numerosas t\u00e9cnicas encuadrables en la \ncategor\u00eda de las pseudoterapias28. Ha de reconocerse, \n22. Por ejemplo, STS 831/2015, de 29 diciembre, o STS 833/2016 de 3 noviembre.\n23. STS 89/2007 de 2 febrero (los dos enga\u00f1ados por un curandero, que persegu\u00edan la curaci\u00f3n del c\u00e1ncer padecido por su padre, eran \nadministrativo y auxiliar de cl\u00ednica). \n24. STS 1612/2002 de 1 abril, conocida por la enorme entidad del caso: m\u00e9dico no especialista en oncolog\u00eda, que se presentaba como tal, \ny que entre otras conductas vendi\u00f3 a precio elevad\u00edsimo a centenares de pacientes un producto no autorizado compuesto de urea y suero \nfisiol\u00f3gico, supuestamente curativo del c\u00e1ncer; STS 407/2005, de 23 de marzo, reativa a un sujeto que se presenta como \u201cdoctor y especialista \nen Biocibern\u00e9tica cu\u00e1ntica hologr\u00e1mica y medicina neurofocal\u201d que diagnostica y/o trata enfermedades por, entre otros, el procedimiento de pasar \nun cilindro por el cuerpo y prescribir la extracci\u00f3n de toda o parte de la dentadura a numerosos pacientes (a los que, adem\u00e1s, induce a abandonar \nel tratamiento convencional), inyectarles proca\u00edna o recetarles una \u201cmedicaci\u00f3n embrionaria\u201d, por todo lo cual cobr\u00f3 importantes cantidades.  \n25. En nuestro pa\u00eds ha sido aplicado por el Juzgado de lo Penal n\u00fam. 18 de Madrid en su sentencia 268/2014, de 4 de julio, en el caso del \nmedicamento Biobac; en Francia es interesante la condena por este delito publicitario dictada en 2015 por el tribunal correcional de Montpellier \ncontra un defensor de la doctrina de la \u201cbiolog\u00eda total\u201d (seg\u00fan la cual toda enfermedad, incluido el c\u00e1ncer, es el resultado de un conflicto interior \nno resuelto), que induc\u00eda a sus seguidores al abandono completo de los tratamientos convencionales (https://france3-regions.francetvinfo.fr/\noccitanie/herault/montpellier-metropole/montpellier/fondateur-biologie-totale-condamne-2-ans-ferme-montpellier-844921.html).\n26. Por ejemplo SAP C\u00e1diz 166/2010, de 23 de abril o, muy recientemente, STS 167/2020, de 19 de mayo.\n27. En este sentido recientemente, por todos, GONZ\u00c1LEZ URIEL, \u00abMedicina alternativa y delito de instrusismo. Algunas consideraciones al hilo de \nla STS 167/2020\u00bb, La Ley Penal  n\u00ba 147, nov-dic 2020, p. 10.\n28. De ah\u00ed la absoluci\u00f3n en el caso, de gran repercusi\u00f3n medi\u00e1tica, de un joven estudiante universitario valenciano aquejado de leucemia \nlinfobl\u00e1stica aguda que acude a un natur\u00f3pata, el cual, seg\u00fan los hechos probados de la sentencia (37/2018 de 29 enero, del Juzgao de lo \nPenal n\u00fam. 10 de Valencia) se limita a recetarle complementos vitam\u00ednicos y una dieta , aconsej\u00e1ndole que consultara con los profesionales su \ncompatibilidad con el tratamiento de quimioterapia. 70\n2021/36 (3): 64-71Carmen Tom\u00e1s-Valiente Lanuza  \nen cualquier caso, que existe una zona gris en la que no \nresulta tan sencillo determinar si el m\u00e9todo empleado para \nel diagn\u00f3stico (pensemos, por ejemplo, en una entrevista \ncon el paciente sobre sus s\u00edntomas) puede considerarse \nmedianamente \u201ccient\u00edfico\u201d y dar por ello lugar al intrusismo. \nUna precisi\u00f3n relevante ata\u00f1e a la prescripci\u00f3n de \nsustancias: siguiendo la anterior l\u00ednea de razonamiento, \ncuando se trate de medicamentos autorizados y que \nrequieran receta m\u00e9dica, nos encontraremos sin duda \nante intrusismo (como acto de \u201ctratamiento\u201d); no ser\u00e1 \nas\u00ed, en cambio, si se prescriben o suministran sustancias \nno autorizadas (lo que en su caso podr\u00e1 suponer un \ndelito contra la salud p\u00fablica de los que trataremos \nenseguida infra), plantas supuestamente medicinales o \ncomplementos vitam\u00ednicos inocuos. \nConviene tener presente, por otro lado, que el mero uso \nde t\u00e9rminos que impl\u00edcita o expl\u00edcitamente remitan a la \nprofesi\u00f3n titulada (\u201ccl\u00ednica\u201d, \u201cconsulta\u201d, \u201cm\u00e9dico oste\u00f3pata, \nhome\u00f3pata, natur\u00f3pata\u201d, etc.) no realiza por s\u00ed mismo \nel delito (por m\u00e1s que pudieran contribuir al enga\u00f1o a \nefectos del delito de estafa), que solo se perfecciona, \ncomo se ha explicado, si se realizan los actos propios de \nla profesi\u00f3n; comprobado esto \u00faltimo, la atribuci\u00f3n p\u00fablica \ndel t\u00edtulo que no se posee (\u201clicenciado en medicina\u201d) s\u00ed da \nlugar a un tipo agravado, con un incremento notable de \nla pena (de la multa del tipo b\u00e1sico se pasa a prisi\u00f3n \nde seis meses a dos a\u00f1os), la misma que se impone \nen caso de que la actividad se ejerciere \u201cen un local o \nestablecimiento abierto al p\u00fablico en el que se anunciare \nla prestaci\u00f3n de servicios propios de aquella profesi\u00f3n\u201d29. \n4. Delito contra la salud p\u00fablica en relaci\u00f3n a \nmedicamentos. El art. 362 del C\u00f3digo penal castiga, \nentre otras conductas, la de fabricar, suministrar, \ncomercializar u ofrecer \u201cmedicamentos (\u2026) que carezcan \nde la necesaria autorizaci\u00f3n exigida por la ley\u201d, siempre \nque \u201ccon ello se genere un riesgo para la salud o la vida \nde las personas\u201d; la pena asignada es de seis meses \na tres a\u00f1os de prisi\u00f3n, multa e inhabilitaci\u00f3n especial. \nA diferencia de la estafa o la publicidad enga\u00f1osa, \nque como se ha se\u00f1alado atienden al aspecto m\u00e1s \npatrimonial de la conducta -y en puridad, m\u00e1s secundario \na los efectos que aqu\u00ed interesan-, el art. 362 y los que le \nsiguen s\u00ed se orientan claramente al bien jur\u00eddico relevante \nen el contexto de las pseudoterapias (la salud p\u00fablica), \nsi bien solo puede aplicarse, como es obvio, a los casos \nen los que de alguna manera se utilicen productos a los \nque se atribuyen propiedades curativas \u2013cosa que no sucede, ni mucho menos, en todas las pr\u00e1cticas\u2013. \nNos encontramos ante lo que en Derecho penal se \ndenomina un \u201cdelito de peligro\u201d, en el que la sanci\u00f3n de \nla conducta no requiere la producci\u00f3n de un resultado \nlesivo (lesiones, muerte); la raz\u00f3n de la sanci\u00f3n se \nencuentra, ya en un momento previo, en su peligrosidad \npara el bien jur\u00eddico. Tal peligrosidad, eso s\u00ed, ha de \nresultar probada, como elemento del delito que es \n-precisamente en ella reside, adem\u00e1s, la frontera entre \nel il\u00edcito meramente administrativo y el penal, pues \nsi comercializar un producto no autorizado por las \nautoridades sanitarias competentes siempre constituye \nil\u00edcito sancionable por la Administraci\u00f3n, hacerlo cuando \ncon ello se pone en riesgo la salud de sus eventuales \nconsumidores se considera ya merecedor de sanci\u00f3n \npenal. Precisamente esta falta de peligrosidad explica \nlas absoluciones reca\u00eddas en casos en que se trataba \nde sustancias inocuas30; ello no es \u00f3bice, sin embargo, \npara que s\u00ed se aprecie el delito cuando, aun trat\u00e1ndose \nde una sustancia inocua per se, se suministre de modo \nque sustituya  el tratamiento convencional, que ser\u00eda \ndonde residir\u00eda la verdadera peligrosidad para la salud31.\n5. Lesiones u homicidio. En los casos de pr\u00e1cticas \nde pseudoterapias que han llegado a los tribunales \npenales en nuestro pa\u00eds son absolutamente infrecuentes \nlas acusaciones por delitos de lesiones u homicidio. \nExisten, sin embargo, supuestos en los que podr\u00eda \nsostenerse la responsabilidad por tales resultados (no \nentraremos aqu\u00ed en si a t\u00edtulo de mera imprudencia o \nde dolo eventual), como sucede si se prescriben o \nvenden productos con efectos perjudiciales probados; \nel que el paciente los hubiera ingerido voluntariamente \nno impedir\u00eda la imputaci\u00f3n si lo hizo desconociendo sus \nefectos adversos. Tampoco ofrecer\u00edan dificultades los \ncasos de suministro de sustancias da\u00f1inas a pacientes \nincompetentes para decidir, como menores con trastorno \nautista. Por otra parte, en la jurisprudencia existe alg\u00fan \ncaso puntual en el que resulta del todo sorprendente que \nla Fiscal\u00eda no acusara por lesiones; me refiero en concreto \nal caso antes citado de la STS 407/2005, de 23 de \nmarzo, en el que se llegaron a producir extracciones de \ntoda la dentadura a algunos pacientes. Ha de recordarse \nque el nuestro ordenamiento penal el hecho de que las \nlesiones sean consentidas solo supone una atenuaci\u00f3n \nde la pena seg\u00fan el art. 155 Cp, y en casos como este, a \nmi juicio, ni siquiera tal cosa, puesto que el consentimiento \nsolo despliega tales efectos atenuatorios si es emitido de \nforma \u201cv\u00e1lida\u201d y \u201clibre\u201d, lo que entiendo que no sucede \n29. No da lugar a intrusismo, en cambio, la realizaci\u00f3n de los actos propios de una determinada especialidad m\u00e9dica que no se posee, si se \nacreditala titulaci\u00f3n b\u00e1sica (raz\u00f3n por la cual se absuelve de intrusismo en la ya citada STS 1612/2002 de 1 abril: el sujeto, que se presentaba \ncomo onc\u00f3logo sin serlo, s\u00ed era licenciado en medicina).\n30. As\u00ed por ejemplo en el conocido como caso Acobiomol, juzgado por la SAP C\u00e1diz 166/2010, de 23 de abril (s\u00ed se conden\u00f3, en cambio, por \nestafa e intrusismo).\n31. El TS dej\u00f3 clara esta interpretaci\u00f3n en la ya citada STS 1612/2002, de 1 de abril; en aplicaci\u00f3n de esta idea, el Juzgado de lo Penal n\u00fam. 18 \nde Madrid en su sentencia 268/2014, de 4 de julio, que entendi\u00f3 del conocido como caso Biobac  absuelve del delito por entender que, adem\u00e1s \nde ser inocuo, el producto no se suministr\u00f3 como sustitutivo de las terapias convencionales.71\n2021/36 (3): 64-71 La intervenci\u00f3n de los poderes p\u00fablicos frente a las pseudoterapias: posibilidades y l\u00edmites\ncuando el sujeto act\u00faa bajo enga\u00f1o pensado que tales \nlesiones van a conseguir curarle de otras afecciones. \nEl problema m\u00e1s complejo de calificaci\u00f3n penal se \npresenta en los supuestos en los que la responsabilidad \npor lesiones u homicidio no pretende derivarse de un \nm\u00e9todo o producto lesivo per se, sino del hecho de haberse \ninducido al abandono del tratamiento convencional. Esto \nfue precisamente lo que sucedi\u00f3, seg\u00fan los hechos \nprobados de la sentencia, en el supuesto enjuiciado por \nla STS 1612/2002, en el que, adem\u00e1s de proporcionarse \nun producto en principio inocuo a cientos de pacientes \noncol\u00f3gicos, se les indujo al abandono de cualquier \notro tratamiento; a pesar de que seg\u00fan la sentencia, la \ngran mayor\u00eda de aquellos hab\u00edan fallecido, ni Fiscal\u00eda ni \nla acusaci\u00f3n particular acusaron por homicidio, lo que \nimpidi\u00f3 al Tribunal Supremo pronunciarse sobre ello \n(aunque s\u00ed tuvo en cuenta el factor mencionado para \nsancionar por delito contra la salud p\u00fablica). M\u00e1s de \nquince a\u00f1os despu\u00e9s, dicha acusaci\u00f3n s\u00ed se formula (por \nel padre del joven fallecido) en el caso resuelto por el JP \nn\u00fam. 10 Valencia 37/2018, 29 enero, que en cambio \nabsuelve de estos cargos al no haber resultado probado \nque se indujera a dicho abandono32. \nLo cierto es, en cualquier caso, que incluso habi\u00e9ndose \nprobado la inducci\u00f3n al abandono de la medicaci\u00f3n o \nel tratamiento, la imputaci\u00f3n de responsabilidad por el \nresultado de muerte se enfrenta a m\u00faltiples dificultades. \nNo resultar\u00e1 sencillo probar, para empezar, hasta \nqu\u00e9 punto este abandono incidi\u00f3 en el curso de una \nenfermedad que ya de entrada pod\u00eda encontrarse muy avanzada; por otra parte, en un sistema penal como \nel espa\u00f1ol, en el que no se sanciona el inducir a otra \npersona a una conducta peligrosa para su salud y ni \nsiquiera el inducir a una autolesi\u00f3n (solo se pena la \ninducci\u00f3n al suicidio en el art. 143.1 del C\u00f3digo penal), \nla \u00fanica manera de imputar el resultado de muerte al \nresponsable de la pseudoterapia pasar\u00eda por considerar \nque el paciente se encontraba absoluta y totalmente \nenga\u00f1ado, que era un mero instrumento ciego en \nmanos de quien le manipulaba por completo. No es \nf\u00e1cil trazar la frontera entre esta situaci\u00f3n y aquella otra \nen la que el paciente, habiendo sido informado por \nsus m\u00e9dicos de lo absurdo y peligroso de su decisi\u00f3n, \nsimplemente elige no creerles \u2013esto es, asume \nlibremente lo que otros le han intentado hacer ver que \nes una conducta peligrosa para su salud\u2013; y ello explica \nquiz\u00e1s la reticencia de la Fiscal\u00eda a acusar por homicidio \no lesiones incluso en estos casos que intuitivamente se \nperciben como muy graves. \nConclusiones\nEste breve repaso ha permitido mostrar los instrumentos \nlegales con los que ya cuentan los poderes p\u00fablicos \nde nuestro pa\u00eds para hacer frente a las pseudoterapias \nque representan un mayor peligro para  la salud de los \nciudadanos. Un arsenal normativo quiz\u00e1s incompleto \ny siempre limitado por determinadas exigencias \nconstitucionales, pero que probablemente podr\u00eda ser \naprovechado y rendir m\u00e1s frutos de los que hasta el \nmomento ha permitido cosechar. \n32. Se considera probado, de hecho, lo contrario: que el acusado recomend\u00f3 al paciente la continuaci\u00f3n de la quimio, y que consultara con sus \nm\u00e9dicos la compatibilidad entre esta y los suplementos vitam\u00ednicos aconsejados (consulta que aparece reflejada en la historia cl\u00ednica). La sentencia \ninsiste en que el joven paciente ya era muy reacio a someterse a quimioterapia antes de acudir a los servicios del acusado, entre otros factores \npor haber recibido dicha influencia en su propia familia. \n1. Sobre la importancia de la terminolog\u00eda en la construcci\u00f3n del discurso sobre el tema, con un recorrido sobre su utilizaci\u00f3n en la esfera de las \npol\u00edticas p\u00fablicas en los \u00faltimos a\u00f1os en Espa\u00f1a, LOPERA PAREJA, \u00abEl debate pol\u00edtico sobre las terapias alternativas y complementarias en Espa\u00f1a \nen la interfaz entre ciencia, pol\u00edtica y sociedad (1979-2018)\u00bb, Perspectivas de la Comunicaci\u00f3n  2019, Vol 12, N\u00ba 2, pp. 155-193.\n1. 20181108 Plan Protecci\u00f3n frente pseudoterapias VF\n1. Plan Nacional 2018, p. 3.\n1. La imbricaci\u00f3n de la falsa informaci\u00f3n con el aspecto conspirativo las hace especialmente dif\u00edciles de contrarrestar, puesto que como muy \nbien explican SUNSTEIN y VERMEULE (\"Conspiracy Theories\", University of Chicago Public Law & Legal Theory Working Paper  No. 199, 2008) \nlas teor\u00edas conspirativas son en esencia autoconfirmatorias (los intentos de desmontarlas por los poderes p\u00fablicos son percibidos y presentados \nprecisamente como una persecuci\u00f3n y por ende la confirmaci\u00f3n de su acierto). \n1. \u00abPreying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed \u2018\u2018Stem Cell Treatments\u2019\u2019 for COVID-19\u00bb, Cell \nStem Cell  26, June 4, 2020.72\n2021/36 (3): 72-75ORIGINAL\nCyto-histological correlation in cervical cytology\nCorrelaci\u00f3n cito-histol\u00f3gica en la citolog\u00eda cervical\nJavier Cort\u00e9s Bordoy      , Ana Forteza Valad\u00e9s      \nCytology Laboratory Dr. Cort\u00e9s, Palma, Spain\n eISSN 2255-0569\nReceived:  3 - IV - 2021\nAccepted:  2 - V - 2021\ndoi: 10.3306/AJHS.2021.36.03.72Corresponding author\nJavier Cort\u00e9s Bordoy   \nCytology Laboratory Dr. Cort\u00e9s \nAlfonso el Magn\u00e1nimo 29, 07004 Palma, Espa\u00f1a    \nE-mail: cortes@ocea.es \nAbstract  \nThe results obtained with the use of a follow-up sheet of cytological results sent to the clinicians responsible for the patients are presented. \n81% of responses have been obtained, which has allowed verifying that the rates of final histological diagnoses have maintained an \nexcellent correlation with the initial cytological results, especially in the essential diagnosis, the high-grade intraepithelial lesion of the cervix, \na 67% specificity, a percentage within the expected range.\nKeywords:  Cytology, quality. \nResumen\nSe presentan los resultados obtenidos con la utilizaci\u00f3n de una hoja de seguimiento de resultados citol\u00f3gicos enviada a los \ncl\u00ednicos responsables de las pacientes. Se ha obtenido un 81% de respuestas, lo que ha permitido comprobar que las tasas de \ndiagn\u00f3sticos histol\u00f3gicos finales han mantenido una excelente correlaci\u00f3n con los resultados citol\u00f3gicos iniciales, especialmente \nen el diagn\u00f3stico esencial, la lesi\u00f3n intraepitelial de alto grado del cuello uterino, una especificidad del 67%, un porcentaje dentro \nde lo esperado. \nPalabras clave:  Citolog\u00eda, calidad. ID ID\nIntroduction\nSince its description by GN Papanicolaou1, cervical \ncytology (CvC) has played a decisive role in the \nprevention of cervical cancer (CC). The impacts on \nits incidence and mortality have been attributed to \nthe systematic application of cytology from first well-\nexecuted and documented experiences, especially the \nso-called Walton Report2, which laid the groundwork \nfor the first cytological population screening to prevent \nCC. Subsequently and to this day, its use has continued \napplying well-established protocols agreed upon by the \nmain regulatory entities, supranational3 or national4.\nThe fundamental objective of CVC is to enable the \nhistological diagnosis of pre-cancerous lesions of \nthe cervix. Knowing well the natural history of CC \nmakes it possible. In this regard, it is necessary to \nclarify important differences related to squamous cell \ncarcinoma and adenocarcinoma, the two most common \nhistological forms of CC, in a ratio of 8 to 2 in terms \nof frequency5. The LAST report6 established the idea \nof a binary classification of squamous pre-cancerous lesions, low and high grade lesions, suppressing the \n\u201cmoderate\u201d ones, a source of diagnostic problems \nand, consequently, therapeutic ones7. This is the \ndichotomous classification in use in the healthcare \nenvironment that we share, and is, consequently, the \none used in this work, always bearing in mind that the \nlow grade represents the histological response to HPV \ninfection8, with little capacity for progression to a high-\ngrade, authentic pre-neoplastic lesion. On the other \nhand, we do not know well the natural history of cervical \nadenocarcinoma. We know that in a high percentage \nit also responds to the infectious aggression of HPV 5 \nbut we have not been able to safely identify its other \npossible primary causes or its pre-neoplastic phases, \nif there are9, leading to all of this to an ineffectiveness \nof the CvC in detecting adenocarcinomas10, causing \nthat, as we have known for some years11, the decrease \nthat in the population registries of tumors is registered \nof the CC, thanks to the population-based screening \nprograms - not the opportunists12 - affects only to the \nsquamous variety.73\n2021/36 (3): 72-75 Cyto-histological correlation in cervical cytology\nThis high effectiveness of CvC has been unequivocally \nrelated with the quality of the cytological take, it means the \nexistence of a good representation of the endocervical \nand / or metaplastic glandular epithelia, a recognized \nmarker of the quality of the cell sample taken13.\nIn the Laboratory where the authors work, an action has \nbeen judged of great interest and has been introduced \ninto our quality control protocols of our work: monitoring \nthe follow-up of reports issued as positive to some degree \n\u2013following the conceptual terminology recommended by \nthe Bethesda System14\u2013 by referring a file to the clinician \nresponsible for the patient ( Figure 1 ), with a double \nobjective: to facilitate him the follow-up of the case and \navoid its loss, and at the same time obtain from him the \ninformation about its final resolution in order to validate \nthe quality of our reports, thus allowing the proper closure \nof the case.\nIn this article we present and discuss the results of this \ncontrol procedure that were obtained between November \n2019 and November 2020.Material and method\nBetween November 30, 2019 and November 30, \n2020, our Laboratory issued 17,731 CVC reports. The \ndistribution of anomalous results was as follows during \nthis period:\n\u00b7 AGC  11 0.06% \n\u00b7 ASC-H 19 0.11%\n\u00b7 ASC-US 49 0.27%\n\u00b7 LG-SIL  71 0.40%\n\u00b7 HG-SIL 31 0.17%\n\u00b7 Ca  0\nTotal  181 1.01%\nAGC: Atypia in Glandular Cells\nASC-H: Atypia in Squamous Cells, intraepithelial lesion is not ruled out\nASC-US: Atypia in Squamous Cells of Uncertain Significance\nLG-SIL: Low Grade Squamous Intraepithelial Lesion\nHG-SIL: High Grade Squamous Intraepithelial Lesion\nCa: Carcinoma\nConsequently, 181 follow-up files have been sent to the \ngynecologists.FOLLOW-UP SHEET  DOCTOR: \nNAME                                      AGE: CLINIC HISTORY:\nCYTOLOGYCAL RESULT: DATE:\nCOLPOSCOPY* (NO) (YES) RESULT: \nBIOPSY (NO) (YES) RESULT:\nHPV DETERMINATION (NO) (YES) RESULT:\n* IFCCP Colposcopy Nomenclature. Available on https://ifcpc.org/medical-professionals/ifcpc-nomeFigure 174\n2021/36 (3): 72-75Javier Cort\u00e9s et al.  \nResults\n147 responses out of 181 files sent have been received: \n81.2% responses, according to the following distribution \nby initial cytological results:\n\u00b7 AGC 9 of 11\n\u00b7 ASC-H 13 of 19\n\u00b7 ASC-US 41 of 49\n\u00b7 LG-SIL 58 of 70\n\u00b7 HG-SIL 27 of 31\nIn the cases reported as ASC-US, following \nrecommended clinical procedures 4, to perform an HPV \ndetermination was recommended. In the cases reported \nas ASC-US / Human Papilloma Virus (HPV) (+) - 15 out of \n41, a 36.6% - or as AGC, ASC-H, LG-SIL and HG-SIL, it \nwas recommended to perform colposcopy4. \nAccording to the information contained in the files \nreceived, biopsies were taken in 73 cases, distributed as \nfollows by initial cytological results:\n\u00b7 AGC 5 of 9\n\u00b7 ASC-H 11 of 13\n\u00b7 ASC-US/HPV + 13 of 15\n\u00b7 LG-SIL 21 of 58\n\u00b7 HG-SIL 23 of 27\nThat is, 73 biopsies taken out of a total of 122 positive \ncytology follow-up reports received.\nThe final histological results, distributed by initial \ncytological result, have been the following:\n\u00b7 AGC: 5 biopsies taken 2 Adenocarcinoma\n 2 Chronic Cervicitis\n 1 Endocervical Hyperplasia\n\u00b7 ASC-H: 11 biopsies taken 6 HG-SIL\n 2 LG-SIL\n 1 Chronic Cervicitis\n 2 Squamous Metaplasia\n\u00b7 ASC-US/HPV+:  1 HG-SIL\n13 biopsies taken 8 LG-SIL\n 3 Squamous Metaplasia\n 1 Chronic Cervicitis\n\u00b7 LG-SIL: 21 biopsies taken 3 HG-SIL\n 16 LG-SIL\n 2 Chronic Cervicitis\n\u00b7 HG-SIL: 23 biopsies taken 1 Squamous Carcinoma\n 20 HG-SIL\n 2 LG-SILDiscussion\nA 1,01% of abnormal cytological results (ACR) is a low \npercentage if we relate it to a historical reference, not \nsubsequently modified, which evaluated the rate of ACR \nin a sample carried out at 14 reference Spanish Cytology \nLaboratories15, with a sample of 409,443 cytological \nresults that contained 3,56% abnormal results. The \nreason is in all probability that our Laboratory receives \nsamples from annual reviews, not triennial reviews, as \nrecommended by the Spanish Gynecology Society12. \nAnnual review yes, but of gynecological health, including \nall its aspects; It is even possible that certain situations of \ngynecological pathology require more frequent controls, \nbut the annual preventive control of cervical cancer \nrepresents an unjustified over-control16. We believe that \nthis explanation is at the base of the low percentage of \ncytological positivities that we are here reporting.\nWe have received 81% of responses to the follow-up files \nsent, a percentage that we believe can be considered \nhighly satisfactory and which, in our opinion, indicates \nthe interest that this control initiative has for clinicians \nwho send cytological samples to our Laboratory. This \nlevel of response obliges us to continue in this line of \ncollaboration.\n73 biopsies have been taken from among the 122 \ncases of positive cytologies in some degree, 60%, \nrelated with complete certainty to the percentage of \npositive colposcopies carried out from the cytological \nresults, following the recommendations formulated by \nthe Scientific Societies and established in good clinical \npractice12. It is a percentage that can be considered \nwithin expectations: in a cervical pathology unit the rate \nof cervical biopsies is around this figure17. As has been \nreflected when previously we have facilitated the results \nof our work, by taking these 73 biopsies the following \nlesions have been diagnosed:\n\u00b7 28 LG-SIL\n\u00b7 30 HG-SIL\n\u00b7 2 Adenocarcinoma\n\u00b7 1 Squamous carcinoma\nIn addition to:\n\u00b7 1 Endocervical Hyperplasia\n\u00b7 6 Squamous Metaplasia\n\u00b7 6 Chronic Cervicitis\nAnalyzing each of these results in terms of the specificity \nof our cytological results, we can deduce the following \ncomments:\n> 28 cases of LG-SIL have been diagnosed, based on \nthe following cytological results:75\n2021/36 (3): 72-75 Cyto-histological correlation in cervical cytology\n > 2 cases of ASC-H\n > 8 cases of ASC-US / HPV +\n > 16 cases of LG-SIL\n > 2 cases of HG-SIL\nConsequently, the specificity for this final diagnosis has \nbeen 57%, an acceptable figure 4, since we are talking \nabout very initial cytological modifications that can overlap \nwith indeterminate atypia, as in our case, 10 out of 28.\n> The 30 cases of histological HG-SIL finally diagnosed \narise from:\n > 1 case of ASC-US / HPV +\n > 3 cases of LG-SIL\n > 20 cases of HG-SIL\nConsequently, the specificity for this final diagnosis has \nbeen 67%, absolutely within the expected range4. The \ncytological result of ASC-H has been the starting point to \nreach the diagnosis of HG-SIL in 6 cases, an expected \nsituation given the cytological characteristics of this result14.\nWe think it is interesting to comment that, as specified, 27 \nHG-SIL cytological results were issued, but 23 biopsies \nwere taken, since in two cases the colposcopy showed \ngrade 1 changes18 ,the clinician deciding not to take a \nbiopsy, as was the case. It occurred in the other two \ncases, with grade 2 changes18 in women under 25 years \nof age in whom strict follow-up of the case was decided, \nfollowing current recommendations4.\n> We note that two cases of adenocarcinoma have \nbeen diagnosed based on AGC results, of which five were issued, with also two cases of chronic cervicitis \nand one case of endocervical hyperplasia as final results. \nHaving detected these two cases of adenocarcinomas \nrepresents good news, even if it is based on a lower-\nrange cytological result.\n> In the set of the cyto-histological correlation that we \nare presenting and commenting on, there is a cytological \nover-diagnosis in thirteen cases. Chronic cervicitis can \ncause cytological changes that are difficult to demarcate \nwith intraepithelial lesions, as well with a very active initial \nprocesses of cervical re-epithelialization, squamous \nmetaplasia. In the first cases and based on these \nresults presented here, requesting post-treatment cyto-\ncolposcopic control of cervicitis that we initially report \nis a procedure that we follow in our Laboratory, always \nsupported by a personalized contact with the responsible \nclinician, commenting on the case.\nConclusions\nA follow-up card for cytological results shared with \nthe clinician responsible for the patient has shown its \nusefulness to establish cyto-histological correlations. \nThis evaluation has shown that the issued results \ncorresponded with the expected cervical intraepithelial \nlesions diagnostic rates.\nEstablishing mechanisms for monitoring and controlling \nthe cytological reports issued by a Cytology Laboratory \nis an essential mechanism to assess the quality of its \nwork and to establish the necessary collaboration with \nthe clinical in charge of the patients.\nBibliography\n1. Papanicolaou GN: New cancer diagnosis. Presented at the Third Race \nBetterment Conference, Battle Creek, Michigan, USA. January 2-6, 1928.\n2. Walton RJ, Blanchet M, Boyes DA, Carmichael J, Marshall KG, Miller AB, et al.: \nDetection of cancer of the cervix uteri. Union Med Can. 1976; 105: 997-1047.\n3. Available at https://www.who.int/activities/screening-for-cervical-cancer   \nAccess 27.05.2021.\n4. Asociaci\u00f3n Espa\u00f1ola de Patolog\u00eda Cervical y Colposcopia. Gu\u00eda de Cribado \ndel C\u00e1ncer de Cuello de \u00datero en Espa\u00f1a, 2014. ISBN 978-84-608-3655-1\n5. Hodgson A, Park KJ: Cervical Adenocarcinomas: A Heterogeneous Group \nof Tumors With Variable Etiologies and Clinical Outcomes. Arch Pathol Lab \nMed. 2019; 143: 34-46.\n6. Nuno T, Garcia F.: The Lower Anogenital Squamous Terminology Project and \nits implications for clinical care. Obstet Gynecol Clin North Am. 2013;40:225-33 \n7. Guedes AC, Zeferino LC, Syrj\u00e4nen KJ, Fernandes-Brenna SM. Short-\nterm outcome of cervical intraepithelial neoplasia grade 2: considerations \nfor management strategies and reproducibility of diagnosis. Anticancer Res \n2010; 30: 2319-23.\n8. Ozaki S, Zen Y, Inoue M: Biomarker expression in cervical intraepithelial \nneoplasia: Potential progression predictive factors for low-grade lesions. \nHum Pathol. 2011; 42: 1007-12.\n9. Stolnicu S, Talia KL, McCluggage WG: The Evolving Spectrum of Precursor \nLesions of Cervical Adenocarcinomas. Adv Anat Pathol. 2020; 27: 278-93.10. Castanon A, Landy R, Sasieni PD: Is cervical screening preventing \nadenocarcinoma and adenosquamous carcinoma of the cervix? Int J Cancer. \n2016; 139: 1040-5.\n11. Cabanes A, Vidal E, Aragon\u00e9s N, P\u00e9rez-G\u00f3mez B, Poll\u00e1n M, Lope V et \nal.: Cancer mortality trends in Spain: 1980-2007. Ann Oncol. 2010; 21 Suppl \n3: iii14-20. \n12. Oncogu\u00eda SEGO: Prevenci\u00f3n del c\u00e1ncer de cuello de \u00fatero. Gu\u00edas de \npr\u00e1ctica cl\u00ednica en c\u00e1ncer ginecol\u00f3gico y mamario. Publicaciones SEGO.\n13. Alameda A, Aso S, Catalina I, Comes MD, Gomez Mateo MC, Granados R \net al.: The Spanish Society of Cytology: Quality control program of gynecological \ncytology. Rev Esp Patol 2018; 51: 71-76.\n14. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et \nal.: The 2001 Bethesda System: terminology for reporting results of cervical \ncytology.  JAMA 2002; 287: 2114-9.\n15. Vilaplana E, Puig Tintor\u00e9 LM, Cort\u00e9s J.: Encuesta Espa\u00f1ola sobre \nresultados citol\u00f3gicos anormales. A\u00f1o 2005. Bolet\u00edn de la AEPCC, n\u00ba 20, 2\u00ba \nSemestre 2006.\n16. Cort\u00e9s J, Dexeus D, L\u00f3pez AC, Palacios S, Serrano L.: La Prevenci\u00f3n del C\u00e1ncer \nGinecol\u00f3gico en la Asistencia Privada. Prog Obstet Ginecol 2017; 60: 160-75.\n17. Cort\u00e9s J, Torn\u00e9 A, And\u00eda A, Centeno C, Coronado P , Dexeus D, Morillo C \net al.: Situaci\u00f3n de las Unidades de Patolog\u00eda Cervical en Espa\u00f1a. Resultados \nde una encuesta nacional. Prog Obstet Ginecol. 2013; 56: 515-42.\n18. IFCCP Colposcopy Nomenclature. Available at https://ifcpc.org/medical-\nprofessionals/ifcpc-nomenclature/   Access 31.06.21.76\n2021/36 (3): 76-80ORIGINAL\nGenotypic and phenotypic assessment of antibiotic \nresistance of MRSA bacteria isolated from food stuffs\nEvaluaci\u00f3n genot\u00edpica y fenot\u00edpica de la resistencia a los antibi\u00f3ticos \nde bacterias MRSA aisladas de alimentos\nSeyyed Shahab Aldin Hosseini1      , Seyed Amirshayan Makkie2      , \nBahareh Tavakoli-Far3,4      , Farhad Safarpoor Dehkordi5      \n1. Faculty of Veterinary Medicine, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.\n2. Faculty of Science, Earth Sciences Building, 2207 Main Mall, Vancouver, British Columbia, Canada.\n3. Dietary Supplements and Probiotic Research Center, Alborz University of Medical Sciences, Karaj, Iran. \n4. Department of Physiology and Pharmacology, School pf Medicine, Alborz University of Medical Sciences, Karaj, Iran.\n5. Halal Research Center of IRI, FDA, Tehran, Iran. eISSN 2255-0569\nReceived:  29 - IV - 2021\nAccepted:  1 - VI - 2021\ndoi: 10.3306/AJHS.2021.36.03.76Corresponding author\nSeyed Amirshayan Makkie   \nFaculty of Science, Earth Sciences Building, \n2207 Main Mall, Vancouver, British Columbia, Canada    \nE-mail: shayaneo@gmail.comID ID\nID ID\nAbstract  \nBackground:  Methicillin-Resistant Staphylococcus aureus  (MRSA) bacteria are one of the chief causes of food-borne diseases. \nThis survey was done to assess the genotypic and phenotypic profiles of antibiotic resistance of MRSA isolates of foodstuffs.\nMethods:  Forty MRSA strains isolated from foodstuffs were selected. Isolates were approved using the biochemical tests and also \ncefoxithin and oxacillin susceptibility testing. MRSA isolates were phenotypically assessed by the disk diffusion. DNA was extracted \nfrom the MRSAS isolates and subjected to PCR identification of antibiotic resistance genes.\nResults:  MRSA bacteria harbored the high prevalence of resistance toward penicillin (100%), tetracycline (95.00%), eryhtromicin \n(90.00%), and gentamicin (87.50%) antibiotics. AacA-D  (55.00%), ermA  (50.00%), and tetK (50.00%) had the highest distributions \namongst examined antibiotic resistance genes.\nConclusion: Foodstuffs may be sources of resistant-MRSA, which pose a hygienic threat concerning their consumption. Neverthe -\nless, further investigations are compulsory to understand additional epidemiological and molecular features of MRSA in foodstuffs.\nKeywords:  Methicillin-resistanmt Staphylococcus aureus , phenotype, genotype, antibiotic resistance, foodstuffs.\nResumen\nAntecedentes: La bacteria Staphylococcus aureus resistente a la meticilina (SARM) es una de las principales causas de enfer -\nmedades transmitidas por los alimentos. Este estudio se realiz\u00f3 para evaluar los perfiles genot\u00edpicos y fenot\u00edpicos de la resistencia \na los antibi\u00f3ticos de los aislados de SARM de los alimentos. \nM\u00e9todos: Se seleccionaron 40 cepas de SARM aisladas de productos alimenticios. Los aislados se aprobaron mediante prue -\nbas bioqu\u00edmicas y tambi\u00e9n de susceptibilidad a la cefoxitina y la oxacilina. Los aislados de SARM se evaluaron fenot\u00edpicamente \nmediante la difusi\u00f3n en disco. Se extrajo el ADN de los aislados de SARM y se someti\u00f3 a la identificaci\u00f3n por PCR de los genes \nde resistencia a los antibi\u00f3ticos.\nResultados: Las bacterias MRSA presentaron una alta prevalencia de resistencia a los antibi\u00f3ticos penicilina (100%), tetraciclina \n(95,00%), eritromicina (90,00%) y gentamicina (87,50%). AacA-D (55,00%), ermA (50,00%) y tetK (50,00%) tuvieron las distribu -\nciones m\u00e1s altas entre los genes de resistencia a los antibi\u00f3ticos examinados.\nConclusi\u00f3n: Los productos alimenticios pueden ser fuentes de SARM resistentes, lo que supone una amenaza higi\u00e9nica en relaci\u00f3n \ncon su consumo. No obstante, es necesario realizar m\u00e1s investigaciones para conocer otras caracter\u00edsticas epidemiol\u00f3gicas y mo -\nleculares del SARM en los alimentos.\nPalabras clave:  Staphylococcus aureus resistente a la meticilina, fenotipo, genotipo, resistencia a los antibi\u00f3ticos, productos \nalimenticios.77\n2021/36 (3): 76-80 Genotypic and phenotypic assessment of antibiotic resistance of MRSA bacteria isolated from food stuffs\nIntroduction\nMethicillin-Resistant Staphylococcus aureus (MRSA) is \na a Gram-positive and catalase-positive bacterium and \ncommon phenomena of the S. aureus bacteria resistant \nto penicillins and cephalosporins1. The bacterium is \nresponsible for severe cases of human clinical infections, \nincluding respiratory tract, urinary tract, blood, soft \ntissues, wound, burn and cerebrospinal infections with \nhigh distribution amongst hospithalized patients2, 3. It is \nresponsible for about 100,000 infectious cases and 20-\n30% mortality in the United States4. MRSA bacteria are \nalso substantial causes of food-borne diseases known \nwith several clinical signs, particularly short incubation \nperiod and weakness vomiting, nausea, abdominal \ncramps, and toxic shock syndrome5, 6. \nMRSA bacteria caused more complicated diseases for a \nmore extended period compared to other bacteria. Most \nof their isolates harboured complete resistance toward \ndiverse classes of antibiotic agents, particularly fluoro -\nquinolones, aminoglycosides, tetracyclines, macrolides, \ncephalosporins, penicillins, and carbapenems7. Genet -\nically, diverse antibiotic resistance genes are mainly re -\nsponsible for the occurrence of antibiotic resistance in \nMRSA bacteria. TetK, ermA, gyrA, dfrA, rpoB, and aa -\ncA-D were considered as the most important antibiotic \nresistance genes in the MRSA isolates8.\nRendering the high MRSA importance as a food-borne \npathogen, the present survey was performed to assess \nthe genotypic and phenotypic patterns of resistance of \nMRSA bacteria isolated from numerous ready-to-eat \nfood samples.\nMaterials and methods\nMRSA isolates\nThe present research was performed according to the \nCanadian Guidelines of Research Ethics in Medical \nSciences. Through the summer of 2020, 40 MRSA \nisolates of numerous food samples were selected \nfor this survey. Isolates were identified using Gram \nstaining, hemolytic activity on sheep blood agar (Merck, \nGermany), catalase test, coagulase test (rabbit plasma), \noxidase test, OF glucose test, bacitracin sensitivity test \n(0.04 U), mannitol fermentation on Mannitol salt agar \n(Merck, Germany), urease activity, nitrate reduction, \nphosphatase, deoxyribonuclease (DNase, Merck, \nGermany) test, Voges-Proskauer (VP) (Merck, Germany) \ntest and carbohydrate (xylose, sucrose, trehalose and \nmaltose, fructose, lactose, mannose) fermentation tests9. \nMRSA identification was performed using cefoxitin and \noxacillin susceptibility testing10.\nPhenotypically survey of antibiotic resistance\nMueller\u2013Hinton agar (Merck, Germany) and principles of the Clinical Laboratory Standard Institute (CLSI) were \napplied for this purpose11. Phenotypic resistance of \nMRSA bacteria was assessed toward gentamicin (10 \u00b5g/\ndisk), ciprofloxacin (5 \u00b5g/disk), clindamycin (2 \u00b5g/disk), \nerythromycin (15 \u00b5g/disk), penicillin (10 \u00b5g/disk), and \ntetracycline (30 \u00b5g/disk) (Oxoid, UK)12, 13. \nGenotypically survey of antibiotic resistance\nDNA was extracted from MRSA isolates of food samples \nusing DNA extraction kit (Thermo Fisher Scientific, St. \nLeon-Rot, Germany)14-16. Quality and quantity of extracted \nDNA were then checked17-19. Antibiotic resistance genes \nwere detected using the Polymerase Chain Reaction \n(PCR) (Eppendorf Mastercycler 5330, Eppendorf-\nNethel-Hinz GmbH, Hamburg, Germany). Table I  shows \nthe PCR circumstances for antibiotic resistance genes \ndetectionm20-22. Electrophoresis was done according to \nstandard procedure23, 24.\nResults\nAll 40 MRSA isolates were assessed by the disk diffusion \nand PCR for phenotypicall and genotypicall assessment \nof antibiotic resistance, respectively. Table II shows \nthe phenotypic resistance pattern of MRSA isolates. \nDisk diffusion showed that MRSA bacteria harbored the \nhigh prevalence of resistance toward penicillin (100%), \ntetracycline (95.00%), eryhtromicin (90.00%), and \ngentamicin (87.50%) antibiotics. The lowest resistance \nrate was obtained against  ciprofloxacin (62.50%) and \nclindamycin (50.00%).\nTable III  shows the genotypic resistance pattern of MRSA \nisolates. AacA-D  (55.00%), ermA  (50.00%), and tetK \n(50.00%) had the highest distributions. However, gyrA \n(25.00%) and rpoB (30.00%) had the lowest distribution.\nTable IV  shows the simultaneous presence of antibiotic \nresistance encoding genes amongst the examined \nMRSA isolates. Majority of isolates harboured aacA-D + \nermA  (25.00%), aacA-D + tetK  (25.00%), and aacA-D \n+ rpoB  (25.00%) antibiotic resistance encoding genes.\nDiscussion\nMRSA is a nosocomial pathogen with both healthcare \nand community sources.It is also considered as a \nfoodborne pathogens responsible for severe morbidity \nglobally25. Contaminated food stuffs, especially those \nwith animal origin, are determined as one of the likely \ncauses of MRSA transmission to human26. Thus, MRSA \nin food stuffs has two paramount importance: food-borne \ndiseases and transmission of antibiotic resistance.\nThe present survey was addressed the MRSA genotypic \nand phenotypic patterns of antibiotic resistance. MRSA 78\n2021/36 (3): 76-80Seyyed Shahab Aldin Hosseini et al.  \nTable I: Primers and following conditions of the PCR20.\nTarget gene Primer sequence (5'-3') PCR product (bp) PCR programs PCR volume (50\u00b5L)\nAacA-D  F: TAATCCAAGAGCAATAAGGGC 227\n R: GCCACACTATCATAACCACTA \n \nermA  F: AAGCGGTAAACCCCTCTGA 190 \n R: TTCGCAAATCCCTTCTCAAC \ntetK F: GTAGCGACAATAGGTAATAGT 360 \n R: GTAGTGACAATAAACCTCCTA \n \ngyrA F: AATGAACAAGGTATGACACC 223\n R: TACGCGCTTCAGTATAACGC\ndfrA F: CTCACGATAAACAAAGAGTCA 201\n R: CAATCATTGCTTCGTATAACG\nrpoB  F: ACCGTCGTTTACGTTCTGTA 460\n R: TCAGTGATAGCATGTGTATC1 cycle:\n94 0C ------------ 5 min.\n25 cycle:\n94 0C ------------ 60 s\n55 0C ------------ 70 s\n72 0C ------------ 60 s\n1 cycle:\n72 0C ------------ 10 min\n1 cycle:\n94 0C ------------ 10 min.\n25 cycle:\n94 0C ------------ 20 s\n52 0C ------------ 20 s\n72 0C ------------ 50 s\n1 cycle:\n72 0C ------------ 5 min\n1 cycle:\n94 0C ------------ 2 min.\n30 cycle:\n94 0C ------------ 60 s\n50 0C ------------ 60 s\n72 0C ------------ 60 s\n1 cycle:\n72 0C ------------ 5 min\n1 cycle:\n94 0C ------------ 5 min.\n32 cycle:\n94 0C ------------ 60 s\n56 0C ------------ 45 s\n72 0C ------------ 60 s\n1 cycle:\n72 0C ------------ 10 min5 \u00b5L PCR buffer 10X\n1.5 mM Mgcl2\n200 \u00b5M dNTP (Fermentas)\n0.5 \u00b5M of each primers F & R\n1.25 U Taq DNA polymerase (Fermentas)\n2.5 \u00b5L DNA template\n5 \u00b5L PCR buffer 10X\n2 mM Mgcl2\n150 \u00b5M dNTP (Fermentas)\n0.75 \u00b5M of each primers F & R\n1.5 U Taq DNA polymerase (Fermentas)\n3 \u00b5L DNA template\n5 \u00b5L PCR buffer 10X\n2 mM Mgcl2\n150 \u00b5M dNTP (Fermentas)\n0.75 \u00b5M of each primers F & R\n1.5 U Taq DNA polymerase (Fermentas)\n3 \u00b5L DNA template\n5 \u00b5L PCR buffer 10X\n2 mM Mgcl2\n150 \u00b5M dNTP (Fermentas)\n0.75 \u00b5M of each primers F & R\n1.5 U Taq DNA polymerase (Fermentas)\n3 \u00b5L DNA templateisolates of foodstuffs harboured the maximum resistance \nrate against penicillin (100%), tetracycline (95.00%), \neryhtromicin (90.00%), and gentamicin (87.50%). \nAdditionally, they harboured aacA-D  (55.00%), ermA  \n(50.00%), and tetK (50.00%) antibiotic resistance genes. \nThus, phenotypic pattern of resistance was approved \nby the genotypic pattern. Iregular and indiscriminate \nantibiotic prescription are the main reasons for the high \nprevalence of resuistance amid the MRSAisolates. \nSimilarly, high MRSA resistance rate toward penicillin, \ntetracycline, eryhtromicin, and gentamicin was also \nreported previously. Safarpoor Dehkordi et al. (2017)27 \nreported that the S. aureus  resistance rate toward \npenicillin, ceftaroline, gentamicin, amikacin, kanamycin, \nazithromycin, erythromycin, tetracycline, doxycycline, \nciprofloxacin, levofloxacin, clindamycin, trimethoprim-\nsulfamethoxazole, chloramphenicol and rifampin \nantibiotic agents were 100%, 10%, 81.08%, 70.27%, \n43.24%, 59.45%, 86.48%, 100%, 81.08%, 48.64%, \n43.24%, 48.64%, 83.78%, 29.72%, and 35.13%, \nrespectively. They also showed that the distribution \nof aacA-D, tetK, tetM, msrA, ermA, ermC,  and linA \nantibiotic resistance genes were 62.16%, 72.97%, \n27.02%, 64.86%, 72.97%, 27.02%, and 43.24%, \nrespectively. Findings of the present survey and those of \nSafarpoor Dehkordi et al. (2017)27 were similar to those \nof Fowoyo and Ogunbanwo (2017)28 and Akanbi et al. (2017)29. High distribution of antibiotic resistance genes \nwas also reported in surveys conducted in Algeria30, \nChina31, and Egypt32. \nRendering our results, only some of the MRSA bacteria, \nwhich harboured resistance to a particular group \nor a specific antibiotic carried the specific antibiotic \nresistance encoding gene to that particular antibiotic \nagent. This matter also found for other antibiotic agents \nand resistance genes. This finding is maybe because \nthe presence of antibiotic resistance genes is only one \nof the known procedures for the occurrence of antibiotic \nresistance in bacteria33-35. \nConclusion\nIn conclusion, MRSA isolates of foodstuffs harboured \nhigh prevalence of resistance and distribution of \nantibiotic resistance genes. This finding may show the \nrole of food stuffs in the transmission of MRSA bacteria \nto human populations. Using high-quality raw materials, \nproper hygienic circumstances in food processing, \nadequate cooking of food samples, cross-contamination \nprevention, and antibiotic prescription rendering the \noutcomes of disk diffusion can diminish the risk of MRSA. 79\n2021/36 (3): 76-80 Genotypic and phenotypic assessment of antibiotic resistance of MRSA bacteria isolated from food stuffs\nTable II: Phenotypic resistance pattern of MRSA isolates.\nN. MRSA Isolates N (%) isolates resistant to each antibiotic\n P10* Gen Ert Tet Cip Clin\nFood stuffs (40)  40 (100) 35 (87.50) 36 (90.00) 38 (95.00) 25 (62.50) 20 (50.00)\n*P10: penicillin (10 \u00b5g/disk), Gen: gentamicin (10 \u00b5g/disk), Ert: erythromycin (15 \u00b5g/disk), Tet: tetracycline (30 \u00b5g/disk), Cip: ciprofloxacin (5 \u00b5g/disk), Clin: clindamycin (2 \u00b5g/disk). \nTable III: Genotypic resistance pattern of MRSA isolates. \nN. MRSA Isolates N (%) isolates harbored each antibiotic resistance genes\n aacA-D ermA tetK gyrA dfrA rpoB\nFood stuffs (40)  22 (55.00) 20 (50.00) 20 (50.00) 10 (25.00) 15 (37.50) 12 (30.00)\nTable IV: Simultaneous presence of antibiotic resistance encoding genes amongst the examined MRSA isolates. \n N (%) isolates harbored each antibiotic resistance genes\n aacA-D  aacA-D  aacA-D  aacA-D  aacA-D  ermA  ermA  ermA  ermA  tetK tetK\n + ermA + tetK + gyrA + dfrA1 + rpoB + tetK + gyrA + dfrA1 + rpoB + gyrA + dfrA1\n 10 (25.00) 10 (25.00) 5 (12.50) 8 (20.00) 6 (15.00) 10 (25.00) 5 (12.50) 7 (17.50) 6 (15.00) 6 (15.00) 8 (20.00)N. MRSA Isolates\nFood stuffs (40)\nReferences\n1. Madahi H, Rostami F, Rahimi E, Dehkordi FS. Prevalence of \nenterotoxigenic Staphylococcus aureus isolated from chicken nugget in \nIran. Jundishapur journal of microbiology. 2014 Aug;7(8).\n2. Daum RS. Skin and soft-tissue infections caused by methicillin-\nresistant Staphylococcus aureus. New England Journal of Medicine. \n2007 Jul 26;357(4):380-90.\n3. Khalili H, Sisakhtpour R, Abdollahzadeh S. Identification of biofilm \nproducing bacterial species causing dental caries and their sensitivity \nto zoocin A and clove hydroalcoholic extract. Immunopathol Persa. \n2018;4(2):e27.\n4. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, \nHarrison LH, Lynfield R, Dumyati G, Townes JM. Invasive methicillin-\nresistant Staphylococcus aureus infections in the United States. Jama. \n2007;298:1763-71.\n5. Momtaz H, Dehkordi FS, Rahimi E, Asgarifar A, Momeni M. Virulence \ngenes and antimicrobial resistance profiles of Staphylococcus aureus \nisolated from chicken meat in Isfahan province, Iran. Journal of Applied \nPoultry Research. 2013 Dec 1;22(4):913-21.\n6. Afhami S, Ali Borumand M, Esmailpour Bazzaz N, Saffar H, \nHadadi A, Jafary Nezhad M, et al. Antimicrobial resistance pattern of \nAcinetobacter; a multicenter study, comparing European Committee \non Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and \nLaboratory Standards Institute (CLSI); evaluation of susceptibility testing \nmethods for polymyxin. Immunopathol Persa. 2021;7(1):e04.\n7. Hasanpour Dehkordi A, Khaji L, Sakhaei Shahreza MH, Mashak \nZ, Safarpoor Dehkordi F, Safaee Y, Hosseinzadeh A, Alavi I, Ghasemi \nE, Rabiei-Faradonbeh M. One-year prevalence of antimicrobial \nsusceptibility pattern of methicillin-resistant Staphylococcus aureus \nrecovered from raw meat. Trop Biomed. 2017;34(2):396-404.8. Abdolmaleki Z, Mashak Z, Dehkordi FS. Phenotypic and genotypic \ncharacterization of antibiotic resistance in the methicillin-resistant \nStaphylococcus aureus strains isolated from hospital cockroaches. \nAntimicrobial Resistance & Infection Control. 2019 Dec;8(1):1-4.\n9. Abdolmaleki Z, Mashak Z, Safarpoor Dehkordi F. Molecular and \nvirulence characteristics of methicillin-resistant Staphylococcus aureus \nbacteria recovered from hospital cockroaches. Jundishapur Journal of \nMicrobiology. 2019 Dec 31;12(12).\n10. Rahi A, Kazemeini H, Jafariaskari S, Seif A, Hosseini S, Dehkordi FS. \nGenotypic and Phenotypic-Based Assessment of Antibiotic Resistance \nand Profile of Staphylococcal Cassette Chromosome mec in the \nMethicillin-Resistant Staphylococcus aureus Recovered from Raw Milk. \nInfection and drug resistance. 2020;13:273.\n11. CLSI. Performance Standards for Antimicrobial Susceptibility \nTesting; Twenty-Fifth Informational Supplement. CLSI document \nM100-S25. 2015.\n12. Momeni Shahraki M, Shakerian A, Rahimi E, Safarpoor Dehkordi \nF. Study the frequency of enterotoxin encoding genes and antibiotic \nresistance pattern of methicillin-resistant Staphylococcus aureus \nisolated from vegetable and salad samples in Chaharmahal Va Bakhtiari \nprovince. Journal of Food Microbiology. 2020 Jun 21;7(2):55-69.\n13. Ranjbar R, Yadollahi Farsani F, Safarpoor Dehkordi F. Antimicrobial \nresistance and genotyping of vacA, cagA, and iceA alleles of the \nHelicobacter pylori strains isolated from traditional dairy products. \nJournal of Food Safety. 2019 Apr;39(2):e12594.\n14. Dehkordi FS. Prevalence study of Bovine viral diarrhea virus by \nevaluation of antigen capture ELISA and RT-PCR assay in Bovine, Ovine, \nCaprine, Buffalo and Camel aborted fetuses in Iran. AMB express. 2011 \nDec;1(1):1-6.80\n2021/36 (3): 76-80Seyyed Shahab Aldin Hosseini et al.  Genotypic and phenotypic assessment of antibiotic resistance of MRSA bacteria isolated from food stuffs\n15. Dehkordi FS, Saberian S, Momtaz H. Detection and segregation \nof Brucella abortus and Brucella melitensis in Aborted Bovine, Ovine, \nCaprine, Buffaloes and Camelid Fetuses by application of conventional \nand real-time polymerase chain reaction. The Thai Journal of Veterinary \nMedicine. 2012 Mar 1;42(1):13.\n16. Ranjbar R, Seif A, Safarpoor Dehkordi F. Prevalence of antibiotic \nresistance and distribution of virulence factors in the shiga toxigenic \nEscherichia coli recovered from hospital food. Jundishapur Journal of \nMicrobiology. 2019 May 31;12(5).\n17. Dehkordi FS. Prevalence study of Coxiella burnetii in aborted ovine \nand caprine fetuses by evaluation of nested and real-time PCR assays. \nAmerican Journal of Animal and Veterinary Sciences. 2011.\n18. Ranjbar R, Farsani FY, Dehkordi FS. Phenotypic analysis of antibiotic \nresistance and genotypic study of the vacA, cagA, iceA, oipA and babA \ngenotypes of the Helicobacter pylori strains isolated from raw milk. \nAntimicrobial Resistance & Infection Control. 2018 Dec;7(1):1-4.\n19. Dehkordi FS, Momtaz H, Doosti A. Application of Real-Time PCR for \ndetection of Aspergillus species in aborted ruminant foetuses. Bulgarian \nJ. Vet. Med. 2012 Mar 1;15(1):30-6.\n20. Momtaz H, Hafezi L. Meticillin-resistant Staphylococcus aureus \nisolated from Iranian hospitals: virulence factors and antibiotic \nresistance properties. Bosnian journal of basic medical sciences. 2014 \nNov;14(4):219.\n21. Mashak Z, Jafariaskari S, Alavi I, Shahreza MS, Dehkordi FS. \nPhenotypic and genotypic assessment of antibiotic resistance and \ngenotyping of vacA, cagA, iceA, oipA, cagE, and babA2 alleles of \nHelicobacter pylori bacteria isolated from raw meat. Infection and drug \nresistance. 2020;13:257.\n22. Ranjbar R, Dehkordi FS, Heiat M. The frequency of resistance genes \nin Salmonella enteritidis strains isolated from cattle. Iranian Journal of \nPublic Health. 2020 May;49(5):968.\n23. Dehkordi FS, Khamesipour F, Momeni M. Brucella abortus and \nBrucella melitensis in Iranian bovine and buffalo semen samples: The \nfirst clinical trial on seasonal, Senile and geographical distribution using \nculture, conventional and real-time polymerase chain reaction assays. \nKafkas Univ Vet Fak Dergisi. 2014;20(6):821-.\n24. Dehkordi FS, Valizadeh Y, Birgani TA, Dehkordi KG. Prevalence \nstudy of Brucella melitensis and Brucella abortus in cow's milk using \ndot enzyme linked immuno sorbent assay and duplex polymerase chain \nreaction. J Pure Appl Microbiol. 2014;8(2):1065-9.25. Sergelidis D, Angelidis AS. Methicillin-resistant Staphylococcus \naureus: a controversial food-borne pathogen. Letters in Applied \nMicrobiology. 2017 Jun;64(6):409-18.\n26. Fetsch A, Johler S. Staphylococcus aureus as a foodborne \npathogen. Current Clinical Microbiology Reports. 2018 Jun;5(2):88-96.\n27. Safarpoor Dehkordi F, Gandomi H, Akhondzadeh Basti A, Misaghi \nA, Rahimi E. Phenotypic and genotypic characterization of antibiotic \nresistance of methicillin-resistant Staphylococcus aureus isolated from \nhospital food. Antimicrobial Resistance & Infection Control. 2017;6:104.\n28. Fowoyo P , Ogunbanwo S. Antimicrobial resistance in coagulase-\nnegative staphylococci from Nigerian traditional fermented foods. \nAnnals of clinical microbiology and antimicrobials. 2017;16:4.\n29. Akanbi OE, Njom HA, Fri J, Otigbu AC, Clarke AM. Antimicrobial \nSusceptibility of Staphylococcus aureus Isolated from Recreational \nWaters and Beach Sand in Eastern Cape Province of South Africa. \nInternational journal of environmental research and public health. \n2017;14:1001.\n30. Achek R, Hotzel H, Cantekin Z, Nabi I, Hamdi TM, Neubauer H, \nEl-Adawy H. Emerging of antimicrobial resistance in staphylococci \nisolated from clinical and food samples in Algeria. BMC research notes. \n2018;11:663.\n31. Li S-M, Zhou Y-F, Li L, Fang L-X, Duan J-H, Liu F-R, Liang H-Q, Wu \nY-T, Gu W-Q, Liao X-P . Characterization of the Multi-Drug Resistance \nGene cfr in Methicillin-Resistant Staphylococcus aureus (MRSA) Strains \nIsolated From Animals and Humans in China. Frontiers in microbiology. \n2018;9:2925.\n32. Osman K, Badr J, Al-Maary KS, Moussa IM, Hessain AM, Girah Z, \nAmin M, Abo-shama UH, Orabi A, Saad A. Prevalence of the antibiotic \nresistance genes in coagulase-positive-and negative-staphylococcus \nin chicken meat retailed to consumers. Frontiers in microbiology. \n2016;7:1846.\n33. Bolte J, Zhang Y, Wente N, Mahmmod YS, Svennesen L, Kr\u00f6mker \nV. Comparison of phenotypic and genotypic antimicrobial resistance \npatterns associated with Staphylococcus aureus mastitis in German and \nDanish dairy cows. Journal of dairy science. 2020 Apr 1;103(4):3554-64.\n34. Reygaert WC. An overview of the antimicrobial resistance \nmechanisms of bacteria. AIMS microbiology. 2018;4(3):482.\n35. Hafizi M, Rajaei-Isfahani M, Noorian K. The effect of daily change of \nsterile urinary bag on bacteriuria and catheter\u2013associated urinary tract \ninfections. J Renal Inj Prev. 2018;7(4):240-5.81\n2021/36 (3): 81-87ORIGINAL\nAntibiotic resistance pattern of methicillin-resistant \nStaphylococcus aureus  isolates from powdered packaged \nmedicinal plants and bottle herbal distillates\nPatr\u00f3n de resistencia a los antibi\u00f3ticos de los Staphylococcus aureus aislados \nresistentes a la meticilina procedentes de plantas medicinales envasadas \nen polvo y destilados de hierbas en botella\nMaedeh Rajabi1      , Zohreh Mashak2      , Roshanak Jazayeri3      , Bahareh Tavakoli-Far4,5      \n1. Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran.\n2. Department of Food Hygiene, Karaj Branch, Islamic Azad University, Karaj, Iran.\n3. Asistant Professor of Medical Genetics, Non-Communicable Diseases Research Center, \nFaculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran.\n4. Dietary Supplements and Probiotic Research Center, Alborz University of Medical Sciences, Karaj, Iran.\n5. Department of Physiology and Pharmacology, School pf Medicine, Alborz University of Medical Sciences, Karaj, Iran. eISSN 2255-0569\nReceived:  26 - V - 2021\nAccepted:  24 - VI - 2021\ndoi: 10.3306/AJHS.2021.36.03.81Corresponding author\nBahareh Tavakoli-Far \nDietary Supplements and Probiotic Research Center, \nAlborz University of Medical Sciences, Karaj, Iran    \nE-mail: b.tavakolifar@abzums.ac.irID ID ID ID\nAbstract  \nBackground:  Human involvement in the medicinal plant's and herbal distillate's processing caused a potential risk of microbial \ncontamination, particularly with Staphylococcus aureus. The present research was performed to assess the prevalence and anti -\nbiotic resistance of methicillin-resistant S. aureus bacteria isolated from diverse kinds of powdered packaged medicinal plant and \nbottle herbal distillate samples.\nMethods:  Three-hundred different powdered packaged medicinal plant and bottle herbal distillate samples were collected and \nexamined by the culture method. MRSA strains were identified using oxacillin and cefoxitin disk diffusion. The pattern of antibiotic \nresistance of MRSA isolates was examined using disk diffusion.\nResults:  Eighteen out of 300 (6.00%) examined samples were contaminated with MRSA. Rosa damascene  medicinal plant \n(13.33%) and Alhagi maurorum  bottle distillate (10%) had the highest MRSA bacteria contamination rate. Bottle herbal distillate \nsamples had a higher contamination rate of MRSA ( P <0.05). MRSA isolates harbored the highest prevalence of resistance toward \ntrimethoprim-sulfamethoxazole (100%), cefixime (100%), ampicillin (100%), tetracycline  (88.88%), erythromycin  (88.88%), and \nrifampin (83.33%) antibiotic agents.\nConclusion: Medicinal plants and herbal distillates were potential sources of antibiotic-resistant-MRSA bacteria.\nKeywords:  Medicinal plants, herbal distillates, methicillin-resistant Staphylococcus aureus, antibiotic resistance.\nResumen\nAntecedentes: La participaci\u00f3n del hombre en el procesamiento de plantas medicinales y destilados de hierbas provoc\u00f3 un \nriesgo potencial de contaminaci\u00f3n microbiana, en particular con Staphylococcus aureus. La presente investigaci\u00f3n se llev\u00f3 a \ncabo para evaluar la prevalencia y la resistencia a los antibi\u00f3ticos de las bacterias S. aureus resistentes a la meticilina aisladas de \ndiversos tipos de muestras de plantas medicinales envasadas en polvo y de destilados de hierbas en botella. \nM\u00e9todos: Se recogieron 300 muestras diferentes de plantas medicinales envasadas en polvo y de destilados de hierbas en bo -\ntella y se examinaron mediante el m\u00e9todo de cultivo. Las cepas de SARM se identificaron mediante difusi\u00f3n en disco de oxacilina \ny cefoxitina. El patr\u00f3n de resistencia a los antibi\u00f3ticos de los aislados de SARM se examin\u00f3 mediante difusi\u00f3n en disco.\nResultados: Dieciocho de las 300 (6,00%) muestras examinadas estaban contaminadas con SARM. La planta medicinal Rosa \ndamascena (13,33%) y el destilado de botella Alhagi maurorum (10%) presentaron el mayor \u00edndice de contaminaci\u00f3n por bacte -\nrias SARM. Las muestras de destilado de botella de hierbas ten\u00edan un mayor \u00edndice de contaminaci\u00f3n por SARM (P <0,05). Los \naislados de SARM presentaron la mayor prevalencia de resistencia a los agentes antibi\u00f3ticos trimetoprim-sulfametoxazol (100%), \ncefixima (100%), ampicilina (100%), tetraciclina (88,88%), eritromicina (88,88%) y rifampicina (83,33%).\nConclusi\u00f3n: Las plantas medicinales y los destilados de hierbas fueron fuentes potenciales de bacterias SARM resistentes a los \nantibi\u00f3ticos.\nPalabras clave:  Plantas medicinales, destilados de hierbas, Staphylococcus aureus resistente a la meticilina, resistencia a los \nantibi\u00f3ticos. 82\n2021/36 (3): 81-87Maedeh Rajabi et al.  \nIntroduction\nMedicinal plants and herbal distillates are rich sources of \ntherapeutic agents with high beneficial effects on human \nhealth. They have a comprehensive role in Iranian folk \nmedicine1, 2. Diverse kinds of medicinal plants including \nZataria multiflora (Z. multiflora), Satureja bachtiarica \n(S. bachtiarica), Aloysia citrodora (A. citrodora), Rosa \ndamascene (R. damascene), Lavandula angustifolia (L. \nangustifolia), Alhagi maurorum (A. maurorum), Cichorium \nintybus (C. intybus), Melissa officinalis (M. officinalis), \nMentha piperita (M. piperita), and Fumaria officinalis \n(F. officinalis)  are extensively used as antimicrobial, \nantioxidant, anticancer, anti-neoplasia, food additive, anti-\ninflammation, wound healing, antiseptic, anti-diabetic, \ndiuretic, expectorant, stimulating the central nervous \nsystem, digestive, anti-mutagenic, sedative, analgesic, \netc. agents among people al-around the world3-10. They \nalso have an export aspect. Thus, it is essential to ensure \nthe quality and safety of these products.\nHuman involvement in the packaging, powdering, and \nfurther procedures of medicinal plants and preparation \nof bottle herbal distillates caused their unintentional \nmicrobial contamination, particularly with foodborne \npathogens11-17. Staphylococcus aureus (S. aureus)  is a \nfoodborne pathogen that originated from the skin and \nupper respiratory tract. The bacterium is responsible for \nsevere nosocomial and community-acquired infections, \nfoodborne diseases, and food poisoning. Food-related \ndiseases and disorders caused by S. aureus  are \nmainly known by abdominal cramps, nausea, vomiting, \nweakness, diarrhea, and toxic shock syndrome (TSS)18. \nMethicillin-resistant S. aureus  (MRSA) is an antibiotic-\nresistant strain with simultaneous resistance toward \ncephalosporins and penicillins groups of antibiotics10. \nMRSA bacteria mainly harbored the mecA  gene \nresponsible for the occurrence of resistance toward \npenicillins19. MRSA bacteria harbored higher resistance \ntoward commonly used antibiotic agents, particularly \npenicillins, cephems, glycopeptides, aminoglycosides, \nmacrolides, and tetracyclines fluoroquinolones, \nnitrofurantoin, lincosamides, folate pathway antagonists, \nphenols, ansamycins, and even streptogramins20-23. \nAccording to MRSA's uncertain role as a foodborne \nbacterium in medicinal plants and herbal distillates, the \npresent survey was performed to assess MRSA isolates' \nprevalence and antibiotic resistance from powdered \npackaged medicinal plants and bottle herbal distillates. \nMaterials and methods\nSamples\nFrom May 2019 to January 2020, a total of 300 diverse \nkinds of powdered packaged medicinal plants including \nZ. multiflora  (n= 30), S. bachtiarica  (n= 30), A. citrodora  (n= 30) and R. damascene  (n= 30) and bottle herbal \ndistillates including L. angustifolia  (n= 30), A. maurorum  \n(n= 30), C. intybus  (n= 30), M. officinalis  (n= 30), M. \npiperita  (n= 30) and F. officinalis  (n= 30) were randomly \ncollected from shopping centers, Tehran, Iran. A total \nof 50 g samples were collected from each powdered \npackaged medicinal plant and bottle herbal distillate \nsample using a sterile laboratory tube. All bottle herbal \ndistillates were produced conventionally in small traditional \nproducing units. Additionally, all collected powdered \npackaged medicinal plants were dried, powdered, and \npacked conventionally in traditional production units. \nSpecifications about samples were recorded according \nto their labels. All samples were directly transferred to the \nlaboratory at 4\u00b0C.\nIsolation and identification of S. aureus\nTwenty-five grams of each collected powdered packaged \nmedicinal plant and bottle herbal distillate samples were \nblended with 225 mL of buffered peptone water (Merck, \nGermany). At that time, solutions were homogenized \nusing Stomacher (Interscience, Saint-Nom, France). At \nthat point, five milliliters of the achieved solution was \ntransferred into 50 mL Trypticase Soy Broth (TSB, Merck, \nGermany) supplemented with 10% NaCl and 1% sodium \npyruvate and incubated for 18 h at 35\u00b0C. At that moment, \na loopful of the culture was transferred into Baird-Parker \nagar supplemented with egg yolk tellurite emulsion \n(Merck, Germany) and incubated at 37\u00b0C for about 24 \nh. Black shiny colonies enclosed with significant zones \nidentified using biochemical tests including Gram staining, \noxidase test, catalase activity, resistance to bacitracin \n(0.04 U), coagulated test (rabbit plasma), urease activity, \nglucose O/F test, Voges-Proskauer (Merck, Germany) \ntest, nitrate reduction, phosphatase, deoxyribonuclease \n(DNase, Merck, Germany) test, mannitol fermentation, \nhemolysis activity on blood agar (Merck, Germany) and \ncarbohydrate (xylose, sucrose, trehalose and maltose, \nfructose, lactose, mannose) fermentation tests23.\nIdentification of MRSA isolates\nMRSA bacteria were recognized using cefoxitin (30 \u00b5g) \nand oxacillin (1 \u00b5g) susceptibility test24. Principles of the \nClinical and Laboratory Standards Institute (CLSI) was \napplied24.\nAntibiotic resistance of MRSA isolates\nThe phenotypic pattern of antibiotic resistance of \nMRSA bacteria isolated from powdered packaged \nmedicinal plant and bottle herbal distillate samples \nwas assessed using the disk diffusion method using \nthe Mueller-Hinton agar (Merck, Germany) medium. A \n0.5 McFarland standard concentration of MRSA was \nprepared and used for the disk diffusion. Ideologies of \nClinical and Laboratory Standards Institute (CLSI) were \nused for this goal24. Diverse kinds of antibiotic groups 83\n2021/36 (3): 81-87 Methicillin-resistant Staphylococcus aureus in medicinal plants and herbal distillates\nincluding tetracycline (30 \u00b5g/disk), doxycycline (30 \u00b5g/\ndisk), trimethoprim-sulfamethoxazole (1.25/23.75 \u00b5g/\ndisk), erythromycin (15 \u00b5g/disk), kanamycin (30 \u00b5g/\ndisk), cefixime (30 \u00b5g/disk), chloramphenicol (30 \u00b5g/\ndisk), rifampin (5 \u00b5g/disk), imipenem (10 \u00b5g/disk), \nand ampicillin (10 \u00b5g/disk) were applied for this goal \n(Oxoid, UK)25. The method was performed using the \nway designated previously23. Media were incubated \naerobically at 37\u00b0C for about 24 h. Afterward, the \ndiameter of the bacteria's growth inhibition zone was \nmeasured and compared with those recorded by \nthe CLSI. MRSA BAA 2313 was prepared from the \nDepartment of Microbiology, Faculty of Veterinary \nMedicine, University of Tehran, Tehran, Iran, and used \nas control.\nDNA extraction and quality examination\nMRSA isolates were sub-cultured on TSB media (Merck, \nGermany) and incubated for 48 h at 37\u00baC. Genomic \nDNA was extracted from MRSA colonies using the DNA \nextraction kit (Thermo Fisher Scientific, St. Leon-Rot, \nGermany). Guidelines of the producing company were \nperformed for this purpose. The purity (A260/A280) of \nextracted DNA was examined by the NanoDrop device \n(NanoDrop, Thermo Scientific, Waltham, MA, USA)26-28. The \nextracted DNA quality was examined using electrophoresis \non 2% agarose gel29-31.\nDetection of the methicillin-resistance \nencoding gene\nThe mecA  gene in the MRSA isolates was examined \nusing polymerase chain reaction (PCR). Table I  \nshows the PCR conditions used for the detection \nof the mecA  gene32. All PCR and electrophoresis \ningredients were prepared commercially (Thermo \nFisher Scientific, Germany). Eppendorf Mastercycler \n(Hamburg, Germany) device was applied in PCR. All \nruns included a negative DNA control of sterile PCR \ngrade water (Thermo Fisher Scientific, Germany) and \npositive DNA control consisting of positive DNA of \neach target gene. Ten microliters of PCR products \nwere examined by electrophoresis in a 2% agarose \ngel in 1\u00d7 TBE buffer at 90 V for 30-40 min, stained \nwith SYBR Green (Thermo Fisher Scientific, Germany). \nMRSA (BAA 2313) (Faculty of Veterinary Medicine, \nUniversity of Tehran) and PCR-grade water (Thermo \nFisher Scientific, Germany) were used as positive and \nnegative controls, respectively.\nStatistical analysis\nStatistical analysis was done using the SPSS 21.0 \nstatistical software (SPSS Inc., Chicago, IL, USA). Chi-\nsquare test and Fisher's exact two-tailed test were used \nto assess any significant relationship between the data \nachieved in this survey. P-value <0.05 was considered a \nsignificant statistical level33, 34. \n Results\nThe presence of the mecA  gene was confirmed in all of \nthe MRSA isolates ( Figure 1 ).\nTable II shows MRSA bacteria's prevalence in diverse \nkinds of powdered packaged medicinal plant and \nbottle herbal distillate samples. Eighteen out of 300 \n(6.00%) powdered packaged medicinal plant and \nbottle herbal distillate samples were contaminated \nwith MRSA. R. damascene powdered packaged \nmedicinal plant (13.33%) and A. maurorum bottle \nherbal distillate (10%) had the highest prevalence \nof MRSA bacteria. Statistically significant difference \nwas obtained for the prevalence of MRSA between \npowdered packaged medicinal plants and bottle \nherbal distillates (P <0.05).\nTable III  shows MRSA bacteria's antibiotic resistance \npattern isolated from diverse powdered packaged \nmedicinal plant and bottle herbal distillate samples. \nMRSA isolates showed the highest prevalence of \nresistance against trimethoprim-sulfamethoxazole \n(100%), cefixime (100%), ampicillin (100%), \ntetracycline (88.88%), erythromycin (88.88%), and \nrifampin (83.33%) antibiotic agents. The prevalence \nof resistance toward imipenem (27.77%) and \ndoxycycline (44.44%) was lower than other examined \nantibiotic agents. A statistically significant difference \nwas obtained between the type of samples and the \nprevalence of antibiotic resistance ( P <0.05). Figure 1: PCR gel electrophoresis of the mecA gene in the MRSA isolates. M: \nMarker (100 bp, Thermo Fisher Scientific, Germany), 1: Negative control (PCR-\ngrade water, Thermo Fisher Scientific, Germany), 2: Negative sample, 3-7: Positive \nsamples for the mecA gene (532 bp), 8: Positive control (MRSA ATCC BAA2313).\n84\n2021/36 (3): 81-87Maedeh Rajabi et al.  \nTable II: Prevalence of MRSA bacteria in examined samples.\n Types of N. samples N. samples contaminated  Distribution of mecA  \n samples collected with MRSA (%) gene in MRSA isolates (%)\nMedicinal plants M. piperita  30 1 (3.33) 1 (100)\n Z. multiflora  30 1 (3.33) 1 (100)\n S. bachtiarica  30 1 (3.33) 1 (100)\n A. citrodora  30 1 (3.33) 1 (100)\n R. damascene  30 4 (13.33) 4 (100)\n Total 150 8 (5.33) 8 (100)\nHerbal Distillates L. angustifolia  30 2 (6.66) 2 (100)\n A. maurorum  30 3 (10) 3 (100)\n C. intybus  30 2 (6.66) 2 (100)\n M. officinalis  30 1 (3.33) 1 (100)\n F. officinalis  30 2 (6.66) 2 (100)\n Total 150 10 (6.66) 10 (100)\n Total 300 18 (6.00) 18 (100)\nTable II: Antibiotic resistance pattern of MRSA bacteria isolated from examined samples.\n*Tet: tetracycline (30 \u00b5g/disk), Dox: doxycycline (30 \u00b5g/disk), Tr-sol: trimethoprim-sulfamethoxazole (1.25/23.75 \u00b5g/disk), Ert: erythromycin (15 \u00b5g/disk), Kan: kanamycin \n(30 \u00b5g/disk), Cef: cefixime (30 \u00b5g/disk), C30: chloramphenicol (30 \u00b5g/disk), Rif: rifampin (5 \u00b5g/disk), Imp: imipenem (10 \u00b5g/disk), Am: ampicillin (10 \u00b5g/disk).Types of samples (N. MRSA) N. samples contaminated with MRSA (%)\n  Tet* Dox Tr-sol Ert Kan Cef C30 Rif Imp Am\n M. piperita  (1) 1 (100) - 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) - 1 (100)\n Z. multiflora  (1) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100)\n S. bachtiarica  (1) 1 (100) - 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) - 1 (100)\n A. citrodora  (1) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) - 1 (100)\n R. damascene  (4) 3 (75) 2 (50) 4 (100) 3 (75) 3 (75) 4 (100) 2 (50) 2 (50) 2 (50) 4 (100)\n Total (8) 7 (85.50) 4 (50) 8 (100) 7 (85.50) 7 (85.50) 8 (100) 6 (75) 6 (75) 3 (37.50) 8 (100)\n L. angustifolia  (2) 2 (100) 1 (50) 2 (100) 2 (100) - 2 (100) 1 (50) 2 (100) 1 (50) 2 (100)\n A. maurorum  (3) 2 (66.66) 1 (33.33) 3 (100) 2 (66.66) 2 (66.66) 3 (100) 1 (33.33) 2 (66.66)  1 (33.33) 3 (100)\n C. intybus  (2) 2 (100) 1 (50) 2 (100) 2 (100) - 2 (100) 1 (50) 2 (100)  2 (100)\n M. officinalis  (1) 1 (100) - 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100)  1 (100)\n F. officinalis  (2) 2 (100) 1 (50) 2 (100) 2 (100) - 2 (100) 1 (50) 2 (100) 1 (50) 2 (100)\n Total (10) 9 (90) 4 (40) 10 (100) 9 (90) 3 (30) 10 (100) 5 (50) 9 (90) 3 (30) 10 (100)\n Total (18) 16 (88.88) 8 (44.44) 18 (100) 16 (88.88) 10 (55.55) 18 (100) 11 (61.11) 15 (83.33) 5 (27.77) 18 (100)Medicinal \nplants\nHerbal \nDistillatesTable I: PCR conditions used for the detection of the mecA gene32.\nTarget gene Primer sequence (5'-3') PCR product (bp) PCR programs PCR volume (50\u00b5L)\nmecA  F: AAAATCGATGGTAAAGGTTGGC 532\n R: AGTTCTGCAGTACCGGATTTGC 1 cycle:\n94 0C ------------ 2 min.\n30 cycles:\n94 0C ------------ 30 s\n55 0C ------------ 30 s\n72 0C ------------ 30 s\n1 cycle:\n72 0C ------------ 4 min5 \u00b5L PCR buffer 10X\n2 mM MgCl2\n150 \u00b5M dNTP\n0.75 \u00b5M of each primers F & R\n1.5 U Taq DNA polymerase \n3 \u00b5L DNA template\nDiscussion\nS. aureus  and MRSA are bacteria that reside on \nthe skin and respiratory tract, contamination of \npowdered packaged medicinal plant and bottle herbal \ndistillate samples occurs unintentionally. Additionally, \nmanipulating medicinal plants and herbal distillates \nduring their processing in the manufacturing units is \ncrucial for their contamination. \nThe present survey was performed to assess MRSA \nbacteria's prevalence and antimicrobial resistance \nisolated from powdered packaged medicinal plant and \nbottle herbal distillate samples. The prevalence of MRSA \nin examined samples was 6.00%. Isolates showed \nhigher resistance toward trimethoprim-sulfamethoxazole, \ncefixime, ampicillin, tetracycline, erythromycin, and \nrifampin antibiotic agents. Some of the examined samples, such as Z. multiflora  and S. bachtiarica  \nmedicinal plants and M. officinalis , and M. piperita herbal \ndistillates, had a lower contamination S. aureus  rate. \nOne of the probable reasons for this finding is the high \nantimicrobial effects of  Z. multiflora, S. bachtiarica, M. \nofficinalis, M. piperita , and C. intybus against diverse \nkinds of bacteria35-38. Thus, S. aureus' growth and \nsurvival have been decreased and even stopped in \nthese medicinal plants and their derived products. \nS. aureus  is most expected to originate from herbal \nproduct's contact with food handlers throughout \nharvesting, processing, and storage, and its absence \nreflects acceptable hygiene practices. Our findings also \nrevealed that herbal distillates had a higher contamination \nrate with MRSA than medicinal plants. The probable reason 85\n2021/36 (3): 81-87 Methicillin-resistant Staphylococcus aureus in medicinal plants and herbal distillates\nis maybe the extinction of MRSA bacteria during medicinal \nplants' drying process. Additionally, the processing of \nherbal distillates requires more human involvement and \nmanipulation. Thus, MRSA bacteria's transmission from \nthe infected staff and workers producing units to the \nherbal distillates may be another reason for MRSA's \nhigh prevalence in these samples. Despite the high \nimportance of the topic, many limited surveys have been \nconducted in this field. A survey concocted by Sousa \nLima et al. (2020)39 disclosed that the prevalence of S. \naureus bacteria amongst the homemade and commercial \nherbal medicine samples ( Lippia alba, Peumus boldus \nMolina, Cymbopogon citratus, Carapa guianensis, \nCopaifera langsdorffii, Stryphnodendron adstringens, \nCostus spicatus, and Arrabidaea chica ) was 88.50% and \n23.50%, respectively. Kaume et al. (2012)40 described that \nthe prevalence of S. aureus  amongst the medicinal plants \nmarketed to patients who suffered from the HIV infection \nin Kenya was 71.40%, which was entirely higher than our \nfindings. Esimone et al. (2007)41 also reported that the \nprevalence of S. aureus  amongst the medicinal plants sold \nin Nigeria was 8.70%. Similarly, a high contamination rate of \nherbal products with S. aureus  and other Staphylococcal \nspecies has been reported previously from Bangladesh42, \nKorea43, Germany44, Sudan45, and Saudi Arabia46. Species \nof examined medicinal plants, methods of examination, \nthe hygienic condition of producing factories, and their \nstaff are essential factors that affected the prevalence \nof staphylococcal contamination in medicinal plants and \nherbal distillates. \nIrregular and unauthorized prescription of antibiotics is the \nmain reason for the high prevalence of antibiotic resistance \nin MRSA isolates. Ngemenya et al. (2019)47 described that the S. aureus  strains isolated from herbal remedies in \nCameroon were resistant against five classes of examined \nantibiotic agents (amikacin, cefotaxime, cefuroxime, \nimipenem, trimethoprim, and ceftriaxone). Braide et \nal. (2013)48 stated that the S. aureus  bacteria isolated \nfrom herbal remedies were susceptible to ofloxacin, \nchloramphenicol, gentamicin, pefloxacin, ciprofloxacin, \nand erythromycin antibiotic agents. Presence of infectious \nagents other that MRSA has also been reported in different \ninvestigations conducted in Iran49-54. \nConclusion\nAs it showed, medicinal plants and herbal distillates \nsamples were potential sources of antibiotic-resistant-\nMRSA bacteria. It seems that their consumption may \ncause foodborne infections caused by MRSA bacteria, \nwhich pose an essential public health threat. The present \nsurvey is the first report of the prevalence of antibiotic-\nresistant-MRSA isolated from Z. multiflora, S. bachtiarica, \nA. citrodora , and R. damascene  powdered packaged \nmedicinal plants and L. angustifolia, A. maurorum, \nC. intybus, M. officinalis, M. piperita  and F. officinalis \nbottle herbal distillates, globally. Bottle herbal distillates \nharbored a higher prevalence of MRSA isolates and also \nhigher antibiotic resistance. \nAcknowledgments\nThe authors would like to thank the Alborz University \nof Medical Sciences laboratory practitioners for their \npractical supports. 86\n2021/36 (3): 81-87Maedeh Rajabi et al.  \nReferences\n1. Dehkordi FS, Tirgir F, Valizadeh Y. Effects of Guajol\u00ae ointment \nsynthesized from medicinal smoke condensate of jennet feces \non burn wound healing on Wistar rat. Veterinary Research Forum. \n2017;8(3):215-21.\n2. Rafieian-Kopaei M, Baradaran A, Rafieian M. Plants antioxidants: \nFrom laboratory to clinic. J Nephropathology. 2013; 2(2):152-3.\n3. Dehghan Shahreza F. Vascular protection by herbal antioxidants; \nrecent views and new concepts. J Prev Epidemiol. 2016; 1(1):e05. \n4. Asgharpour M, Tolouian A, Bhaskar LVKS, Tolouian R, Massoudi N. \nHerbal antioxidants and renal ischemic-reperfusion injury; an updated \nreview. J Nephropharmacol. 2021:10(1):e03.\n5. Aghajani Delavar M, Soheilirad Z. Drug and herbal medicine-induced \nnephrotoxicity in children; review of the mechanisms. J Renal Inj Prev. \n2020; 9(3): e21.\n6. Dehghan Shahreza F. Oxidative stress, free radicals, kidney disease \nand plant antioxidants. Immunopathol Persa. 2017;3(2):e11.\n7. Khan Ahmadi M, Rezazadeh S. Review on Iranian medicinal plants \nwith antioxidant properties. J Med Plants. 2010;9:19-32.\n8. Buso P , Manfredini S, Reza Ahmadi-Ashtiani H, Sciabica S, \nBuzzi R, Vertuani S, Baldisserotto A. Iranian Medicinal Plants: From \nEthnomedicine to Actual Studies. Medic. 2020;56:97.\n9. Sharafzadeh S, Alizadeh O. Some medicinal plants cultivated in Iran. \nJ Appl Pharm Sci. 2012;2:134-7.\n10. Lotfipour F, Nazemiyeh H, Fathi-Azad F, Garaei N, Arami S, Talat S, \nSadegpour F, Hasanpour R. Evaluation of antibacterial activities of some \nmedicinal plants from North-West Iran. Iranian Journal of Basic Med Sci. \n2008;11:80-5.\n11. Dehkordi FS, Valizadeh Y, Birgani T, Dehkordi K. Prevalence study of \nBrucella melitensis and Brucella abortus in cow's milk using dot enzyme \nlinked immuno sorbent assay and duplex polymerase chain reaction. J \nPure Appl Microbiol. 2014;8:1065-9.\n12. Ranjbar R, Farsani FY, Dehkordi FS. Phenotypic analysis of antibiotic \nresistance and genotypic study of the vacA, cagA, iceA, oipA and babA \ngenotypes of the Helicobacter pylori strains isolated from raw milk. \nAntimicrob Resist Infect Control. 2018;7:115.\n13. Ranjbar R, Yadollahi Farsani F, Safarpoor Dehkordi F. Antimicrobial \nresistance and genotyping of vacA, cagA, and iceA alleles of the \nHelicobacter pylori strains isolated from traditional dairy products. J \nFood Safety. 2019;39:e12594.\n14. Ranjbar R, Seyf A, Dehkordi FS, Chen T, Tang W, Chen Y, Zhang J, Xie \nX, Etemadi A, Moniri R. Prevalence of Antibiotic Resistance and Distribution \nof Virulence Factors in the Shiga Toxigenic Escherichia coli Recovered \nfrom Hospital Food. Jundishapur J Microbiol. 2019;12:e82659.\n15. Rahi A, Kazemeini H, Jafariaskari S, Seif A, Hosseini S, Dehkordi FS. \nGenotypic and Phenotypic-Based Assessment of Antibiotic Resistance \nand Profile of Staphylococcal Cassette Chromosome mec in the \nMethicillin-Resistant Staphylococcus aureus Recovered from Raw Milk. \nInfect Drug Resist. 2020;13:273.\n16. Mashak Z, Banisharif F, Banisharif G, Reza Pourian M, Eskandari S, \nSeif A, Safarpoor Dehkordi F, Alavi I. Prevalence of Listeria Species and \nSerotyping of Listeria monocytogenes Bacteria Isolated from Seafood \nSamples. Egyptian J Vet Sci.52:1-9.17. Kneifel W, Czech E, Kopp B. Microbial contamination of medicinal \nplants-a review. Planta Med. 2002;68:5-15.\n18. Abdolmaleki Z, Mashak Z, Safarpoor Dehkordi F. Molecular and \nVirulence Characteristics of Methicillin-Resistant Staphylococcus \naureus Bacteria Recovered From Hospital Cockroaches. Jundishapur \nJ Microbiol. 2019;12.\n19. Abdolmaleki Z, Mashak Z, Dehkordi FS. Phenotypic and genotypic \ncharacterization of antibiotic resistance in the methicillin-resistant \nStaphylococcus aureus strains isolated from hospital cockroaches. \nAntimicrob Resist Infect Control. 2019;8:1-14.\n20. Hasanpour Dehkordi A, Khaji L, Sakhaei Shahreza M, Mashak Z, \nSafarpoor Dehkordi F, Safaee Y, Hosseinzadeh A, Alavi I, Ghasemi \nE, Rabiei-Faradonbeh M. One-year prevalence of antimicrobial \nsusceptibility pattern of methicillin-resistant Staphylococcus aureus \nrecovered from raw meat. Trop Biomed. 2017;34:396-404.\n21. Madahi H, Rostami F, Rahimi E, Dehkordi FS. Prevalence of \nenterotoxigenic Staphylococcus aureus isolated from chicken nugget \nin Iran. Jundishapur J Microbiol. 2014;7:e10237.\n22. Momtaz H, Dehkordi FS, Rahimi E, Asgarifar A, Momeni M. Virulence \ngenes and antimicrobial resistance profiles of Staphylococcus aureus \nisolated from chicken meat in Isfahan province, Iran. J App Poultry Res. \n2013;22:913-21.\n23. Dehkordi FS, Gandomi H, Basti AA, Misaghi A, Rahimi E. Phenotypic \nand genotypic characterization of antibiotic resistance of methicillin-\nresistant Staphylococcus aureus isolated from hospital food. Antimicrob \nResist Infect Control. 2017;6:104.\n24. CLSI. Performance Standards for Antimicrobial Susceptibility \nTesting; Twenty-eight Informational Supplement. 2018.\n25. Ranjbar R, Dehkordi FS, Heiat M. The Frequency of Resistance \nGenes in Salmonella enteritidis Strains Isolated from Cattle. Iranian J \nPub Health. 2020;49:968-74.\n26. Dehkordi FS. Prevalence study of Bovine viral diarrhea virus by \nevaluation of antigen capture ELISA and RT-PCR assay in Bovine, \nOvine, Caprine, Buffalo and Camel aborted fetuses in Iran. AMB \nexpress. 2011;1:1-6.\n27. Dehkordi FS, Saberian S, Momtaz H. Detection and segregation \nof Brucella abortus and Brucella melitensis in Aborted Bovine, \nOvine, Caprine, Buffaloes and Camelid Fetuses by application of \nconventional and real-time polymerase chain reaction. Thai J Vet \nMed. 2012;42:13.\n28. Nejat S, Momtaz H, Yadegari M, Nejat S, Safarpour Dehkordi F, \nKhamesipour F. Seasonal, geographical, age and breed distributions of \nequine viral arteritis in Iran. Kafkas Univ Vet Fak Derg. 2015;21:111-6.\n29. Dehkordi FS. Prevalence study of Coxiella burnetii in aborted ovine \nand caprine fetuses by evaluation of nested and real-time PCR assays. \nAmerican Journal of Animal and Veterinary Sciences. 2011.\n30. Dehkordi FS, Momtaz H, Doosti A. Application of Real-Time PCR \nfor detection of Aspergillus species in aborted ruminant foetuses. Bulg \nJ Vet Med. 2012;15:30-6.\n31. Afshar D, Moghadam SO, Dehkordi FS, Ranjbar R, Hasanzadeh \nA. Psp140: an immunodominant antigen in the supernatant of \nStreptococcus pneumoniae culture. Iranian J Microbiol. 2020;12:338.87\n2021/36 (3): 81-87 Methicillin-resistant Staphylococcus aureus in medicinal plants and herbal distillates\n32. Murakami K, Minamide W, Wada K, Nakamura E, Teraoka H, \nWatanabe S. Identification of methicillin-resistant strains of staphylococci \nby polymerase chain reaction. J Clin Microbiol. 1991;29:2240-4.\n33. Dehkordi FS, Rafsanjani MS. Prevalence study of Coxiella burnetii \nin aborted fetuses of small ruminants in various partum and seasons in \nIran. African J Microbiol Res. 2012;6:5594-600.\n34. Nayebpoor F, Momeni M, Dehkordi FS. Incidence of ochratoxin A in \nraw and salted dried fruits using high performance liquid chromatography. \nAm Eur J Toxicol Sci. 2013;5:1-6.\n35. Mahboubi M, Kazempour N. In vitro antimicrobial activity of some \nessential oils from Labiatae family. J Essential Oil Bearing Plants. \n2009;12:494-508.\n36. Saeidi S, Mohsenbeygi M, Roustakhiz J, Javadian F, Hassanshahian \nM. Antimicrobial and Anti-Biofilm Effects of Mentha piperita and Zataria \nmultiflora on Pathogenic Bacteria. J Med Bacteriol. 2019;8:37-44.\n37. Rabbani M, Etemadifar Z, Karamifard F, Borhani MS. Assessment \nof the antimicrobial activity of Melissa officinalis and Lawsonia inermis \nextracts against some bacterial pathogens. Comparat Clin Pathol. \n2016;25:59-65.\n38. Heidari-Sureshjani M, Tabatabaei-Yazdi F, Alizadeh-Behbahani B, \nMortazavi A. Antimicrobial effect of aqueous, ethanol, methanol and \nglycerin extracts of Satureja bachtiarica on Streptococcus pyogenes, \nPseudomonas aeruginosa and Staphylococcus epidermidis. Zahedan \nJ Res Med Sci. 2015;17.\n39. de Sousa Lima CM, Fujishima MAT, de Paula Lima B, Mastroianni \nPC, de Sousa FFO, da Silva JO. Microbial contamination in herbal \nmedicines: a serious health hazard to elderly consumers. BMC \nComplement Med Therap. 2020;20:17.\n40. Kaume L, Foote JC, Gbur EE. Microbial contamination of herbs \nmarketed to HIV-infected people in Nairobi (Kenya). South African J Sci. \n2012;108:1-4.\n41. Esimone C, Oleghe P , Ibezim E, Okeh C, Iroha I. Susceptibility-\nresistance profile of micro-organisms isolated from herbal medicine \nproducts sold in Nigeria. African J Biotechnol. 2007;6:2766-75.\n42. Sharmin M, Nur IT, Acharjee M, Munshi SK, Noor R. Microbiological \nprofiling and the demonstration of in vitro anti-bacterial traits of the \nmajor oral herbal medicines used in Dhaka Metropolis. SpringerPlus. \n2014;3:739.\n43. Ham H. Distributions of Listeria spp., Bacillus spp., Enterococcus \nspp., Staphylococcus spp., and Coliforms Isolated from Agricultural \nHerb Products from the Market. J Bacteriol Virol. 2017;47:171-8.44. Becker B, Stoll D, Schulz P , Kulling S, Huch M. Microbial \ncontamination of organically and conventionally produced fresh \nvegetable salads and herbs from retail Markets in Southwest Germany. \nFoodborne Patho Dis. 2019;16:269-75.\n45. Abdelkarim M, Eithar karar M, Aleman M. Assessment of bacterial \ncontamination of some medicinal plants available in sudanese local \nmarket. IJIPSR 2016;4:1152-61.\n46. Alwakeel SS. Microbial and heavy metals contamination of herbal \nmedicines. Res J Microbiol. 2008;3:683-691.\n47. Ngemenya MN, Djeukem GGR, Nyongbela KD, Bate PNN, \nBabiaka SB, Monya E, Kanso RK. Microbial, phytochemical, toxicity \nanalyses and antibacterial activity against multidrug resistant bacteria \nof some traditional remedies sold in Buea Southwest Cameroon. BMC \nComplement Alternat Med. 2019;19:150.\n48. Braide W, Oranusi S, Nwaoguikpe R, Offor-Emenike I, Nwosu \nI, Akobondu C, Chike-Reginald C, Popgbara L. Evaluation of the \nmicrobiological status and antibacterial susceptibility pattern of some \nherbal remedies administered orally in Nigeria. Res J Engin App Sci. \n2013;2:35-42.\n49. Halaji M, Farahani A, Ranjbar R, Heiat M, Dehkordi FS. Emerging \ncoronaviruses: first SARS, second MERS and third SARS-CoV-2: \nepidemiological updates of COVID-19. Infez Med. 2020 Jun 1;28(suppl \n1):6-17.\n50. Sheikhshahrokh A, Ranjbar R, Saeidi E, Dehkordi FS, Heiat M, \nGhasemi-Dehkordi P , Goodarzi H. Frontier therapeutics and vaccine \nstrategies for sars-cov-2 (COVID-19): A review. Iranian Journal of Public \nHealth. 2020 Jul 11.\n51. Rashidiani J, Eskandari K, Ranjbar R, Kooshki H, Afshar D, Safarpoor \nDehkordi F. Application of Gold Core-Shell Magnetic Nanoparticles \nas an Immunosensor for the Detection of Vibrio cholerae. Journal of \nApplied Biotechnology Reports. 2021 Mar 1;8(1).\n52. Ranjbar R, Mahmoodzadeh Hosseini H, Safarpoor Dehkordi \nF. A Review on Biochemical and Immunological Biomarkers used \nfor Laboratory Diagnosis of SARS-CoV-2 (COVID-19). The Open \nMicrobiology Journal. 2020 Dec 15;14(1).\n53. Dehkordi FS, Tavakoli-Far B, Jafariaskari S, Momtaz H, Esmaeilzadeh \nS, Ranjbar R, Rabiei M. Uropathogenic Escherichia coli in the high \nvaginal swab samples of fertile and infertile women: virulence factors, \nO-serogroups, and phenotyping and genotyping characterization of \nantibiotic resistance. New Microbes and New Infections. 2020 Nov \n1;38:100824.\n54. Shakerian A, Rahimi E, Dehkordi FS. Identification and \ncharacterization of resistant Arcobacter spp. isolated from meat \nproducts. Online Journal of Veterinary Research. 2017;21(12):766-76.88\n2021/36 (3): 88-92ORIGINAL\nEffect of estrogen and insulin sensitivity due to exercise \ntraining with dual intensities in female rats with estradiol \nvalerate-induced PCOS\nEfecto de la sensibilidad a los estr\u00f3genos y la insulina debido al entrenamiento \ncon ejercicios de intensidad dual en ratas hembras con SOP inducido \npor valerato de Estradiol\nMaryamosadat Miri1      , Foroozandeh Zaravar2      , Mohsen Davoodi3\n1. PhD in Exercise Physiology, Biochemistry and Metabolism, Department of Sport Scinces, Shiraz University, Shiraz, Iran.\n2. Faculaty member at Physical Education ,Department of Physical Education, School of Paramedical Scinces, Shiraz University of \nMedical Sciences, Shiraz, Iran.\n3. Assistant Professor of Exercise Physiology, Department of Physical Education, School of Paramedical Sciences, Shiraz \nUniversity of Medical Sciences, Shiraz, Iran.eISSN 2255-0569\nReceived:  9 - V - 2021\nAccepted:  30 - V - 2021\ndoi: 10.3306/AJHS.2021.36.03.88Corresponding author\nFrozandeh Zaravar \nFaculaty member at Physical Education, Department of Physical \nEducation, School of Paramedical Scinces, Shiraz University of \nMedical Sciences, Shiraz, Iran    \nE-mail: foroozandehzaravar@yahoo.comID ID ID\nAbstract  \nBackground:  Exercise training can improve polycystic ovary syndrome (PCOS). However, the effect of various intensities of \nexercise training is unclear, hence the purpose of this study was to evaluate the effect of exercise training with dual intensities on \nestrogen and insulin sensitivity in female rats with estradiol valerate-induced PCOS.\nMethods:  In this semi experimental study, forty adult (Wistar rats weight: 180\u00b120 gr) after induction of PCOS, were divided into four \ngroups (n=10):healthy control (HC), polycystic control (PC), low intensity training (LI) and moderate intensity training (MI) groups. Ex -\nercise training consisted of eight-week exercise with 50-55% maximal oxygen consumption (20m/min speed) and 70-75% maximal \noxygen consumption (28m/min speed), 3 days a week for 60 minutes. Data analysis was performed using SPSS software (version \n16.0, SPSS). One-was ANOVA test was used for data analysis. The level of significance was set at p<0.05.\nResults:  Significant difference was observed between glucose concentration of MI and PC (p=0.039), also there was significant \ndifference between LI and PC (p=0.005). Insulin significantly redreased in MI compared to PC (p=0.002). Also, significant difference \nwas found between LI and PC (p=0.005).\nConclusion: It seems that exercise training with low and moderate intensity may reduce insulin and glucose level. Low intensity may \nimprove insulin sensitivity, and can be considered as a non-pharmacological treatment method to regulate glucose hemostasis in \npolycystic ovary syndrome patients.\nKeywords:  Polycystic ovary syndrome, exercise training, insulin sensitivity, estrogen.\nResumen\nAntecedentes: El entrenamiento con ejercicios puede mejorar el s\u00edndrome de ovario poliqu\u00edstico (SOP). Sin embargo, el efecto de \nvarias intensidades de entrenamiento  no est\u00e1 claro, por lo tanto, el prop\u00f3sito de este estudio fue evaluar el efecto del entrenam -\niento  con intensidades duales en los estr\u00f3genos y la sensibilidad a la insulina en ratas hembras con SOP inducido por valerato \nde estradiol. \nM\u00e9todos: En este estudio semiexperimental, cuarenta ratas adultas (peso de las ratas Wistar: 180\u00b120 gr) tras la inducci\u00f3n del \nSOP , fueron divididas en cuatro grupos (n=10): control sano (HC), control poliqu\u00edstico (PC), entrenamiento de baja intensidad (LI) y \nentrenamiento de intensidad moderada (MI). El entrenamiento consist\u00eda en ocho semanas de ejercicio con un 50-55% de consu -\nmo m\u00e1ximo de ox\u00edgeno (velocidad de 20 m/min) y un 70-75% de consumo m\u00e1ximo de ox\u00edgeno (28m/min de velocidad), 3 d\u00edas a \nla semana durante 60 minutos. El an\u00e1lisis de los datos se realiz\u00f3 con el software SPSS (versi\u00f3n 16.0, SPSS). Para el an\u00e1lisis de \nlos datos se utiliz\u00f3 la prueba de ANOVA de una variable. El nivel de significaci\u00f3n se fij\u00f3 en p<0,05.\nResultados: Se observ\u00f3 una diferencia significativa entre la concentraci\u00f3n de glucosa de MI y PC (p=0,039), tambi\u00e9n hubo \nuna diferencia significativa  entre LI y PC (p=0,005). La insulina se redujo significativamente en el IM en comparaci\u00f3n con el CP \n(p=0,002). Tambi\u00e9n se encontr\u00f3 una diferencia significativa entre el IM y el CP (p=0,005).\nConclusiones: Parece que el entrenamiento con ejercicios de baja y moderada intensidad puede reducir el nivel de insulina y \nglucosa. La baja intensidad puede mejorar la sensibilidad a la insulina, y puede considerarse como un m\u00e9todo de tratamiento no \nfarmacol\u00f3gico para regular la hemostasia de la glucosa en pacientes con s\u00edndrome de ovario poliqu\u00edstico.\nPalabras clave:  S\u00edndrome de ovario poliqu\u00edstico, entrenamiento con ejercicios, sensibilidad a la insulina, estr\u00f3genos.89\n2021/36 (3): 88-92 Effect of estrogen and insulin sensitivity due to exercise training with dual intensities in female rats with estradiol valerate-induced PCOS\nIntroduction\nIt is obvious that infertility is one of the main problems that \nhave been increased since 1955 and also 10%-15% of \nindividuals are suffering from it. Polycystic ovary syndrome \n(PCOS) is one of the causes of infertility .PCOS is the \nmost common endocrine abnormality in premenopausal \nwomen. It seems that genetic etiology plays an important \nrole in this disorder1. The most prevalent characteristic of \nPCOS are irregular menstrual cycles, imbalance of sex \nhormones and polycystic ovarian morphology. It is reported \nthat metabolic disorders, such as insulin resistance is \nassociated with PCOS. Severity and incidence of PCOS \nis characterized by life style2. So the result frightening \nthe life is consists of Breast cancer risk, cardio vascular \ndisease and type two diabetes1. Diabetes mellitus is \nalso associated with central obesity and  increased level \nof incomplete  insulin functions of pancreatic cells and \nincreased level of leptin3, 4. In accordance to previous \nresearches 50-70 percent of females have some \nlevel of PCO and resistance to insulin. This resistance \nmaybe due to obesity or hyperandrogenism5. Previous \nstudies reported that PCOS is not the malfunction of \nsome specific part of body because recent findings \nshow that hormonal changes might play role in this \nsyndrome such as increased level of androgens, \n17 alpha hydroxyprogesterone and estrogen6. Also \nincreased serum level of LH is prevalent among female \nwith PCOS. The increased release of LH is associated \nwith free Estradiol and estrogen7. Nevertheless, there is a \nspecific relationship between serum level of estrogen and \nbiochemical index of insulin resistance in PCOS females. \nScientists believe that regular exercise training is a safe \nmethod of treatment without regarding clinical actions2. \nJedel et al. (2011) conducted a research to investigate \nthe effect of exercise training on hyperandrogenism. \n84 PCOS females participated in a period of long term \ntraining and finally results revealed that estrogen and \nandrogen reduced due to exercise8. Also literatures \nstudying PCOS showed that exercise training  change  \nlevel of sexual hormone such as estrogen without \nregarding weight change or insulin sensitivity9. In addition \nto hormonal disorders ,PCOS are faced with metabolic \ndisturbance such as insulin resistance4. Its mechanism \nin PCOS is different and about 60 percent of PCOS \npatients are struggling with insulin resistance too. It is \nreported that the mean number of PCOS patient are more \nthan healthy people especially in the obese individuals10. \nAlso exercise training is recommended for prevention \nand treatment of these patients with insulin sensitivity. \nDoing exercise training regularly accompanied with \ndietary regimen are those elements that lead to weight \nreduction and hormonal adjustment in females11. In this \nfield, exercise training ensue reduction in insulin levels \nand improvement in glucose usage and insulin sensitivity \nwhich could decrease body fat12, 13. Researchers believe \nthat not high intensity but probably regular exercise is a \nnatural healthy cure. In this direction, Benrick et al. (2013) reported that exercise training led to significant reduction \nof glucose comparing to PCOS control14. Qui and et \nal. 2009 investigated the effect of training on insulin \nresistance in 20 wistar rats undertaken PCOS. The rats \nswam 120 min for 2 weeks. The final result showed that \nserum level of insulin decreased after exercise training \nbut no significant change was observed in plasma \nglucose compared to control group15. Since there is a \ncontradiction about the intensity of exercise training and \nthe effect of exercise intensity in PCOS have not been \nclearly determined regarding the influence of exercise \ntraining in improvement of hormonal imbalance and \nglucose hemostasis, in the aim of the present study was \nto investigate changes of estrogen and insulin sensitivity \ndue to exercise training with dual intensities in female rats \nwith estradiol valerate-induced PCOS. \nMaterial and methods\nAnimals\nForty female Wistar rats were (180 \u00b1 20 g) were \nselected and kept in animal house. They had every 2 \nto 3 consecutive estrous cycles during 12 to14 day. \nTheir cages were clarified three times per week with \nalcohol and adequate water in appropriate container \nwas catered.\nApproval\nThis research was confirmed by ethical committee of \nJahrom University of Medical Sciences and morality was \nconsidered.\nInduction of PCOS\nA variety of hormonal and non-hormonal methods \nto PCO phenotype, consisting long-term use of \nlight, testosterone, dehydroepiandrosterone (DHT), \nadrenocorticotropic and estradiol valerate. In this study, \nwe utilized estradiol Valerate. 30 female rats were \nrandomly singled out from forty. 4 mg of estradiol validate \ndissolved in 0.2 mg of Sesame oil was injected (IM) in \nthigh area16.\nProtocol design\nInitially, subjects were divided into control (n = 10) and \npolycystic (n = 30) groups that were overtaken PCOS \nby intramuscular estradiol valerate injection following 60 \ndays. The PCOS subjects were split into 3 groups of \npolycystic control (PC) (n =10), low-intensity exercise \n(LI) (n =10) and moderate intensity exercise (MI) (n \n=10). Training was executed 1 h/day, 6 days/week \nfor eight weeks. Moderate intensity: (28 m/min-70%-\n75%VO2Max), and Low intensity (20 m/min-50%-\n55%VO2Max) running were performed at 0 slope.\nExercise training protocol\nThe LI and MI were trained on a rodent motor-driven \ntreadmill at a 0\u00b0 slope. For induction of adaptation, rats 90\n2021/36 (3): 88-92Maryamosadat Miri et al.  \nexercised at Treadmill velocity of 10 m/min for 15min during \nthe 1st work of training. The treadmill velocity and exercise \nduration elevated gradually until the animals ran for 1 h/day \nduring the 2nd and 3rd work of training. The treadmill speed \nand exercise duration were constant.  Frequency (6d/\nwork) and duration (1 h/d) were constant during the study. \nVaginal smears and blood sampling\nmicroscopic analysis of the predominant cell types \nqualified estrus cycle stage obtained through daily vaginal \nsmears16 Vaginal smear test was done in two month for \ncertitude of  PCOS induction within subjects. After the \ntest, we selected those having 2 or 3 regular estrous  \ncycle within 12-14 days. Blood sample was directly \ntaken from their heart through a 5 cc syringe following \n32 hours after the last exercise bout. After isolation of \nblood serum, dependent variables were assessed.\nBlood collection and tissue preparation\nTo minimize the effect of last exercise session, the \nsubjects were finally anesthetized with diethyl ether \nand sodium pentobarbital (50 mg/kg, intraperitioneal \ninjection) after a12-h fasting and 32 h after the last \nexercise session and their blood was obtained from the \nheart. Tubes containing plasma sample aliquots were \nkept frozen at -80\u00b0C until being analyzed16.\nMeasurement\nEstrogen was assessed by ELISA kit (monobind e2).Insulin \nsensitivity was calculated by quantitative insulin sensitivity \ncheck index ( QUICKI ) formula: 1 / (log (fasting insulin \u00b5U/\nmL) + log (fasting glucose mg/dL)). ELISA kits specific for \nthe rat were used to determine plasma insulin (BioVendor \nShibayagi, Japan), and serum glucose was measured \nvia spectrophotometry method (spectrophotometer \nwavelength was adjusted in 650 nm).\nAnalyzing method\nA Shapiro-wilk test was applied to determine normality of \ndistribution which was found to be normally distributed. \nA one-way analysis of variance (ANOVA) was performed \nto determine the differences in a parameter among the \ngroups. Significant differences were identified using a \nleast significant difference (Bonferroni) post-hoc test.\nResults\nTable I  shows the indicates biochemical blood \nparameters in groups (mean\u00b1S.D).Estrogen\nNo significant difference was observed between MI \n(119.01\u00b150.56) and PC (144.79\u00b1121.53) also, there \nwas no statistical change between LI (104.84\u00b166.22) \nand PC, although both MI and LI showed  reduction \ncomparing to PC. No significance reduction was in \nLI compared to PC. Comparing HI and PC showed a \nsignificant difference, ( Figure 1 ). \nGlucose\nAccording to finding illustrated in the table I , significant \nreduction was observed between glucose concentration \nof MI(157.08\u00b131.7) and PC(203.2\u00b152.9) (p=0.039), also \nthere was significant decrease between LI (145.02\u00b122.8) \nand PC (p=0.005) but no significant change was seen \nbetween MI and LI, ( Figure 2 ). \nInsulin\nAfter 8 week exercise training, serum level of insulin \ndid significantly change in MI (0.41\u00b10.3) comparing to \nPC (1.5\u00b10.75) (p=0.002). Also statistically significant \nreduction was observed between LI (0.566\u00b10.25) and \nPC (p=0.00). There was no significant change between \nMI and LI, ( Figure 3 ). \nTable I: Indicates biochemical blood parameters in groups (mean\u00b1S.D).\nGroups Estrogen Glucose Insulin Insulin\n (ng/ml) (mg/dl) (\u00b5U/ml) sensitivity\nMI 119.01\u00b150.56 157.08\u00b131.7 * 0.56\u00b10.25 * 0.54\u00b10.06\nLI 104.84\u00b166.22 145.02\u00b122.8 * 0.41\u00b10.3 * 0.6\u00b10.14 *\nPC 144.79\u00b1121.53 203.2\u00b152.9 1.5\u00b10.75 0.41\u00b10.04\nHC 86.98\u00b167.99 94.7\u00b117.5 0.65\u00b10.52 0.63\u00b10.1\nValues are mean \u00b1 SD         * p < 0.05 vs. PCFigure 1: Glucose level of groups after 8 week.\nMI LIEstrogen (mg/ml)\nPC HC300\n250\n200\n150\n100\n50\n0\n*significant comparing to PC (p<0.05)\nFigure 2: Glucose level of groups after 8 week.\nMI LI**Glucose (mg/ml)\nPC HC300\n250\n200\n150\n100\n50\n0\n*significant comparing to PC (p<0.05)\nPC HCFigure 3: Insulin level of groups after 8 week.\nMI LI* *Insulin (\u00b5U/ml)2,5\n2\n1,5\n1\n0,5\n0\n*significant comparing to PC (p<0.05)91\n2021/36 (3): 88-92 Effect of estrogen and insulin sensitivity due to exercise training with dual intensities in female rats with estradiol valerate-induced PCOS\nInsulin sensitivity\nBase on table I , a significant elevation was observed \nbetween LI (0.6\u00b10.14) and PC (0.41\u00b10.04), (p=0.003), \nbut no significant change was between MI (0.54\u00b10.06) \nand PC, Also no statistical difference was found between \nMI and LI, ( Figure 4 ). \nPC HCFigure 4: Insulin level of groups after 8 week.\nMI LI*Insulin sensetvity0,8\n0,6\n0,4\n0,2\n0\n*significant comparing to PC (p<0.05)\nDiscussion\nThe aim of this study was to examine the effect of eight \nweeks exercise training with different intensities on levels \nof estrogen and insulin, glucose and insulin sensitivity \ndue to exercise training with dual intensities in female \nrats with polycystic ovary syndrome. The results of the \npresent investigation showed that the eight-week exercise \ntraining induced a significant change in glucose level in low \nintensity group in comparison to PC ( Figure 2 ). This finding \nwas supported by previous researches17,18. However, \nthere is a controversy in the results obtained by Holm \nand colleagues (2010)19. Benrick et al. (2013) conducted \na research on rats with polycystic ovary syndrome, and \nfinally concluded that exercise training leads to the a \nsignificant declined in glucose level in these rats, moreover, \nexercise can  lead to decrease in Insulin resistance in rats \nwith polycystic disease18. Qiu et al. (2009)15 examined the \neffect of exercise on improvement of Insulin resistance in \n21 day wistar rats with polycystic disease for 120 minutes \nof swimming per day for two weeks, concluded that \ntestosterone and insulin levels in practice was significantly \nlower than control group. But, they did not observe the \nsignificant differences among groups in glucose and \nprogesterone values. Among the mechanisms that lead to \ndecrease glucose level after aerobic exercise, included the \nincreased of post-insulin recipient's message20; increase \nin expression of transfer protein of glucose, GIULT-421; \nincreasing the activity of glycogen synthase hexokinase22; \nReduction of secretion and elevation of clarification of free \nfatty acids; glucose uptake  from the blood to muscle  \ncan be due to the increase of the muscle capillaries and \nalteration in muscle structure in order to increase intake \nof glucose23. Therefore, one of the methods of reducing \ninsulin resistance and risk of cardiac disease, type II \ndiabetes, is aerobic exercise particularly in overweight and \nPCOS patients. One of the limitation of this research was \nthat these models do not reproduce exactly what happens  \nin the real syndrome which may affect our findings.In non-inflammation situation, TNF-alpha is derived from \nadipose tissue and its plasma level is associated with body \nfat mass. TNF-a opposites by insulin Message forming \nthrough signaling reduction by means of phosphorylation \nserine24. In this research it was revealed that insulin level \nwas significantly decreased -%73 in LI and -%62 in MI \ncomparing to PC. This finding was supported by previous \ninvestigations17, 18. However, there is a controversy in the \nresults obtained by Holm and colleagues (2010)19. Fasting \nhyperinsulinemia is abundant in obese PCOS patients \nand this is, in part, secondary to increased basal insulin \nsecretion rates25. Insulin responses to an oral glucose load \nare elevated in lean and obese PCOS patients, but acute \ninsulin responses to an intravenous glucose load (AIRg), \nfirst-phase insulin secretion, are similar to weight-matched \ncontrol women. When the relationship between insulin \nsecretion and sensitivity is examined lean and obese PCOS \nwomen fall below the relationship in weight-matched control \nwomen, and the disposition index is significantly decreased \nby PCOS as well as by obesity26. In this study, training \nperiod was considered as 8-weeks. In addition, the training \nwas performed with two intensities (low and moderate) for \n60 minutes. Furthermore, recently some studies showed \nthat training with low to moderate-intensity training can \ncause weight loss and body fat percent loss and increased \nfat oxidation27, 28, Hence, the low intensity exercise, is a \ncommon type exercise in researches due to the decline \nof weight and considered as appropriate intensity. In the \nstudy, we observed no significant change in estrogen level \nin PCOS groups. Gonadotropin is the glycoprotein that is \nreleased in response to gonadotropin-releasing hormone \n(GnRH) from the pituitary. The sinus mood release of GnRH \ncauses production of estrogen concentrations. Response of \nestrogen levels to exercise depends on menstrual cycle which \ncomplicates sexual hormones response to physical activity. \nAnother aspect of this complexity are reduction of body fat \nthat can induce some changes in estrogen secretion29. On \nthe other hand, physical activity can increase hormone of \nbeta endorphin which cause reduction in GnRH, followed by \ndecrease in estrogen levels30. The results obtained from this \nstudy imply the role of intensity/volume of training on insulin \nsensitivity which are considered as crucial variables that can \ndetermine healing process of PCOS31, 32.\nConclusion\nAs a result, according to this result, Low and moderate \nintensity exercise may be effective in reduction of \nglucose and insulin level. Low intensity could elevate \ninsulin sensitivity, and could be considered as a non-\npharmacological treatment method to regulate glucose \nhemostasis in polycystic ovary syndrome patients. \nAlthough, due to the lack of research evaluating the \ninfluence of different exercise intensities on patients with \nPolycystic syndrome future studies are recommended \nfor more clarification.92\n2021/36 (3): 88-92Effect of estrogen and insulin sensitivity due to exercise training with dual intensities in female rats with estradiol valerate-induced PCOSMaryamosadat Miri et al.  \nReferences\n1. Sarvari A, Naderi MM, Heidari M, Zarnani AH, Jeddi-Tehrani M, Sadeghi \nMR, Akhondi MM. Effect of environmental risk factors on human fertility. J \nReprod Infert 2010;11(4):211-25.\n2. Tymchuk CN, Tessler SB, Barnard RJ. Changes in sex hormone-binding \nglobulin, insulin, andserum lipids in postmenopausal women on alow-fat, \nhigh-fiber diet combined with exercise. Nutr Cancer 2000;38(2):158-62.\n3. Lamb JD, Johnstone EB, Rousseau JA, Jones CL, Pasch LA, Cedars \nMI, Huddleston HG. Physical activity in women with polycystic ovary \nsyndrome: prevalence, predictors, and positive health associations. Am \nJ Obstet Gynecol 2011;204(4):352-e1.\n4. Franks S, Adams J, Mason HD, Polson D. Ovulatory disorders in women \nwith polycystic ovary syndrome. Clin Obstet Gynaecol 1985;12(3):605-32.\n5. Viengchareun S, Zennaro MC, Pascual-Le Tallec L, Lombes M. Brown \nadipocytes are novel sites of expression and regulation of adiponectin and \nresistin. FEBS Let 2002 Dec 18;532(3):345-50.\n6. Orio Jr F, Palomba S, Cascella T, Milan G, Mioni R, Pagano C, Zullo F, \nColao A, Lombardi G, Vettor R. Adiponectin levels in women with polycystic \novary syndrome. J Clin Endocrinol Metabolism 2003;88(6):2619-23.\n7. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, \nAzziz R. Prevalence of the polycystic ovary syndrome in unselected black \nand white women of the southeastern United States: a prospective study. \nJ Clin Endocrinol Metabolism. 1998;83(9):3078-82.\n8. Jedel E, Labrie F, Od\u00e9n A, Holm G, Nilsson L, Janson PO, Lind AK, \nOhlsson C, Stener-Victorin E. Impact of electro-acupuncture and physical \nexercise on hyperandrogenism and oligo/amenorrhea in women with \npolycystic ovary syndrome: a randomized controlled trial. Am J Physiol-\nEndocrinol Metabolism 2011;300(1):E37-45.\n9. Moro C, Pasarica M, Elkind-Hirsch K, Redman LM. Aerobic exercise \ntraining improves atrial natriuretic peptide and catecholamine-mediated \nlipolysis in obese women with polycystic ovary syndrome. J Clin Endocrinol \nMetabolism. 2009;94(7):2579-86.\n10. Benitez R, Petermann T, Palomino A, Angel B, Maliqueo M, P\u00e9rez F, \nCalvillan M. Prevalence of metabolic disorders among family members of \npatients with polycystic ovary syndrome. Rev M\u00e9d Chile 2001;129(7):707-12.\n11. Bauer J, Jarre A, Klingm\u00fcller D, Elger CE. Polycystic ovary syndrome \nin patients with focal epilepsy: a study in 93 women. Epilepsy Res \n2000;41(2):163-7.\n12. Momb BA, Headley SA, Matthews TD, Germain MJ. Intradialytic \nexercise increases cardiac power index. J Nephropathol 2020;9(1):e07.\n13. Akbari M, Zohari-Anboohi S, Borzabadi-Farahani Z, Nasiri M, Esteki \nT. Comparison of body mass index and waist circumference of patients \nwith and without nonalcoholic fatty liver in Tehran. Immunopathol Persa \n2018;4(2):e30-.\n14. Benrick A, Maliqueo M, Miao S, Villanueva JA, Feng Y, Ohlsson C, \nDuleba AJ, Stener-Victorin E. Resveratrol is not as effective as physical \nexercise for improving reproductive and metabolic functions in rats with \ndihydrotestosterone-induced polycystic ovary syndrome. Evid-Based \nCompl Alter Med 2013;2013.\n15. Qiu S, Wu C, Lin F, Chen L, Huang Z, Jiang Z. Exercise training \nimproved insulin sensitivity and ovarian morphology in rats with polycystic \novary syndrome. Hormone Metabolic Res 2009;41(12):880-5.\n16. Miri M, Jashni HK, Alipour F. Effect of exercise intensity on weight \nchanges and sexual hormones (androstenedione and free testosterone) in female rats with estradiol valerate-induced PCOS. J Ovarian Res \n2014;7(1):1-7.\n17. Motahari-Tabari N, Shirvani MA, Shirzad-e-Ahoodashty M, Yousefi-\nAbdolmaleki E, Teimourzadeh M. The effect of 8 weeks aerobic exercise \non insulin resistance in type 2 diabetes: a randomized clinical trial. Global \nJ Health Sci 2015;7(1):115. \n18. Liu Y, Ye W, Chen Q, Zhang Y, Kuo CH, Korivi M. Resistance exercise \nintensity is correlated with attenuation of HbA1c and insulin in patients with \ntype 2 diabetes: a systematic review and meta-analysis. Int J Environ Res \nPubl Health 2019 Jan;16(1):140. \n19. Manner\u00e5s Holm L. Polycystic ovary syndrome-Studies of metabolic \nand ovarian disturbances and effects of physical exercise and electro-\nacupuncture. University of Gutenberg, 2010.\n20. Rice B, Janssen I, Hudson R, Ross R. Effects of aerobic or resistance \nexercise and/or diet on glucose tolerance and plasma insulin levels in \nobese men. Diabetes Care 1999;22(5):684-91.\n21. Holten MK, Zacho M, Gaster M, Juel C, Wojtaszewski JF, Dela F. \nStrength training increases insulin-mediated glucose uptake, GLUT4 \ncontent, and insulin signaling in skeletal muscle in patients with type 2 \ndiabetes. Diabetes 2004;53(2):294-305.\n22. Poehlman ET, Dvorak RV, DeNino WF, Brochu M, Ades PA. Effects \nof resistance training and endurance training on insulin sensitivity in \nnonobese, young women: a controlled randomized trial. J Clin Endocrinol \nMetabolism 2000;85(7):2463-8.\n23. Eriksson J, Taimela S, Eriksson K, Parviainen S, Peltonen J, Kujala \nU. Resistance training in the treatment of non-insulin-dependent diabetes \nmellitus. Int J Sport Med 1997;18(04):242-6.\n24. Reaven GM, Laws A, editors. Insulin resistance: the metabolic \nsyndrome X. Springer Sci Business Media, Vol 12, 1999.\n25. Ehrmann DA. 7 Relation of functional ovarian hyperandrogenism to \nnon-insulin dependent diabetes mellitus. Bailli\u00e8re's Clin Obstet Gynecol. \n1997;11(2):335-47.\n26. Ehrmann DA. Polycystic ovary syndrome. New England J Med \n2005;352(12):1223-36.\n27. Talanian JL, Galloway SD, Heigenhauser GJ, Bonen A, Spriet LL. Two \nweeks of high-intensity aerobic interval training increases the capacity for fat \noxidation during exercise in women. J Appl Physiol 2007;102(4):1439-47.\n28. Perry CG, Heigenhauser GJ, Bonen A, Spriet LL. High-intensity aerobic \ninterval training increases fat and carbohydrate metabolic capacities in \nhuman skeletal muscle. Appl Physiol, Nutr Metabolism 2008;33(6):1112-23.\n29. Elias AN, Wilson AF. Exercise and gonadal function. Human Reprod \n1993;8(10):1747-61.\n30. Grossman A, Moult PJ, Gaillard RC, Delitala G, Toff WD, Rees LH, \nBesser GM. The opioid control of LH and FSH release: effects of a met-\nenkephalin analogue and naloxone. Clin Endocrinol 1981;14(1):41-7.\n31. Dashti, M., The effect of programmed exercise on body compositions \nand heart rate of 11-13 years-old male students. Zahedan J Res Med Sci \n2011;13(6):40-3.\n32. Wu C, Jiang F, Wei K, Lin F, Jiang Z. Effects of exercise combined with \nfinasteride on hormone and ovarian function in polycystic ovary syndrome \nrats. Int J Endocrinol 2019;2019:1-7.93\n2021/36 (3): 93-98ORIGINAL\nEvaluation of risk factors, risk assessment and health-related \nquality of life in patients with dyslipidemia in Kempegowda \nInstitute of Medical Sciences (Kims) Hospital and Research \nCentre, Bangalore, India\nEvaluaci\u00f3n de los factores de riesgo, valoraci\u00f3n del riesgo y calidad de vida relacionada \ncon la salud en pacientes con dislipidemia en el Hospital y Centro de Investigaci\u00f3n del \nInstituto Kempegowda de Ciencias M\u00e9dicas (Kims), Bangalore, India\nZahra Dehghanian\nDoctor of Pharmacy, Department of Pharmacy Practice, Visveswarapura Institute of Pharmaceutical Sciences, Bengaluru, India.eISSN 2255-0569\nReceived:  7 - V - 2021\nAccepted:  26 - V - 2021\ndoi: 10.3306/AJHS.2021.36.03.93Corresponding author\nZahra Dehghanian \nDepartment of Pharmacy Practice, \nVisveswarapura Institute of Pharmaceutical Sciences, Bengaluru, India    \nE-mail: zahradehghanian92@gmail.comID\nAbstract  \nBackground:  The research aims to evaluate the risk factors, risk assessment, and health-related quality of life in patients with \ndyslipidemia.\nMethods:  This is an observational study conducted for 3 months in a tertiary care hospital setting. All the patients meeting the \nselected criteria were identified in the outpatient clinic and inpatient wards of the Department of General Medicine. The patients or \nthe caregivers were briefed about the study, and consent was obtained to be recruited.\nResults:  A total of 200 patients were enrolled in the study based on the inclusion and exclusion criteria, out of which 55% (n=111) \nwere male, and 45% (n=89) were female. The mean age of our study subjects was found to be 55.5\u00b112.1 years. The health-re -\nlated quality of life of the patient is a combined assessment of the physical component summary (PCS), and mental component \nsummary (MCS). The average of PCS and MCS was 37.1 and 47.3, respectively, indicating an overall average of HRQOL as 42.2, \nwhich represents low HRQOL in patients with dyslipidemia.\nConclusion: The result of our study show age, gender, lack of physical activity, overweight, HTN, DM, consumption of alcohol, \nand smoking were risk factors for dyslipidemia. The present study highlights that patients with dyslipidemia have poor HRQOL as \nthe overall PCS and MCS scores were low. Focus on dyslipidemia management is urgently required in India to halt the rising tide of \ncoronary heart disease.\nKeywords:  Risk factors, risk assessment, quality of life, dyslipidemia.\nResumen\nAntecedentes:  La investigaci\u00f3n tiene como objetivo evaluar los factores de riesgo, la evaluaci\u00f3n del riesgo y la calidad de vida \nrelacionada con la salud en pacientes con dislipidemia.\nM\u00e9todos:  Se trata de un estudio observacional realizado durante 3 meses en un entorno hospitalario de atenci\u00f3n terciaria. Se \nidentific\u00f3 a todos los pacientes que cumpl\u00edan los criterios seleccionados en la consulta externa y en las salas de hospitalizaci\u00f3n del \nDepartamento de Medicina General. Se inform\u00f3 a los pacientes o a los cuidadores sobre el estudio y se obtuvo el consentimiento \npara ser reclutados.\nResultados:  Un total de 200 pacientes fueron incluidos en el estudio en base a los criterios de inclusi\u00f3n y exclusi\u00f3n, de los cuales \nel 55% (n=111) eran hombres, y el 45% (n=89) eran mujeres. La edad media de los sujetos del estudio fue de 55,5\u00b112,1 a\u00f1os. \nLa calidad de vida relacionada con la salud del paciente es una evaluaci\u00f3n combinada del resumen del componente f\u00edsico (PCS), \ny del resumen del componente mental (MCS). La media de PCS y MCS fue de 37,1 y 47,3, respectivamente, lo que indica una \nmedia general de CVRS de 42,2, que representa una CVRS baja en los pacientes con dislipidemia.\nConclusiones: El resultado de nuestro estudio muestra que la edad, el sexo, la falta de actividad f\u00edsica, el sobrepeso, la HTA, la \nDM, el consumo de alcohol y el tabaquismo fueron factores de riesgo de dislipidemia. El presente estudio pone de manifiesto que \nlos pacientes con dislipidemia tienen una mala CVRS, ya que las puntuaciones globales de PCS y MCS fueron bajas. Es necesario \ncentrarse urgentemente en el tratamiento de la dislipidemia en la India para detener la creciente ola de enfermedades coronarias.\nPalabras clave:  Factores de riesgo, evaluaci\u00f3n del riesgo, calidad de vida, dislipidemia.94\n2021/36 (3): 93-98Zahra Dehghanian  \nIntroduction\nDespite the high advances in the medical sciences, \nsome diseases caused morbidity and mortality1-10. \nDyslipidemia is considered a major cause of death in \ndeveloped and developing countries, according to the \nestimates by the World Health Organization (WHO), \ndyslipidemia is associated with more than half of the \ncases of coronary artery disease and more than four \nmillion deaths per year, globally. Lipid abnormalities, \nincluding total cholesterol and a high level of low-density \nlipoprotein cholesterol (LDL-C) and low level of high-\ndensity lipoprotein cholesterol (HDL-C), are the most \nimportant risk factors for cardiovascular diseases.11, \n12 It is considered a major risk factor for cardiovascular \ncomplications. Many studies such as those conducted \nby the World Health Organization and Framingham have \nestablished the association of plasma cholesterol level \nwith the risk of cardiovascular disease. This association \nalso confirmed with the results of a meta-analysis of 10 \ncohort studies, which stated that for a reduction of 0.6 \nmmol/L of serum total cholesterol in adults aged over 60 \nyears, the risk of fatal cardiovascular disease decreased \nby 27%.13, 14\nThe Indian Council of Medical Research (ICMR) \nsurveillance project reported a prevalence of dyslipidemia \nof 37.5% among adults aged 15-64 years, with an even \nhigher prevalence of dyslipidemia 62% among young \nmale industrial workers.11 Various studies also reported \ngreater triglyceride levels in rural and urban populations \nassociated with low HDL cholesterol levels.12, 16\nAn important shortcoming of Indian epidemiological \nstudies is the lack of large studies with details of patterns \nof dyslipidemia. Compared with Western populations, \nIndians and migrant South Asians tend to have higher \ntriglyceride levels and lower HDL cholesterol while \ntotal cholesterol levels are lower than in the US and \nthe UK. Only a few extensive studies have reported \nthe prevalence of different forms of lipid abnormalities \namong Indians. India Heart Watch study carried out \namong urban middle-class subjects in 11 cities of India \nwith fasting lipid estimation revealed alarming facts that \nIndia is undergoing a rapid epidemiological transition with \nincreasing population, economic prosperity, urbanization, \nand ageing with associated risk factor transition. An \nincrease in cardiovascular risk and hypercholesterolemia \nis also associated with increased adverse lifestyles \nsuch as greater smoking and tobacco use, change in \nnutritional habits with greater intake of unhealthy diets, \nand increasingly sedentary lifestyle. All the risk mentioned \nabove factors have contributed to the sharp rise in the \nburden of non-communicable diseases, especially \ncoronary heart disease (CHD). Even in rural areas of \nIndia, non-communicable and chronic diseases have \nbecome the leading causes of death.12-16Health-related quality of life (HRQOL) includes the \nphysical, mental, and social aspects of health and is \nan essential outcome measure that has gained much \nattention in recent years. HRQOL specifically focuses on \nan individual\u2019s perception of health and life satisfaction \nthat may be linked with the World Health Organization \n(WHO) definition of health as \u2018\u2018the state of complete \nphysical, mental, and social wellbeing, and not merely \nthe absence of disease and infirmity.15 HRQOL was \nassessed by the SF-36, a short form of the Medical \nOutcome Study. It contains 36 questions. The SF-36 \nassesses eight health dimensions: physical functioning, \nrole physical limitation, bodily pain, general health, social \nfunctioning, role emotional limitation, mental health, and \nvitality. From these eight scales, it is possible to calculate \ntwo summary scores, physical component summary \n(physical functioning, role physical limitation, bodily pain, \nand general health) and mental component summary \n(social functioning, role emotional limitation, mental \nhealth, and vitality), and also the overall HRQOL. Certain \nstudies conducted on the impact of health-related quality \nof life of the patients with dyslipidemia have established \na direct association of dyslipidemia with low HRQOL. \nThe major contributing factors identified were rigid \ndietary prescriptions, medication side effects, the need \nfor regular medical care, and psychological effects.12 \nImprovement of HRQOL would be very important in \nthe management of patients with dyslipidemia. The \nexpanding pattern in patients with dyslipidemia makes \nthis assessment exceptionally applicable, to more readily \noversee dyslipidemia patients and therefore improve their \nQOL. The alarming rise in the global prevalence and \ndisease burden of dyslipidemia makes the reports of \nthese studies highly relevant for the effective management \nof dyslipidemia patients and consequently improve their \nHRQOL.13,17 Therefore, this study is proposed with the \nprimary objective to concentrate on identifying various risk \nfactors, risk assessment associated with dyslipidemia, \nand measuring its impact on patient\u2019s HRQOL. Secondary \nobjectives are to evaluate the drug-related problem \nassociated with dyslipidemia management and assess \nthe knowledge, attitude, and practice of dyslipidemia \npatients towards their illness and treatment. \nMaterials and methods\nThe study was conducted at Kempegowda Institute of \nMedical Sciences (Kims) Hospital and Research Centre, \na 500 bedded hospital with state-of-the-art facilities for \npatients. This study was conducted on patients drawn \nfrom the Outpatient clinic and Inpatient wards of the \nDepartment of General Medicine.\nPatients\u2019 meeting with inclusion and exclusion criteria \nwere included in the study. The purpose of the study was \nexplained to the patient and consent was taken. A self-\ndesigned case report form was used to collect the patients\u2019 95\n2021/36 (3): 93-98 Evaluation of risk factors, risk assessment and health-related quality of life in patients with dyslipidemia\ndemographic data, medical issues, past medical history, \nlaboratory data, and other relevant information collected by \ninterviewing and referring to their medical records in the \nhospital (both inpatient and outpatient) documented. Also, \nthe SF-36 (Short form survey) questionnaire was used to \ninterview the patient to assess the patient\u2019s health status. \nThe knowledge, attitude, and practice of dyslipidemia \npatients towards their illness were assessed using the KAP \nquestionnaire. JBS-3, a risk calculator was used to assess \nthe risk factors and risk assessment, both 10-year risk \nand lifetime risk of CVD in all individuals. This is done by \nentering the laboratory values obtained during interviewing/\ndata collection in the JBS-3 risk calculator. PCNE v8.01 \nis a classification tool used to evaluate drug-related \nproblems by using the data obtained during interviewing/\ndata collection. All the data collected were entered into \nMicrosoft Excel and an appropriate statistical analysis tool \nwas applied. Categorical variables were presented using \ntables and graphs. Continuous variables were presented \nas mean +/- SD. Descriptive statistical methods were used \nto measure the mean, median, and standard deviation.\nResult and discussion\nThis study included a total of 200 patients drawn from the \nOutpatient clinic and Inpatient wards of the Department \nof General Medicine in Kempegowda Institute of Medical \nSciences (Kims) Hospital and Research Centre, Bengaluru. \nThe study was conducted from January 2018 to March \n2018. Out of the 200 sets of the population enrolled \nfor the study 55.00% were male (n=111), 45.00% were \nfemale (n=89). Among the 200 patients, about 60 patients \ni.e.30%, had habits such as smoking, alcohol, and tobacco \nuse, and the remaining 70% had none. Out of 60 patients\u2019 \nhighest number were among the use of both alcohol and \nsmoking and the least were the use of all three. Prevalence \nof abnormal total cholesterol (TC), triglyceride (TG), high-\ndensity lipoprotein (HDL), and very-low-density lipoprotein \n(VLDL) in women was higher than in men whereas the level \nof (LDL) was higher in men, as shown in figure 1 .\nOut of the 200 patients involved in the study, most of \nthe patients were found to be between the age group \nof 55-64 (31.5%), thus as the age increases there is a \nproportionate increase in the risk of acquiring dyslipidemia. Prevalence of the disease was seen more in the male \npopulation 55% (n=111), than in the female population \n45% (n=89). Figure 2  shows the risk factors of patients.\nThe majority of patients in the study i.e. 74.00% (n=148) \nwere found to have lack of physical activity as a chief risk \nfactor and the least percentage of risk factor was among \npatients who were smoking i.e. 23.00% (n=46), and other \nrisk factors included hypertension, overweight, diabetes, \nand alcohol consumption as shown in figure 3 .\nCharlson Co-Morbidity Index (CCI) scoring was done for \nall the 200 patients in the study to assess the ten-year \nmortality for a patient who may have a range of comorbid \nconditions, and the highest average of 2.53 was seen in \npatients between the age group of 55-64.\nRisk Assessment:  Joint British Societies-3 (JBS-3) risk \nscore analysis revealed that 55.5% of the study population \nhave the risk of 0-20% for developing CVD in the next 10 \nyears and the least of 5% study population is in between \n61-80, as shown in figure 4 .\nFigure 1: Prevalence of dyslipidemia.Figure 2: Risk factors of a patient.\nFigure 3: Risk assessment in the male population.\nFigure 4: Risk assessment of patient.\n96\n2021/36 (3): 93-98Zahra Dehghanian  \nRisk Assessment in Male Population:  JBS-3 risk \nscore analysis to evaluate the risk assessment in the male \npopulation revealed 48.6% have risk between 0-20% \nfor developing CVD in the next 10 years, as depicted in \nfigure 3 .\nRisk Assessment in Female Population: JBS-3 risk \nscore analysis to evaluate the risk assessment in the \nfemale population revealed 64.04% have risk between \n0-20% for developing CVD in the next 10 years, as \ndepicted in figure 5 .\nA risk assessment done on a study population of 200, \nhave shown variation by 13.8 years in heart age from \nchronological age. The average chronological and heart \nage was 55.5\u00b112.1 and 69.3\u00b117.1 years respectively.\nHealth-Related Quality of Life Assessment:\nPhysical component summary (PCS):  Analysis of \nHRQOL in the study population using SF-36 revealed the \naverage of physical functioning (PF), role limitation due to \nphysical health (RLPH), pain, and health change to be \n45.7, 28.8, 39.3, and 34.7 respectively. The physical \nfunctioning dimension had a better average and the least \naverage was seen in role limitation due to physical health, \nas shown in figure 6 .\nMental component summary (MCS): Analysis of mental \ncomponent revealed the average of social functioning, \nrole limitation due to emotional problems (RLEP), energy, \nFigure 5: Risk assessment in the female population.Figure 7: Mental component summary.\nFigure 8: Physical and Mental component summary.\nFigure 6: Physical component summary.\nand emotional well-being to be 47.6, 31, 53.9, and 56.8, \nrespectively. Emotional well-being had a better average \nand the least average was seen in role limitation due to \nemotional problems, as shown in figure 7 .\nPhysical and mental component summary: The total \naverage of four dimensions each under MCS and PCS \nwere 47.3 and 37.1 respectively and the overall average \nof both PCS and MCS was 42.2, as shown in figure 8 .\nDrug-Related Problems: The drug-related problems \nidentified in our study population includes an inappropriate \ncombination of drugs, the patient uses/takes less drug \nthan prescribed or does not take the drug at all, patient \nstores drug inappropriately and inappropriate timing or \ndosing intervals, as shown in table I .\nSimilar researches have been performed in thie filed. Farhat \net al. (2016)18 reported a lower overall QOL score among \ndyslipidemic patients compared with controls (57.9% \nand 76.5%, respectively; p < 0.001). Waterpipe smoking \n(adjusted odds ratio (ORa) = 4.113, 95% confidence \ninterval (CI): 1.696-9.971, p = 0.002), hypertension (ORa \n= 3.597, 95% CI: 1.818-7.116, p < 0.001), diabetes \n(ORa = 3.441, 95% CI: 1.587-7.462, p = 0.002), Table I: Drug-related problems of the patient.\n Drug-Related Problems Number of patients \n C1.4* 05\n C7.1 05\n C7.6 04\n C7.7 04\n Total number of DRP 18\n*C1.4: Inappropriate combination of drugs or drugs and herbal medication \nC7.1: Patient uses/takes less drug than prescribed or does not take the drug at all \nC7.6: Patient stores drug inappropriately \nC7.7: Inappropriate timing or dosing intervals 97\n2021/36 (3): 93-98 Evaluation of risk factors, risk assessment and health-related quality of life in patients with dyslipidemia\ncigarette smoking (ORa = 2.966, 95% CI: 1.516\u20135.804, \np = 0.001), and passive smoking (ORa = 2.716, 95% CI: \n1.376\u20135.358, p = 0.004) were significantly associated \nwith dyslipidemia in individuals older than 30 years. \nA higher overall QOL score ( p = 0.013) was observed \nin patients treated with statins compared to other lipid-\nlowering medications. In a survey of Tziallas et al. (2012)19, \nThree hundred and fifty-nine subjects were involved of \nwhom 206 (57.4%) met the diagnostic criteria for the \nMetSyn (\u201ccases\u201d) and 153 (42.6%) did not (\u201ccomparator \ngroup\u201d). Comparisons of SF-36 scores between patients \nwith and without MetSyn revealed statistically significant \ndifferences except bodily pain subscale. A predominance \nof anxiety (60%) and depressive symptoms (67%) was \nobserved among subjects with MetSyn. Patients with \nMetSyn undergoing a therapeutic approach showed no \nimprovement in its general and mental health (p: NS). \nSimilar findings were reported in surveys conducted in \nBrazil20, Iran21, Romani22, and USA23.\nConclusion\nThe study was conducted in a tertiary care teaching hospital \nin urban premises of Bengaluru comprising of patients \nwho met the inclusion and exclusion criteria. The majority \nof the patients enrolled in the study were males, the age \ndistribution seen highest in the age group between 55-64.\nThe results of our study show age, gender, lack of \nphysical activity, overweight, HTN, DM, consumption of alcohol, and smoking were found. The result of risk \nassessment revealed 55.5% of the study population has \na risk of \u2264 20% and 44.4% of the study population have \na risk \u2265of 21% of developing CVD in the next 10 years. \nComparing actual age and heart age data has shown \nvariation by 13.8 years in heart age from the actual age. \nThe average actual age and heart age were 55.5\u00b112.1 \nand 69.3\u00b117.1 years, respectively. \nThe present study highlights the fact that patients with \ndyslipidemia have poor HRQOL as the overall PCS and \nMCS scores were low. KAP assessment revealed out \nof the 200 study population that most of the population \nlacks knowledge about the disease, but in case of \npractice and attitude towards the disease, the majority \nof the population has a positive response. Evaluation of \nDRPs showed a majority of them were potential drug \ninteractions and poor medication adherence. \nHence, these results highlight the pivotal role of the \npharmacist as a health care team provider in the \nmanagement of dyslipidemia through routine screening \nprograms for blood lipid levels and appropriate intervention \nprograms aimed at risk factor reduction, improve the \nHRQOL and to reduce the risk percentage for developing \nCVD in the future, and also improve the knowledge about \nthe disease to the patients, as more information about \nthe disease and its management will empower patients \nto manage their conditions better.  Focus on dyslipidemia \nmanagement is urgently required in India to halt the rising \ntide of coronary heart disease.98\n2021/36 (3): 93-98Zahra Dehghanian  \nReferences\n1. Dehkordi FS, Valizadeh Y, Birgani TA, Dehkordi KG. Prevalence study of \nBrucella melitensis and Brucella abortus in cow's milk using dot enzyme \nlinked immuno sorbent assay and duplex polymerase chain reaction. J \nPure Appl Microbiol. 2014;8(2):1065-9.\n2. Dehkordi FS, Khamesipour F, Momeni M. Brucella abortus and Brucella \nmelitensis in Iranian bovine and buffalo semen samples: The first clinical \ntrial on seasonal, Senile and geographical distribution using culture, \nconventional and real-time polymerase chain reaction assays. Kafkas Univ \nVet Fak Dergisi. 2014;20(6):821-.\n3. Dehkordi FS, Haghighi N, Momtaz H, Rafsanjani MS, Momeni M. \nConventional vs real-time PCR for detection of bovine herpes virus type \n1 in aborted bovine, buffalo and camel foetuses. Bulgarian Journal of \nVeterinary Medicine. 2013 Jun 1;16(2).\n4. Ranjbar R, Farsani FY, Dehkordi FS. Phenotypic analysis of antibiotic \nresistance and genotypic study of the vacA, cagA, iceA, oipA and babA \ngenotypes of the Helicobacter pylori strains isolated from raw milk. \nAntimicrobial Resistance & Infection Control. 2018 Dec;7(1):1-4.\n5. Dehkordi FS. Prevalence study of Bovine viral diarrhea virus by \nevaluation of antigen capture ELISA and RT-PCR assay in Bovine, Ovine, \nCaprine, Buffalo and Camel aborted fetuses in Iran. AMB express. 2011 \nDec;1(1):1-6.\n6. Halaji M, Farahani A, Ranjbar R, Heiat M, Dehkordi FS. Emerging \ncoronaviruses: first SARS, second MERS and third SARS-CoV-2: \nepidemiological updates of COVID-19. Infez Med. 2020 Jun 1;28(suppl \n1):6-17.\n7. Dehkordi FS, Saberian S, Momtaz H. Detection and segregation of \nBrucella abortus and Brucella melitensis in Aborted Bovine, Ovine, \nCaprine, Buffaloes and Camelid Fetuses by application of conventional \nand real-time polymerase chain reaction. The Thai Journal of Veterinary \nMedicine. 2012 Mar 1;42(1):13.\n8. Nejat S, Momtaz H, Yadegari M, Nejat S, Safarpour Dehkordi F, \nKhamesipour F. Seasonal, geographical, age and breed distributions \nof equine viral arteritis in Iran. Kafkas Univ Vet Fak Derg. 2015 Jan \n1;21(1):111-6.\n9. Abdolmaleki Z, Mashak Z, Dehkordi FS. Phenotypic and genotypic \ncharacterization of antibiotic resistance in the methicillin-resistant \nStaphylococcus aureus strains isolated from hospital cockroaches. \nAntimicrobial Resistance & Infection Control. 2019 Dec;8(1):1-4.\n10. Dehkordi FS, Haghighi N, Momtaz H, Rafsanjani MS, Momeni M. \nConventional vs real-time PCR for detection of bovine herpes virus type \n1 in aborted bovine, buffalo and camel foetuses. Bulgarian Journal of \nVeterinary Medicine. 2013 Jun 1;16(2).\n11. Ebrahimi, H., Emamian, M. H., Hashemi, H., & Fotouhi, A. (2016). \nDyslipidemia and its risk factors among urban middle-aged Iranians: \nA population-based study. Diabetes & Metabolic Syndrome: Clinical \nResearch & Reviews, 10(3), 149-56.12. Gupta, R., Rao, R. S., Misra, A., & Sharma, S. K. (2017). Recent \ntrends in epidemiology of dyslipidemias in India. Indian heart journal, 69(3), \n382-92.\n13. Farhat, A., Al-Hajje, A., Rachidi, S., Zein, S., Zeid, M. B., Salameh, \nP ., ... & Awada, S. (2016). Risk factors and quality of life of dyslipidemic \npatients in Lebanon: a cross-sectional study. Journal of epidemiology and \nglobal health, 6(4), 315-23.\n14. Pahan, K. (2006). Lipid-lowering drugs. Cellular and molecular life \nsciences CMLS, 63(10), 1165-78.\n15. Qi, L., Ding, X., Tang, W., Li, Q., Mao, D., & Wang, Y. (2015). \nPrevalence and risk factors associated with dyslipidemia in Chongqing, \nChina. International journal of environmental research and public health, \n12(10), 13455-65.\n16. Kaliyaperumal, K. I. E. C. (2004). Guideline for conducting a knowledge, \nattitude and practice (KAP) study. AECS illumination, 4(1), 7-9.\n17. Tripathy, J. P ., Thakur, J. S., Jeet, G., Chawla, S., Jain, S., Pal, A., & \nPrasad, R. (2017). Burden and risk factors of dyslipidemia-results from a \nSTEPS survey in Punjab India. Diabetes & Metabolic Syndrome: Clinical \nResearch & Reviews, 11, S21-S27.\n18. Farhat A, Al-Hajje A, Rachidi S, Zein S, Zeid MB, Salameh P , Bawab \nW, Awada S. Risk factors and quality of life of dyslipidemic patients in \nLebanon: a cross-sectional study. Journal of epidemiology and global \nhealth. 2016 Dec 1;6(4):315-23.\n19. Tziallas D, Kastanioti C, Savvas K, Kostapanos MS, Tziallas V, \nSkapinakis P , Elisaf MS, Mavreas V. Evaluation of health related quality \nof life in patients with metabolic syndrome. Health Science Journal. \n2012;6(1):116.\n20. Martinelli LM, Mizutani BM, Mutti A, D'elia MP , Coltro RS, Matsubara \nBB. Quality of life and its association with cardiovascular risk factors in a \ncommunity health care program population. Clinics. 2008;63(6):783-8.\n21. Rezaei M, Fakhri N, Pasdar Y, Moradinazar M, Najafi F. Modeling the \nrisk factors for dyslipidemia and blood lipid indices: Ravansar cohort study. \nLipids in health and disease. 2020 Dec;19(1):1-8.\n22. Vlad CE, Foia L, Florea L, Costache II, Covic A, Popescu R, Reurean-\nPintilei D, Covic A. Evaluation of cardiovascular risk factors in patients with \nfamilial hypercholesterolemia from the North-Eastern area of Romania. \nLipids in Health and Disease. 2021 Dec;20(1):1-6.\n23. Ponte-Negretti CI, Isea-P\u00e9rez J, Lanas F, Medina J, G\u00f3mez-\nMancebo J, Morales E, Acevedo M, Pirskorz D, Machado L, Lozada A, \nBryce A. Atherogenic dyslipidemia in Latin America: prevalence, causes \nand treatment. Consensus. Revista mexicana de cardiolog\u00eda. 2017 \nJun;28(2):57-85.Evaluation of risk factors, risk assessment and health-related quality of life in patients with dyslipidemia99\n2021/36 (3): 99-103ORIGINAL\nHelicobacter pylori  distribution in dental plaque specimens \ncollected from individuals referred to dental clinics\nDistribuci\u00f3n de Helicobacter pylori en muestras de placa dental \nrecolectadas de individuos remitidos a cl\u00ednicas dentales\nAshkan Salehi\nDepartment of Dentistry, University of Traditional Medicine of Armenia (UTMA), Armenia.eISSN 2255-0569\nReceived:  17 - V - 2021\nAccepted:  8 -VI - 2021\ndoi: 10.3306/AJHS.2021.36.03.99Corresponding author\nAshkan Salehi \nDepartment of Dentistry, \nUniversity of Traditional Medicine of Armenia (UTMA), Armenia    \nE-mail: ashkansalehip@gmail.comID\nAbstract  \nBackground:  According to documented thesis, dental plaques may be sources of Helicobacter pylori  in the oral cavity. The pres -\nent research was performed to assess the distribution of H. pylori  in dental plaque samples collected from individuals referred to \ndental clinics.\nMethods:  Four hundred patients referred to the dental clinics for routine check-ups were assessed in this survey. Dental plaque \npresence is the prominent inclusion factor. All patients who had received antimicrobial options or antibacterial mouthwashes three \nmonths before the experiment were excluded from the research. Two hundred and fifty dental plaque samples were collected from \nincluded patients. Samples were taken from the gingival crevice at the most profound pocket reading and removed from the clinical \nsite using a sterile universal curette. Samples were cultured, and suspected colonies were confirmed using the biochemical tests \nand the polymerase chain reaction (PCR). \nResults:  The mean age of the included population was 54.5 year, with a male to female ratio of 140/110. Molar (45.2%) dental \nplaque was the most commonly identified, followed by premolar (35.8%).  H. pylori  was detected in 42 out of 250 (16.8%) dental \nplaque specimens. Molar teeth plaque specimens (19.4%) had the highest distribution of H. pylori , while incisor teeth (12.0%) \nharboured the lowest.\nConclusion: The role of dental plaques, particularly in the molar and premolar areas as H. pylori  reservoirs, was determined. Oral \nhygiene observation and proper antimicrobial uses can diminish the H. pylori  distribution.\nKeywords:  Helicobacter pylori , diagnosis, distribution, dental plaque.\nResumen\nAntecedentes:  Seg\u00fan tesis documentadas, las placas dentales pueden ser fuentes de Helicobacter pylori  en la cavidad oral. La \npresente investigaci\u00f3n se llev\u00f3 a cabo para evaluar la distribuci\u00f3n de H. pylori  en muestras de placa dental recogidas de individuos \nremitidos a cl\u00ednicas dentales.\nM\u00e9todos:  En este estudio se evaluaron 400 pacientes remitidos a las cl\u00ednicas dentales para revisiones rutinarias. La presencia de \nplaca dental es el principal factor de inclusi\u00f3n. Se excluyeron de la investigaci\u00f3n todos los pacientes que hab\u00edan recibido opciones \nantimicrobianas o colutorios antibacterianos tres meses antes del experimento. Se recogieron 250 muestras de placa dental de los \npacientes incluidos. Las muestras se tomaron de la hendidura gingival en la lectura m\u00e1s profunda de la bolsa y se extrajeron del \nsitio cl\u00ednico utilizando una cureta universal est\u00e9ril. Las muestras se cultivaron y las colonias sospechosas se confirmaron mediante \nlas pruebas bioqu\u00edmicas y la reacci\u00f3n en cadena de la polimerasa (PCR). \nResultados:  La edad media de la poblaci\u00f3n incluida fue de 54,5 a\u00f1os, con una relaci\u00f3n hombre/mujer de 140/110. La placa \ndental molar (45,2%) fue la m\u00e1s com\u00fanmente identificada, seguida de la premolar (35,8%). Se detect\u00f3 H. pylori  en 42 de los 250 \n(16,8%) espec\u00edmenes de placa dental. Las muestras de placa de los dientes molares (19,4%) presentaban la mayor distribuci\u00f3n \nde H. pylori , mientras que los dientes incisivos (12,0%) albergaban la menor.\nConclusiones: Se determin\u00f3 el papel de las placas dentales, especialmente en las zonas molares y premolares, como reservorios \nde H. pylori . La observaci\u00f3n de la higiene oral y el uso adecuado de antimicrobianos pueden disminuir la distribuci\u00f3n de H. pylori .\nPalabras clave:  Helicobacter pylori , diagn\u00f3stico, distribuci\u00f3n, placa dental.100\n2021/36 (3): 99-103Ashkan Salehi  \nIntroduction\nThe human body includes 1013 somatic cells and 1014 \nnormal or commensal microbes1. These commensal \nbacteria reside on the surfaces of teeth or prostheses \nwithin complex ecosystems termed biofilm. Dental \nplaque is the host-associated biofilm. Supragingival and \nsubgingival plaque provide an optimal aerophilic and \nmicroaerophilic environment for the survival of these \nmicroorganisms. Approximately six billion microbes \nrepresenting 300-500 reside in these environments in \nthe oral cavity.\nAn association between oral infections and systemic \ndiseases has been suspected for centuries. Assyrians \nproposed the effect of oral health on the rest of the body \nin the 7th century BC. In the 18th century, a Pennsylvanian \nphysician2 named Benjamin Rush was quoted as \nremarking that arthritis could be treated in some people \nafter infected teeth were extracted.\nOver the past decade, a growing body of scientific \nevidence suggests an exquisite association between \noral infection (e.g., viruses, bacteria, yeast) and systemic \ndiseases (e.g., atherosclerosis, cardiovascular disease, \ncerebrovascular disease, premature, low birth weight, \nand pulmonary diseases and disorders), and also \nbetween systemic diseases (e.g., arthritic, diabetic, \nHIV, and osteoporotic) and oral, dental, and craniofacial \ndisorders3.\nIt has long been speculated that dental plaque might \nharbour Helicobacter pylorus ( H. pylori ) and, therefore, \nmight be a source of reinfection of the gastric mucosa4. \nH. pylori  is a microaerophilic and Gram-negative spiral \ncoccoid bacterium known as a causative agent for gastric \nadenocarcinoma, peptic ulcer disease, duodenal ulcer, \ntype B gastritis, and B-cell lymphoma5. The area around \nthe dental plaque has a low oxidation potential promoting \nthe growth of facultative anaerobes. Newman6 suggested \nthat bacteria fermenting carbohydrates in food produce \na low pH in the dental plaque, and this microaerophilic \nacidic environment with an average oral temperature of \n35-37\u00b0C can be ideal for the growth of H. pylori . \nAbout 50% of the subjects living in developed and \ndeveloping countries are affected by H. pylori . These \ninfections are complicated to eradicate, and it has \nbeen postulated that a sanctuary or sanctuaries which \nallow them to evade antimicrobial therapy much exists. \nDesai and Majmudar7 suggested that recrudescence \nof infection following cessation of therapy may occur, \nowing to the recolonization of the stomach from the H. \npylori present in dental plaque are unaffected by the \nantimicrobial treatment. Knowledge of this pathogenic \norganism will permit a target for therapeutic procedures \nand a monitoring tool for therapy efficacy and learn about \nthe various transmission routes.According to the high importance of bacteria and the \nabsence of epidemiological surveys in this field, the \npresent research was performed to assess the H. pylori  \ndistribution in dental plaque specimens collected from \nindividuals referred to dental clinics.\nMaterials and methods\nEthics\nAll personal information of individuals included in the study \nwere kept secret. Written informed consent was taken from \nall individuals. The study protocol was ethically approved \nby the University of Traditional Medicine of Armenia.\nInclusion and exclusion criteria\nA total of 400 patients referred to the Armenia dental \nclinics for routine check-ups were assessed in this \nsurvey. All patients with dental plaque samples were \nincluded in this survey. Dental plaque presence is the \nprominent inclusion factor. All patients who had received \nantimicrobial options or antibacterial mouthwashes three \nmonths before the experiment were excluded from the \nresearch. All of the selected patients were non-smokers. \nDental specimens\nFrom January to April 2021, 250 male and female patients \nwith dental plaque will different age were included in the \nstudy. A dental plaque sample was taken from the gingival \ncrevice at the most profound pocket reading and removed \nfrom the clinical site using a sterile universal curette. The \ncurette tip was inserted into the depths of the crevice/\npocket, moved coronally while in contact with the tooth \nsurface to remove both sub and supragingival plaque.\nH. pylori  isolation ad identification\nThe dental plaque sample from each patient was \ncultured into a sterile tube containing 5% sheep \nblood agar, chocolate agar and a selective medium \nand transported to the microbiology laboratory to be \nincubated microaerophically (5% oxygen, 85% nitrogen, \nand 10% CO2) using the MART system (MART system, \nLichtenvoorde, The Netherland) at a temperature of 37\u00b0C \nfor seven days. Culture media were supplemented with \n5% of horse serum (Sigma, St. Louis, MO, USA), nalidixic \nacid (30 mg/L), vancomycin (10 mg/L), cycloheximide \n(100 mg/L), and trimethoprim (30 mg/L) (Sigma, St. \nLouis, MO, USA)8-14. Suspected colonies were then \nidentified using Gram stain, motility, colony morphology, \nand biochemical tests such as urease, oxidase, and \ncatalase tests15. For comparison, a reference strain of  H. \npylori  (ATCC 43504) was employed.\nPolymerase Chain Reaction (PCR) identification \nof bacterial isolates\nPCR was used to definitely identified the H. pylori  \nisolates16. For this purpose, genomic DNA was extracted 101\n2021/36 (3): 99-103 Helicobacter pylori distribution in dental plaque specimens collected from individuals referred to dental clinics\nusing a DNA extraction kit (Thermo Fisher Scientific, St. \nLeon-Rot, Germany). The technique was performed \nrendering to the factory guidelines17, 18. Purity (A260/A280) \nand concentration of extracted DNA were then plaids \n(NanoDrop, Thermo Scientific, Waltham, MA, USA), and \nthe DNA quality was scrutinized by electrophoresis19-22. \nPCR was accompanied using a PCR thermal cycler \n(Eppendorf Co., Hamburg, Germany) rendering to the \ndescribed procedure23-25. H. pylori  (26695) was positive, \nwhile sterile PCR grade water (Thermo Fisher Scientific, \nGermany) was used as negative controls. Electrophoresis \nwas performed using 2% agarose gel stained with \nethidium bromide run in a 90 V for about 30 min26-28. \nBriefly, Ten microliters of PCR product were exposed to \nelectrophoresis in a 2% agarose gel in 1X TBE buffer at \n80 V for 30 min, stained with SYBR Green. The UVI doc \ngel documentation systems (Grade GB004, Jencons \nPLC, London, UK) were applied to analyze images29-33.\nData analysis \nData were subjected to Microsoft Office Excel (version \n15; Microsoft Corp., Redmond, WA, USA). The statistical \nanalysis was performed employing the SPSS 21.0 \nsoftware (SPSS Inc., Chicago, IL, USA). Chi-square \ntest and Fisher's exact two-tailed test were applied to \nmeasure any significant relationship. P-value <0.05 was \nconsidered as a significant numerical level34-36. \nResults\nDemographic characters\nTable I shows the demographic characters of the study \npopulation. As shown, the mean age of the studied \npopulation was 54.5 year, with a male to female ratio of \n140/110. Totally, 20.8% of the study population had a \nhistory of alcohol. Molar (45.2%) dental plaque was the \nmost commonly identified, followed by premolar (35.8%).\nH. pylori  distribution\nPCR procedure was used to detect H. pylori  in \ndental plaque specimens. Table II shows the H. \npylori  distribution amongst examined dental plaque \nspecimens. Forty-two out of 250 (16.8%) dental plaque \nspecimens were positive for H. pylori . Molar teeth plaque \nspecimens (19.4%) harboured the highest distribution of H. pylori , while incisor teeth (12.0%) harboured the \nlowest. Statistically, a significant difference was obtained \nbetween the site of dental plaque samples and H. pylori  \ndistribution ( P <0.05)\nDiscussion\nDespite high advances in medical sciences, diverse \nissues have been kept complicated in this field of \nscience38-40. In this regard, H. pylori  have become an \nessential public health issue in the last century41. Several \ninvestigations have been focused on finding the exact \nroute of H. pylori  infection. Some researchers found \nthat the human dental plaques can be the reservoir of \nH. pylori42. Others showed that the oral cavity (dental \nplaque, tongue, saliva, root canals, tonsil tissue, oral \nmucosa) are essential sources of H. pylori  other than the \ngastric mucosa43. In the present survey, H. pylori  was \ndetected in 16.8% of the dental plaque samples, with a \nhigher distribution amongst the plaques collected from \nmolar teeth. Food accumulation in the molar teeth and \ndifficult access to cleaning and brushing can probably \nlead to H. pylori  growth in this area. \nDiverse researches have been conducted to determine \nthe role of dental plaques as sources of H. pylori  \ninfections44,45. Chitsazi et al. (2006)46 stated that H.pylori  \nwas detected in 34.1% of dental plaque specimens. \nThe H. pylori  prevalence of infection in dental was \n31.8% and 36.4% in patients with and without gastric \ninfection. Medina et al. (2010)47 mentioned that H. pylori  \nwas detected in 18.3% of oral samples and 88.3% of \ngastric biopsies. Saudia authors48 showed that 65.0% of \npatients had  H. pylori -positive dental plaque, and more \nthan 50% harboured the bacteria in their stomach. They \nalso showed that periodontitis patients had a significantly \nhigher H. pylori  percentage in their dental plaque (79.0% \nversus 43.0%; P <0.05) and the stomach (60.0% versus \n33.0%; P <0.05) than those without periodontitis. Even \nthough H. pylori  may be detected in the stomach of about \n50% of the world's population, its individual to individual \ntransmission mechanisms are not yet identified. H. pylori  \ntransmission could occur through faecal-oral and oral-\noral routes. The bacterium may be transmitted orally and \ndetected in dental plaque and saliva49. High distribution \nof H. pylori  in dental plaque has been reported in surveys \nconducted in Mexico50, Iran51, Japan52, and Morocco53. \nAn Iranian survey54 revealed that the frequency of \ndetection of H. pylori  in the dental plaque samples were Table I: The study population of the present survey.\n Demographic characters Individuals (250 people)\n Mean age (SD) 54.5 (15.2)\n  Sex (M/F) 140/110\n Mean weight (SD) 68.3 (12.6)\n Mean BMI (SD) 24.2 (3.9)\n Alcohol (%) 20.8\n Dental plaque location\n Incisor teeth (%) 25 (10.0)\n Canine teeth (%) 30 (12.0) \n Premolar teeth (%) 82 (32.8)\n Molar teeth (%) 113 (45.2)Table II: H. pylori  distribution amongst examined dental plaque specimens.\n Study N. collected N. specimens positive \n groups specimens for H. pylori  (%)\nDental Incisor teeth 25 3 (12.0)\nplaque Canine teeth 30 4 (13.3)\nposition Premolar teeth 82 13 (15.8)\n Molar teeth 113 22 (19.4)\nTotal  250 42 (16.8)102\n2021/36 (3): 99-103Ashkan Salehi  \n44% (20/45), 66.67% (30/45) and 77.78% (35/45) using \nPCR, loop-mediated isothermal amplification (LAMP) \nand positivity for both tests, respectively. In the current \nsurvey, all H. pylori  isolates were identified by biochemical \ntests and definitely PCR.due to the high sensitivity and \nspecificity of applied diagnostic tests, results have a high \nconfidence level.\nThe present survey was preliminary research on the \ndistribution of H. pylori  in the dental plaque samples. It \nis limited to the lack of the study of the nutritional and \ngastrointestinal diseases of the examined population and \ntheir relations with the H. pylori  distribution. Additionally, the absence of results about the role of alcohol \nconsumption in H. pylori  distribution among patients is \nanother limitation.\nConclusion\nThis survey showed the relatively high H. pylori  prevalence \namongst the dental plaque specimens. The role of \ndental plaque as a source of H. pylori  was determined \nin this survey. Oral hygiene observation, dental plaques \nremoval, mouthwash, and regular brushing can reduce \nthe H. pylori  distribution. \nReferences\n1. Sender R, Fuchs S, Milo R. Revised estimates for the number of human \nand bacteria cells in the body. PLoS biology. 2016;14(8):e1002533.\n2. Genco R. Textbook of Periodontal Medicine. 2000. pp. 1-10.\n3. Sudhakar U, Anusuya CN, Ramakrishnan T, Vijayalakshmi R. Isolation \nof Helicobacter pylori from dental plaque: A microbiological study. Journal \nof Indian society of periodontology. 2008;12(3):67.\n4. Pay\u00e3o SL, Rasmussen LT. Helicobacter pylori and its reservoirs: \nA correlation with the gastric infection. World journal of gastrointestinal \npharmacology and therapeutics. 2016 6;7(1):126.\n5. Kusters JG, Van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter \npylori infection. Clinical microbiology reviews. 2006;19(3):449-90.\n6. Nisengard N. Periodontal microbiology, Glickman's Clinical \nPeriodontology. 1996; 8:614-34.\n7. Desai HG, Gill HH, Shankaran K, Mehta PR, Prabhu SR. Dental plaque: \nA permanent reservoir of helicobacter pylori. Scand J Gastroenterol. \n1991;26:1205-8. \n8. Atapoor S, Dehkordi FS, Rahimi E. Detection of Helicobacter pylori \nin various types of vegetables and salads. Jundishapur Journal of \nMicrobiology. 2014 May;7(5).\n9. Mousavi S, Dehkordi FS. Virulence factors and antibiotic resistance \nof Helicobacter pylori isolated from raw milk and unpasteurized dairy \nproducts in Iran. Journal of Venomous Animals and Toxins including \nTropical Diseases. 2015 Jan 20;20:1-7.\n10. Ghorbani F, Gheisari E, Dehkordi FS. Genotyping of vacA alleles \nof Helicobacter pylori strains recovered from some Iranian food items. \nTropical Journal of Pharmaceutical Research. 2016 Sep 5;15(8):1631-6.\n11. Ranjbar R, Farsani FY, Dehkordi FS. Phenotypic analysis of antibiotic \nresistance and genotypic study of the vacA, cagA, iceA, oipA and babA \ngenotypes of the Helicobacter pylori strains isolated from raw milk. \nAntimicrobial Resistance & Infection Control. 2018 Dec;7(1):1-4.\n12. Ranjbar R, Yadollahi Farsani F, Safarpoor Dehkordi F. Antimicrobial \nresistance and genotyping of vacA, cagA, and iceA alleles of the \nHelicobacter pylori strains isolated from traditional dairy products. Journal \nof Food Safety. 2019 Apr;39(2):e12594.\n13. Mashak Z, Jafariaskari S, Alavi I, Shahreza MS, Dehkordi FS. \nPhenotypic and genotypic assessment of antibiotic resistance and \ngenotyping of vacA, cagA, iceA, oipA, cagE, and babA2 alleles of Helicobacter pylori bacteria isolated from raw meat. Infection and drug \nresistance. 2020;13:257.\n14. Mousavi S, Safarpoor Dehkordi F, Valizadeh Y. Genotyping of \nHelicobacter pylori strains isolated from raw milk and dairy products. \nJournal of Food Microbiology. 2017 Nov 22;4(3):41-53.\n15. Al-Refai AN, Fathalla SE, Nagamani R, Al-Momen S. Incidence of \nhelicobacter pylori in dental plaque of saudi gastritis patients. Journal of \nfamily & community medicine. 2002;9(2):27.\n16. Ho SA, Hoyle JA, Lewis FA, Secker AD, Cross D, Mapstone NP , Dixon \nMF, Wyatt JI, Tompkins DS, Taylor GR. Direct polymerase chain reaction \ntest for detection of Helicobacter pylori in humans and animals. J Clin \nMicrobiol. 1991 Nov; 29(11):2543-9.\n17. Dehkordi FS. Prevalence study of Bovine viral diarrhea virus by \nevaluation of antigen capture ELISA and RT-PCR assay in Bovine, Ovine, \nCaprine, Buffalo and Camel aborted fetuses in Iran. AMB express. 2011 \nDec;1(1):1-6.\n18. Dehkordi FS, Saberian S, Momtaz H. Detection and segregation \nof Brucella abortus and Brucella melitensis in Aborted Bovine, Ovine, \nCaprine, Buffaloes and Camelid Fetuses by application of conventional \nand real-time polymerase chain reaction. The Thai Journal of Veterinary \nMedicine. 2012 Mar 1;42(1):13.\n19. Nejat S, Momtaz H, Yadegari M, Nejat S, Safarpour Dehkordi F, \nKhamesipour F. Seasonal, geographical, age and breed distributions of \nequine viral arteritis in Iran. Kafkas Univ Vet Fak Derg. 2015 Jan 1;21(1):111-6.\n20. Ranjbar R, Seif A, Safarpoor Dehkordi F. Prevalence of antibiotic \nresistance and distribution of virulence factors in the shiga toxigenic \nEscherichia coli recovered from hospital food. Jundishapur Journal of \nMicrobiology. 2019 May 31;12(5).\n21. Rahi A, Kazemeini H, Jafariaskari S, Seif A, Hosseini S, Dehkordi FS. \nGenotypic and Phenotypic-Based Assessment of Antibiotic Resistance \nand Profile of Staphylococcal Cassette Chromosome mec in the \nMethicillin-Resistant Staphylococcus aureus Recovered from Raw Milk. \nInfection and drug resistance. 2020;13:273.\n22. Dehkordi FS. Prevalence study of Coxiella burnetii in aborted ovine \nand caprine fetuses by evaluation of nested and real-time PCR assays. \nAmerican Journal of Animal and Veterinary Sciences. 2011.\n23. Dehkordi FS, Momtaz H, Doosti A. Application of Real-Time PCR for \ndetection of Aspergillus species in aborted ruminant foetuses. Bulgarian \nJ. Vet. Med. 2012 Mar 1;15(1):30-6.103\n2021/36 (3): 99-103 Helicobacter pylori distribution in dental plaque specimens collected from individuals referred to dental clinics\n24. Abdolmaleki Z, Mashak Z, Safarpoor Dehkordi F. Molecular and \nvirulence characteristics of methicillin-resistant Staphylococcus aureus \nbacteria recovered from hospital cockroaches. Jundishapur Journal of \nMicrobiology. 2019 Dec 31;12(12).\n25. Ranjbar R, Dehkordi FS, Heiat M. The frequency of resistance genes \nin Salmonella enteritidis strains isolated from cattle. Iranian Journal of \nPublic Health. 2020 May;49(5):968.\n26. Abdolmaleki Z, Mashak Z, Dehkordi FS. Phenotypic and genotypic \ncharacterization of antibiotic resistance in the methicillin-resistant \nStaphylococcus aureus strains isolated from hospital cockroaches. \nAntimicrobial Resistance & Infection Control. 2019 Dec;8(1):1-4.\n27. Dehkordi FS, Haghighi N, Momtaz H, Rafsanjani MS, Momeni M. \nConventional vs real-time PCR for detection of bovine herpes virus type \n1 in aborted bovine, buffalo and camel foetuses. Bulgarian Journal of \nVeterinary Medicine. 2013 Jun 1;16(2).\n28. Dehkordi FS, Khamesipour F, Momeni M. Brucella abortus and \nBrucella melitensis in Iranian bovine and buffalo semen samples: The \nfirst clinical trial on seasonal, Senile and geographical distribution using \nculture, conventional and real-time polymerase chain reaction assays. \nKafkas Univ Vet Fak Dergisi. 2014;20(6):821-.\n29. Dehkordi FS, Valizadeh Y, Birgani TA, Dehkordi KG. Prevalence study \nof Brucella melitensis and Brucella abortus in cow's milk using dot enzyme \nlinked immuno sorbent assay and duplex polymerase chain reaction. J \nPure Appl Microbiol. 2014;8(2):1065-9.\n30. Hasanpour Dehkordi A, Khaji L, Sakhaei Shahreza MH, Mashak Z, \nSafarpoor Dehkordi F, Safaee Y, Hosseinzadeh A, Alavi I, Ghasemi E, \nRabiei-Faradonbeh M. One-year prevalence of antimicrobial susceptibility \npattern of methicillin-resistant Staphylococcus aureus recovered from raw \nmeat. Trop Biomed. 2017;34(2):396-404.\n31. Dehkordi FS, Barati S, Momtaz H, Ahari SN, Dehkordi SN. \nComparison of shedding, and antibiotic resistance properties of Listeria \nmonocytogenes isolated from milk, feces, urine, and vaginal secretion of \nbovine, ovine, caprine, buffalo, and camel species in Iran. Jundishapur \nJournal of Microbiology. 2013 May 1;6(3):284.\n32. Rahimi E, Sepehri S, Dehkordi FS, Shaygan S, Momtaz H. Prevalence \nof Yersinia species in traditional and commercial dairy products in Isfahan \nProvince, Iran. Jundishapur Journal of Microbiology. 2014 Apr;7(4).\n33. Ranjbar R, Dehkordi FS, Shahreza MH, Rahimi E. Prevalence, \nidentification of virulence factors, O-serogroups and antibiotic resistance \nproperties of Shiga-toxin producing Escherichia coli strains isolated \nfrom raw milk and traditional dairy products. Antimicrobial Resistance & \nInfection Control. 2018 Dec;7(1):1-1.\n34. Rahimi E, Yazdanpour S, Dehkordi FS. Detection of Toxoplasma \ngondii antibodies in various poultry meat samples using enzyme linked \nimmuno sorbent assay and its confirmation by polymerase chain reaction. \nJ Pure Appl Microbiol. 2014;8(1):421-7.\n35. Dehkordi FS, Tirgir F, Valizadeh Y. Effects of Guajol\u00ae ointment \nsynthesized from medicinal smoke condensate of jennet feces on burn \nwound healing on Wistar rat. InVeterinary Research Forum 2017 (Vol. 8, \nNo. 3, p. 215). Faculty of Veterinary Medicine, Urmia University, Urmia, Iran.\n36. Nayebpoor F, Momeni M, Dehkordi FS. Incidence of ochratoxin A in \nraw and salted dried fruits using high performance liquid chromatography. \nAm Eur J Toxicol Sci. 2013;5:1-6.\n37. Mirzaie A, Halaji M, Dehkordi FS, Ranjbar R, Noorbazargan H. A \nnarrative literature review on traditional medicine options for treatment \nof corona virus disease 2019 (COVID-19). Complementary Therapies in \nClinical Practice. 2020 Jun 17:101214.\n38. Ranjbar R, Mahmoodzadeh Hosseini H, Safarpoor Dehkordi F. A Review on Biochemical and Immunological Biomarkers used for Laboratory Diagnosis of \nSARS-CoV-2 (COVID-19). The Open Microbiology Journal. 2020 Dec 15;14(1)\n39. Halaji M, Farahani A, Ranjbar R, Heiat M, Dehkordi FS. Emerging \ncoronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological \nupdates of COVID-19. Infez Med. 2020 Jun 1;28(suppl 1):6-17.\n40. Sheikhshahrokh A, Ranjbar R, Saeidi E, Dehkordi FS, Heiat M, \nGhasemi-Dehkordi P , Goodarzi H. Frontier therapeutics and vaccine \nstrategies for sars-cov-2 (COVID-19): A review. Iranian Journal of Public \nHealth. 2020 Jul 11.\n41. Saxena A, Mukhopadhyay AK, Nandi SP . Helicobacter pylori: \nPerturbation and restoration of gut microbiome. Journal of Biosciences. \n2020 Dec;45(1):1-5.\n42. Pay\u00e3o SL, Rasmussen LT. Helicobacter pylori and its reservoirs: \nA correlation with the gastric infection. World journal of gastrointestinal \npharmacology and therapeutics. 2016 Feb 6;7(1):126.\n43. Czesnikiewicz-Guzik M, Bielanski W, Guzik TJ, Loster B, Konturek \nSJ. Helicobacter pylori in the oral cavity and its implications for gastric \ninfection, periodontal health, immunology and dyspepsia. Journal of \nphysiology and pharmacology. 2005 Dec 1;56:77.\n44. B\u0131cak DA, Akyuz S, K\u0131ratl\u0131 B, Usta M, Urganci N, Alev B, Yarat A, Sahin F. \nThe investigation of Helicobacter pylori in the dental biofilm and saliva samples \nof children with dyspeptic complaints. BMC oral health. 2017 Dec;17(1):1-2.\n45. Valdez-Gonzales JA, Mares-Moreno PC, Kawolik MJ, Valdez- \nGonzales JA, Gonzales- Salazar F, De la Garza-Ramos MA. Detection of \nHelicobacter pylori in dental plaque of Mexican children by real-time PCR. \nHealth J. 2014;6(4):231-5.\n46. Chitsazi MT, Fattahi E, Zadeh Farahani RM, Fattahi S. Helicobacter pylori \nin the dental plaque: is it of diagnostic value for gastric infection?. Medicina \nOral, Patolog\u00eda Oral y Cirug\u00eda Bucal (Internet). 2006 Jul;11(4):325-8.\n47. Medina ML, Medina MG, Mart\u00edn GT, Pic\u00f3n SO, Bancalari A, Merino \nLA. Molecular detection of Helicobacter pylori in oral samples from patients \nsuffering digestive pathologies.\n48. Al Asqah M, Al Hamoudi N, Anil S, Al-hamoudi WK. Is the presence of \nHelicobacter pylori in the dental plaque of patients with chronic periodontitis \na risk factor for gastric infection?. Canadian Journal of Gastroenterology. \n2009 Mar 1;23(3):177-9.\n49. Anand PS, Kamath KP , Anil S. Role of dental plaque, saliva and \nperiodontal disease in Helicobacter pylori infection. World journal of \ngastroenterology: WJG. 2014 May 21;20(19):5639.\n50. Mendoza-Cant\u00fa A, Urrutia-Baca VH, Urbina-R\u00edos CS, la Garza-Ramos D, \nAng\u00e9lica M, Garc\u00eda-Mart\u00ednez ME, Torre-Mart\u00ednez HH. Prevalence of Helicobacter \npylori vacA genotypes and cagA gene in dental plaque of asymptomatic \nMexican children. BioMed research international. 2017 Nov 1;2017.\n51. Navabi N, Nazeri M. The possible role of dental plaque as extra-gastric \nreservoir of Helicobacter pylori in gastric re-infection: A science-metric \nstudy. Journal of Oral Health and Oral Epidemiology. 2019 Jan 1;8(1):1-8.\n52. Iwai K, Watanabe I, Yamamoto T, Kuriyama N, Matsui D, Nomura R, \nOgaya Y, Oseko F, Adachi K, Takizawa S, Ozaki E. Association between \nHelicobacter pylori infection and dental pulp reservoirs in Japanese adults. \nBMC oral health. 2019 Dec;19(1):1-8.\n53. Regragui A, Benaouda A, El Feydi AE, Abdedine A, Ennibi O. \nHelicobacter Pylori in the dental plaque. International Journal of Medical \nand Dental Sciences. 2014 Jul 1;3(2):396-402.\n54. Amiri N, Abiri R, Eyvazi M, Zolfaghari MR, Alvandi A. The frequency of \nHelicobacter pylori in dental plaque is possibly underestimated. Archives \nof oral biology. 2015 May 1;60(5):782-8.104\n2021/36 (3): 104-112ORIGINAL\nComparative study of clinical symptoms, laboratory and \nradiological findings of COVID-19 patients admitted to ICU ward \nwith internal ward of Forghani Hospital in Qom: a case series\nEstudio comparativo de s\u00edntomas cl\u00ednicos, hallazgos de laboratorio y radiol\u00f3gicos \nde pacientes COVID-19 ingresados   en la sala de UCI con sala interna \ndel Hospital Forghani en Qom: una serie de casos\nAbolfazl Mozafari1      , Foroozan Yarahmadi2\n1. Associate Professor, Department of Medical Sciences, Qom Branch, Islamic Azad University, Qom, Iran.\n2. Department of Medical Sciences, Qom Branch, Islamic Azad University, Qom, Iran.eISSN 2255-0569\nReceived:  9 - V - 2021\nAccepted:  22 - V - 2021\ndoi: 10.3306/AJHS.2021.36.03.104Corresponding author\nAbolfazl Mozafari \nDepartment of Medical Sciences, \nQom Branch, Islamic Azad University, Qom, Iran\nE-mail: a_mozafari@hotmail.comID ID\nAbstract  \nThis analytical study was performed in Forqani Hospital of Qom from April to June of the year with the aim of comparing laboratory \nand radiological findings in patients with coronavirus 2020. Laboratory and radiological findings were performed between 50 pa -\ntients with coronary artery hospitalization in the inpatient ward and 50 patients admitted to the ICU of Qom. After collecting informa -\ntion, data analysis was performed with SPSS24 software. \u201cIn patients admitted to the inpatient ward, the age of patients was 54 \n\u00b12.29 years and 54% were male and the mean age of patients admitted to intensive care units was 60 + 2 +01 years and 64% \nwere male. Based on radiological findings in patients admitted to the inpatient ward and ICU, bilateral lung involvement was 68% \nand 84%, respectively (p <0.05). The finding of grand glass in the lungs in patients admitted to the inpatient ward was significantly \nhigher than the ICU patients and also the finding of consolidation in the lungs in patients admitted to the ICU was significantly more \nthan the patients admitted to the inpatient ward (P <0.05). In laboratory findings, there was a significant difference between WBC, \nlymphocyte, BUN and creatinine and CRP in patients admitted to the ICU with patients admitted to the inpatient ward (P <0.05). \nThe results of this study show that in patients with coronavirus diagnosis, there was a significant difference in radiological and lab -\noratory findings in patients with COVID-19 admitted to the inpatient and intensive care units such as blood oxygen levels, WBC, \nlymphocyte platelets, CRP , creatinine. There was a significant difference between urea and lung CT scan findings and diagnosis of \nlung consolidation in patients admitted to the ICU compared with patients admitted to the ward. \nKeywords:  Coronavirus infection, SARS CoV-2, critical care, clinical features.\nResumen\nEste estudio anal\u00edtico se realiz\u00f3 en el Hospital Forqani de Qom de abril a junio del a\u00f1o con el objetivo de comparar los hallazgos \nde laboratorio y radiol\u00f3gicos en pacientes con coronavirus 2020. Se realizaron hallazgos de laboratorio y radiol\u00f3gicos entre 50 \npacientes con coronavirus ingresados en la sala de hospitalizaci\u00f3n y 50 pacientes ingresados en la UCI de Qom. Tras recoger la \ninformaci\u00f3n, se realiz\u00f3 el an\u00e1lisis de los datos con el software SPSS24. En los pacientes ingresados en la sala de hospitalizaci\u00f3n, \nla edad de los pacientes era de 54 \u00b1 2/29 a\u00f1os y el 54% eran hombres y la edad media de los pacientes ingresados en las uni -\ndades de cuidados intensivos era de 60 \u00b1 2 \u00b1 01 a\u00f1os y el 64% eran hombres. Seg\u00fan los hallazgos radiol\u00f3gicos en los pacientes \ningresados en la sala de hospitalizaci\u00f3n y en la UCI, la afectaci\u00f3n pulmonar bilateral fue del 68% y del 84%, respectivamente (p \n<0,05). El hallazgo de gran vidrio en los pulmones en los pacientes ingresados en la sala de hospitalizaci\u00f3n fue significativamente \nmayor que en los pacientes de la UCI y tambi\u00e9n el hallazgo de consolidaci\u00f3n en los pulmones en los pacientes ingresados en la \nUCI fue significativamente mayor que en los pacientes ingresados en la sala de hospitalizaci\u00f3n (p <0,05). En cuanto a los resulta -\ndos de laboratorio, hubo una diferencia significativa entre el recuento de gl\u00f3bulos blancos, los linfocitos, el BUN, la creatinina y la \nPCR en los pacientes ingresados en la UCI y en los pacientes ingresados en la sala de hospitalizaci\u00f3n (P <0,05). Los resultados de \neste estudio muestran que en los pacientes con diagn\u00f3stico de coronavirus hubo una diferencia significativa en los hallazgos radi -\nol\u00f3gicos y de laboratorio en los pacientes con COVID-19 ingresados en la sala de hospitalizaci\u00f3n y en las unidades de cuidados \nintensivos, como los niveles de ox\u00edgeno en sangre, los gl\u00f3bulos blancos, los linfocitos, las plaquetas, la PCR y la creatinina. Hubo \nuna diferencia significativa entre los hallazgos de la urea y la tomograf\u00eda computarizada de pulm\u00f3n y el diagn\u00f3stico de consolidaci\u00f3n \npulmonar en los pacientes ingresados en la UCI en comparaci\u00f3n con los pacientes ingresados en la sala.\nPalabras clave:  Coronavirus infection, SARS CoV-2, critical care, clinical features105\n2021/36 (3): 104-112Comparative study of clinical symptoms, laboratory and radiological findings of COVID-19 patients admitted to ICU ward with internal ward of forghani hospital in Qom: a case series\nIntroduction\nSARS-CoV-2 (The Severe Acute Respiratory Syndrome \nCoronavirus 2), formerly known as the New Coronavirus \n(2019-Ncov), is a new virus that appeared in December \n2019 and causes COVID-191. The virus causes a \nsyndrome that in some cases can lead to a dangerous \nrespiratory condition, which will require specialized \nmanagement of the disease in the ICU2 It is also known \nas an intensive care unit. It is the seventh known \ncoronavirus to infect humans. Other beta-coronaviruses \nhave already caused other epidemics in the last two \ndecades in Asia, such as SARS-COV from 2002 to 2003 \nin China and later from 2012 to 2013 in Saudi Arabia \nas MERS-COV3. Similarities and differences observed \nin epidemiology, clinical manifestations and treatment of \nSARS, MERS and COVID, although the clinical form of \nSARS, MERS and COVID-19 is similar, differences have \nbeen observed in the initial reports4. Preliminary research \nhas shown patterns in chest CXR and CT. For example, \nan early prospective study in Wuhan showed 98% (40 \nout of 41 cases) of bilateral CT chest involvement among \npatients, with consolidation being the most common \nfinding in this study5. Other researchers have examined \nchest CT in patients, the appearance of grand-glass and \nconsolidation was common among patients8. \nCovid-19 is an emerging disease and its clinical, \nlaboratory and radiological characteristics are unknown \nand there are many differences in different studies. \nHuman-to-human transmission is common in this \ndisease. Respiratory droplets and human-to-human \ncommunication are the main routes of transmission of \nthe virus. In the early stages of the disease, symptoms of \nacute respiratory infection are observed, and a number \nof patients quickly develop ARDS and other severe \nsymptoms, which eventually lead to organ damage. \nHistorically, coronaviruses have been formally identified \nas a new viral family in the 1960s following the discovery \nof several new human respiratory pathogens. These \nviruses are known to have structures on their surface \ncalled spikes. Almost 40 years after the identification of \nthis group of viruses and in late 2002 and early 2003, a \ncoronavirus caused severe respiratory complications in \nhumans known as SARS (COAR) or Acute Respiratory \nSyndrome8. The sudden emergence of SARS led to \nnew research to understand the main mechanisms \nof reproduction and pathogenicity of members of this \nviral family with the aim of controlling them worldwide. \nThe outbreak of SARS-COV infected 8096 people and \nkilled 794 people and the mortality rate of this virus was \n9.8%. Then in 2012, another virus of this family broke \nout again in the Middle East, especially in Saudi Arabia, \ncalled MERS (MERS-COV), infecting a total of 2.260 \npeople and causing 35.5% human deaths. Seven years \nafter the onset of Morse disease, the onset of COVID 19 \ndisease by RNA - SARS-CoV-2 virus in December 2019 \nin Wuhan City, Hui Province, China, was associated with symptoms of acute respiratory syndrome and \nwidespread and rapid outbreak. The moon reached the \nstage of a global epidemic9. In late December 2019, \na series of unexplained cases of pneumonia were \nreported in Wuhan, China. The government and health \nresearchers in China took swift action to control the \nepidemic, and began etiological research10. On January \n12, 2020, the WHO temporarily named the new virus \nas the New Coronavirus-2019. In the present study, the \nsame phrase \"New Coronavirus-2019\" has been used11. \nOn January 30, 2020, the WHO announced the New \nCoronavirus Epidemic 2019 as an International Public \nHealth Emergency (PHEIC)12. On February 11, 2020, the \nWHO officially named the disease caused by the New \nCoronavirus Disease 2019 (COVID-19). On the same \nday, the International Virus Classification Committee \n(CSG) Study Group named it Severe Acute Respiratory \nSyndrome, and on February 23, 2020, 77041 cases \nof Covid-19 infections were confirmed in China. This \nnumber of infections has exceeded the prevalence of \nAcute Respiratory Syndrome (SARS) in China in 200213. \nStructure of Coronavirus-2019 Coronaviruses are \nenveloped, non-segmented viruses with single-stranded, \nPositive-sense RNA of animal origin and belong to the \nfamily Corona. The size of the virus genome is between \n26 and 32 kg, which is one of the largest RNA viruses. \nThese viruses have two different types of surface proteins \nand get their name from this appearance. The family of \ncoronaviruses is serologically divided into four genera: \nalpha, beta, gamma and delta14. Approximately 30 types \nof coronavirus have been identified in humans, mammals \nand birds. Human coronaviruses are caused by alpha and \nbeta genera. Coronaviruses are one of the most common \nviruses, with 30 to 60 percent of the population having \nantibodies against it15. New Coronavirus-2019 (SARS-\nCOV-2) is a beta-coronavirus coronavirus. Covid-19 is \nthe third known animal coronavirus disease after SARS \nand MERS Middle East Respiratory Syndrome, both of \nwhich belong to the beta-coronavirus category16. Origin \nof New Coronavirus-2019 an epidemiological study of \nearly cases of modern coronavirus pneumonia-2019 \nshowed that many cases were exposed to the Hanan \nseafood market in Wuhan, China17. The WHO report also \nstates that the new Carnavirus-2019 has been detected \nin environmental samples collected from Hanan seafood \nmarkets18. But it is not yet clear what specific species \nof animals will carry the new coronavirus-2019. 33 of \nthe 585 environmental samples available in the Hanan \nSeafood Market were positive for New Coronavirus-2019. \nSome of these include a variety of live animals, such as \nhedgehogs, badgers, snakes, turtles, birds, and possibly \nanteaters, but bats do not19. Therefore, bats were not \nlikely to have direct contact with humans and did not have \ndirect transmission to humans, and direct transmission of \nthe virus from bats to humans seems unlikely20. A study \nby Ji et al. Showed that the New Coronavirus-2019 is a \nchimeric virus between bat coronavirus and coronavirus 106\n2021/36 (3): 104-112Abolfazl Mozafari et al.  \nof unknown origin. Compared to other animals, they \nfound that snakes are very likely to be the reservoir of \nthe new coronavirus-201921. A study by Benvenuto et al. \nShowed that the New Coronavirus 2019 is closely related \nto closely isolated coronaviruses of a particular type of \nChinese bat22. Their research supports the theory that the \nchain of transmission from bats to humans has begun. \nChan et al. confirmed that the new coronavirus-2019 was \na new coronavirus highly associated with the SARS bat \ncoronavirus23. Recently, Zhou et al. And Wu et al. found \nthat the sequence similarity between New Coronavirus \n2019 and SARS coronavirus is 79.5%. They also found \nthat the new coronavirus-2019 is highly homologous \nto bat coronavirus. Thus, current evidence strongly \nsupports that New Cronavirus-2019 was derived from \nbats, although the intermediate or intermediate hosts of \nNew Cronavirus-2019 are not yet known24. \nThe study by Wang et al. showed that from January 10 to \n24, 2020, the number of people infected with Covid-19 \ninfection in China increased 31.4 times. On February 23, \n2020, the number of patients with Covid-19 in China \nwas 1879, equal to January 10, 2020. They estimated \nthe mortality rate of Covid-19 based on the number of \npatients at 2.84%. The researchers also found that the \nmale-to-female mortality rate was 3.25 to 1, the median \nage of death was 75 years, the median time from the \nfirst symptoms to death was 14 days, and the median \ntime from initial symptoms to death in people 70 years of \nage and older (5/11 days) is shorter than people under \n70 (20 days). These findings suggest that the disease \nmay progress faster in adults than in young people25. The \nstudy by Li et al. Reported that the mean age of 425 \npatients infected with modern coronavirus-2019 was 59 \nyears, of which 56% were male, the mean incubation \nperiod was 5.2 days, and approximately half of adult \npatients were 60 years and older. In the early stages, the \nnumber of infected patients doubled every 7.4 days. The \nrate of disease transmission from the infected person \nwas 2.2. Although 55% of the first patients infected \nwith Covid-19 were related to the Hanan seafood \nmarket, the number of unrelated cases has increased \nlogarithmically since late December 201926. Of the 41 \npatients with Covid-19 infection in their study, Huang et \nal. Showed that 73% of patients were male and 32% of \npatients had underlying diseases including diabetes (8 \npatients), hypertension (6 patients), and diseases. Were \ncardiovascular (6 patients). He was 49 years old. Of \nthe 41 patients, 27 were related to the Hanan seafood \nmarket. The mortality rate of coronavirus patients in this \nstudy was reported to be 15%27. The study by Wu et \nal. estimated the transmission rate of infected patients \nto be 0.3. The mortality rate of patients with coronavirus \nin this study was reported to be 14%28. Preliminary \nstudies have shown that people with underlying diseases \nare at higher risk for complications and mortality from \nCovid-19 disease. Approximately 50% of hospitalized \npatients suspected of having a new coronavirus have other chronic diseases, and about 40% of hospitalized \npatients with confirmed new SARS-COV-2 coronavirus \ninfection have cardiovascular or cerebrovascular \ndisease. They are vascular. The researchers also found \nlarge differences in mortality by age group, with Guan et \nal. Reporting 1,099 cases of Covid-19 infection. They \nfound that fever of 87.9% and cough of 67.7% were the \nmost common symptoms. Diarrhea 3.7% and vomiting \n5% were rare. Abnormalities in chest CT images were \nobserved in 96% of patients infected with Covid-19 \nand in 82.1% of them lymphopenia was recorded29. In \nthe study of the radiological findings of 81 patients with \nCOVID-19 in Wuhan, China: A descriptive study of 81 \npatients with COVID-19, in which 42 men and 30 women \nparticipated and the mean age of the company they \nare equal to 49.5 years. The average number of lung \nsegments involved is 10.5. The most common patterns \nof bilateral involvement were 79%, peripherals 54%, \ngrand glass 65%, and the lower lobe of the lung 27%. \nSymptoms are as follows: 73% fever, shortness of breath \n70%, cough 59%, sputum 19%, weakness 9%, vomiting \n5%, headache 6%, dizziness 2%, diarrhea 4%. The mean \nof laboratory findings is also reported as follows: WBC \n8100, Lymphocyte 1100, Platelet 212200, Hemoglobin \n12.3, CRP 6.47, ALT 2.46, AST 40.8, D-dimer 6.5. In \nWang et al.'s study entitled Frequency and Distribution \nof Chest Radiographic Findings in COVID-19 Patients, \n64 patients were studied. The study involved 26 men \nand 38 women, and the average age of patients was 56 \nyears. 31% of patients had normal CXR. 59% of patients \nhad consolidation and 41% had left lung involvement. \n63% of patients had significant lower lung involvement \nand none of the patients had upper lung involvement. PE \nwas also observed in 2% of patients, pulmonary nodules \nwere not observed in any of the patients30&33.\nIn a study by Burnheim et al. Entitled Chest CT Findings \nin Coronavirus Disease: Relationship to Duration of \nInfection, 121 symptomatic patients were studied. In \nthis study, 61 men and 60 women were studied, the \naverage age of the participants was 45.3 years. The \nradiological appearance of 22% of patients was normal, \n34% of patients with radiological changes had only a \ngrand glass view, 2% did not have a consolidation view, \nand the rest of the patients had both a grand glass \nview and consolidation. 15% of patients had single \nlobe involvement, 12% had two lobe involvement, 9% \nhad 3 lobe involvement, 15% had 4 lobe involvement, \nand 27% had 5 lung involvement34. In a study by Ming \nYin et al. Entitled COVID-19 infection imaging profile: \nradiological findings and review of sources, 21 patients \nwere examined, of which 13 were male and 8 were \nfemale. 86% of patients had grand glass facade, 19% \nhad grand glass nodules and 62% had consolidation. \nThe two patients had no chest radiological changes. \n86% of patients with peripheral involvement had 1 \npre-hilar involvement. 90% of patients had fever, 48% \ncough, 15% sputum, 10% sore throat, 10% diarrhea and 107\n2021/36 (3): 104-112Comparative study of clinical symptoms, laboratory and radiological findings of COVID-19 patients admitted to ICU ward with internal ward of forghani hospital in Qom: a case series\n5% chest pain. The mean of laboratory results was as \nfollows: hemoglobin 13.8, WBC 5.3, neutrophils 3.33, \nlymphocytes 1.29, and platelets 169, PT 36, D-dimer \n0.4, Na 139, K 3.86, and Urea 45/4. In a study by Xavi \net al. Entitled Clinical Findings in a Group of COVID-19 \nPatients outside Wuhan, China: A retrospective case \nstudy, 62 COVID-19 patients were studied, 35 were \nfemale and 27 were male. The mean of laboratory findings \nwas as follows: WBC 4.7, neutrophil 2.9, lymphocyte 1, \nhemoglobin 13.7, platelet 176, D-dimer 0.2, also 52 \npatients had bilateral lung involvement35&36.\nResearch methods \nThe present study is an analytical study. In this study, \n100 hospitalization cases related to Covid-19 were \nreviewed. Of these 100 patients, 50 were hospitalized in \nthe inpatient ward and 50 were hospitalized in the ICU. \nPatients were selected from those whose diagnosis of \nCOVID-19 was confirmed based on diagnostic methods \nand with the opinion of a pulmonologist. After selecting \npatients, information about clinical signs, laboratory and \nradiological findings are recorded in a researcher-made \nchecklist. The prepared form had 3 sections to record the \nrequired information, the first part included demographic \ninformation of patients such as age, gender, duration \nof symptoms, and length of hospital stay, ward and the \nsecond part included laboratory findings such as WBC \nnumber, platelet count, ESR level, CRP , and the fourth \npart included radiological findings such as unilateral \nor bilateral pulmonary involvement, the presence of \nconsolidation, grand glass view, etc. \nCalculate the sample size  \nConsidering alpha (first study error) as 0.05, d (study \naccuracy) as 0.1, P as 0.8, 100 people enter the study\nData analysis method   \nThe collected data were analyzed using SPSS24 \nstatistical software and T-test at the significant level of P \nvalue <0.05. \nResearch results    \nIn the present study, clinical symptoms, laboratory and \nradiological findings in patients with coronary artery in \nthe ICU and the internal ward were compared, and the \nfindings were presented in two descriptive and analytical \nsections. Age distribution of patients with coronary artery disease, the mean age of patients with coronary \nhospitalization in the inpatient ward was 54 + 2.29 years \nand the mean age of patients admitted to the intensive \ncare unit was 60 + 2 + 01 years. The mean age of \npatients admitted to the ICU was higher than that of \npatients admitted to the ICU, but this difference was not \nsignificant (P = 0.06).\nN= [P (1-P)] \u00d7 (Z 1- \u03b1/2)\u00b2 \u2192 N= (0.54 \u00d7 0.3) \u00d7 5 \u2192 N= 50    (1)\n(d)\u00b2 (0.1)\u00b2Figure 1: Comparison of the mean age of patients with coronary artery inpatient \nand ICU.\nInpatient\nGroupAge\n54,159,9Mean\nICU60\n50\n40\n30\n20\n10\n0\nFigure 2: Percentage of relative frequency of gender in patients with coronary \nartery in two groups.\nMaleInpatient\nICU\n54,0%46,0%64,0%\n36,0%Percent\nFemale60%\n40%\n20%\n0%Gender distribution of patients \nwith coronary artery disease    \nIn patients with coronary hospitalization in the internal \nward, 54% of patients were male and 46% female and \nin patients with coronary artery in the ICU, gender was \n64% male and 36% female. Frequency of male patients \nadmitted to the ICU compared to hospitalized patients It \nwas higher in the internal part but this difference was not \nsignificant (P = 0.31).\nRadiological findings     \nFrequency of unilateral lung involvement in \npatients with coronary artery disease  \nIn patients with coronary hospitalization in the internal \nward, unilateral lung involvement was diagnosed in 32% 108\n2021/36 (3): 104-112Abolfazl Mozafari et al.  \nof patients and in patients with coronary hospitalization in \nthe ICU, unilateral lung involvement was diagnosed in 16% \nof patients. The frequency of unilateral lung involvement \nin patients admitted to the inpatient ward was higher \ncompared to patients admitted to the intensive care unit, \nwhich was a significant difference (P = 0.05).\nFrequency of bilateral lung involvement in patients \nwith coronary artery disease \nBilateral lung involvement was diagnosed in 68% of \npatients with coronary hospitalization in the internal ward \nand bilateral lung involvement was diagnosed in 72% of \npatients admitted to the ICU. The frequency of bilateral \nlung involvement in patients admitted to the intensive \ncare unit was significantly higher compared to patients \nadmitted to the intensive care unit (P = 0.048).\nFrequency of grand-glass, consolidation and \nnodules in the lungs of patients with coronavirus \nIn patients with coronary hospitalization in the inpatient \nward, the diagnosis of grand-glass in 62%, grand glass \n/ consolidation 32% and consolidation alone in 4% of \npatients and in patients with coronary hospitalization in \nthe ICU diagnosis of grand glass lung in 14%, Grand - Glass / consolidation was 48% and consolidation alone \nin 38% of patients. In general, radiological findings of \ngrand glass in patients admitted to the inpatient ward \nwere higher than patients in the intensive care unit (P \n= 0.0001) and in patients admitted to intensive care \nunits, more radiological findings were grand-glass / \nconsolidation and consolidation alone. (0001/0 = P).\nFigure 3: Percentage of relative frequency of unilateral involvement in coronary \nartery disease in the two groups.\nYes\nUnilateral lung involvementInpatient\nICU\n32,0%68,0%\n16,0%84,0%Percent\nNo100%\n80%\n60%\n40%\n20%\n0%\nFigure 4: Percentage of relative frequency of unilateral involvement in patients \nwith corona in the two groups.\nYes\nBilateral lung involvementInpatient\nICU\n68,0%\n32,0%84,0%\n16,0%Percent\nNo100%\n80%\n60%\n40%\n20%\n0%Figure 7: The relative frequency of the diagnosis of consolidation in patients with \ncoronary artery disease in the two groups.\nYes\nConcealed PassionInpatient\nICU\n6,0%94,0%\n38,0%62,0%Percent\nNo100%\n80%\n60%\n40%\n20%\n0%Figure 5: Relative frequency of Grand-Glass diagnosis in patients with coronary \nartery disease in the two groups.\nYes\nGrand Glass viewInpatient\nICU\n62,0%\n38,0%\n14,0%86,0%Percent\nNo100%\n80%\n60%\n40%\n20%\n0%\nFigure 6: Relative frequency of Grand-Glass/Consolidation diagnosis in patients \nwith coronary artery disease in the two groups.\nYesInpatient\nICU\n32,0%68,0%\n48,0%\n52,0%Percent\nNo60%\n40%\n20%\n0%\nConcealed Passion / Grand Glass view109\n2021/36 (3): 104-112Comparative study of clinical symptoms, laboratory and radiological findings of COVID-19 patients admitted to ICU ward with internal ward of forghani hospital in Qom: a case series\nLaboratory findings      \nComparison of blood oxygen levels \nin patients with coronary heart disease  \nIn patients with coronary hospitalization in the inpatient \nward, the mean SPO2 was 91.3 + 5.9% and in patients \nadmitted to the intensive care unit was 84.6 + 10.7%. As \nit is known, blood oxygen level in patients with coronary \nartery in the ICU is significantly lower than patients in the \ninpatient ward (P = 0.0001). \nComparison of WBC changes \nin patients with coronary artery disease   \nIn patients with coronary artery hospitalization in the \ninpatient ward, the mean of WBC was 7046.3 + 554.16 \nand in patients admitted to the intensive care unit was \n12845 + 29.58 + 12845. As it is known, the number \nof WBCs in patients with coronary artery in the ICU \nwas significantly higher than the patients in the inpatient \nward (P = 0.045), which in most of these patients was \nleukocytosis.\nComparison of lymphocyte changes \nin patients with coronary artery disease    \nIn patients with coronary artery hospitalization, the mean \nlymphocyte was 22.8 + 1.61 and in patients admitted to \nthe intensive care unit was 14.5 + 1.56. As it is known, \nthe number of lymphocytes in patients with coronary Comparison of hemoglobin changes \nin patients with coronary artery disease\nIn patients with coronary hospitalization in the inpatient \nward, the mean hemoglobin was 13.6+ 1.53 and in \npatients admitted to the intensive care unit was 12.9 \n+ 2.06. As it is clear that no significant difference was \nobserved between serum hemoglobin levels in the two \ngroups of patients (P = 0.07). \nComparison of platelet changes \nin patients with coronary artery disease \nIn patients with coronary artery hospitalization in the \ninternal ward, the mean platelet count was 283860 + \n66364.19 and in patients admitted to the intensive \ncare unit was 210560 + 9901/48. As it is clear that no \nsignificant difference was observed between platelet \nlevels in the two groups of patients (P = 0.27). However, \nthe mean platelet count was higher in the inpatient group \ncompared to the ICU patients, which could be due to the \nadministration of anticoagulants in the ICU patients.hospitalization in the ICU was significantly lower than \npatients admitted to the inpatient ward (P = 0.0001).\nFigure 8: Comparison of mean SPO2 in hospitalized patients.\nInpatientSPO2\n91,384,6Mean\nICU100%\n80%\n60%\n40%\n20%\n0%\nFigure 9: Comparison of mean white blood cell count in patients with coronary \nartery disease in the study groups.\nInpatientWBC\n7.046,31.2845,5Mean\nICU12.500\n10.000\n7.500\n5.000\n2.500\n0Figure 10: Comparison of the mean number of lymphocytes in patients with \ncoronary artery disease in the study groups.\nInpatientLYMPH\n22,8\n14,5Mean\nICU30\n25\n20\n15\n10\nFigure 11: Comparison of mean hemoglobin in patients with coronary artery \ndisease in the study groups.\nInpatientHGB\n13,612,9Mean\nICU16\n12\n8\n4\n0110\n2021/36 (3): 104-112Abolfazl Mozafari et al.  \nFigure 12: Comparison of mean platelets in patients with coronary artery disease \nin the study groups.\nInpatientPLT\n283.860\n210.560Mean\nICU300.000\n200.000\n100.000\n0\nComparison of changes in urea nitrogen (BUN) \nin patients with coronary artery disease  \nIn patients with coronary hospitalization in the inpatient \nward, the mean serum level of BUN was 59.2 + 64.88 \nand in patients admitted to the intensive care unit was \n90.6 + 81.02. As it is known, there is a significant \ndifference between serum BUN levels in the two groups \nof patients (P = 0.035). The mean BUN in the group of \npatients admitted to the inpatient ward was significantly \nlower compared to patients admitted to the ICU.\nComparison of creatinine (Cr) changes \nin patients with coronary artery disease   \nIn patients with coronary hospitalization in the internal \nward, the mean serum level of Cr is 1.32 + 0.21 and in \npatients admitted to the intensive care unit is 2.1 + 0.21. \nAs it is known, there is a significant difference between \nserum creatinine levels in the two groups of patients (P \n= 0.014). The mean Cr in the group of patients admitted \nto the inpatient ward was significantly lower compared to \npatients admitted to the ICU.Comparison of CRP index \nin patients with coronary artery disease    \nIn patients with coronary hospitalization in the inpatient \nward, CRP (qualitative) index in 16% (8 cases) negative, \n28% (14 cases) +1, in 26% (13 cases) +2 and in 30% (15 \ncases) +3 and in patients admitted to the intensive care \nunit in 4% (2 cases) negative, in 10% (5 cases) +1, in 22% \n(11 cases) +2, in 56% (28 cases) +3 and in 8 % (4 cases) \nwas more than +3. As it is known, there is a significant \ndifference between the inflammatory index of CRP in the \ntwo groups of patients (P = 0.003). So that this index was \nsignificantly lower in the group of patients admitted to the \ninpatient ward compared to patients admitted to the ICU.\nFigure 13: Comparison of mean BUN in patients with coronary artery disease in \nthe study groups.\nInpatientBUN\n59,290,6Mean\nICU100\n80\n60\n40\n20\n0\nFigure 14: Comparison of mean creatinine in patients with coronary artery \ndisease in the study groups.\nInpatientCr\n1,32,1Mean\nICU2,50\n2,00\n1,50\n1,00\n0,50\n0Figure 15: Percentage of CRP inflammatory index in patients with coronary artery \ndisease in the study groups.\nNegative 1+ 2+ 3+ >3+\nCRPInpatient\nICU\n16%28%\n26%30%\n22%56%\n8%\n4%10%Percent60%\n50%\n40%\n30%\n20%\n10%\n0%\nDiscussion \nIn this study, which compared the laboratory and \nradiological findings of patients with COVID-19 admitted \nto the inpatient and intensive care units of Forghani \nHospital in Qom, patients in two groups of 50 people \nwere studied. According to the findings of this study, in \npatients admitted to the inpatient ward, the age of patients \nwas 54.2 29 2.29 years and 54% were male patients and \nthe mean age of patients admitted to intensive care units \nwas 60 + 2.01 years and 64% of patients were male. \nThe overall mean age and mortality of male patients in \nthe ICU ward were higher (P <0.05). In patients admitted \nto the inpatient ward, unilateral lung involvement 32% \nof patients 68% bilateral involvement, and in patients \nwith coronary hospitalization in ICU 16% of patients had \nunilateral lung involvement and 84% of patients had \nbilateral lung involvement (p <0.05) . In patients admitted \nto the inpatient ward, the mean SPO2 was 91.3 + 5.9% \nand in patients admitted to the intensive care unit was \n84.6 + 10.7%. (0001/0 = P). In patients admitted to the \ninpatient department and ICU, respectively, the mean 111\n2021/36 (3): 104-112Comparative study of clinical symptoms, laboratory and radiological findings of COVID-19 patients admitted to ICU ward with internal ward of forghani hospital in Qom: a case series\nof WBC was 7046.3 55 554.16 and 12845 + 29.08 + \n0845 (P = 0.045), in most of these patients leukocytosis \nwas present. The mean lymphocytes in patients admitted \nto the inpatient and ICU wards were 22.8 + 1.61 and \n14.5 + 1.56, respectively (P = 0.0001). +1 was 6/13 \nand 6/02 + was 12.9 (P = 0.07). The mean platelet \ncount was 283860 + 66364.19 and in patients admitted \nto the intensive care unit was 210560 + 9901/48 (P = \n0.27). However, the mean platelet count was higher in \nthe inpatient group compared to the ICU patients, which \ncould be due to the administration of anticoagulants in \nthe ICU patients. In patients admitted to the inpatient and \nintensive care units, the mean serum level of BUN was \n59.2 + 64.88 and 90.6 + 81.02, respectively. As it is \nknown, there is a significant difference between serum \nBUN levels in the two groups of patients (P = 0.035). \nIn patients admitted to the inpatient ward and ICU, \nthe mean serum level of Cr is 1.32 + 0.21 and 2.1 + \n0.21, respectively. As it is known, there is a significant \ndifference between serum creatinine levels in the two \ngroups of patients (P = 0.014). The mean of Cr in the \ngroup of patients admitted to the inpatient ward was \nsignificantly lower compared to patients admitted to the \nICU. Also, there was a significant difference between the \ninflammatory index of CRP in the two groups of patients \n(P = 0.003). . So that this index in the group of patients \nadmitted to the inpatient ward was significantly lower \ncompared to patients admitted to the ICU. In the study \nof colleagues and colleagues, which was conducted \non 72 patients, 42 men and 30 women participated and the average age of the company The laboratory \nfindings included: WBC 8100, lymphocyte 1100, platelet \n212200, hemoglobin 12.3, CRP 6.47, ALT 2.46, AST \n40.8, D-dimer 6.5 (68). ). In my study, the laboratory \nfindings of hemoglobin, platelets, and lymphocytes were \nconsistent with the findings of this study, but the mean \nage of the patients in our study was higher than the mean \nage of the patients in this study.\nConclusion  \nBased on the findings of this study, there was a significant \ndifference in radiological and laboratory findings in \npatients with COVID-19 hospitalized in the inpatient \nand intensive care units, such as blood oxygen levels, \nWBC, lymphocyte platelets, CRP , creatinine and urea \nand related findings. There was a significant difference \nbetween CT scan of the lung and diagnosis of lung \nconsolidation in patients admitted to the ICU compared \nwith patients admitted to the ward. Due to the significant \ndifference between laboratory and radiological findings \nin patients with coronary artery, inpatient hospitalization \nwith patients admitted to the ICU is recommended. If \nlaboratory and radiological findings in patients with this \nstudy match, to provide medical services and care \nPatients in the decision-making of hospitalization of \npatients in special wards, decisions should be made that \ndue to the widespread epidemic of this disease, special \nbeds can be managed in medical centers.\nReferences\n1. Bonilla-Aldana DK, Dhama K, Rodriguez-Morales AJ. Revisiting the \none health approach in the context of COVID-19: a look into the ecology \nof this emerging disease. Adv Anim Vet Sci, 2020;8(3):234-7.\n2. Chan,J, FW, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial \ncluster of pneumonia associated with the 2019 novel coronavirus \nindicating person-to-person transmission: a study of a family cluster. \nThe Lancet 2020; 395(10223):514-23. \n3. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y et al. \nEpidemiological and clinical characteristics of 99 cases of 2019 novel \ncoronavirus pneumonia in Wuhan, China: a descriptive study. The \nLancet 2020: 395(10223):507-13.\n4.  Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y et al. Clinical \nfeatures of patients infected with 2019 novel coronavirus in Wuhan, \nChina. The Lancet 2020; 395(10223):497-506. \n5. Lancet T. Emerging understandings of 2019-nCoV.The Lancet \n2020:395(10221):311. \n6. Bastola A, Sah R, Rodriguez-Morales AJ, Lal BK, Jha R, Ojha HC, et \nal. The first 2019 novel coronavirus case in Nepal. The Lancet Infectious \nDiseases 2020; 20(3):279-80.7. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, \net al. A novel coronavirus associated with severe acute respiratory \nsyndrome. New England Journal of Medicine 2003;348(20):1953-66.\n8. Drosten C, G\u00fcnther S, Preiser W, Van Der Werf S, Brodt HR, Becker \nS, et al. Identification of a novel coronavirus in patients with severe acute \nrespiratory syndrome. New England Journal of Medicine 2003; 348(20), \n1967-76. \n9. Kuiken T., Fouchier R. A., Schutten M., Rimmelzwaan G. F., Van \nAmerongen G., Van Riel D. Newly discovered coronavirus as the \nprimary cause of severe acute respiratory syndrome. The Lancet 2003; \n362(9380):263-70. \n10. De Wit E, Van Doremalen N, Falzarano D, Munster VJ. SARS and \nMERS: recent insights into emerging coronaviruses. Nature Reviews \nMicrobiology 2016: 14(8):523.\n11. Bonilla-Aldana DK, Quintero-Rada K, Montoya-Posada JP , Ram\u00edrez-\nOcampo S, Paniz-Mondolfi A, Rabaan, AA, et al. SARS-CoV, MERS-\nCoV and now the 2019-novel CoV: Have we investigated enough about \ncoronaviruses?\u2013A bibliometric analysis. Travel Medicine and Infectious \nDisease 2020; 33:101566. 112\n2021/36 (3): 104-112Comparative study of clinical symptoms, laboratory and radiological findings of COVID-19 patients admitted to ICU ward with internal ward of forghani hospital in Qom: a case seriesAbolfazl Mozafari et al.  \n12. Al-Tawfiq JA, Zumla A, Memish ZA. Travel implications of emerging \ncoronaviruses: SARS and MERS-CoV. Travel Medicine and Infectious \nDisease 2014; 12(5), 422-8. \n13. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as \ncauses of pneumonia. Respirology 2018; 23(2):130-7.\n14. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in \nWuhan, China: challenges for global health governance. JAMA; 2020: \n323(8):709-10. \n15. Fang Y, Zhang H, Xu Y, Xie J, Pang P , Ji W. CT manifestations of two \ncases of 2019 novel coronavirus 2019-nCoV pneumonia. Radiology \n2020; 295(1):208-9.\n16. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of \npatients infected with 2019 novel coronavirus in Wuhan, China. The \nLancet 2020: 395(10223):497-506. \n17. Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X. CT \nimaging features of 2019 novel coronavirus (2019-nCoV). Radiology \n2020; 295(1):202-7.\n18. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of \npatients infected with 2019 novel coronavirus in Wuhan, China. The \nLancet 2020;395(10223):497-506.\n19. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J. Clinical characteristics \nof 138 hospitalized patients with 2019 novel coronavirus\u2013infected \npneumonia in Wuhan, China. Jama 2020; 323(11): 1061-9. \n20. Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic \ncharacterization of the 2019 novel human-pathogenic coronavirus \nisolated from a patient with atypical pneumonia after visiting Wuhan. \nEmerging Microbes & Infections. 2020; 9(1):221-36.\n21. Fehr AR, Perlman S. Coronaviruses: An overview of their replication \nand pathogenesis, in Coronaviruses 2015, Springer. p. 1-23.\n22. Lu R, Zhao X, Li J. Genomic Characterisation and Epidemiology of \n2019 Novel Coronavirus: Implications For Virus Origins And Receptor \nBinding. Lancet 2020; 395(10224): 565-74.\n23. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features \nof patients infected with 2019 novel coronavirus in Wuhan, China. \nLancet. 2020 Feb 15;395(10223):497-506. \n24. Wu P , Hao X, Lau EH, Wong JY, Leung KS, Wu JT, et al. Real-\ntime tentative assessment of the epidemiological characteristics of \nnovel coronavirus infections in Wuhan, China, as at 22 January 2020. \nEurosurveillance. 2020; 25(3).  \n25. Emery SL, Erdman DD, Bowen MD, Newton BR, Winchell JM, \nMeyer RF, et al. Real-time reverse transcription\u2013polymerase chain reaction assay for SARS-associated coronavirus. Emerging infectious \ndiseases 2004; 10(2):311-6.\n26. Gaunt ER, Hardie A, Claas EC, Simmonds P , Templeton KE. \nEpidemiology and clinical presentations of the four human coronaviruses \n229E, HKU1, NL63, and OC43 detected over 3 years using a novel \nmultiplex real-time PCR method. Journal of clinical microbiology. 2010; \n48(8):2940-7.\n27. Alhazzani W, M\u00f8ller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. \nSurviving Sepsis Campaign: guidelines on the management of critically \nill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care \nMed 2020: 1-34.\n28. Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ, Li FB, et al. Diagnosis and \ntreatment recommendations for pediatric respiratory infection caused \nby the 2019 novel coronavirus. World J Pediatr 2020; 16(3):240-246.\n29. Abrishami A, Samavat S, Behnam B, Arab-ahmadi M, Nafar M, \nSanei Taheri M. Clinical Course, Imaging Features, and Outcomes of \nCOVID-19in Kidney Transplant Recipients. EUROPEAN UROLOGY. \n2020; 78, 281-286.\n \n30. Bloomgarden Z .Diabetes and Covid19. Journal of Diabetes 2020; \n12: 347-9\n31. Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, Yuen KY. Genomic \ncharacterization of the 2019 novel human-pathogenic coronavirus \nisolated from a patient with atypical pneumonia after visiting Wuhan. \nEmerging Microbes & Infections. 2020; 9(1):221-36.\n32. Lu R, Zhao X, Li J, et al. Genomic Characterisation and Epidemiology \nof 2019 Novel Coronavirus: Implications for Virus Origins And Receptor \nBinding. Lancet 2020; 395(10224): 565-74.\n33. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features \nof patients infected with 2019 novel coronavirus in Wuhan, China. The \nLancet. 2020; 395(10223):497-506.\n34. Emery SL, Erdman DD, Bowen MD, Newton BR, Winchell JM, \nMeyer RF, et al. Real-time reverse transcription\u2013polymerase chain \nreaction assay for SARS-associated coronavirus. Emerging infectious \ndiseases. 2004; 10(2): 311-6.\n35. Gaunt ER, Hardie A, Claas EC, Simmonds P , Templeton KE. \nEpidemiology and clinical presentations of the four human coronaviruses \n229E, HKU1, NL63, and OC43 detected over 3 years using a novel \nmultiplex real-time PCR method. Journal of clinical microbiology. 2010; \n48(8):2940-7.\n36. Jing Yang. Prevalence of comorbidities and its effects in patients \ninfected with SARS-CoV-2: a systematic review and meta-analysis. J. \nYang et al. / International Journal of Infectious Diseases 94. 2020 91-95113\n2021/36 (3): 113-116ORIGINAL\nDirect instruction and inquiry-based method in teaching \nendodontics among preclinical dentistry students\nInstrucci\u00f3n directa y m\u00e9todo basado en la indagaci\u00f3n en la ense\u00f1anza \nde la endodoncia entre los estudiantes de odontolog\u00eda precl\u00ednica\nMaria Lourdes E. Cantor1      , Joseph M. Acosta1\n1. Faculty of School of Dentistry, University of Baguio, Baguio City, Philippines.eISSN 2255-0569\nReceived:  29 - IV - 2021\nAccepted:  2 - VI - 2021\ndoi: 10.3306/AJHS.2021.36.03.113Corresponding author\nMaria Lourdes E. Cantor\nFaculty of School of Dentistry, University of Baguio,\nBaguio City, Philippines 2600\nE-mail: marialourdescantor@yahoo.comID ID\nAbstract  \nBackground:  As part of the education and training of preclinical students in endodontics, traditional lectures on the content are \nnormally delivered, and laboratory exercises on extracted tooth specimens are carried out. Innovative methods to improve the \neffectiveness and quality of teaching dental students have been proposed, such as inquiry-based teaching.  This study aimed to \ncompare the effectiveness of direct instruction and inquiry-based teaching on the performance in root canal treatment exercises \nof preclinical students.\nMethods:  A total of 49 students enrolled in the preclinical course in Endodontics during the first semester of 2016-2017 in a Den -\ntistry school in the Philippines agreed to participate in the study.  The students were first exposed to direct instruction then followed \nby inquiry-based teaching. The performance of the students in their root canal treatment exercise in both methods was recorded. \nThe performance of the students using the two methods was compared using the t-test.  \nResults:  Based on the students' scores in the exercise after direct teaching, a greater percentage failed, while after the in -\nquiry-based method, their scores showed that the percentage of students who passed has markedly increased. There is a signif -\nicant difference in the students' performance using direct teaching only and their performance after the inquiry-based teaching at \n0.05 level of significance.\nConclusion: Therefore, inquiry-based teaching is effective in improving the preclinical students' performance in endodontics.\nKeywords:  Direct instruction, inquiry-based teaching, performance, root canal treatment exercise.\nResumen\nAntecedentes:  Como parte de la educaci\u00f3n y la formaci\u00f3n de los estudiantes precl\u00ednicos de endodoncia, normalmente se im -\nparten conferencias tradicionales sobre el contenido y se realizan ejercicios de laboratorio con espec\u00edmenes de dientes extra\u00eddos. \nSe han propuesto m\u00e9todos innovadores para mejorar la eficacia y la calidad de la ense\u00f1anza de los estudiantes de odontolog\u00eda, \ncomo la ense\u00f1anza basada en la indagaci\u00f3n.  El objetivo de este estudio es comparar la eficacia de la instrucci\u00f3n directa y la \nense\u00f1anza basada en la indagaci\u00f3n sobre el rendimiento en los ejercicios de tratamiento del conducto radicular de los estudiantes \nprecl\u00ednicos.\nM\u00e9todos:  Un total de 49 estudiantes matriculados en el curso precl\u00ednico de Endodoncia durante el primer semestre de 2016-\n2017 en una escuela de Odontolog\u00eda en Filipinas aceptaron participar en el estudio.  Los estudiantes fueron expuestos primero a \nla instrucci\u00f3n directa y luego a la ense\u00f1anza basada en la indagaci\u00f3n. Se registr\u00f3 el rendimiento de los estudiantes en su ejercicio \nde tratamiento de conductos en ambos m\u00e9todos. Se compar\u00f3 el rendimiento de los estudiantes con los dos m\u00e9todos mediante \nla prueba t. \nResultados:  Seg\u00fan las puntuaciones de los estudiantes en el ejercicio despu\u00e9s de la ense\u00f1anza directa, un mayor porcentaje \nfracas\u00f3, mientras que despu\u00e9s del m\u00e9todo basado en la indagaci\u00f3n, sus puntuaciones mostraron que el porcentaje de estudi -\nantes que aprobaron ha aumentado notablemente. Existe una diferencia significativa en el rendimiento de los estudiantes utilizando \ns\u00f3lo la ense\u00f1anza directa y su rendimiento despu\u00e9s de la ense\u00f1anza basada en la indagaci\u00f3n a un nivel de significaci\u00f3n de 0,05.\nConclusi\u00f3n: Por lo tanto, la ense\u00f1anza basada en la indagaci\u00f3n es eficaz para mejorar el rendimiento de los estudiantes precl\u00ednicos \nde endodoncia.\nPalabras clave:  Ense\u00f1anza directa, ense\u00f1anza basada en la indagaci\u00f3n, rendimiento, ejercicio de tratamiento de conductos.114\n2021/36 (3): 113-116Maria Lourdes E. Cantor et al.  \nIntroduction\nEndodontic treatment is performed in a major portion \nof dental emergencies worldwide, and there is an \nincreasing need to educate and train dental students \nin this specialty, such that they are prepared to perform \nbetter and predict treatment outcomes1. The emphasis \non inquiry-based teaching is especially important in \nlaboratory courses, as these are the courses in which \nstudents apply the process of science2. Over the past \ndecade, repeated calls have been made to incorporate \nmore active teaching and learning in undergraduate \nbiology courses3.  \nThe twenty-first century's onset and its challenges require \ndeveloping a learning community where accomplished \nteachers make sure that both teachers and students \nmeet today's challenges. In this regard, Arends and \nKilcher4 stressed that a true learning community had \nbeen created for teachers and for their students, one \nthat helps them meet the many and varied challenges of \nteaching in twenty-first-century schools.\nTeaching practices in the twenty-first century are \nguided by several learning theories, the most popular of \nconstructivism. This theory stresses that the students/\nlearners reconstruct their conceptions in active, \nmeaningful experiences. Thus, teaching is student-\ncentered in the constructivist viewpoint5. \nThe direct instruction model is straightforward. It is designed \nto promote mastery of skills (procedural knowledge) and \nfactual knowledge (declarative knowledge)6.\nDirect instruction aims at accomplishing two major \nlearner outcomes: mastery of well-structured knowledge \nand acquisition of varied skills7.\nTeacher use of direct instruction, particularly the lecture \nmethod, comprises many classroom time in traditional \nclassrooms. However, the primary criticism of direct \ninstruction is that it is teacher-centered and emphasizes \nteacher-talk8.\nSubject areas in dental education embody scientific \nconcepts and skills. As a result, dental science instruction \nhas become highly constructive, such that it has shifted \nfrom an emphasis on acquiring content knowledge to \nconstructing scientific understanding. This has led to \napplying constructivist teaching and learning strategies \nsuch as the discovery approach, inquiry approach, \nintegrative teaching, and cooperative learning.  In this \ncurrent study, the researchers applied an inquiry-based \napproach as a type of student-initiated model.\nInquiry-based teaching is a constructivist model conceived \nto help students understand how phenomena work and \nthe processes used to investigate these phenomena9.Inquiry-based teaching requires a high degree of \ninteraction among the learner, the teacher, the materials, \nthe content, and the environment. The most crucial \naspect of the inquiry teaching model is that it allows \nboth student and teacher to become persistent seekers, \naskers, interrogators, questioners, and ponderers10. \n \nThe instructional learner outcomes of inquiry-based \nteaching are as follows: acquire an understanding \nof the focus problem; develop thinking skills that \nunderlie scientific reasoning; develop dispositions \nand commitment to scientific processes; and develop \nmetacognitive skills and learner autonomy11.\nOverall, the inquiry-based model promotes an inquisitive \nand investigative mindset among the learners. Moreover, \nsince the inquiry-based model is student-centered, it \npromotes active learning on the part of the students.\nIn this study, two teaching models are compared as \nregards effectiveness: direct instruction and inquiry-\nbased teaching.\nThere are studies conducted to measure the performance \nof preclinical dental students in performing root canal \ntreatment exercises. These studies utilized other methods \nof instruction.\nAccording to Friedlander and Anderson12, the teaching \nof advanced endodontic courses at the predoctoral level \nis common, but it cannot be easy to assess teaching \neffectiveness. Advanced modules placed later in the dental \ncurriculum provide the opportunity to introduce a new topic, \nrevisit and reinforce concepts learned previously, and instill \nthe notion of lifelong learning. At any level, the introduction \nof new techniques to novices must be based on recognition \nof their prior knowledge and experience and their need for \nexplicit direction, stepwise instruction, and comprehensive \nfeedback. Assessment of students' performance should \nprovide insights into what they know and can do and steer \nthem towards desired outcomes.  In addition, assessment \ncan provide valuable feedback on teaching effectiveness.\nA module was piloted for inclusion in the University of \nOtago (New Zealand) fourth-year dental curriculum13.  \nThis involved the use of tapered hand and rotary nickel-\ntitanium files for root canal preparation and was taught \nthrough a didactic program (lectures and problem-based \nlearning seminars) and a series of preclinical hands-\non sessions. Findings from formative and summative \nassessments and student, peer, and self-evaluation \nindicated that the module's objectives were met and that \nit was effective in both providing students with the basic \nskills for using this type of instrumentation and increasing \ntheir understanding and enthusiasm for endodontics.\n  \nIn a previous study, endodontics students had access \nto simulated models, and endodontic emergency care 115\n2021/36 (3): 113-116 Direct instruction and inquiry-based method in teaching endodontics among preclinical dentistry students\npractice also included feedback sessions after each \nclinical session. It was found that the intervention gave \nsignificantly improved their grades, which support \nthe implementation and further evaluation of similar \ninterventions in other areas of teaching and learning \ndentistry subjects14.\nThis study's major purpose was to determine the \ncomparative effectiveness of direct instruction and inquiry-\nbased teaching on the learning performance of preclinical \ndental students in root canal treatment exercises.\nSpecifically, this study aimed to determine the following:  \n1. The performance of the preclinical dental students \nin root canal treatment exercise after direct instruction; \n2. The performance of the preclinical dental students \nin root canal treatment exercise after inquiry-based \nteaching; and 3. The comparison of the performance \nof the preclinical dental students in root canal treatment \nexercise in the two methods of teaching and if the \ndifference is significant.\nMaterials and methods\nThis experimental study involved a single group exposed \nto two methods of teaching. A total of 49 students \nenrolled in the preclinical course in Endodontics during \nthe first semester of 2016-2017 agreed to participate \nin the study. Ethical issues were thrashed out, and \nthe study's purpose was explained to the participants, \nincluding the nature of their participation. The students \nwere first exposed to direct instruction then followed \nby inquiry-based teaching. The exercise was done on \nextracted tooth specimens which were checked and \napproved by the instructor. The root canal exercise \ninvolved the sequence of steps from access preparation, \ndetermination of working length, biomechanical \npreparation, and obturation. The performance level of \nthe students in their root canal treatment exercise in the \ntwo methods of teaching was recorded. In addition, the \nperformance of the students using the two methods was \ncompared using the t-test.  \nResults and discussion\nThe mean score of the students in the root canal exercise \nafter being exposed to the direct instruction method is \n93.35 out of the highest possible score of 135. Based \non a passing score for this exercise which is 94.50, \nthe mean score of the students is considered as failed.  \nConsidering the number of students who passed, only \n48.98% of the students got scores within and above \nthe passing mark. Although almost half of the students \npassed, this result can be explained by observing that \ndirect instruction emphasizes more on teacher talk15. \nHence the students were not actively involved.The preclinical students had a mean score of 113.39 \nin their exercise after being exposed to inquiry-based \nteaching. This means that the students passed the \nexercise. Also, the number of students who passed the \nexercise comprised 95.92%, showing a marked increase \nin the passing rate. The students' higher scores using \ninquiry-based teaching show that a student-centered \napproach can help improve students' performance in \na laboratory course16. The t-test result shows that the \ncomputed value is greater than the tabular value at \nalpha .05 level of significance (12.22 > 2.021), which \nfails to accept the null hypothesis. There is a significant \ndifference between the mean scores of the students \nin the two methods (p < .05). Therefore, the preclinical \nstudents performed better after being exposed to the \ninquiry-based method.  Similar results were found in a \nprevious study where students' grades in endodontics \nimproved after an intervention using simulation and \nfeedback sessions17. \nConclusions\nThe preclinical students performed better in the \nendodontics exercise after being exposed to the inquiry-\nbased method than their performance in the direct \ninstruction method.  The marked improvement in their \nscores shows that a student-centered method that \nleads to active student involvement helps students learn \nbetter in a laboratory course such as endodontics.  The \ndifference between the two methods was found to be \nsignificant therefore, based on the findings of this study, \nthe inquiry-based method is more effective in teaching \nendodontics compared to direct instruction. Therefore, \nthe inquiry-based method is appropriate for laboratory \ncourses in the dental curriculum and other fields.\nAcknowledgments\nThe authors would like to thank Siavash Samadi Khasragi \n(DMD, University of Baguio, Philippines), for his important \ndata collection, analysis, and all cooperation in the study \nprocedure.116\n2021/36 (3): 113-116Direct instruction and inquiry-based method in teaching endodontics among preclinical dentistry studentsMaria Lourdes E. Cantor et al.  \nReferences\n1. Narayanaraopeta U, AlShwaimi E. Preclinical endodontic teaching: A \nsurvey of Saudi dental schools. Saudi medical journal. 2015;36(1):94. \n2. Beck C, Butler A, Burke da Silva K. Promoting inquiry-based teaching \nin laboratory courses: are we meeting the grade?. CBE\u2014Life Sciences \nEducation. 2014 Sep;13(3):444-52. \n3. Baillie C, Hazel E. Teaching materials laboratory classes. The UK \nCentre for Materials Education, edited by Caroline Baillie and Leone \nBurton. 2003. \n4. Arends IR, Kilcher A. Teaching for student learning. New York and \nLondon, 2010.\n5. Altun S, Y\u00fccel-Toy B. The Methods of Teaching Course Based on \nConstructivist Learning Approach: An Action Research. Journal of \nEducation and Training Studies. 2015 Nov;3(6):248-70. \n6. Arends, R. Learning to teach.  New York: McGraw-Hill.  2012.\n7. Fan Y, Tian F, Qin T, Li XY, Liu TY. Learning to teach. arXiv preprint \narXiv:1805.03643. 2018 May 9. \n8. Magliaro SG, Lockee BB, Burton JK. Direct instruction revisited: A \nkey model for instructional technology. Educational technology research \nand development. 2005 Dec 1;53(4):41-55. \n9. Scheer A, Noweski C, Meinel C. Transforming constructivist learning \ninto action: Design thinking in education. Design and Technology \nEducation: An International Journal. 2012 Oct 31;17(3). 10. Orlich DC, Harder RJ, Callahan RC, Trevisan MS, Brown AH. \nTeaching strategies: A guide to effective instruction. Cengage Learning; \n2012. \n11. Audet RH, Jordan LK, editors. Integrating inquiry across the \ncurriculum. Corwin Press; 2005 Apr 13. \n12. Friedlander L, Anderson V. A new predoctoral endodontic module: \nevaluating learning and effectiveness. Journal of dental education. 2011 \nMar;75(3):351-9. \n13. Boyer KR, Chui BS, Ywom J, Farah-Franco SM. Teaching preclinical \nendodontics virtually. J Dent Educ. 2020 Jun 2;1:3. \n14. Alcota M, Fuenzalida A, Barrientos C, Garrido M, de Gauna PR, \nGonz\u00e1lez FE. An \u201cXL\u201d endodontics intervention for dental students \nrequired to repeat the course: changing frustration to improved grades \nand attitudes. Journal of dental education. 2015 Apr;79(4):399-408. \n15. Dean Jr D, Kuhn D. Direct instruction vs. discovery: The long view. \nScience Education. 2007 May;91(3):384-97. \n16. Madhuri GV, Kantamreddi VS, Prakash Goteti LN. Promoting higher \norder thinking skills using inquiry-based learning. European Journal of \nEngineering Education. 2012 May 1;37(2):117-23. \n17. Torabinejad M, Fouad A, Shabahang S. Endodontics e-book: \nPrinciples and practice. Elsevier Health Sciences; 2020 Jun 25.117\n2021/36 (3): 117-121ORIGINAL\nEnterotoxigenic profiles of Staphylococcus aureus  \nstrains isolated from sweet samples\nPerfiles enterotoxig\u00e9nicos de cepas de Staphylococcus aureus \naisladas en muestras de dulces\nMohammadreza Mahmoodi Sadr1      , Amir Shakerian2      , \nEbrahim Rahimi2      , Hasan Momtaz3\n1. Department of Food Hygiene, Faculty of Veterinary Medicine, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran \n2. Research Center of Nutrition and Organic Products, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran\n3. Department of Microbiology, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran eISSN 2255-0569\nReceived:  4 - V - 2021\nAccepted:  13 - VI - 2021\ndoi: 10.3306/AJHS.2021.36.03.117Corresponding author\nAmir Shakerian \nProfessor of the Department of Food Hygiene, Faculty of Veterinary Medicine, \nShahrekord Branch, Islamic Azad University, Shahrekord, Iran\nE-mail: amshakerian@iaushk.ac.irID ID\nID ID\nAbstract  \nBackground:  Enterotoxigenic Staphylococcus aureus  is considered to be one of the major cause of foodborne diseases \nworldwide. The present investigation was done to study the enterotoxigenic genes distribution of S. aureus  strains isolated from \nsweet samples.\nMethods:  Sixty S. aureus  strains were isolated from sweet samples using culture. S. aureus  strains were identified using the \nbiochemical tests. Enterotoxigenic gene profile of the isolates was studied using the PCR.  \nResults:  Sec (10.0%) harbored the highest distribution amongst examined isolates, while seb (1.0%) and sed (1.0%) harbored the \nlowest. Among all isolates of all examined sweet brands, brand C isolates harbored the highest distribution of sea (8.0%), sec (12.0%), \nand sed (4.0%) enterotoxigenic genes. Brand B isolates harbored the highest distribution of the seb (5.0%) enterotoxigenic gene. \nConclusion: Enterotoxigenic genes distribution was related to the types of samples. Simultaneous presence of several enterotoxigenic \ngenes in some isolates showed an important public health issue.\nKeywords:  Prevalence, enterotoxigenic genes, Staphylococcus aureus , sweet.\nResumen\nAntecedentes:  El Staphylococcus aureus  enterotoxig\u00e9nico se considera una de las principales causas de enfermedades de \ntransmisi\u00f3n alimentaria en todo el mundo. La presente investigaci\u00f3n se llev\u00f3 a cabo para estudiar la distribuci\u00f3n de los genes \nenterotoxig\u00e9nicos de las cepas de S. aureus  aisladas de muestras de dulces.\nM\u00e9todos:  Se aislaron sesenta cepas de S. aureus  de muestras de dulces mediante cultivo. Las cepas de S. aureus  se identificaron \nmediante pruebas bioqu\u00edmicas. Se estudi\u00f3 el perfil gen\u00e9tico enterotoxig\u00e9nico de los aislados mediante la PCR. \nResultados:  Sec (10,0%) alberg\u00f3 la mayor distribuci\u00f3n entre los aislados examinados, mientras que seb (1,0%) y sed (1,0%) \nalbergaron la menor. Entre todos los aislados de todas las marcas de dulces examinadas, los aislados de la marca C albergaron \nla mayor distribuci\u00f3n de genes enterotoxig\u00e9nicos seb (8,0%), sec (12,0%) y sed (4,0%). Los aislados de la marca B albergaron la \nmayor distribuci\u00f3n del gen enterotoxig\u00e9nico seb (5,0%). \nConclusi\u00f3n: La distribuci\u00f3n de los genes enterotoxig\u00e9nicos estaba relacionada con los tipos de muestras. La presencia simult\u00e1nea \nde varios genes enterotoxig\u00e9nicos en algunos aislados puso de manifiesto un importante problema de salud p\u00fablica.\nPalabras clave:  Prevalencia, genes enterotoxig\u00e9nicos, Staphylococcus aureus , sweet.118\n2021/36 (3): 117-121Mohammadreza Mahmoodi Sadr et al.  \nIntroduction\nS. aureus  is a Gram-positive and cocci-shaped bacterium \nresponsible for nosocomial and community-acquired \ninfections and foodborne diseases1-3. Foodborne \ndiseases caused by S. aureus  are characterized by \nnausea, vomiting, weakness, abdominal cramps, \ndiarrhea, and toxic shock syndrome4,5. \nS. aureus  bacteria secrete a group of extracellular \nenzymes, ease tissue extinction and dispersal, and \nmembrane damaging toxins that cause catalytic \neffects on host cells and tissue damage6. They are \nlow-molecular-mass and single-chain proteins with 23 \ndifferent major types (SEA to SEV). Sea, seb, sec , and \nsed are the most commonly detected types in the cases \nof foodborne diseases and food poisonings7.\nRendering the high importance of enterotoxigenic S. \naureus  and the absence of epidemiological surveys on \nits prevalence, the current research was done to study \nthe distribution of enterotoxigenic genes of the S. aureus  \nstrains isolated from sweet samples. \nMaterials and methods\nIsolates\nSixty S. aureus  isolates of traditional sweet samples \n(three different brands) were included in this study. \nIsolates were cultured in Trypticase Soy Broth (TSB, \nMerck, Germany) supplemented with 10% NaCl and \n1% sodium pyruvate (incubated at 37\u00b0C for 24 h). \nIn addition, S. aureus  isolates were identified using \ncultured into Baird-Parker agar supplemented with egg \nyolk tellurite emulsion (Merck, Germany) and Gram \nstaining, hemolytic activity on sheep blood agar (Merck, \nGermany), catalase activity, coagulated test (rabbit \nplasma), oxidase test, glucose O/F test, resistance to \nbacitracin (0.04 U), mannitol fermentation on Mannitol \nsalt agar (Merck, Germany), urease activity, nitrate \nreduction, phosphatase, deoxyribonuclease (DNase, \nMerck, Germany) test, Voges-Proskauer (Merck, \nGermany) test and carbohydrate (xylose, sucrose, \ntrehalose and maltose, fructose, lactose, mannose) \nfermentation tests8.DNA extraction\nS. aureus  isolates were sub-cultured on Tryptic Soy Broth \nmedia (TSB, Merck, Germany) and further incubated \nfor 48 h at 37 oC9. Genomic DNA was extracted \nfrom bacterial colonies using the DNA extraction kit \n(Thermo Fisher Scientific, Germany), according to the \nmanufacturer\u2019s instruction. After extraction, the DNA \nsamples were quantified (NanoDrop, Thermo Scientific, \nWaltham, MA, USA), their purity checked (A260/A280), \nand their concentrations adjusted to 50 ng/\u03bcL. The \nintegrity of the DNA was evaluated on a 2% agarose \ngel stained with ethidium bromide (0.5 \u03bcg/mL) (Thermo \nFisher Scientific, Germany). The DNA concentration was \nalso estimated by spectrophotometric absorbance at \n257 nm (Hach, DR5000, USA). The DNA was stored at \n-20\u00b0C pending subsequent PCR analysis10-17. \nEnterotoxigenic genes identification \nTable I  represents the oligonucleotide primers and PCR \nconditions used to amplify enterotoxigenic genes18. \nA programmable DNA thermo-cycler (Eppendorf \nMastercycler 5330, Eppendorf-Nethel-Hinz GmbH, \nHamburg, Germany) was used in all PCR reactions. All \nruns included a negative DNA control consisting of sterile \nPCR grade water (Thermo Fisher Scientific, Germany) and \npositive DNA control consisting of positive DNA of each \ntarget gene. Fifteen microliters of amplified PCR products \nwere subjected to electrophoresis in a 2% agarose gel in \n1\u00d7 TBE buffer at 90 V for 30-40 min, stained with SYBR \nGreen (Thermo Fisher Scientific, Germany)19-22.\nStatistical analysis\nStatistical analysis was done using the SPSS 25.0 \nstatistical software (SPSS Inc., Chicago, IL, USA). Chi-\nsquare test and Fisher\u2019s exact two-tailed test were used \nto assess any significant relationship between data \ncollected in this survey. P-value <0.05 was considered \nas a statistical significant level23-27. \n  \nResults\nEnterotoxigenic gene distribution \nbased on isolates\nA total of 60 S. aureus isolates were assessed in the present \nstudy to found their enterotoxigenic gene profiles. Table II  \nTable I: PCR conditions used for enterotoxin genes detection18.\nTarget gene Primer sequence (5'-3') PCR product (bp) PCR programs PCR volume (50\u00b5L)\nSea F: TTGGAAACGGTTAAAACGAA 120\n R: GAACCTTCCCATCAAAAACA \nSeb F: TCGCATCAAACTGACAAACG 478\n R: GCAGGTACTCTATAAGTGCC\nSec F: GACATAAAAGCTAGGAATTT 257\n R: AAATCGGATTAACATTATCC\nSed F: CTAGTTTGGTAATATCTCCT 317\n R: TAATGCTATATCTTATAGGG1 cycle:\n940C ------------ 2 min.\n30 cycles:\n940C ------------ 120 s\n550C ------------ 120 s\n720C ------------ 60 s\n1 cycle:\n720C ------------ 8 min5 \u00b5L PCR buffer 10X\n2 mM Mgcl2\n150 \u00b5M dNTP \n0.75 \u00b5M of each primers F & R\n1.5 U Taq DNA polymerase\n3 \u00b5L DNA template (Thermo Fisher Scientific)119\n2021/36 (3): 117-121 Enterotoxigenic profiles of Staphylococcus aureus in sweet \ncharacterizes the enterotoxigenic gene profile of S. aureus  \nstrains isolated from sweet samples. Sec (10.0%) harbored \nthe highest distribution amongst examined isolates, while \nseb (1.0%) and sed (1.0%) harbored the lowest.\nEnterotoxigenic gene distribution \nbased on brands of sweet samples\nTable III  assesses the S. aureus  enterotoxigenic gene \nprofiles according to the brand of sweet samples. \nAmong all isolates of all examined sweet brands, brand \nC isolates harbored the highest distribution of sea (8.0%), \nsec (12.0%), and sed (4.0%) enterotoxigenic genes. \nBrand B isolates harbored the highest distribution of the \nseb (5.0%) enterotoxigenic gene.\nDiscussion\nSeveral kinds of infectious diseases caused significant \ndisorders globally28-31. In this survey, the role of \nenterotoxigenic S. aureus  as an important cause of \nfoodborne diseases was determined. S. aureus  is one \nof the most frequent causes of food poisoning. The \nmain food poisoning etiologic agents are staphylococcal \nenterotoxins. There are diverse SE kinds; types A \n(SEA) and B (SEB) are the most clinically significant \nenterotoxins. In this survey, sweet samples were the \nsources of enterotoxigenic S. aureus . S. aureus  was also detected in sweet samples assessed in previous \ninvestigations conducted in Brazil (12.00%)32, Pakistan \n(6.70%)33, Spain (6.10%)34 and Japan (19.40%)35.\nSome of probable reasons for the presence of \nenterotoxigenic genes amongst the S. aureus  isolates \nwere contamination of raw materials used to make \nsweets such as milk, eggs and even flour with the S. \naureus , use of insufficient temperature to produce sweet \nsamples, sweet maintenance at high temperatures and \nhumidity, which has led to the enterotoxin production, \nand finally transmission of enterotoxin-producing strains \nfrom contaminated hands and nose of producing staffs \nduring sweet production. \nHeat stable SEs produced by enterotoxigenic S. aureus  \nstrains are considered as major cause of food poisoning. \nFindings showed that sec and sea were the most \ncommonly detected enterotoxigenic genes. Song et al. \n(2015)36 stated that 5.60% of S. aureus  bacteria carried \nthe sea, and 3.50% harbored the seb enterotoxins. \nZhang et al37 signifies that the sea gene was obtained \nin 24.10% and the seb gene in 4.20% of S. aureus  \nbacteria. They also described that 20.50% of S. aureus  \nisolates carried the sed gene, 6.80% carried the sec \ngene, and 0.60% carried the see gene. Kroning et al32 \ndescribed the high prevalence of sea (33.4%) and seb \n(16.6%) enterotoxigenic genes. \nConclusions\nSweet samples were considered as sources of \nenterotoxigenic S. aureus . Type A and C enterotoxigenic \ngenes were identified as the most abundant. \nSimultaneous presence of enterotoxigenic gene in some \nS. aureus isolates must be considered as serious health \nhazard regarding the consumption of Iranian sweet \nsamples. Proper time and temperature for cooking \nof sweet samples is important, but preventing cross-\ncontamination is the most effective ways to prevent \noccurrence of S. aureus  in sweet samples. Table II: Enterotoxin genes distribution amongst S. aureus  strains.\nSamples N   (%) isolates harbor each\n(N S. aureus )  each enterotoxigenic gene\n sea seb sec sed\nSweet samples (60) 3 (5.0) 1 (1.6) 6 (10.0) 1 (1.6)\nTable III: Enterotoxigenic genes profile of S. aureus  isolates according to the \nbrands of sweet samples.\nSamples N   N (%)isolates harbor\n(N S. aureus )  each enterotoxigenic gene\n sea seb sec sed\nBrand A (15) - - 1 (6.6) -\nBrand B (20) 1 (5.0) 1 (5.0) 2 (10.0) -\nBrand C (25) 2 (8.0) - 3 (12.0) 1 (4.0)\nTotal (60) 3 (5.0) 1 (1.6) 6 (10.0) 1 (1.6)120\n2021/36 (3): 117-121Mohammadreza Mahmoodi Sadr et al.  \nReferences\n1. Momtaz H, Dehkordi FS, Rahimi E, Asgarifar A, Momeni M. Virulence \ngenes and antimicrobial resistance profiles of Staphylococcus aureus \nisolated from chicken meat in Isfahan province, Iran. Journal of Applied \nPoultry Research. 2013 Dec 1;22(4):913-21.\n2. Abdolmaleki Z, Mashak Z, Safarpoor Dehkordi F. Molecular and \nvirulence characteristics of methicillin-resistant Staphylococcus aureus \nbacteria recovered from hospital cockroaches. Jundishapur Journal of \nMicrobiology. 2019 Dec 31;12(12).\n3. Hasanpour Dehkordi A, Khaji L, Sakhaei Shahreza MH, Mashak \nZ, Safarpoor Dehkordi F, Safaee Y, et al. One-year prevalence of \nantimicrobial susceptibility pattern of methicillin-resistant Staphylococcus \naureus recovered from raw meat. Trop Biomed. 2017;34(2):396-404.\n4. Uematsu H, Yamashita K, Kunisawa S, Fushimi K, Imanaka Y. \nEstimating the disease burden of methicillin-resistant Staphylococcus \naureus in Japan: retrospective database study of Japanese hospitals. \nPloS one. 2017 Jun 27;12(6):e0179767. \n5. Ito T, Kuwahara-Arai K, Katayama Y, Uehara Y, Han X, Kondo Y, \nHiramatsu K. Staphylococcal cassette chromosome mec (SCCmec) \nanalysis of MRSA. InMethicillin-Resistant Staphylococcus Aureus \n(MRSA) Protocols 2014 (pp. 131-148). Humana Press, Totowa, NJ.\n6. Abdeen EE, Mousa WS, Salam SY, Al-Maary KS, Mubarak \nAS, Moussa IM, et al. Antibiogram and phylogenetic diversity of \nenterotoxigenic Staphylococcus aureus strains from milk products and \npublic health implications. Saudi Journal of Biological Sciences. 2020 \nAug 1;27(8):1968-74.\n7. Holeckov\u00e1 B, Holoda E, Fotta M, Kalin\u00e1cov\u00e1 V, Gondol J, Grolmus J. \nOccurence of enterotoxigenic Staphylococcus aureus in food. Annals \nof Agricultural and Environmental Medicine. 2002;9:179-82.\n8. Dehkordi FS, Gandomi H, Basti AA, Misaghi A, Rahimi E. Phenotypic \nand genotypic characterization of antibiotic resistance of methicillin-\nresistant Staphylococcus aureus isolated from hospital food. \nAntimicrobial Resistance & Infection Control. 2017 Dec;6(1):1-1.\n9. Abdolmaleki Z, Mashak Z, Dehkordi FS. Phenotypic and genotypic \ncharacterization of antibiotic resistance in the methicillin-resistant \nStaphylococcus aureus strains isolated from hospital cockroaches. \nAntimicrobial Resistance & Infection Control. 2019 Dec;8(1):1-4.\n10. Dehkordi FS. Prevalence study of Bovine viral diarrhea virus by \nevaluation of antigen capture ELISA and RT-PCR assay in Bovine, Ovine, \nCaprine, Buffalo and Camel aborted fetuses in Iran. AMB express. 2011 \nDec;1(1):1-6.\n11. Ranjbar R, Seif A, Safarpoor Dehkordi F. Prevalence of antibiotic \nresistance and distribution of virulence factors in the shiga toxigenic \nEscherichia coli recovered from hospital food. Jundishapur Journal of \nMicrobiology. 2019 May 31;12(5).\n12. Dehkordi FS, Saberian S, Momtaz H. Detection and segregation \nof Brucella abortus and Brucella melitensis in Aborted Bovine, Ovine, \nCaprine, Buffaloes and Camelid Fetuses by application of conventional \nand real-time polymerase chain reaction. The Thai Journal of Veterinary \nMedicine. 2012 Mar 1;42(1):13.\n13. Nejat S, Momtaz H, Yadegari M, Nejat S, Safarpour Dehkordi F, \nKhamesipour F. Seasonal, geographical, age and breed distributions \nof equine viral arteritis in Iran. Kafkas Univ Vet Fak Derg. 2015 Jan \n1;21(1):111-6.14. Dehkordi FS. Prevalence study of Coxiella burnetii in aborted ovine \nand caprine fetuses by evaluation of nested and real-time PCR assays. \nAmerican Journal of Animal and Veterinary Sciences. 2011.\n15. Ranjbar R, Dehkordi FS, Heiat M. The frequency of resistance genes \nin Salmonella enteritidis strains isolated from cattle. Iranian Journal of \nPublic Health. 2020 May;49(5):968.\n16. Dehkordi FS, Momtaz H, Doosti A. Application of Real-Time PCR for \ndetection of Aspergillus species in aborted ruminant foetuses. Bulgarian \nJ. Vet. Med. 2012 Mar 1;15(1):30-6.\n17. Abdolmaleki Z, Mashak Z, Safarpoor Dehkordi F. Molecular and \nvirulence characteristics of methicillin-resistant Staphylococcus aureus \nbacteria recovered from hospital cockroaches. Jundishapur Journal of \nMicrobiology. 2019 Dec 31;12(12).\n18. Madahi H, Rostami F, Rahimi E, Safarpoor Dehkordi F, Jalali M. \nDetection of classical enterotoxins of Staphylococcus aureus isolates \nfrom chicken nugget and ready to eat foods in Esfahan province by \nELISA technique. Food Hygiene. 2013 Nov 22;3(3 (11)):1-0.\n19. Rahi A, Kazemeini H, Jafariaskari S, Seif A, Hosseini S, Dehkordi FS. \nGenotypic and Phenotypic-Based Assessment of Antibiotic Resistance \nand Profile of Staphylococcal Cassette Chromosome mec in the \nMethicillin-Resistant Staphylococcus aureus Recovered from Raw Milk. \nInfection and drug resistance. 2020;13:273.\n20. Momeni Shahraki M, Shakerian A, Rahimi E, Safarpoor Dehkordi \nF. Study the frequency of enterotoxin encoding genes and antibiotic \nresistance pattern of methicillin-resistant Staphylococcus aureus \nisolated from vegetable and salad samples in Chaharmahal Va Bakhtiari \nprovince. Journal of Food Microbiology. 2020 Jun 21;7(2):55-69.\n21. Dehkordi FS, Haghighi N, Momtaz H, Rafsanjani MS, Momeni M. \nConventional vs real-time PCR for detection of bovine herpes virus type \n1 in aborted bovine, buffalo and camel foetuses. Bulgarian Journal of \nVeterinary Medicine. 2013 Jun 1;16(2).\n22. Dehkordi FS, Khamesipour F, Momeni M. Brucella abortus and \nBrucella melitensis in Iranian bovine and buffalo semen samples: The \nfirst clinical trial on seasonal, Senile and geographical distribution using \nculture, conventional and real-time polymerase chain reaction assays. \nKafkas Univ Vet Fak Dergisi. 2014;20(6):821-.\n23. Dehkordi FS, Valizadeh Y, Birgani TA, Dehkordi KG. Prevalence \nstudy of Brucella melitensis and Brucella abortus in cow's milk using \ndot enzyme linked immuno sorbent assay and duplex polymerase chain \nreaction. J Pure Appl Microbiol. 2014;8(2):1065-9.\n24. Rahimi E, Sepehri S, Dehkordi FS, Shaygan S, Momtaz H. \nPrevalence of Yersinia species in traditional and commercial dairy \nproducts in Isfahan Province, Iran. Jundishapur Journal of Microbiology. \n2014 Apr;7(4).\n25. Ranjbar R, Dehkordi FS, Shahreza MH, Rahimi E. Prevalence, \nidentification of virulence factors, O-serogroups and antibiotic resistance \nproperties of Shiga-toxin producing Escherichia coli strains isolated \nfrom raw milk and traditional dairy products. Antimicrobial Resistance & \nInfection Control. 2018 Dec;7(1):1-1.\n26. Dehkordi FS, Barati S, Momtaz H, Ahari SN, Dehkordi SN. \nComparison of shedding, and antibiotic resistance properties of Listeria \nmonocytogenes isolated from milk, feces, urine, and vaginal secretion of \nbovine, ovine, caprine, buffalo, and camel species in Iran. Jundishapur \nJournal of Microbiology. 2013 May 1;6(3):284.121\n2021/36 (3): 117-121 Enterotoxigenic profiles of Staphylococcus aureus in sweet \n27. Ranjbar R, Mahmoodzadeh Hosseini H, Safarpoor Dehkordi \nF. A Review on Biochemical and Immunological Biomarkers used \nfor Laboratory Diagnosis of SARS-CoV-2 (COVID-19). The Open \nMicrobiology Journal. 2020 Dec 15;14(1)\n28. Halaji M, Farahani A, Ranjbar R, Heiat M, Dehkordi FS. Emerging \ncoronaviruses: first SARS, second MERS and third SARS-CoV-2: \nepidemiological updates of COVID-19. Infez Med. 2020 Jun 1;28(suppl \n1):6-17.\n29. Mirzaie A, Halaji M, Dehkordi FS, Ranjbar R, Noorbazargan H. A \nnarrative literature review on traditional medicine options for treatment \nof corona virus disease 2019 (COVID-19). Complementary Therapies in \nClinical Practice. 2020 Jun 17:101214.\n30. Sheikhshahrokh A, Ranjbar R, Saeidi E, Dehkordi FS, Heiat M, \nGhasemi-Dehkordi P , et al. Frontier therapeutics and vaccine strategies \nfor sars-cov-2 (COVID-19): A review. Iranian Journal of Public Health. \n2020 Jul 11.\n31. Ranjbar R, Dehkordi FS, Shahreza MH, Rahimi E. Prevalence, \nidentification of virulence factors, O-serogroups and antibiotic resistance \nproperties of Shiga-toxin producing Escherichia coli strains isolated \nfrom raw milk and traditional dairy products. Antimicrobial Resistance & \nInfection Control. 2018 Dec;7(1):1-1.32. Kroning IS, Iglesias MA, Sehn CP , Gandra TK, Mata MM, da \nSilva WP . Staphylococcus aureus isolated from handmade sweets: \nbiofilm formation, enterotoxigenicity and antimicrobial resistance. Food \nmicrobiology. 2016 Sep 1;58:105-11. \n33. Sahir KH, Mirani ZA, Khan MN, Naz S, Khan SI. Occurrence of \nStaphylococcus aureus in Milk based sweet products consumed in \nKarachi, Pakistan. Biological Sciences-PJSIR. 2013 Apr 25;56(1):56-8. \n34. Guti\u00e9rrez D, Delgado S, V\u00e1zquez-S\u00e1nchez D, Mart\u00ednez B, Cabo ML, \nRodr\u00edguez A, et al. Incidence of Staphylococcus aureus and analysis of \nassociated bacterial communities on food industry surfaces. Applied \nand environmental microbiology. 2012 Dec 15;78(24):8547-54. \n35. Shimamura Y, Kidokoro S, Murata M. Survey and properties \nof Staphylococcus aureus isolated from Japanese-style desserts. \nBioscience, biotechnology, and biochemistry. 2006:0606070009-.\n36. Song M, Bai Y, Xu J, Carter MQ, Shi C, Shi X. Genetic diversity \nand virulence potential of Staphylococcus aureus isolates from raw and \nprocessed food commodities in Shanghai. International Journal of Food \nMicrobiology. 2015 Feb 16;195:1-8.\n37. Zhang C, Shen Y, Dong M. Distribution, polymorphism and temporal \nexpression of egc in Staphylococcus aureus isolates from various foods \nin China. Food Control. 2013 Jan 1;29(1):279-85.122\n2021/36 (3): 122-125ORIGINAL\nPrescriptions analysis for various effects of polypharmacy \nin Kempegowda Institute of Medical Sciences (Kims) \nHospital and research centre, India\nAn\u00e1lisis de prescripciones para diversos efectos de la polifarmacia en el Hospital y centro \nde investigaci\u00f3n del Instituto de Ciencias M\u00e9dicas de Kempegowda (Kims), India\nShamimeh Fallah Ghorbani1      , Tejasvinii M1      , Kiran Nagaraju1\n1. Doctors of Pharmacy, Department of Pharmacy Practice, Visveswarapura Institute of Pharmaceutical Sciences, Bengaluru, IndiaeISSN 2255-0569\nReceived:  8 - V - 2021\nAccepted:  12 - VI - 2021\ndoi: 10.3306/AJHS.2021.36.03.122Corresponding author\nShamimeh Fallah Ghorbani\nDepartment of Pharmacy Practice, \nVisveswarapura Institute of Pharmaceutical Sciences, Bengaluru, India\nE-mail: shamimfallahghorbani@gmail.comID ID ID\nAbstract  \nBackground:  To assess the polypharmacy and appropriateness of prescriptions in patients in Kempegowda Institute of Medical \nSciences (KIMS) Hospital and Research Centre, India.\nMethods:  This investigation was completed on 1000 patients of age both males and females. Data was gathered through the \nreview of case sheets. Polypharmacy was noticed as dependent on admission and discharge prescriptions. The prescription \ncomponents, drug utilization behavior, and prescribing compliance to hospital formulary were noted and subjected for Analysis of \nprescriptions for various impacts of polypharmacy.  \nResult:  A total of 1.000 patients, 530 (53%) were males and 470 (47%) were females. Polypharmacy was present in 300 \nprescriptions (30%). The highest prevalence of polypharmacy was found in the 70-79 years age group compared to the other \ngroups and it was measurably significant. and the average number of drugs per patient was 7. According to 1000 prescriptions \nanalyzed, 142 prescriptions comprised of potential drug interactions and it was found that 235 drug interactions were present. From \ndrug interactions, aspirin/clopidogrel and clopidogrel/atorvastatin were the most common drug interaction pairs observed among \nprescribed medications. Out of the 235 interventions proposed, the most incessant recommendation was on observing for adverse \neffect (44.01%) followed by dose adjustment (15.81%). \nConclusion: As the population ages, polypharmacy increases. The elderly often require multiple medications to treat multiple health-\nrelated conditions. The demographic details of the study population show that 70 % of polypharmacy occurred in elderly people. \nFrom the current investigation, we can conclude that polypharmacy prompts more potential drug-drug interactions. To improve drug \nsafety in this high-risk population, appropriate prescribing is vital.\nKeywords:  Polypharmacy, prescription, elderly, drug interactions, adverse drug interaction.\nResumen\nAntecedentes:  Evaluar la polifarmacia y la idoneidad de las prescripciones en los pacientes del Kempegowda Institute of Medical \nSciences (KIMS), India.\nM\u00e9todos:  Esta investigaci\u00f3n se llev\u00f3 a cabo en 1.000 pacientes de ambos sexos. Los datos se recogieron mediante la revisi\u00f3n \nde las hojas de los casos. Se observ\u00f3 que la polifarmacia depend\u00eda de las prescripciones al ingreso y al alta. Los componentes de \nla prescripci\u00f3n, el comportamiento de utilizaci\u00f3n de los f\u00e1rmacos y el cumplimiento de la prescripci\u00f3n en el formulario del hospital \nse anotaron y se sometieron a un an\u00e1lisis de prescripciones para diversos impactos de la polifarmacia. \nResultados:  De un total de 1.000 pacientes, 530 (53%) eran varones y 470 (47%) eran mujeres. La polifarmacia estaba presente en \n300 prescripciones (30%). La mayor prevalencia de polifarmacia se encontr\u00f3 en el grupo de edad de 70-79 a\u00f1os, en comparaci\u00f3n \ncon los dem\u00e1s grupos, y fue notablemente significativa, y el n\u00famero medio de f\u00e1rmacos por paciente fue de 7. Seg\u00fan las \n1.000 prescripciones analizadas, 142 prescripciones conten\u00edan posibles interacciones farmacol\u00f3gicas y se descubri\u00f3 que hab\u00eda \n235 interacciones farmacol\u00f3gicas. En las interacciones farmacol\u00f3gicas, aspirina/clopidogrel y clopidogrel/atorvastatina fueron los \npares de interacciones farmacol\u00f3gicas m\u00e1s comunes observados entre medicamentos prescritos. De las 235 intervenciones \npropuestas, la recomendaci\u00f3n m\u00e1s incesante fue la de observar los efectos adversos (44,01%), seguida del ajuste de la dosis \n(15,81%). \nConclusiones: A medida que la poblaci\u00f3n envejece, la polifarmacia aumenta. Los ancianos suelen necesitar varios medicamentos \npara tratar m\u00faltiples de salud. Los detalles demogr\u00e1ficos de la poblaci\u00f3n estudiada muestran que el 70% de la polifarmacia \nse produjo en personas mayores. A partir de la presente investigaci\u00f3n, podemos concluir que la polifarmacia provoca m\u00e1s \ninteracciones farmacol\u00f3gicas potenciales.  Para mejorar la seguridad de los medicamentos en esta poblaci\u00f3n de alto riesgo, es vital \nuna prescripci\u00f3n adecuada.\nPalabras clave:  Polifarmacia, prescripci\u00f3n, ancianos, interacciones farmacol\u00f3gicas, interacci\u00f3n farmacol\u00f3gica adversa.123\n2021/36 (3): 122-125 Prescriptions analysis for various effects of polypharmacy in Kempegowda Institute of Medical Sciences (Kims) \nIntroduction\nPolypharmacy is most usually characterized as the use \nof five or more medications day by day by a person. \nA few studies additionally by and large characterize \npolypharmacy as the utilization of different simultaneous \nmedications or synchronous long haul utilization of \ndifferent medications by the equivalent individual.1-5 \nThe prevalence of polypharmacy is estimated to be \nsomewhere in the range of 10% and 90% relying upon \nthe definition utilized, the age group examined, and the \ngeographic area.6\nPolypharmacy isn't foolish, yet in numerous cases can \nprompt negative results or helpless treatment viability, \nfrequently being more harmful than helpful or presenting \ntoo much risk for too little advantage. Therefore, health \nprofessionals consider it a situation that requires monitoring \nand review to validate whether all of the medications are \nstill necessary. Concerns about polypharmacy include \nincreased adverse drug reactions, interactions of drugs, \nprescribing cascade, and higher costs. Polypharmacy is \noften associated with a diminished quality of life, including \ndecreased mobility and cognition.7, 8\nIn this day and age where medical decision-making is \nfrequently affected and sometimes controlled by financial \nconsiderations, it is usually for specialists to become \ndisappointed and regularly resentful when cost turns into \nan issue in deciding the fitting treatment for a patient. The \nmost well-known situation for such a response is the point \nat which a physician is informed that there is an elective \ntreatment that is nearly as great and significantly more \naffordable. When the third parties interject themselves into \nthe specialist-patient relationship in this way, it is simple \nfor a physician to feel that the financial requirements and \nnot nature of consideration are leading American drugs \nin the 21st century. Despite all this, however, the cost \nmust be considered as an issue for determining the \ntreatment plan. Once again, if the expense of a specific \nblend of medications makes it unthinkable for patients to \nget the medications, they won't take them, and all things \nconsidered, the prescription regimen will be incapable. \nIndeed, even the most liberal protection plans have \nimpediments or copy on medications. It is significant while \nthinking about polypharmacy to think about the financial \nimpact at least on the patient, if not on the healthcare \nsystem as a whole. The more medications recommended, \nthe higher the expense and the more intricacies are made \nas a result.9 For all the above cases, prescriptions Analysis \nfor various effects of polypharmacy in a south Indian tertiary \ncare hospital is so significant and Need for study.\nMaterials and methods\nOur study was led in the Department of Pediatrics, \nKempegowda Institute of Medical Science (KIMS) Hospital and Research Centre, Inida. It is 1200 beds tertiary care \nteaching and super specialty hospital, with an Outpatient \nand Inpatient facility. The hospital provides specialized \nhealthcare services to all strata of people in and around \nBangalore. This study was carried out on 1000 patients of \nage both males and females. In this strategy, the inpatient \nreview of case sheets and medicines was screened for \nprescriptions Analysis for various effects of polypharmacy \non a consistent schedule. All the recommended drugs \nalongside different prescriptions and significant data were \nnoted in a modified information accumulation structure \nto discover polypharmacy and others. The investigation \npatients were pursued day by day until their release. The \nMicromedex, Medscape, articles, and relevant reference \nbooks were used as tools to review the collected data. The \nprescribed medication was checked for their existence in \nthe hospital and also the relevant dosing calculation and \npolypharmacy. Check for any error in prescription such \nas doses, frequency, and route of administration, and \nanalysis of prescription for any polypharmacy, etc. The \nprescription components, drug utilization conduct, and \nendorsing consistency to hospital formulary were noted \nand oppressed for Analysis of prescriptions for different \nimpacts of polypharmacy. Polypharmacy was observed \nbased on admission and discharge prescriptions.10, 11 \nResult and discussion\nDrug usage\nIn our study population out of 300 patients' prescriptions \ncontains polypharmacy, which that 159 were male and \n141 were female and in the pediatric population 53% \nwere male and 47% were female ( Table I ).\nA total of 300 drugs were prescribed, and thus the \naverage number of drugs per patient was 7. Among \nstudied patients, 3.67% were using 1-3 medications \nfollowed by 27.14% of patients using 4-6 medications. \nAccording to table 2,3 Extensive (70%), polypharmacy \nwas observed in the study population.\nin our study various classes of drug-like Pantoprazole, \nAspirin, Paracetamol, Zincovit, Levocetrizin, Atorvastatin, \netc. Were prescribed. Out of which 53% males, 47 % \nfemales have prescribed Pantoprazole which was highest \namong monotherapy. A different class of medications is \nendorsed in our study populace dependent on the patient \ncondition and comorbidities .out of which 87males, Table I: Number of drug usage by study patients.\nN=300 Male Female Total\n N % N % N %\n 7 2.25 4 1.43 11 3.67\n 46 15.51 35 11.63 81 27.14\n 106 35.31 101 33.88 207 69.181,2,3\n4,5,6\n7,8,9Number \nof Drug \nDispensed124\n2021/36 (3): 122-125Shamimeh Fallah Ghorbani  et al.  \n47 females are prescribed atorvastatin drugs which \nwere the highest followed. Totally 20.74% atorvastatin \nwas prescribed. 16.41% of patient used Pantoprazole, \n10.22 H. Actapid, 6.81% Zicovit, 6.5% Ceftriaxone, 5.27 \nParacetamol.\nPotential Drug-Drug Interaction\nConcerns about polypharmacy include increased adverse \ndrug reactions, drug interactions, Pharmacists Intervention, \nprescribing cascade, and higher costs. Polypharmacy is \noften associated with decreased quality of life, including \ndecreased mobility and cognition ( Table II ).\nDrug interaction frequency\nOut of 300 prescriptions analyzed, 142 prescriptions \ncomprised of potential drug interactions and it was found \nthat 235 drug interactions were present. The incidence of \npotential drug interaction was 63.64%. Among 235 drug \ninteractions, 90 types of interaction combinations were \nidentified. The studied prescription comprised 58.11% \nmoderate interaction, 40.59% major drug interactions, and \n1.28 minor drug interactions. Among them, 57.26% were \npharmacodynamic drug interactions followed by 36.75% \nof pharmacokinetic interaction and 5.98% of unknown \nmechanism interactions ( Table III ).\nIn most patients, the cases of one potential drug interaction \nwere identified with a median of 1.67 potential drug-drug \ninteractions. Among them, 30% of prescriptions had two \npotential drug-drug interactions.\nPharmacists Intervention\nOut of the 235 interventions proposed, the most frequent \nsuggestion was on monitoring for adverse effect (44.01%) \nfollowed by dose adjustment (15.81%). 25.64% of \ninterventions were accepted and therapy was changed. \nVarious interventions provided by the pharmacist and their \nresult are presented in table IV . The pharmacist's role concerning clinical results of \ndifferent adverse events is very significant as pDDIs are \na noteworthy factor for the hospitalization of patients. \nA clinical pharmacist can help in the improvement of \npharmacotherapy. A clinical pharmacist can discover \nfactors that may result in irrational prescriptions. Such \nfactors are called \u2018\u2018drug-related problems\u2019\u2019 and may \nchange the ideal impacts of medications. The role of the \npharmacist in the created world is all around perceived but \nthis profession is not well established in the developing \nnations including India. The absence of an appropriate role \nof the pharmacist in less-created nations is driving patients \nwith a higher ratio of drug-related problems. This can be \nreduced by the clinical pharmacist\u2019s active participation in \ndirect patient care.12-14\nThe incidence rate of adverse drug interactions was found \nto be 20%. This rate is similar to the study conducted \nin Iran12. Another study reported 17.53% of observed \ndrug interaction which is lower than this study. The \nmost common drug interaction pair resulting in adverse \ndrug reactions was aspirin/clopidogrel (5). Bleeding was \nthe most important interaction in 8 cases followed by \nhypoglycemia (4) and QT-interval prolongation (4). The \nmost common objective drug is aspirin and the precipitant \ndrug is clopidogrel. Similarly, Bleeding was the most \ncommon clinical effect of observed drug interaction in a \nSouth Indian study.10-13 (Tables V, VI ).\nConclusion\nAs the population ages, polypharmacy increases. The \nelderly often require multiple medications to treat multiple \nhealth-related conditions wich requires more cuasions Table II: Potential drug-drug interaction inpatient.\n  Total\n   N %\n  Major 101 40.59\n  Moderate 145 58.11\n  Minor 6 1.28\n Pharmacodynamic Interaction 147 57.26\n Pharmacokinetic Interaction 91 36.75\n Unknown Mechanism 18 5.98\n  Monitoring 185 73.93\n  Dose adjustment 38 13.67ManagementSeverityParameters\nTable III: Frequency of drug interaction in the study population.\nN=142 Male Female Total\n N % N % N %\n 52 37.14 23 16.42 75 53.57\n 25 17.85 18 12.14 43 30\n 14 10 5 3.57 19 13.57\n 2 1.42 0 0 2 1.42\n 2 1.42 0 0 2 1.421\n2\n3\n4\n5Frequency \nof \npDDITable IV: Types of pharmacist intervention to prevent pDDI.\n Types of Total\n intervention N %\n Substitution 24 10.25\n Stop/avoid/dose adjustment 37 15.81\n Monitoring 103 44.01\n No change 70 29.91\nTable V: Observed adverse drug-drug interaction.\nObject Precipitant No. of adverse Adverse\nDrug Drug drug-drug interaction outcome\nEnalapril Spironolactone 2 Hyperkalemia\nAspirin Clopidogrel 6 GI bleeding\nAmiodarone Atorvastatin 1 Muscle pain\nClopidogrel Acenocoumarol 2 bleeding\nVenlafaxine Ivabradine 1 QT prolong\nFurosemide Hydrocortisone 2 Hypokalemia\nAspirin Acenocoumarol 3 Bleeding\nDomperidone Cilnidipine 2 QT prolong\nInsulin Aspirin 1 Hypoglycemia\nAspirin Heparin 1 bleeding\nClopidogrel Atorvastatin 2 thrombocytopenia\nAspirin Telmisartan 1 Increase creatinine\nInsulin Nebivolol 1 hypoglycemia\nDomperidone Atorvastatin 1 QT prolong\nAmiodarone Nebivolol 1 bradycardia\nSpironolactone Aspirin 1 hyperkalemia\nMetformin Ramipril 2 hypoglycemia125\n2021/36 (3): 122-125 Prescriptions analysis for various effects of polypharmacy in Kempegowda Institute of Medical Sciences (Kims) \nparticularly on renal function. The demographic details of \nthe study population showed that 70 % of polypharmacy \noccurred in elderly people because they use 6 or more \nmedicine. This study shows that DDIs are frequent among \nhospitalized cardiac patients. The majority of interactions \nwere pharmacodynamic, having moderate severity. Anti-platelets and anti-coagulants were commonly implicated \nin many PDDIs in this study and therefore require intensive \nmonitoring during therapy. From the current study, we can \nreason that polypharmacy leads to more potential drug-\ndrug interactions. To improve drug safety in this high-risk \npopulation, appropriate prescribing is vital.Table VI: Details of observed drug interaction (adverse drug interaction).\nInteracting drug No. Effect WHO causality Naranjo Causality Severity\nEnalapril/Spironolactone 2 Hyperkalaemia probable Probable Mild\nAspirin/Clopidogrel 66 bleeding probable Probable Major\nAmiodarone/atorvastatin 1 Muscle pain possible Possible Mild\nClopidogrel/Acenocoumarol 2 bleeding probable Probable Moderate\nVenlafaxine/Ivabradine 1 QT prolong possible Possible Moderate\nFurosemide/Hydrocortisone 2 Hypokalaemia probable Probable Mild\nAspirin/Acenocoumarol 3 Bleeding possible Probable Moderate\nDomperidone/Cilnidipine 2 QT prolong possible Possible Mild\nInsulin/aspirin 1 Hypoglycaemia probable Possible Moderate\nAspirin/Heparin 1 bleeding possible Possible Moderate\nAspirin/Telmisartan 1 Increase creatinine possible Probable Mild\nInsulin/nebivolol 1 hypoglycaemia probable Probable Moderate\nDomperidone/Atorvastatin 1 QT prolong possible Probable Mild\nAmiodarone/nebivolol 1 bradycardia possible Probable Moderate\nSpironolactone/aspirin 1 hyperkalaemia probable Probable Moderate\nMetformin/Ramipril 2 hypoglycaemia possible Possible Mild\nReferences\n1. Payne RA, Avery AJ. Polypharmacy: one of the greatest prescribing \nchallenges in general practice. Br J Gen Pract. 2011 Feb;61(583):83-4. \n2. Abu Farha RK, Mukattash TL, Al-Sakran L, Abu Hammour K, \nZawiah M. Prevalence and predictors of polypharmacy in Jordanian \nhospitalised patients: A cross-sectional Study. International Journal of \nClinical Practice. 2021 Apr;75(4):e13742. \n3. Levy HB. Polypharmacy reduction strategies: tips on incorporating \nAmerican Geriatrics Society Beers and screening tool of older \npeople's prescriptions criteria. Clinics in geriatric medicine. 2017 Feb \n14;33(2):177-87. \n4. Abidi A, Gupta S, Kansal S, Ramgopal R. Prescription auditing and \ndrug utilization pattern in a tertiary care teaching hospital of western UP . \nInt J Basic Clin Pharmacol. 2012 Dec;1(3):184-90. \n5. Tahery N, Mahmodi N, Shirzadegan R. The prevalence and causes \nof herbal drug use in pregnant women referring to Abadan health \ncenters; a cross-sectional study in southwest Iran. J Prev Epidemiol. \n2018;3(2):e08. \n6. Allard J, H\u00e9bert R, Rioux M, Asselin J, Voyer L. Efficacy of a \nclinical medication review on the number of potentially inappropriate \nprescriptions prescribed for community-dwelling elderly people. Cmaj. \n2001 May 1;164(9):1291-6. \n7. Cadogan CA, Ryan C, Hughes CM. Appropriate polypharmacy and \nmedicine safety: when many is not too many. Drug safety. 2016 Feb \n1;39(2):109-16. \n8. Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: evaluating \nrisks and deprescribing. American family physician. 2019 Jul \n1;100(1):32-8.9. Khandeparkar A, Rataboli PV. A study of harmful drug\u2013drug \ninteractions due to polypharmacy in hospitalized patients in Goa Medical \nCollege. Perspectives in clinical research. 2017 Oct;8(4):180. \n10. Hoel RW, Connolly RM, Takahashi PY. Polypharmacy management \nin older patients. InMayo Clinic Proceedings 2021 Jan (Vol. 96, No. 1, \npp. 242-256). Elsevier.\n11. Patel VK, Acharya LD, Rajakannan T, Surulivelrajan M, Guddattu \nV, Padmakumar R. Potential drug interactions in patients admitted to \ncardiology wards of a south Indian teaching hospital. The Australasian \nmedical journal. 2011;4(1):9. \n12. Mohamed MR, Ramsdale E, Loh KP , Xu H, Patil A, Gilmore N, \nObrecht S, Wells M, Nightingale G, Juba KM, Faller B. Association of \npolypharmacy and potentially inappropriate medications with physical \nfunctional impairments in older adults with cancer. Journal of the \nNational Comprehensive Cancer Network. 2021 Jan 22;19(3):267-74. \n13. Dhakal P , Lyden E, Muir KL, Al-Kadhimi ZS, Koll T, Maness LJ, \nGundabolu K, Bhatt VR. Prevalence and effects of polypharmacy on \noverall survival in acute myeloid leukemia. Leukemia & lymphoma. 2020 \nJun 6;61(7):1702-8.\n14. Valizadeh R, Dadashzadeh N, Zakeri R, James Kelllner S, Rahimi \nMM. Drug therapy in hospitalized patients with very severe symptoms \nfollowing COVID-19. J Nephropharmacol. 2020;9(2):e21.\n15. Sabatino D, Tillman M, Pawasauskas J, Brothers T. Nonsteroidal \nanti-inflammatory drug induced acute kidney injury; A review and case \nstudy. J Renal Inj Prev. 2020; 9(4): e30.\n16. Hasanpour Dehkordi A, Keikhaei B, Bahadoram M, Razmjoo S, \nBarahman M. Keep the corners; impact of chemotherapy on renal \nfunction. J Nephropathol. 2020;9(1):e02.126\n2021/36 (3): 126-129ORIGINAL\nEvaluation of arch bar fixation without surgical aid \nin jaw fracture treatment\nEvaluaci\u00f3n de la fijaci\u00f3n de barras de arco sin ayuda quir\u00fargica \nen el tratamiento de fracturas de mand\u00edbula\nFarnaz Dehabadi1, Seyed Hadi Hosseini2  \n1. Department of Oral and maxillofacial surgery, Dental School, Mashhad University of Medical Sciences, Mashhad, Iran\n2. Department of maxillofacial surgery, Dental School, Guilan University of Medical Sciences, Rasht, Iran.eISSN 2255-0569\nReceived:  17 - V - 2021\nAccepted:  11 - VI - 2021\ndoi: 10.3306/AJHS.2021.36.03.126Corresponding author\nFarnaz Dehabadi\nDepartment of Oral and maxillofacial surgery, Dental School, \nMashhad University of Medical Sciences, Mashhad, Iran\nE-mail: dehabadif961@mums.ac.irID\nAbstract  \nBackground:  In traumatic patients, head, neck, and facial bone fractures are common. Inter-maxillary fixation (IMF) in jaw fracture surgery helps to \nimprove the position of the maxilla and mandible, as well as the use of elastics in the postoperative period of fractures. IMF is performed with the \nuse of wires applied directly on the teeth, or with quick-fix screws or with arch bars attached to them. Arch bar is the most complete technique for \njaw fixation. This technique is time-consuming and manipulation of the wires lead to the increasing risk of glove puncture and needle stick injury to \nthe surgeon or assistants. These problems lead to inventing alternative techniques. \nMaterials and Methods:  This study was a clinical trial in which 36 patients require arch bar fixation were selected. They were randomly divided into \ntreatment and control groups by cluster randomization. the first group treated with arch bar in the new method and the second group treated with \nthe classic method of arch bar placement. For the new method the surgeon prebend the wires like U and pass their all trough interdental spaces \nby his own. These two groups were compared in terms of the time of placing arch bars, its vertical mobility after one week and one month, and the \nnumber of glove perforations. Finally, the data were analyzed using SPSS (version 22) software.  \nResult:  A total number of 36 patients were included in this study, results showed that the average time for arch bar wiring in the classical and \nexperimental groups was 40/39 \u00b13/071 and 29/33\u00b12/567 minute respectively (p0.135). There was a statistically significant difference in the number \nof glove perforations between the classic and the experimental group (p0.024). In the present study, 61/1% of gloves in the experimental group were \nwithout holes, but in the classic group, 33/3% of gloves were without holes. In the classic group, 44/4% of gloves had 2 holes and 5/6% of gloves \nhad 3 holes. None of the gloves in the experimental group had 3 holes. One week after wiring arch bar, there was no significant difference between \nthose groups in the looseness rate (p 0.560). But after 1 month, a significant difference was found between groups because the average looseness \nrate in the experimental group was higher (p 0.016).\nConclusion: With due attention to statistical data, presented method had more efficiency due to less working time, fewer glove perforations, and \nsimpler arch bar opening. Even there is no need for any professional assistants.\nKeywords:  Arch bar, jaw fractures, Intermaxillary fixation.\nResumen\nAntecedentes:  En los pacientes traumatizados, las fracturas de cabeza, cuello y huesos faciales son frecuentes. La fijaci\u00f3n intermaxilar (FMI) en la \ncirug\u00eda de fracturas de mand\u00edbula ayuda a mejorar la posici\u00f3n del maxilar y la mand\u00edbula, as\u00ed como el uso de el\u00e1sticos en el postoperatorio de las \nfracturas. La FMI se realiza con el uso de alambres aplicados directamente sobre los dientes, o con tornillos de fijaci\u00f3n r\u00e1pida o con barras de arco \nunidas a ellos. La barra de arco es la t\u00e9cnica m\u00e1s completa para la fijaci\u00f3n de la mand\u00edbula. Esta t\u00e9cnica requiere mucho tiempo y la manipulaci\u00f3n \nde los alambres conlleva un riesgo creciente de perforaci\u00f3n del guante y de lesiones por pinchazo de aguja para el cirujano o los asistentes. Estos \nproblemas llevan a inventar t\u00e9cnicas alternativas. \nMateriales y m\u00e9todos:  Este estudio fue un ensayo cl\u00ednico en el que se seleccionaron 36 pacientes que requer\u00edan la fijaci\u00f3n de la barra del arco. \nSe dividieron aleatoriamente en grupos de tratamiento y de control mediante aleatorizaci\u00f3n por grupos. El primer grupo fue tratado con la barra de \narco en el nuevo m\u00e9todo y el segundo grupo fue tratado con el m\u00e9todo cl\u00e1sico de colocaci\u00f3n de la barra de arco. En el nuevo m\u00e9todo, el cirujano \npredobl\u00f3 los alambres en forma de U y los pas\u00f3 por completo a trav\u00e9s de los espacios interdentales. Estos dos grupos se compararon en cuanto \nal tiempo de colocaci\u00f3n de las barras del arco, su movilidad vertical despu\u00e9s de una semana y un mes, y el n\u00famero de perforaciones del guante. \nPor \u00faltimo, los datos se analizaron mediante el programa inform\u00e1tico SPSS (versi\u00f3n 22).\nResultados:  Un n\u00famero total de 36 pacientes fueron incluidos en este estudio, los resultados mostraron que el tiempo medio de cableado de las \nbarras de arco en los grupos cl\u00e1sico y experimental fue de 40/39 \u00b13/071 y 29/33\u00b12/567 minutos respectivamente (p 0.135). Hubo una diferencia \nestad\u00edsticamente significativa en el n\u00famero de perforaciones del guante entre el grupo cl\u00e1sico y el experimental (p 0.024). En el presente estudio, el \n61/1% de los guantes del grupo experimental no ten\u00edan perforaciones, pero en el grupo cl\u00e1sico, el 33/3% de los guantes no ten\u00edan perforaciones. \nEn el grupo cl\u00e1sico, el 44/4% de los guantes ten\u00edan 2 agujeros y el 5/6% de los guantes ten\u00edan 3 agujeros. Ninguno de los guantes del grupo \nexperimental ten\u00eda 3 agujeros. Una semana despu\u00e9s de alambrar la barra del arco, no hubo diferencias significativas entre esos grupos en la tasa \nde aflojamiento (p 0.560). Pero despu\u00e9s de 1 mes, se encontr\u00f3 una diferencia significativa entre los grupos porque la tasa media de aflojamiento \nen el grupo experimental fue mayor (p 0.016).  \nConclusi\u00f3n: prestando la debida atenci\u00f3n a los datos estad\u00edsticos, el m\u00e9todo presentado fue m\u00e1s eficaz debido al menor tiempo de trabajo, el \nmenor n\u00famero de perforaciones del guante y la apertura m\u00e1s sencilla de la barra del arco. Incluso no hay necesidad de ning\u00fan asistente profesional.\nPalabras clave:  Barra de arco, fracturas de mand\u00edbula, fijaci\u00f3n intermaxilar.127\n2021/36 (3): 126-129 Evaluation of arch bar fixation without surgical aid in jaw fracture treatment \nIntroduction\nThe treatment of jaw fractures has a long history, from \nancient Egypt to the present. Historical insight improves \nunderstanding of current techniques and provides \nthe basis for the development of new methods. Since \nancient times, physicians have described many different \ntechniques for treating mandibular fractures, the principle \nof which has always been repositioned and immobilization \nof the bone fragments. However, during the past 50 \nyears, an improvement of anesthetic and radiographic \ntechniques, the introduction of antibiotics, specially \ndesigned instruments, and advances in biomaterial have \nallowed maxillofacial surgeons to improve outcomes while \nreducing morbidity. The main objective in all treatments \nfor treating fractures is to obtain proper occlusion and \nstable joint movements by appropriate insertion of \nbroken parts1. Recently, typical surgical methods for \nthe treatment of mandibular fractures is the arch bar \nmethod. Arch bar is composed of a hooked, stainless \nsteel wire called Arch and ligated to teeth with stainless \nsteel wires. However, arch bars can damage the teeth \nand periodontal tissue and tend to be uncomfortable \nfor patients during the fixation period. Moreover, daily \nmaintenance of oral hygiene is difficult for patients with \nan arch bar2. Surgeons are also exposed to the risk of \nblood-transmitted diseases through skin punctures by \nwires when affixing these devices. The speed of action \nin arch wiring is very important during surgery2. Arch bar \nis a simple and an initial treatment for most jaw fractures, \nespecially for the mandible. Treatment by the arch bar \nis also necessary in some cases where the treatment \nplan includes insertion and rigid fixation. In some cases, \nit can be as a final treatment without the need for a \nhard fixation3,4. There are several types of the arch bar \nfor IMF, such as Erich, Winters, handmade, and plastic \n/ polymeric4,5. IMF helps maxilla-mandibular positioning \nin orthognathic surgery, and the use of elastics in the \npostoperative period of fractures or orthognathic surgery. \nThe most complete IMF procedure comes with the arch \nbar. However, it has been performed with the use of wires \napplied directly on the teeth, or with arch bars wired to \nthem6. These procedures are time-consuming, and \nmanipulation of the wires lead to the increasing risk of \nglove puncture and needle stick injury to the surgeon or \nassistants. These problems lead to inventing alternative \ntechniques. Therefore, aim of the present study was \nthe evaluation of arch fixation without surgical aid in jaw \nfracture treatment.\nMaterials and methods\nThirty six patients with mandible fractures who were \nreferred to Poursina Hospital and needed to Arch bar \nwere selected. The patients were divided into two groups. \nGroup I, consisted of 18 patients who were randomly \ntreated with arch bar fixation without an assistant. Group II consisted of 18 patients treated with arch bar fixation \nwith an assistant as a control group. Then, two groups \nwere compared in terms of the time of the wiring arch bar \nand its vertical mobility after one week and one month, \nand the number of glove perforations. Arch bar wires \nused were stainless steel. This new technique consist \nof following steps; while starting surgery, arch bar and \nprepared wires are placed on the patient's chest. The \nwires are prepared in the shape of U, that one arm is \nlonger than another arm ( Figure 1 ).\nThe right-handed surgeon stands on the right side of the \npatient's head. Then, the assistant only holds the retractor \nand suction in his hands. Overall during this technique \nthe assistant`s role is just retracting and do suction. In \nthis step, the surgeon choose a quadrant (upper right) \nand holds a farabeuf retractor in one hand and wire \nholder forceps in the other hand. Also the assistant hold a \ntongue retractor (Minnesota retractor) and suction ( Figure \n2), then the surgeon begin to pass the U shape wire \nacross the interdental space from the patient's posterior \nupper jaw teeth one by one to anterior teeth. The surgeon \nshould catch on U wires by a wire holder from the longer \narm and pass it through lingual side of each interdental \ntooth space. After the long arm of U wire passed through \nthe distal interdental of each tooth, the surgeon takes \nanother arm on lingual side by wire holder and pass it \nthrough mesial interdental space of the same tooth. When \nFigure 1: U-shaped wires with a longer arm to fix the arch bar in the study method.\nFigure 2: (a) surgical instruments holding technique at the beginning of surgery \nby the surgeon and his assistant. (b) the opposite lower quadrant.\n128\n2021/36 (3): 126-129Farnaz Dehabadi et al.  \nthe short arm of the wire appears in the Buccal area the \nsurgeon takes both arms of U wire on the buccal side and \npull it out until the wire fix beyond the tooth. This process \ncontinues for each tooth from posterior to anterior of the \nquadrant. After that the surgeon goes to another quadrant \n(its better the upper left side quadrant) and does the steps \nsimilar to process that done in the previous quadrant. At \nthis stage, the surgeon immediately gives the farabeuf \nto his assistant and takes the Minnesota retractor from \nhim for retracting tongue. Then the process continues as \nabove while the assistant retract the buccal with farabeuf \nand suctioning ( Figure 2 ). \nThe surgeon passes wires from lingual distal and mesial \ninterdental spaces to buccal side and fix it by pulling out \nand continues this process for each tooth from posterior \nto anterior. After passing all the wires in the upper jaw \nand bending them, it is time to place the arc bar between \narms in the buccal side and ties wires around arch bar \n(Figure 3 ).\nAfter finishing the upper arch bar the surgeon all process \nas previous for the lower jaw arch bar from right to left and \nposterior to anterior on each quadrant. Finally, after the \nsurgery, the surgeon recorded the operation time, and \nthen pulled out his gloves in the scrub room. Then, he \nfills his gloves (MAXTER\u00ae) with normal saline to find any \nperforations ( Figure 4 ).\nIn the control group, the conventional wiring method was \nused. With a professional assistant that mainly helps for \nfixing arch bars.\nThe postsurgical evaluation of the patients arch bars \nwas done in two steps, one in the first week and one in the first month for measurement the arch bar vertical \ndisplacement, looseness rate, by counting vertical \ndisplacement in three sites of each quadrant (posterior \nleft, posterior right and anterior). Data were analyzed using \nSPSS software. Mann Whitney test was used to compare \nthe non-parametric variables between two groups.\nResults\nIn the present study, we have evaluated the arch fixation \nmethod between two groups. They were compared in \nterms of the time of the wiring arch bar, the number of \nglove perforations and the looseness rate of the arch. \nShapiro-Wilk analysis showed that, the data follow the \nnormal distribution, except for the number of glove \nperforations variable ( Table I ).\nTherefore, Mann Whitney test was used to compare \nthe number of glove perforations between two groups \nand independent t-test was used for other variables. \nThere was a statistically significant difference in the \nnumber of glove perforations between the classic and \nthe experimental group (p=0/024). We observed that, \n61/1% of gloves in the experimental group were without \nholes, but in the classic group, 33/3% of gloves were \nwithout holes. In the classic group, 44/4% of gloves had \n2 holes and 5/6% of gloves had 3 holes. None of the \ngloves in the experimental group had 3 holes ( Figure 5 ).Figure 3: Arch bar insertion after passing wires around the upper jaw.\nFigure 4: Saline filled surgical gloves at the end of operation for punctures.\nTable I: Determination of variables normality.\n P value Statistic variable\n 168/0 984/0 Time of wiring arch bar (minute)\n 179/0 951/0 Time of wiring arch bar (second)\n 112/0 061/0 Number of glove perforations\n 237/0 994/0 Looseness rate of the arch after one week (mm) \n 102/0 950/0 Looseness rate of the arch after one month (mm)129\n2021/36 (3): 126-129Evaluation of arch bar fixation without surgical aid in jaw fracture treatment\nOne week after wiring arch bar, there was no significant \ndifference between those groups in the looseness rate \n(p_0/560). But after 1 month, a significant difference was \nfound between groups because the average looseness \nrate in the experimental group was higher (p_0/016). \nDiscussion\nAccording to the study of Chhabr, one of the criteria \nfor success in fixing arches in jaw fractures is a smaller \nincidence of surgical glove perforations7. In the present \nstudy, the lowest number of glove perforations was seen \nin the experimental group. Despite the progress made in \nthe fixation of jaw fractures, the IMF is still considered as a necessity. Therefore, it is necessary to achieve a more \nappropriate, faster and more complete method to fixing an \narch bar that requires a little time. The minimal risk of infection \ntransmission is one of the most suitable criteria for treating \njaw fractures and IMF. Prolonged surgical time, aggressive \ntreatment and the use of sharp instruments during surgery \ncan lead to failure of routine infection control8. The method \nmentioned in this study reduced the surgical time, reduced \nthe risk of infection transmission and the penetration of \nsharp instruments into the surgeon's hands. Fixation of the \narch bar is actually the most dangerous part of treating \njaw fractures. The purpose of the present study was not \nonly to present a new method for fixing arch bar as a safe \nmethod, but also was to compare the new method with \nthe classic method, which was successful in this regard. \nPatients requiring arch bar are exposed to high HIV risk9. \nIn the present study, the risk of transmission of infection \nwas lower compared to the classical method. Reaching a \nmore appropriate and more effective method to fixing the \narch bar has been studied by some researchers10,11. The \narch bar fixing time in our presented method was shorter \nthan the classic method for 11 minutes. The shorter fixation \ntime in our study compared to the study conducted by \nAbassi11 and Lagvankar10, indicates the importance of the \none handed method.\nConclusion\nThe results of this study showed that the placement of \nthe arch bar without the help of a professional assistant is \npossible. According to statistical data, presented method \nhad more efficiency due to less working time, fewer glove \nperforations, and simpler arch bar opening. This technique \nwas called the One Hand Arch bar Placement method by \nthe authors that could be used by surgeons in the future.Figure 5: Frequency and number of glove perforations in control and experimental \ngroups.\n0 1 2 3\nPerforationsClassic One hand\n16,7%33,3%44,4%\n5,6% 5,6%\n0%61,1%\n33,3%70%\n60%\n50%\n40%\n30%\n20%\n10%\n0%\nReferences\n1. Mukerji R, Mukerji G, McGurk M. Mandibular fractures: Historical \nperspective. British Journal of Oral and Maxillofacial Surgery. 2006; 44 \n(3): 222-8.\n2. Imazawa T, Komuro Y, Inoue M, Yanai A. Mandibular fractures treated \nwith maxillomandibular fixation screws (MMFS method). Journal of \nCraniofacial Surgery. 2006; 17(3): 544-9.\n3. Onishi K, Maruyama Y. Simple intermaxillary fixation for \nmaxillomandibular osteosynthesis. Journal of Craniofacial Surgery. \n1996; 7(2): 170-2.\n4. Bell RB, Wilson DM. Is the use of arch bars or interdental wire fixation \nnecessary for successful outcomes in the open reduction and internal \nfixation of mandibular angle fractures?. Journal of Oral and Maxillofacial \nSurgery. 2008; 66(10):2116-22.\n5. Fonseca Raymond J, Walker Robert V, Norman Bett J.Oral and \nmaxillofacial trauma. Elsevier (USA) Ed3, 2005; 569-613.\n6. Texhammar R, Schmoker R. Stable internal fixation in maxillofacial bone surgery: a manual for operating room personnel. Springer Science \n& Business Media; 2012.\n7. Chhabra N, Chhabra S, Thapar D. Evaluation of two different methods \nof arch bar application: A comparative prospective study. Journal of \nmaxillofacial and oral surgery. 2015; 14(2): 432-40.\n8. Pigadas N, Whitley SP , Roberts SA, McAlister K, Ameerally P , Avery \nCM. A randomized controlled trial on cross-infection control in maxillofacial \ntrauma surgery: a comparison of intermaxillary fixation techniques. \nInternational journal of oral and maxillofacial surgery. 2008; 37(8): 716-22.\n9. Crosher RF, Llewelyn J, MacFarlane A. Should patients with facial \nfractures be regarded as high risk for HIV?. British Journal of Oral and \nMaxillofacial Surgery. 1997;35(1):59-63.\n10. Lagvankar SP . A new method for arch bar fixation. British Journal of \nOral and Maxillofacial Surgery. 1990;28(2):131-2.\n11. Abbasi AJ, Parvin M. New method of arch bar fixation. British Journal \nof Oral and Maxillofacial Surgery. 2017; 6(10):2116-22.130\n2021/36 (3): 130-135ORIGINAL\nThe efficacy of Cognitive-behavior therapy \nbased parenting for anxious children with cancer\nLa eficacia de la crianza basada en la terapia cognitivo-conductual \npara los ni\u00f1os ansiosos con c\u00e1ncer\nMehri Moradi1      , Shayan Alamdarifar2      , \nMasoud Besharati3      , Aliasghar Asgharnejad4      \n1. Department of Clinical Psychology, School of Behavioral Sciences and Mental Health (Tehran Institute of Psychiatry), Iran \nUniversity of Medical Sciences, Tehran, Iran\n2. MSc Student of Psychology, Shiraz Islamic Azad University, Shiraz, Iran\n3. Msc of Psychology, Isfahan Payame Noor University, Isfahan, Iran\n4. Department of Clinical Psychology, School of Behavioral Sciences and Mental Health (Tehran Institute of Psychiatry), Iran \nUniversity of Medical Sciences, Tehran, IraneISSN 2255-0569\nReceived:  6 - V - 2021\nAccepted:  24 - V - 2021\ndoi: 10.3306/AJHS.2021.36.03.130Corresponding author\nShayan Alamdarifar \nMSc Student of Psychology, \nShiraz Islamic Azad University, Shiraz, Iran\nE-mail: alamdarifar.shayan@gmail.comID\nID IDID\nAbstract  \nAim:  Cancer is one of the most distressing and life-threatening diseases. In many cases, people with cancer experience many \npsychological problems. Therefore, the design and implementation of psychotherapy interventions in this group is very important.\nMethod:  This study was a randomized clinical trial with two CBT-based groups, plus pharmacotherapy and pharmacotherapy \nalone. Twenty-seven subjects participated in the present study.  \nResult:  The results of repeated measure analysis indicated a significant difference between the two groups of intervention and \ntreatment as usual in the severity of anxiety after post-test (p <0.001). \nConclusion: It seems that group CBT based parenting has a significant effect on reducing the severity of anxiety in children with \ncancer. Future studies are suggested to designing appropriate interventions to meet the needs of children with cancer.\nKeywords:  Cognitive-behavior therapy based parenting, anxiety, cancer.\nResumen\nObjetivo:  El c\u00e1ncer es una de las enfermedades m\u00e1s angustiosas y amenazantes para la vida. En muchos casos, las personas \ncon c\u00e1ncer experimentan muchos problemas psicol\u00f3gicos. Por lo tanto, el dise\u00f1o y la implementaci\u00f3n de intervenciones \npsicoterap\u00e9uticas en este grupo es muy importante.\nM\u00e9todo:  Este estudio fue un ensayo cl\u00ednico aleatorio con dos grupos basados en terapia cognitivp conductual (TCC), m\u00e1s \nfarmacoterapia y farmacoterapia sola. Veintisiete sujetos participaron en el presente estudio.\nResultados:  Los resultados del an\u00e1lisis de medidas repetidas indicaron una diferencia significativa entre los dos grupos de \nintervenci\u00f3n y tratamiento habitual en la gravedad de la ansiedad despu\u00e9s de la prueba ( p <0,001).\nConclusi\u00f3n: Parece que la crianza grupal basada en la TCC tiene un efecto significativo en la reducci\u00f3n de la gravedad de la \nansiedad en ni\u00f1os con c\u00e1ncer. Se sugieren futuros estudios para dise\u00f1ar intervenciones adecuadas a las necesidades de los ni\u00f1os \ncon c\u00e1ncer.\nPalabras clave:  Crianza basada en la terapia cognitivo-conductual, ansiedad, c\u00e1ncer.131\n2021/36 (3): 130-135 The efficacy of Cognitive-behavior therapy based parenting for anxious children with cancer\nIntroduction\nCancer is a growing chronic disease, and it is expected \nthat by 2030 more than 3 million people in the UK will \nbe diagnosed with cancer1. The prevalence of cancer \nin people aged 0-19 in the United States is 16,592 per \nmillion people2. Also, in Iran, the prevalence of cancer \nin children was estimated at 48-112 girls and 51-144 \nboys per million in 20103. However, in recent decades, \nscientific advances have made significant contributions \nto cancer treatment and the likelihood that people will \nsurvive; the studies suggest that about greater than \n80% of children with cancer will have a chance of 5-year \nsurvival4,5. As a result, many children in the world have \nexperienced cancer and been successfully treated in the \nfuture. Therefore, the child has gone through this crisis \nphysically. However, the negative psychological effects \nof cancer will remain in the child for the next years6-8. \nAnxiety is one of the major problems that people with \ncancer will experience even years after cancer treatment. \nMoreover, this anxiety will negatively affect their quality of \nlife9,10. Studies indicate that anxiety in cancer survivors is \nfrom 9 % to 33%11-13.\nIn addition, cancer and its treatment procedure may \nalso lead to pain disabilities14,15. Therefore, it may people \nwith cancer not be able to participate in psychotherapy \nand appropriate interventions. Therefore parent-focused \ntreatment without children's contribution is more helpful in \nthis group of children.\nMany studies indicated that the most effective treatments \nfor anxiety in children are CBT-based approaches16-18. \nTherefore, many studies have examined appropriate and \nadapted alternative approaches in children. Rapee et al. \nimplemented the CBT approach on parents to reduce \nchildren's anxiety and indicated that parents-focused \nprograms could indirectly reduce children's anxiety16.\n \nSimilarly, Cartwright et al. designed a parenting-based \ngroup intervention known as \"from timid to tiger\" for \nanxious young children. This intervention is a CBT-based \nparenting program19. The results of a study found that the \nintervention can help reduce children's anxiety (18). The \npresent study investigated the effect of this program on \nanxious children with cancer.\nThis program is derived from two broad categories of \ncognitive-behavioral therapy and parental behavioral \ntraining19. The efficacy of CBT approaches in adult anxiety \nis well established, and several meta-analyses support \nthe efficacy of CBT in anxiety disorders20, 21. On the \nother hand, many parenting behavioral training programs \nhave been designed. These programs are widely used \nin the treatment of many childhood disorders, especially \nexternalization problems. Parenting programs have been \nused for decades, and there is ample evidence of their \nefficacy in anxiety disorders22-25.  CBT helps patients identify cognitive distortions for \nreality testing, and learn new skills to challenge irrational \nthoughts26. In the present intervention, the CBT \ntechniques are taught to the parents, and the children \nare transferred. Furthermore, many studies show \nthat inappropriate parenting has a significant positive \nrelationship with anxiety disorders. Many components, \nincluding parental punishment and anger27, rejection28, \nand neglect29, have been identified in children's anxiety. \nImproving this environment and educating parents can \nplay an important role in reducing children's anxiety. The \npresent study aimed to perform \"from timid to tiger\" in \nanxious children with cancer. \nMaterials and methods\nEthics\nThis study was approved by the Iran University of medical \nsciences Ethics Committee (IR.IUMS.REC.1398.851) \nand confirmed in the Iranian Registry of Clinical Trials \n(IRCT20200728048237N1). \nParticipants\nThirty-eight children and their caregiver were recruited \nthrough the regular treatment of children referred to the \nAli-Asghar hospital for any type of cancer and high level \nof anxiety. The children were between 6 and 10 years \nold. Inclusion criteria for a child's participation in the study \nwere:  at least six months had passed since the diagnosis \nof cancer and the acute period of the disease, and the \nchild score on the CBCL scale internalization scale was \nabove clinical cutoff. Exclusion criteria also included: the \nchild or parent had moderate to severe learning disabilities, \nand the child had bipolar disorder or psychotic disorders. \nProcedure \nThe present study was a randomized controlled trial. \nBoth groups were assessed in four stages through pre-\ntest, fifth session, post-test, and follow-up. In the present \nstudy, all children received the same dose of medication \nto treat their anxiety. After one month of medication, \nindividuals were randomly divided into two groups of \nmedication and medication with the present intervention. \nThe intervention group used a parenting-based group \nintervention for anxious children (based on the treatment \nguide of Cartwright et al. (2010))19.\n \nMeasures\nParent Report. Child Behavior Checklist (CBCL)\nThis scale is one of the assessment instruments in the \nfamily and was designed to assess children's emotional-\nbehavioral problems and abilities30. It measures three \ndimensions of internalizing problems, externalizing \nproblems, and general problems. In this study, the \nsymptoms related to internalizing were considered. The \nCBCL has excellent internal consistency, test-retest \nreliability, and validity31. 132\n2021/36 (3): 130-135Mehri Moradi et al.  \nSpence Children's Anxiety Scale\nThis questionnaire was prepared to assess the severity \nof children's anxiety. The Spence Anxiety Scale is a self-\nreport scale and consists of 44 items and six subscales.  \nIn the original version of the internal consistency \nquestionnaire, this scale was 0.92 for general anxiety and \n0.60 to 0.82 for other subscales. Reliability results of the \nretest were reported to be 0.63 for the whole scale and \n0.51 to 0.75 for the subscales during 12 weeks32. This \ninstrument has good psychometric properties in children \naged 6-12 years33 in Iran.\nResults\nThe results of this study indicated that there is no significant \ndifference between the studied groups in gender (x2 = \n0.068, sig = 0.795), mother (sig = 0.441, x2= 9.99) and \nfather education level (sig = 0.452, x2=11.925).\nThe age range of the study participants was between \n6-10 years, and their birth order was 1-3. Also, the mean \nand standard deviation of the total age of the participants \nwere 8.92 and 1.16, respectively. There was no \nsignificant difference between the two groups in the age \nvariable. Descriptive characteristics of anxiety severity are \npresented in table I .\nIn order to analyze the effectiveness of the present \nintervention in reducing the level of anxiety in children, \nrepeated measures analysis of variance was used. \nBefore using this test, Leven's test, Box's test of equality \nof covariance, and Mauchely's Test of Sphericity were \nused, and none of them were significant. The results of \ntests of within-subjects effects are presented in table II . \nThe above table results indicate that the effect of time \nhas a significant effect on the scores of children's anxiety \nsymptoms. Therefore, regardless of the type of group, \nthere was a significant difference between the pre-\ntest, fifth session, post-test, and follow-up scores. The interaction between time and treatment group is also \nsignificant. Therefore, there is a significant difference \nbetween the two groups over time. Figure 1  shows the \ndifference between the two groups in the four stages of \nassessing child anxiety.\nDiscussion \nThe study results indicated that the present intervention \neffectively reduces anxiety symptoms in the post-test \nevaluation phase in the intervention group, and there \nis a significant difference between the two groups. The \nresearcher did not find a study that specifically examines \nthe efficacy of the present intervention in the anxiety \nof children with cancer, and previous studies have \nexamined the present intervention only on the anxiety of \nnon-cancerous children18. However, the results of this \nstudy were consistent with studies that have examined \nthis intervention in children with anxiety disorders16. \nAlso, in the other studies, the parent-based intervention \nreduced the children's anxiety. For example, Ginsburg \n& Schlossberg34 study, a parent-centered CBT-based \ntherapy, was able to help reduce children's anxiety. \nThompson et al.35. Also performed a parent-centered \nintervention on children; the results showed that the \npresent intervention could improve the internalization \nsymptoms of children. Finally, the manual of present \nintervention claims that through parenting, the same \neffects of cognitive-behavioral therapy can be created in \nchildren19. According to the researcher's data, there was \nno inconsistency with the current finding. \nOn the other hand, many studies on pediatric cancer \nstudies have examined the effectiveness of cognitive-Table I: Descriptive characteristics of anxiety severity in children.\n Time Mean SD\n  Pre-test 33.17 6.91\nIntervention  Fifth-session 29.25 6.70\n Post test 23.58 6.21\n Follow-up 22.42 4.19\n Pre-test 32.73 9.85\nTreatment  Fifth-session 30.46 9.87\nas usual  Post test 29.87 8.59\n Follow-up 27.27 8.54GroupVariable\nTable II: Results of repeated-measures analysis of variance for within-subjects effects.\nSource  Type III Sum of Squares df Mean Square  F Sig. Effect size  Power\nTime 1017.238 3 339.079 23.395 0.001 0.483 1.00\nTime*group  194.461 3 64.820 4.472 0.006 0.152 0.863\nError  1087.021 75 14.494 - - - -Figure 1: Comparison of changes in child anxiety symptoms in four stages.\n1 2 3 4\nTimeinterventiongroup\ncontrol\n32,50\n30,00\n27,50\n25,00\n22,50133\n2021/36 (3): 130-135 The efficacy of Cognitive-behavior therapy based parenting for anxious children with cancer\nbehavioral psychotherapy. For example, previous \nresearch has shown that cognitive-behavioral play \ntherapy can help improve the symptoms of depression \nand anxiety in children with cancer36. In this intervention, \nthe first important technique of the first session is \nto secure the parent-child relationship through play \ntherapy19, and the findings of this study are in line with \nprevious research. \nIn explaining these findings, paying attention to the \nunderlying approaches of the present intervention \ncan be very helpful. This intervention is based on the \ncognitive-behavioral model and parenting training19. \nIn the cognitive-behavioral model, it is assumed that \nthere is a relatively stable set of dysfunctional beliefs \nin anxiety disorders. Moreover, challenging with these \nthoughts can help reduce anxiety37. In addition, the \ngoal of parenting programs is to change the parenting \nenvironment38, and when the environment changes, child \nproblematic behaviors improve39. In the first session of \nthe present intervention, the fundamental beliefs of a self-\nconfident and healthy child are introduced to the parents. \nFurthermore, all techniques work to create these beliefs19.\nStudies show that CBT interventions that directly treat the \nchild are not very effective18. As in cognitive-behavioral \ntherapy, clients are encouraged to specialize in their \nminds. In this program, parents are encouraged to be \nspecialists in their child's anxiety. Therefore, when new \nproblems arise, parents can provide a solution without \nconsulting a psychologist confidently. Thus, in this \ntreatment, important components of cognitive-behavioral \ntherapy were passed on to children through parents19.\nOn the other hand, in this intervention, parental behavioral \ntraining takes place. Parental behavioral education is also \nbased on the behavioral approach and social learning \ntheory. Many studies have investigated the effectiveness \nof this approach and shown effective results in improving \nchildren's problems19. Another issue that could be \nexplained in this finding was that many parents said that \nreporting children's cancer was very harmful to them and \ntheir children during the sampling. Moreover, often the \nparents did not receive special psychological support at \nthe center after receiving cancer diagnosis. Some parents \neven said that sometimes parents were reprimanded for \ndiagnosing cancer and being late. It seems that one of \nthe reasons for the effectiveness and active participation \nof parents in the present treatment was the strong need \nfor such an environment where parents could receive \nthe necessary psychological support and talk to other \nparents. Numerous studies have shown that support \nand being in a group can be effective on their own40. \nPart of the treatment also introduced a technique for \nparents to hide their unpleasant feelings from their \nchildren19. In this technique, parents were told not to say \nanything or show any emotion if they could not control \nthemselves. The parents reported that the technique was very helpful during the child's physical treatment, \nsuch as injections and chemotherapy. Therefore, \nthe transmission of parental anxiety to children was \nprevented. This finding can be justified by social learning \ntheory, which believes that imitation plays a key role \nin many disorders41. Furthermore, many studies have \nfound the role of imitation and maternal Psychological \nControl in the development of anxiety disorders and \nhave shown that anxious parents are more likely to raise \nanxious children42,43.\nFinally, the present treatment was expressed to parents \nin simple language with metaphor and example. In recent \nyears, many studies had shown that metaphors and \nstories increase the efficacy of treatments44. The most \nimportant metaphors in the intervention were related to \nfight and flight response and avoidance. Many parents \nstated that children showed signs of anxiety before the \npresent intervention (such as heart rate, screaming, etc.) \nduring physical therapy for cancer. Parents were afraid \nthat this anxiety would lead to a recurrence and worsening \nof cancer. However, parents felt more comfortable when \nthe fight and flight response was normal and safe. They \nacknowledged that anxiety is an inevitable part of life and \nthat children who can cope with their fears can better \nmanage their anxiety in the future.\nOn the other hand, sometimes children used to say \"you \ndo not love me\" or \"I do not love you\" and so on during \nthe cancer treatment procedure. When told to parents, \nthese phrases are very common in young children (even \nthose without cancer) and are completely meaningless; \nthey could more easily use the technique of ignoring \nthese sentences and felt better emotions. \nConclusion \nIn this intervention, the principles of cognitive-behavioral \ntherapy were transferred to children through parenting \ncomponents. The results of this study also confirm the \nclaim of the underlying theory of the present intervention. \nFurthermore, the present intervention was able to reduce \nanxiety symptoms in children. The present study had \nseveral limitations that warrant consideration. Firstly, Due \nto the prevalence of coronavirus pandemic, dropout was \nunavoidable. Secondly, In this study, self-report tools \nwere used, which if possible, it is better to use objective \ntools in future studies. Thirdly, the follow-up period was \ntwo months due to time and commuting limitations. \nNaturally, longer follow-up periods can increase the \nassurance of treatment stability. Additionally, further \nefforts are suggested to adjusting a new intensive and \nspecific version of the current manual for reducing \nanxiety in children with cancer. Furthermore, in pandemic \nsituations, designing online parenting programs that \ntarget children with cancer is more suitable for children \nwith disabilities and diseases. 134\n2021/36 (3): 130-135Mehri Moradi et al.  \nReferences\n1. Improvement N. Living with and beyond cancer: taking action to \nimprove outcomes. 2013.\n2. Fan S-Y, Eiser C. Body image of children and adolescents with \ncancer: A systematic review. Body Image. 2009;6(4):247-56.\n3. Norouzirad R, Khazaei Z, Mousavi M, Adineh HA, Hoghooghi M, \nKhabazkhoob M, et al. Epidemiology of common cancers in Dezful \ncounty, southwest of Iran. Immunopathol Persa. 2018;4(1):e10.\n4. Derakhshan M, Baradaran A, Kamrad F, Pezeshki A, Rafiei Javazm \nA. Prevalence of benign and malignant tumors in thyroidectomy \nspecimens. J Prev Epidemiol. 2020;5(1):e12.\n5. Adamson PC. Improving the outcome for children with cancer: \nDevelopment of targeted new agents. CA: a cancer journal for clinicians. \n2015;65(3):212-20.\n6. McArthur BA, Strother D, Schulte F. Positive schemas, \npsychopathology, and quality of life in children with pediatric cancer: \nA pilot study. Journal of psychosocial oncology. 2017;35(3):362-75.\n7. Darakhshandeh A, Momenzadeh M. Cachexia and anorexia in \ncancer; a systematic review. Immunopathol Persa. 2021;7(2):e20.\n8. Schrag NM, McKeown RE, Jackson KL, Cuffe SP , Neuberg RW. \nStress-related mental disorders in childhood cancer survivors. Pediatric \nblood & cancer. 2008;50(1):98-103.\n9. Gasc\u00f3n MRP , Capit\u00e3o CG, Casseb J, Nogueira-Martins MCF, Smid \nJ, de Oliveira ACP . Prevalence of anxiety, depression and quality of life \nin HTLV-1 infected patients. The Brazilian Journal of Infectious Diseases. \n2011;15(6):578-82.\n10. G\u00f6tze H, Friedrich M, Taubenheim S, Dietz A, Lordick F, Mehnert \nA. Depression and anxiety in long-term survivors 5 and 10 years after \ncancer diagnosis. Supportive Care in Cancer. 2020;28(1):211-20.\n11. Mitchell AJ, Ferguson DW, Gill J, Paul J, Symonds P . Depression \nand anxiety in long-term cancer survivors compared with spouses and \nhealthy controls: a systematic review and meta-analysis. The lancet \noncology. 2013;14(8):721-32.\n12. Mols F, Schoormans D, de Hingh I, Oerlemans S, Husson O. \nSymptoms of anxiety and depression among colorectal cancer survivors \nfrom the population-based, longitudinal PROFILES Registry: Prevalence, \npredictors, and impact on quality of life. Cancer. 2018;124(12):2621-8.\n13. Maass SW, Roorda C, Berendsen AJ, Verhaak PF, de Bock \nGH. The prevalence of long-term symptoms of depression and \nanxiety after breast cancer treatment: a systematic review. Maturitas. \n2015;82(1):100-8.\n14. Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United \nStates: age, health, and disability. The Journals of Gerontology Series \nA: Biological Sciences and Medical Sciences. 2003;58(1):M82-M91.\n15. Madi D, Clinton M. Pain and its impact on the functional ability in \nchildren treated at the children's cancer center of lebanon. Journal of \npediatric nursing. 2018;39:e11-e20.\n16. Rapee RM, Kennedy S, Ingram M, Edwards S, Sweeney L. \nPrevention and early intervention of anxiety disorders in inhibited \npreschool children. Journal of consulting and clinical psychology. \n2005;73(3):488.17. Cartwright-Hatton S, Roberts C, Chitsabesan P , Fothergill C, \nHarrington R. Systematic review of the efficacy of cognitive behaviour \ntherapies for childhood and adolescent anxiety disorders. British journal \nof clinical psychology. 2004;43(4):421-36.\n18. Cartwright-Hatton S, McNally D, Field AP , Rust S, Laskey B, Dixon \nC, et al. A new parenting-based group intervention for young anxious \nchildren: Results of a randomized controlled trial. Journal of the American \nAcademy of Child & Adolescent Psychiatry. 2011;50(3):242-51. e6.\n19. Cartwright-Hatton S, Laskey B, Rust S, McNally D. From timid to \ntiger. UK: Wiley-Blackwell. 2010.\n20. Norton PJ, Price EC. A meta-analytic review of adult cognitive-\nbehavioral treatment outcome across the anxiety disorders. The Journal \nof nervous and mental disease. 2007;195(6):521-31.\n21. Deacon BJ, Abramowitz JS. Cognitive and behavioral treatments for \nanxiety disorders: A review of meta-analytic findings. Journal of clinical \npsychology. 2004;60(4):429-41.\n22. Aghebati A, Gharraee B, Shoshtari MH, Gohari MR. Triple p-positive \nparenting program for mothers of ADHD children. Iranian journal of \npsychiatry and behavioral sciences. 2014;8(1):59.\n23. Brinkmeyer MY, Eyberg SM. Parent-child interaction therapy for \noppositional children. 2003.\n24. Sanders MR. Triple P-Positive Parenting Program as a public health \napproach to strengthening parenting. Journal of family psychology. \n2008;22(4):506.\n25. Webster-Stratton C, Reid MJ, Hammond M. Preventing conduct \nproblems, promoting social competence: A parent and teacher \ntraining partnership in Head Start. Journal of clinical child psychology. \n2001;30(3):283-302.\n26. Beck AT, Weishaar M. Cognitive therapy. Comprehensive handbook \nof cognitive therapy: Springer; 1989. p. 21-36.\n27. Perdue O, Spielberger CD. Anxiety and the perception of \npunishment. Mental Hygiene. 1966.\n28. Hudson JL, Rapee RM. Parent-child interactions and anxiety \ndisorders: an observational study. Behaviour research and therapy. \n2001;39(12):1411-27.\n29. Bifulco A, Kwon J, Jacobs C, Moran PM, Bunn A, Beer N. Adult \nattachment style as mediator between childhood neglect/abuse \nand adult depression and anxiety. Social psychiatry and psychiatric \nepidemiology. 2006;41(10):796-805.\n30. Achenbach TM. The Child Behavior Checklist and related \ninstruments. 1999.\n31. Tehrani-Doost M, Shahrivar Z, Pakbaz B, Rezaie A, Ahmadi F. \nNormative data and psychometric properties of the child behavior \nchecklist and teacher rating form in an Iranian community sample. \nIranian journal of pediatrics. 2011;21(3):331.\n32. Spence SH, Barrett PM, Turner CM. Psychometric properties of the \nSpence Children's Anxiety Scale with young adolescents. Journal of \nanxiety disorders. 2003;17(6):605-25.\n33. Mousavi R, Moradi A-R, Farzad V, Mahdavi Harsini SE, Spence S, \nNavabinejad S. Psychometric properties of the Spence children's anxiety scale \nwith an Iranian sample. International Journal of Psychology (IPA). 2007;1(1).135\n2021/36 (3): 130-135 The efficacy of Cognitive-behavior therapy based parenting for anxious children with cancer\n34. Ginsburg GS, Schlossberg MC. Family-based treatment of \nchildhood anxiety disorders. International Review of Psychiatry. \n2002;14(2):143-54.\n35. Tompson MC, Langer DA, Hughes JL, Asarnow JR. Family-focused \ntreatment for childhood depression: Model and case illustrations. \nCognitive and behavioral practice. 2017;24(3):269-87.\n36. Golparvar M, Aghaei A, Bordbar MR. Comparing the effectiveness of \ngroup story therapy and the art-play therapy on anxiety and depression \nin children with cancer: based on the framework, principles and rules \nof cognitive-behavioral approach. Iranian Journal of Rehabilitation \nResearch. 2019;6(1):50-9.\n37. Beck AT. Cognitive therapy of depression: Guilford press; 1979.\n38. Patterson GR. Coercive family process: Castalia Publishing \nCompany; 1982.\n39. Hembree-Kigin TL, McNeil CB. Parent\u2014child interaction therapy: \nSpringer Science & Business Media; 2013.40. Feinstein R, Heiman N, Yager J. Common factors affecting \npsychotherapy outcomes: Some implications for teaching \npsychotherapy. Journal of Psychiatric Practice\u00ae. 2015;21(3):180-9.\n41. Bandura A. Social learning through imitation. 1962.\n42. Woodruff-Borden J, Morrow C, Bourland S, Cambron S. The \nbehavior of anxious parents: Examining mechanisms of transmission \nof anxiety from parent to child. Journal of Clinical Child and Adolescent \nPsychology. 2002;31(3):364-74.\n43. McClure EB, Brennan PA, Hammen C, Le Brocque RM. Parental \nanxiety disorders, child anxiety disorders, and the perceived parent\u2013\nchild relationship in an Australian high-risk sample. Journal of Abnormal \nChild Psychology. 2001;29(1):1-10.\n44. Tay D. Metaphor in psychotherapy: A descriptive and prescriptive \nanalysis: John Benjamins Publishing; 2013.136\n2021/36 (3): 76 -83 2021/36 (3): 76 -83CASE REPORT\nSeckel syndrome associated dental anomaly; case report\nAnomal\u00eda dental asociada al s\u00edndrome de Seckel; reporte de un caso\nSoraya Bakhshani1      , Seyed Hossein Hosseini Zarch2      , \nMahrokh Imani Moghadam2      , Atsa Pakfetrat3      \n1. Department of Oral and Maxillofacial Radiology, Faculty of Dentistry, Zahedan University of Medical Sciences, Zahedan, Iran.\n2. Department of Oral and Maxillofacial Radiology, Mashhad University of Medical Sciences, Mashhad, Iran.\n3. Department of Oral Medicine, Mashhad University of Medical Sciences, Mashhad, IraneISSN 2255-0569\nReceived:  7 - VI - 2021\nAccepted:  22 - VI - 2021\ndoi: 10.3306/AJHS.2021.36.03.136Corresponding author\nSoraya Bakhshani \nDepartment of Oral and Maxillofacial Radiology, Faculty of Dentistry, Zahedan \nUniversity of Medical Sciences, Zahedan, Iran\nE-mail: bakhshani69@gmail.comID\nID IDID\nAbstract  \nSeckel syndrome is a rare autosomal recessive with severe growth retardation, bird-headed profile, and microcephaly. It is characterized \nby short stature, skeletal defects, mental retardation, and characteristic facial features such as microcephaly, micrognathia, and a \nbird-head appearance. Dental findings include hypodontia, enamel hypoplasia, crowding, and Class II malocclusion. Craniofacial \nfeatures may include facial asymmetry, down-slanting palpebral fissures, lobeless ears, and dental abnormalities, including enamel \nhypoplasia, hypodontia, and microdontia in the patients with SS may be at high risk of developing acute myeloid leukemia. The \npurpose of the paper is to report a case of the seckel syndrome with a dental anomaly.\nKeywords:  Seckel syndrome, dental, anomaly, case report.\nResumen\nEl s\u00edndrome de Seckel (SS) es una rara enfermedad autos\u00f3mica recesiva que cursa con un grave retraso del crecimiento, un \nperfil de cabeza de p\u00e1jaro y microcefalia. Se caracteriza por baja estatura, defectos esquel\u00e9ticos, retraso mental y rasgos faciales \ncaracter\u00edsticos como microcefalia, micrognatia y apariencia de cabeza de p\u00e1jaro. Los hallazgos dentales incluyen hipodoncia, \nhipoplasia del esmalte, api\u00f1amiento y maloclusi\u00f3n de clase II. Caracter\u00edsticas craneofaciales pueden incluir asimetr\u00eda facial, fisuras \npalpebrales inclinadas hacia abajo, orejas sin l\u00f3bulos y anormalidades dentales, incluyendo hipoplasia del esmalte, la hipodoncia \ny la microdoncia. Los pacientes con SS pueden tener un alto riesgo de desarrollar leucemia mieloide aguda. El prop\u00f3sito de este \ntrabajo es informar de un caso de s\u00edndrome de Seckel con una anomal\u00eda dental.\nPalabras clave:  S\u00edndrome de Seckel, dental, anomal\u00eda, reporte de caso.\nIntroduction \nSeckel syndrome is an autosomal recessive condition \nwithout any sex predilection, with an incidence reported \nof 1:10,000 live-born children1,2.\nThe syndrome is characterized by severe intrauterine \ngrowth retardation, severe short stature, severe \nmicrocephaly, bird-headed profile, receding chin and \nforehead, sizeable beaked nose, mental retardation, \nand other congenital anomalies. Rudolf Virchow \nintroduced the term \"bird-headed dwarf\" in the context \nof proportionate dwarfism with low birth weight, mental \nretardation, a pointed nose, and micrognathia3.\nPolyarthritis nodosa affects multiple organ systems, \nmost commonly kidneys, gastrointestinal tract, nervous \nsystem, muscles, and soft tissue4.In one-half of cases, head circumference is more \nretarded than height, while it is as retarded as height for \nthe remainder. Other systemic manifestations associated \nwith SS include Fanconi anemia, leukemia, chronic \nnephritis, dysgenesis of the cerebral cortex, corpus \ncallosum, and a vast spectrum of skeletal defects7.\n\u00b7 Small brain with small gyri. The cerebral hemispheres' \nvolume can be reduced to one-third of routine, \nparticularly in the cerebral cortex8. Dental findings include \nhypodontia, enamel hypoplasia, crowding, and Class II \nmalocclusion9.\nThis paper's purpose was to report the case of a female \npatient with Seckel syndrome and describe her dental \nmanifestations.137\n2021/36 (3): 76 -83 2021/36 (3): 76 -83 Seckel syndrome associated dental anomaly; case report\nCase report \nA nine-year-old female child reported to Oral Medicine \nand Radiology department with a chief complaint of \nnoneruptive teeth and micro dent ( Figure 1 ). History \nrevealed that a child with severe growth retardation.\nThe patient had proportional short stature, weight, height, \nand head circumference below the third percentile. On \nphysical examination, she had a short finger ( Figure 2 ).\nThe patient's general appearance was characterized by a \nsmall, prominent forehead, slightly beaked nose, midface \nhypoplasia, hypertelorism, high hair lin whit fin hair, and \neyebrow ( Figure 3 ).Investigation of the orthopantomogram and panoramic \nradiographs ( Figure 1 ) revealed that maxillary permanent \nleft central incisors and right second premolar and \nmandibular permanent second molar were congenitally \nmissing.  The teeth appeared to have enamel hyperplasia \nwhit short roots, partially obliterated pulp. The permanent \nfirst molar had a bulbous crown. \nOn laboratory examinations, results of complete blood \nrevealed low-level hemoglobin (10.9 g/dl, normal \nrange:12-15 g/dl) and MCV(65/9, normal range 77-\n95), while the levels RDWC (18/3, normal range 11-14) \nand platelet count (588 1000/ \u03bcl, normal range 150-450 \n1000/ \u03bcl), D.H.E.A So4 (311 micg/dl, normal range 2/8-\n85/2). The range of 25OH VitD was insufficient.\nDiscussion \nSeckel syndrome (Online Mendelian Inheritance in Man \ndatabase Number 210600) is a rare form of primordial \ndwarfism, which was initially described in 1960.10\nThe syndrome as severe intrauterine growth retardation, \nsevere short stature, severe microcephaly, bird-\nheaded profile, receding chin and forehead, sizeable \nbeaked nose, mental retardation, and other congenital \nanomalies. Rudolf Virchow introduced the term \"bird-\nheaded dwarf\" in the context of proportionate dwarfism \nwith low birth weight, mental retardation, a pointed nose, \nand micrognathia3.\nPresented herein is a child with classic Seckel phenotype, \nwho had both an open and a closed-lip schizencephaly, \nresulting in global developmental delay and bilateral \nsensorineural deafnes11.\nSynostosis of cranial sutures occurs in approximately \n50%. Other craniofacial features may include facial \nasymmetry, down-slanting palpebral fissures, lobeless \nears 12 Dental abnormalities include enamel hypoplasia, \nhypodontia, microdontia, taurodontic root morphology. \nSeveral cases have demonstrated a high-arched palate, \nand cleft palate has also been reported10. \nThis patient had enamel hypoplasia, hypodontia, and \nmicrodontia, but Cleft palate was not observed in \nthe present cases. Regen reported the patient with \nSeckel syndrome type II and described her oriental \nmanifestations. She presented interesting dental \nfindings, including gingival hyperplasia, recession and \nulceration, significant crowding, and early exfoliation \nof the primary dentition with the permanent dentition's \naccelerated eruption.9\nThe dentition has been described sporadically in \nSCKL, focusing on enamel hypoplasia malocclusion \nmicrodontia, dentin dysplasia, and taurodontism13.\nFigure 1: Panoramic view of noneruptive teeth and micro dent were presented in a child.\nFigure 2: A girl case with a short finger.\nFigure 3: The general appearance of a case patient.\n138\n2021/36 (3): 76 -83 2021/36 (3): 76 -83Soraya Bakhshani et al.  \nDe Coster reported a 14-year-old boy is presented with \nbrain hypoplasia, pachygyria, hydrocephaly, enamel \nhypoplasia and root dysplasia in the temporary dentition, \nand oligodontia, severe microdontia, and delayed \neruption of the permanent dentition13.\nAbout 170 cases of Seckel syndrome have been reported \nworldwide, and there is considerable heterogeneity in \ntheir clinical characteristic11.\nHematopoietic disorders have been reported in \napproximately 15% of patients with SS14.\nThe authors suggested that the patients with SS may \nbe at high risk of developing acute myeloid leukemia. \nHowever, the risk of chronic myeloid leukemia was noted \nfollowing the aspiration biopsies of the bone marrow \nof both patients, and the relevant specialists planned \nroutine controls of the patients10.\nKilic et al. reported a case whit low-level vitD and \nosteomalacia15. Our patient had 25OH VitD insufficient. \nVitamin D plays an essential role in skeletal development, \nbone health maintenance, and neuromuscular \nfunctioning16. Clinical features include growth failure, \nhypotonia, rachitic bones, and enamel hypoplasia17.\nThe craniofacial features of Seckel syndrome allow \ndifferentiation from other syndromes of growth deficiency \nwith microcephaly, such as Dubowitz syndrome, fetal \nalcohol syndrome, trisomy 18, de Lange syndrome, \nBloom syndrome, Nijmegen breakage syndrome , and \nFanconi syndrome12 also SS should be differentiated \nfrom closely resembling Cockayne syndrome, progeria, \nHallermann-Streiff  syndrome (HSS) Dyggve-Melchior-\nClausen (DMC) syndrome3.\u00b7 Fanconi anemia is clinically defined by pancytopenia in \nthe first decade of life and complicated by leukemia, \npigmentary changes in the skin, cardiac, kidney, and \nlimb (radius aplasia) malformations. Affected adults are \nalso at high risk for non-hematologic malignancies. \nMild microcephaly (often without intellectual disability) \nis observed in 10%-25% of individuals8.\n\u00b7 Cockayne's syndrome is a rare, autosomal recessive \ndisorder characterized clinically by cachectic dwarfism, \ncutaneous photosensitivity, loss of adipose tissue, mental \nretardation, skeletal and neurological abnormalities, and \npigmentary degeneration of the retina18.\nWhile progeria is a rare premature aging syndrome \ncharacterized by retarded physical development, \nabnormal facies, skeletal abnormalities, and early onset \nof scleroderma19.\nConclusion \nThe knowledge of symptoms and risk factors of Seckel \nsyndrome is essential For early intervention and dental \nproblems prevention.\nAcknowledgments \nThe authors would like to thank the Department of Oral \nand Maxillofacial Radiology, Faculty of Dentistry, Mashhad \nUniversity of Medical Sciences, Mashhad, Iran, for the \nclinical supports.139\n2021/36 (3): 76 -83 2021/36 (3): 76 -83 Seckel syndrome associated dental anomaly; case report\nReferences\n1. D\u2019Angelo VA, Ceddia AM, Zelante L, Florio patient with Seckel \nsyndrome. Child Nerv Syst 1998; 14: 82-84.\n2. Carfagnini F, Tani G, Ambrosetto P . MR findings in Seckel's syndrome: \nreport of a case. Pediatr Radiol 1999; 29: 849-850\n3. Sisodia R, Sundar Raj R.K, Goel V. Seckel syndrome: A rare case \nreport. J Indian Soc Pedod Prev Dent 2014;32:160-3\n4. Oran I, Memis A, Parildar M, Yunten N. Multiple intracranial aneurysms in \npolyarteritis nodosa: MRI and angiography. Neuroradiol 1999;41:436-439\n5. Bakkaloglu SA, Ekim M, Tumer N, Tulunay. O, Ozer T. Severe renal \nimpairment in the case of classic polyarteritis nodosa. Pediatr Nephrol  \n2001;16:148-150\n6. Brogan PA, Davies R, Gordon I, Dillon MJ Renal angiography in \nchildren with polyarteritis nodosa. Pediatr Nephrol 2002;17:277-283.\n7. Shanske A, Caride DG, Menasse-Palmer L, Bogdanow A, Marion \nRW. Central nervous system anomalies in Seckel Syndrome: Report of a \nnew family and review of the literature. Am J Med Genet 1997;70:155-8\n8. Verloes A, Drunat S, Pharm D,  Gressens P , Passemard S. Primary \nAutosomal Recessive Microcephalies and Seckel Syndrome Spectrum \nDisorders. GeneReviews October 31, 2013. \n9. Regen A1, Nelson LP , Woo SB.  Dental manifestations associated with \nSeckel syndrome type II: a case report. Pediatr Dent 2010;32(5):445-50.\n10. Kirzioglu Z, Ozay Erturk M.S, Erdogan Y. Craniofacial morphology \nand dental findings of seckel syndrome: case reports of two siblings. J \nInt Dent Med Res 2011;4(3):139-144.11. Ramasamy  C, Satheesh  S, Selvaraj R . Seckel Syndrome with \nSevere Sinus Bradycardia. Indian J Pediatr 2015;82(3):292-293.\n12. Seymen F, Tuna B, Kayserili H. Seckel syndrome: report of a case. \nJ Clin Pediatr Dent  2002; 26(3): 305-310\n13. De Coster P .J, Verbeeck  R.M.H, Holthaus V, MartensL.C, Vral A. \nSeckel syndrome associated with oligodontia, microdontia, enamel \nhypoplasia, delayed eruption, and dentin dysmineralization: a new \nvariant. J Oral Pathol Med 2006;35:639-41\n14. Chanan-Khan A, Holkova B, Perle MA, Reich E, Wu CD, Inghirami \nG, Takeshita K. T-cell clonality and myelodysplasia without chromosomal \nfragility in a patient with features of Seckel syndrome. Haematologica. \n2003;88(5):ECR14 \n15. Kilic A, K\u00fclc\u00fc \u00c7akmak S, Tuncali T, Koz O, Ozhamamci E, Yasun \nO, Artuz F. Seckel syndrome with cutaneous pigmentary changes: two \nsiblings and a review of the literature. Postepy Dermatologii i Alergologii \n2015;6:470-474.\n16. Bordelon P ,  Ghetu M.V, Langan R, MD. Recognition and Management \nof Vitamin D Deficiecy. Am Family Phys 2009;80(8):841-846\n17. Forestier I.B ,Berdal A, Vinckier F, De ravel T, Pierre Fryns J, Verloes A. \nThe genetic basis of inherited anomalies of the teeth. Part 2: Syndromes \nwith significant dental involvement. Eur J Med Gen 2008;51:383-408.\n18. Gaddam D, Thakur MS, Krothapalli N, Kaniti S. Dental Management \nof a 14-Year-Old with Cockayne Syndrome under General Anesthesia. \nCase Report Den 2014;2014:1-3.\n19. Sowmiya R, Prabhavathy D, Jayakumar S. Progeria in siblings: A \nrare case report. Indian J Dermatol 2011;56:581-2.140\n2021/36 (3): 140-144CASE REPORT\nInestabilidad cef\u00e1lica y derrame peric\u00e1rdico \nCephalic instability and pericardial effusion\nTom\u00e1s Javier Leal Rull\u00e1n1      , Marco Antonio Mart\u00ednez Ortega2      , \nIsabel Amengual Antich2      , Maria Dolors Ramis Estelrich3      , \nManuel del R\u00edo Vizoso4      , Elisa Torres del Pliego4   \n1. Servicio de Cuidados Intensivos.   2. Servicio de Anatom\u00eda Patol\u00f3gica.   \n3. Servicio de Digestivo.   4. Unidad de Hospitalizaci\u00f3n a Domicilio.\nHospital Universitari Son EspaseseISSN 2255-0569\nRecibido:  9 - V - 2021\nAceptado:  20 - VI - 2021\ndoi: 10.3306/AJHS.2021.36.03.140Correspondencia\nElisa Torres del Pliego  \nUnidad de Hospitalizaci\u00f3n a domicilio, Planta 0, modulo F. \nHospital Universitario Son Espases \nCarretera de Valldemossa, 79 \n07010 - Palma de Mallorca \nE-mail: elisa.torres@ssib.esID\nID\nID IDIDID\nResumen\nVar\u00f3n de 68 a\u00f1os, con colitis ulcerosa, que ingresa por inestabilidad objetiv\u00e1ndose derrame peric\u00e1rdico severo. Estudio de \nmiocarditis y tratamiento de soporte con evoluci\u00f3n t\u00f3rpida hasta la muerte.\nPalabras clave:  Miocarditis, derrame peric\u00e1rdico. \nAbstract  \nA 68-year-old man with ulcerative colitis, who was admitted at the hospital due to instability and showing a severe pericardial \neffusion. Study of myocarditis and supportive treatment with torpid evolution leading to death.\nKeywords:  Myocarditis, pericardial effusion.\nPresentaci\u00f3n del caso  \nSe trata de un var\u00f3n de 68 a\u00f1os, sin h\u00e1bitos t\u00f3xicos, \ncon antecedentes de colitis ulcerosa de larga \nevoluci\u00f3n en remisi\u00f3n mantenida con mesalazina. \nAcudi\u00f3 a Urgencias por segunda vez en un mes por \ninestabilidad incapacitante de 3 d\u00edas de evoluci\u00f3n. A \nsu llegada se encontraba con tensi\u00f3n arterial de 70/40 \nmmHg, afebril. El ECG mostr\u00f3 una fibrilaci\u00f3n auricular \ncon RVM de 150 lpm, con lesi\u00f3n subendoc\u00e1rdica de \nV1-V3 ( Figura 1 ). El ecocardiograma reflej\u00f3 un derrame \nperic\u00e1rdico severo, por lo que, dada la inestabilidad \nhemodin\u00e1mica, se dren\u00f3 mediante pericardiocentesis \nguiada por ecograf\u00eda.\n \nSe realiz\u00f3 un ecocardiograma de control, con m\u00ednima \npersistencia del derrame, con hipocinesia inferobasal, \ninferolateral medial y basal, y  fracci\u00f3n de eyecci\u00f3n \npreservada. Anal\u00edticamente destacaba insuficiencia renal \naguda y elevaci\u00f3n marcada de troponina I (15951,4 \nng/L), por lo que se inici\u00f3 doble antiagregaci\u00f3n. El cateterismo card\u00edaco no mostr\u00f3 lesiones coronarias \nsignificativas. Se intent\u00f3 cardioversi\u00f3n el\u00e9ctrica sin \u00e9xito. \nTodas las serolog\u00edas -VHH6, VIH, C.burnetti, C.psittaci, \nC.pneumoniae, M.pneumoniae, VHC, Erytrhrovirus  B19, \nadenovirus, enterovirus y VEB- y los cultivos \u2013incluyendo \nhongos y micobacterias\u2013 fueron inicialmente negativos. \nEl an\u00e1lisis del l\u00edquido peric\u00e1rdico mostr\u00f3 un aumento de \nla celularidad a expensas de linfocitos (230 c\u00e9lulas -91% \nMN-, 570 hemat\u00edes/mm3, glucosa 112 mg/dl, prote\u00ednas \n3.7 g/dl). No se pudo realizar resonancia magn\u00e9tica \ncard\u00edaca por inestabilidad cl\u00ednica. \nEl paciente persist\u00eda hipotenso, inici\u00e1ndose perfusi\u00f3n \nde dobutamina, pero por inestabilidad hemodin\u00e1mica \npersistente se traslad\u00f3 a la UCI. A los tres d\u00edas present\u00f3 \nfiebre, con aislamiento de S.epidermidis linezolid \nresistente en muestras respiratorias. A pesar de \ntratamiento antibi\u00f3tico dirigido y soporte ventilatorio el \npaciente empeor\u00f3 r\u00e1pidamente, siendo finalmente exitus .141\n2021/36 (3): 140-144 Inestabilidad cef\u00e1lica y derrame peric\u00e1rdico \nPresentaci\u00f3n del caso  \nDiscusi\u00f3n del caso cl\u00ednico   \nTeniendo en cuenta el cuadro cl\u00ednico en su conjunto,  \nla primera sospecha cl\u00ednica ser\u00eda miocarditis. Seg\u00fan \nlos criterios diagn\u00f3sticos establecidos por la European \nSociety of Cardiology en 20131 (Tabla I ), el paciente \npresentar\u00eda 2 de las presentaciones cl\u00ednicas \u2013arritmias y \nshock cardiog\u00e9nico\u2013 junto con 3 criterios diagn\u00f3sticos \n-alteraciones electrocardiogr\u00e1ficas, elevaci\u00f3n de \ntroponinas y anomal\u00edas funcionales/estructurales en \nla ecograf\u00eda. Adem\u00e1s, presentar\u00eda como caracter\u00edstica \nauxiliar una enfermedad autoinmune extracard\u00edaca \n(colitis ulcerosa).\nLa miocarditis se trata de una enfermedad inflamatoria \ndel m\u00fasculo card\u00edaco, de etiolog\u00eda variada y con una \nincidencia no bien definida, fundamentalmente por la \ngran variabilidad en la presentaci\u00f3n cl\u00ednica que posee: \nenfermedad subcl\u00ednica, dolor tor\u00e1cico, insuficiencia card\u00edaca, derrame peric\u00e1rdico, arritmias, muerte s\u00fabita, \netc. Las causas se engloban en dos subgrupos, \ninfecciosas (virus, bacterias, hongos y par\u00e1sitos y \nprotozoos) y no infecciosas (autoinmunitarias, por \nhipersensibilidad, por toxinas y por pat\u00f3genos f\u00edsicos). \nUna vez se tiene la sospecha cl\u00ednica, el diagn\u00f3stico \ndefinitivo lo otorgar\u00eda la biopsia endomioc\u00e1rdica, \nuna t\u00e9cnica que realizada por manos expertas es \nde bajo riesgo2. A\u00fan as\u00ed, durante los \u00faltimos a\u00f1os \nse han potenciado las pruebas de imagen card\u00edaca \ncomo m\u00e9todo diagn\u00f3stico, sobre todo la resonancia \nmagn\u00e9tica card\u00edaca. De esta manera se han \nestablecido los criterios de Lake Louise ( Tabla II ) que, \nsi se cumplen 2 o m\u00e1s, consigue una especificidad del \n96% y una sensibilidad del 76%. \nPese a la importancia de obtener el diagn\u00f3stico, \nfinalmente el tratamiento b\u00e1sico de toda miocarditis es \nel de soporte de la insuficiencia card\u00edaca.Figura 1 .\nTabla I: Criterios diagn\u00f3sticos de miocarditis de la Sociedad Europea de Cardiolog\u00eda.Tabla II: Criterios en RM cardiaca diagn\u00f3sticos de miocarditis (criterios de \nconsenso de Lake Louise).\nAnte la sospecha cl\u00ednica de miocarditis, los hallazgos en la RM cardiaca \nson compatibles con inflamaci\u00f3n mioc\u00e1rdica si est\u00e1n presentes al menos \n2 de los siguientes criterios:\n1. Aumento de la se\u00f1al focal o difusaen las secuencias potenciadas en T2.\n2. Realce precoz con Gd (midiendo el realce global relativo del miocardio).\n3. Al menos un foco de realce tard\u00edo focal no isqu\u00e9mico.\nUn estudio de RM cardiaca es compatible con da\u00f1o del miocito y/o \ncicatriz por inflamaci\u00f3n mioc\u00e1rdica si el tercer criterio est\u00e1 presente.\nSi el estudio inicial con RM es normal, se recomienda repetir RM entre \nla primera y la segunda semana si la sospecha cl\u00ednica es muy alta y el \ncomienzo de la cl\u00ednica ha sido muy reciente.\n- La presencia de disfunci\u00f3n del ventr\u00edculo izquierdo o derrame peric\u00e1rdico \nson datos adicionales que favorecen la presencia de miocarditis.142\n2021/36 (3): 140-144Tom\u00e1s Javier Leal Rull\u00e1n et al.  \nEn este caso, debido a la ausencia tanto de la biopsia \nendomioc\u00e1rdica como de la resonancia magn\u00e9tica, la \nprueba anal\u00edtica que mayor informaci\u00f3n nos aporta es \nel an\u00e1lisis del  l\u00edquido peric\u00e1rdico. Es un l\u00edquido seroso \ncon baja celularidad aunque con predominio linfocitario \n(hemat\u00edes 570/ul, leucocitos 230/ul, linfocitos 91%), \ncon glucosa similar a la que hay en sangre y con \nprote\u00ednas elevadas (3\u20197 g/dl), pudi\u00e9ndose orientar \ncomo exudado (aunque no disponemos de la LDH).\nPor lo tanto, iniciando el diagn\u00f3stico diferencial, estas ser\u00edan \nlas principales causas de miocarditis a tener en cuenta3-5:\n\u00b7 Miocarditis viral: se trata de la causa m\u00e1s com\u00fan, \nteniendo como pat\u00f3genos m\u00e1s frecuentes el parvovirus \nB-19, virus herpes humano 6, adenovirus, enterovirus \n(Coxsackie ), Citomegalovirus, Virus Epstein Barr , VIH, \nVirus hepatitis C , gripe, Varicela Z\u00f3ster \u2026 A favor de \neste diagn\u00f3stico tendr\u00edamos el exudado de predominio \nlinfoc\u00edtico. En contra, que las serolog\u00edas para VIH, VHC, \nPVB19, adenovirus y CMV fueron negativas.\n\u00b7 Miocarditis bacteriana: los pat\u00f3genos m\u00e1s frecuentes \nson la mycobacteria, chlamydia, estreptococo, \nmycoplasma, legionella, salmonella, rickettsia, \ncorynebacteria, borrelia\u2026 En este caso se evidenci\u00f3 \ncrecimiento en esputo de Estafilococo Epidermidis  en \nel d\u00eda 6 de ingreso hospitalario, por lo que se engloba \nm\u00e1s dentro de las complicaciones habituales de ingreso \nen Unidad de Cuidados Intensivos que como agente \ncausal de la miocarditis. Por lo dem\u00e1s no hay datos \nde neutrofilia en el l\u00edquido peric\u00e1rdico, y el resto de \ncultivos -hemocultivos, urocultivo, coprocultivo y l\u00edquido \nperic\u00e1rdico- fueron negativos. Ser\u00eda interesante disponer \ntambi\u00e9n de una determinaci\u00f3n de ADA en la bioqu\u00edmica \ndel l\u00edquido, ya que las miocarditis tuberculosas pueden \npresentarse con predominio linfoc\u00edtico.\n\u00b7 Miocarditis autoinmune: suele estar relacionada con \ntrastornos intestinales inflamatorios, miocarditis de c\u00e9lulas \ngigantes, Lupus eritematoso sist\u00e9mico, Sarcoidosis, \ns\u00edndrome de Sj\u00f6gren, S\u00edndrome de Churg-Strauss, \nGranulomatosis de Wegener, Arteritis de Takayasu. A \nfavor de este diagn\u00f3stico tendr\u00edamos el antecedente de \nla colitis ulcerosa y la evoluci\u00f3n fulminante del cuadro. \nEn contra, que estos cuadros suelen ir acompa\u00f1ados de \nbrotes o agudizaciones de las enfermedades autoinmunes \nde base, que no se especifican para este caso.\n\u00b7 Miocarditis por hipersensibilidad: suelen tener lugar \ncomo respuesta al\u00e9rgica a ciertos f\u00e1rmacos como los \nantirreum\u00e1ticos, penicilina, antidepresivos tric\u00edclicos, \nclozapina, sulfamidas, cefalosporinas\u2026 A favor de esta \norientaci\u00f3n estar\u00eda el tratamiento con mesalazina del \npaciente, aunque se trata de una medicaci\u00f3n iniciada \na\u00f1os atr\u00e1s. En contra, que no se ha evidenciado la \neosinofilia t\u00edpica de estas patolog\u00edas ni en suero ni en el \nl\u00edquido peric\u00e1rdico.Por \u00faltimo, ser\u00eda interesante tener en cuenta el s\u00edndrome \nMINOCA6 (acute Myocardial Infarction with Non-\nObstructive Coronary Arteries ) ya que se trata de un \ncaso en el que el paciente presentaba alteraciones \nde la repolarizaci\u00f3n en forma de elevaci\u00f3n del ST \njunto con elevaci\u00f3n de troponinas, aunque con una \ncoronariograf\u00eda sin lesiones significativas. Dicho \ns\u00edndrome engloba m\u00faltiples causas como el espasmo \ncoronario, la trombosis aguda, la disecci\u00f3n coronaria, la \nmiocardiopat\u00eda de Takotsubo, la disfunci\u00f3n microvascular \ny la embolia coronaria, entre otras. Aunque para este \ncaso la cl\u00ednica no cuadrar\u00eda ya que el paciente present\u00f3 \nuna cl\u00ednica subaguda sin dolor tor\u00e1cico, y con evoluci\u00f3n \ndesfavorable r\u00e1pidamente progresiva.\nPor lo tanto, las principales sospechas diagn\u00f3sticas ser\u00edan:\n1. Miocarditis viral: al ser la causa m\u00e1s frecuente junto \ncon un exudado de predominio linfoc\u00edtico.\n2. Miocarditis autoinmune: debido al antecedente de \ncolitis ulcerosa.\n3. Miocarditis por hipersensibilidad: secundario a la \nmesalazina, aunque poco probable al tratarse de un \ntratamiento cr\u00f3nico.\nExamen anat\u00f3mico \ny patol\u00f3gico postmortem    \nEl examen externo mostr\u00f3 un var\u00f3n obeso, con abdomen \nglobuloso, sin que se palpasen masas/visceromegalias. \nEn fosa il\u00edaca derecha, piernas y brazos se observaron \nlesiones equim\u00f3ticas. A la apertura, en la cavidad tor\u00e1cica \nno se observan lesiones. El pulm\u00f3n derecho pesa 620g y \nel izquierdo 520g, con congesti\u00f3n general del izquierdo y \nambos con aspecto antrac\u00f3tico. Presencia de leve derrame \nperic\u00e1rdico de car\u00e1cter seroso. Coraz\u00f3n de tama\u00f1o y peso \nincrementado (550g). No se observan lesiones en pericardio \nni material fibrin\u00e1ceo. Se remite muestra de miocardio al \nservicio de microbiolog\u00eda para estudio de microorganismos. \nA la apertura de cavidades card\u00edacas se observa leve \nincremento de grosor en ventr\u00edculo izquierdo. Placas de \nateroma no oclusivas  en la salida de la coronaria izquierda, \nas\u00ed como tambi\u00e9n en la aorta. Con respecto a la cavidad \nabdominal, se observ\u00f3 hematoma en partes blandas en \nfosa il\u00edaca derecha, as\u00ed como tambi\u00e9n gran hematoma \nen pared abdominal posterior, con afectaci\u00f3n de psoas \nderecho principalmente ( Imagen 1 ). Es\u00f3fago, est\u00f3mago \ne intestino delgado sin lesiones; colon con presencia de \naspecto congestivo en sigma y recto, sin otras alteraciones. \nH\u00edgado de 1930g, de superficie lisa y amarillento al corte. \nVes\u00edcula, v\u00eda biliar, p\u00e1ncreas y suprarrenales sin alteraciones \nmacrosc\u00f3picas. El bazo pes\u00f3 210g, congestivo. Los \nri\u00f1ones de 220g y 210g, de superficie irregular con \nm\u00faltiples, cicatrices corticales, as\u00ed como lesi\u00f3n qu\u00edstica \nde contenido seroso de 4 cm en ri\u00f1\u00f3n derecho. Pr\u00f3stata \nde 20g, sin alteraciones; ambos test\u00edculos presentaron \nhidrocele. Enc\u00e9falo de 1410g con hemisferios sim\u00e9tricos, \ncon surcos y circunvoluciones sin alteraciones.143\n2021/36 (3): 140-144 Inestabilidad cef\u00e1lica y derrame peric\u00e1rdico \nMicrosc\u00f3picamente, se observaron m\u00faltiples focos \nparcheados de distribuci\u00f3n pancard\u00edaca con destrucci\u00f3n \ny necrosis de cardiomiocitos, a expensas de un infiltrado \nmacrof\u00e1gico y linfocitario con fenotipo T (CD3+, CD4+) y \nsin inflamaci\u00f3n aguda ( Imagen 2 )7,8. No se observaron \nmicroorganismos con las tinciones para Citomegalovirus, \nEpstein-Barr, ni hongos mediante PAS/Grocott. Par\u00e9nquima \npulmonar congestivo generalizado, de predominio en l\u00f3bulo \ninferior izquierdo, con focal hemorragia alveolar en algunas \n\u00e1reas ( Imagen 3 ). El resto del par\u00e9nquima pulmonar \nmostr\u00f3 patr\u00f3n enfisematoso en l\u00f3bulos superiores, \nantracosis, presencia de \u00e9mbolos de m\u00e9dula \u00f3sea y se \nobservaron tapones mucoides en bronquios principales \ncon escamas c\u00f3rneas y presencia de estructuras \nf\u00fangicas por probable contaminaci\u00f3n de v\u00edas superiores/\norofarige ( Imagen 4 ). Mucosa gastrointestinal autol\u00edtica, \ncon \u00e1reas congestivas en sigma y recto, sin evidencia \nde inflamaci\u00f3n. Par\u00e9nquima hep\u00e1tico con arquitectura \nconservada, marcada esteatosis macrovacuolada en \nzonas 3 y 2 de Rappaport y congesti\u00f3n sinusoidal. Los \nri\u00f1ones presentaron \u00e1reas de necrosis tubular y cambios \ncongestivos glomerulares y medulares, con quiste simple \nen ri\u00f1\u00f3n derecho. En el estudio histol\u00f3gico cerebral, se \nobserv\u00f3 mediante la inmunotinci\u00f3n para Tau la presencia de dep\u00f3sitos puntiformes en am\u00edgdala, hipocampo anterior \ny posterior y circunvoluciones adyacentes, llamados \ncuerpos argir\u00f3filos ( Imagen 5 ), que se acompa\u00f1an de \npreovillos y ovillos, neuronas balonizadas, astrocitos \u201cen \narbusto\u201d y \u201ccoiled bodies\u201d9-11. El resto de \u00f3rganos no \nmostr\u00f3 alteraciones relevantes.\nImagen 1\nImagen 2Imagen 3\nImagen 5Imagen 4\n144\n2021/36 (3): 140-144Tom\u00e1s Javier Leal Rull\u00e1n et al.  Inestabilidad cef\u00e1lica y derrame peric\u00e1rdico\nLos diagn\u00f3sticos realizados fueron: Miocarditis \nevolucionada idiop\u00e1tica, con cultivos negativos para \nbacterias en la biopsia mioc\u00e1rdica; signos de disfunci\u00f3n \nmultiorg\u00e1nica (con congesti\u00f3n hepatoespl\u00e9nica y \nnecrosis tubular aguda incipiente); arterioesclerosis \ngeneralizada (ateromatosis coronaria y a\u00f3rtica e hipertrofia \ndel ventr\u00edculo izquierdo); enfermedad de los granos \nargir\u00f3filos, estadio III de Saito. Como otros diagn\u00f3sticos \nse identific\u00f3 enfisema pulmonar, \u00e9mbolos de m\u00e9dula \n\u00f3sea pulmonares (en relaci\u00f3n con maniobras de RCP), esteatosis hep\u00e1tica, neoplasia intraepitelial pancre\u00e1tica \n(PanIN) de bajo grado y quiste renal simple de 4 cm.\nSe estableci\u00f3 como probable causa etiol\u00f3gica de la \nmiocarditis un posible origen v\u00edrico, si bien no pudo ser \ndemostrado microbiol\u00f3gicamente. Se descart\u00f3 una \nmiocarditis asociada a mesalazina por tratarse de una \nreacci\u00f3n de hipersensibilidad y no haberse observado \neosin\u00f3filos, as\u00ed como tambi\u00e9n causas bacterianas y \nf\u00fangicas por la ausencia de infiltrado neutrof\u00edlico.\nBibliograf\u00eda\n1. Caforio A, Pankuweit s, Arbustini E, et al. Current state of knowledge \non aetiology, diagnosi, management, and therapy of miocarditis: a \nposition statement of the European Society of Cardiology Working Group \non Myocardial and Pericardial Diseases. Eur Heart J. 2013; 34: 2636.\n2. Dom\u00ednguez F, K\u00fchl U, Pieske B, et al. Actualizaci\u00f3n sobre miocarditis \ny miocardiopat\u00eda inflamatoria: el resurgir de la biopsia endomioc\u00e1rdica. \nRev Esp Cardiol. 2016; 69(2): 178-187.\n3. Kasper d, Fauci A, Hauser S, et al. Miocardiopat\u00edas y miocarditis. \nHarrison: Manual de medicina. 19\u00aa edici\u00f3n. Mc Graw Hill. 2017; 639-644.\n4. Cooper L. Etiology and pathogenesis of miocarditis. En: UpToDate. \n(accedido el 4 abril de 2021).\n5. Cooper L. Clinical manifestations and diagnosis of mYocarditis in \nadults. En: UpToDate. (accedido el 4 abril de 2021).\n6. Filippo C, Niccoli G. Muocardial infarction with no obstructive \ncoronary atherosclerosis. En: UpToDate. (accedido el 4 abril de 2021).\n7. Leone O, Pieroni M, Rapezzi C, Olivotto I. The spectrum of myocarditis: \nfrom pathology to the clinics. Virchows Arch. 2019 Sep;475(3):279-\n301.doi: 10.1007/s00428-019-02615-8. Epub 2019 Jul 11. PMID: \n312975958. Varnavas VC, Reinsch N, Perrey M, Nensa F, Schlosser T, Baba HA, \nGerken G, Erbel R, Janosi RA, Katsounas A. Recurrent lymphocytic \nmyocarditis in a young male with ulcerative colitis. Eur J Med Res. 2014 \nFeb 27;19(1):11. doi: 10.1186/2047-783X-19-11. PMID: 24576324; \nPMCID: PMC3942255.\n9. Williams DR. Tauopathies: classification and clinical update \non neurodegenerative diseases associated with microtubule-\nassociated protein tau. Intern Med J. 2006 Oct;36(10):652-60. doi: \n10.1111/j.1445-5994.2006.01153.x. PMID: 16958643.\n10. Rodriguez RD, Grinberg LT. Argyrophilic grain disease: An \nunderestimated tauopathy. Dement Neuropsychol. 2015 Jan-\nMar;9(1):2-8.doi: 10.1590/S1980-57642015DN91000002. PMID: \n29213935; PMCID: PMC5618985.\n11. Saito Y et al. Staging of argyrophilic grains: an age-associated \ntauopathy. J Neuropathol Exp Neurol. 2004 Sep; 63(9):911-8. doi: \n10.1093/jnen/63.9.911. PMID: 15453090.www.ramib.org \nJunta Directiva de la Reial Acad\u00e8mia de Medicina de les Illes Balears\n President   Maci\u00e0 Tom\u00e0s Salv\u00e0 \n Vicepresident   \u00c1ngel Arturo L\u00f3pez Gonz\u00e1lez\n Secretari General   Antonio Ca\u00f1ellas Trobat\n Vicesecretari   Sebastian Cresp\u00ed Rotger \n Tresorer   Joan Besalduch Vidal \n Bibliotec\u00e0ria   Antonia Barcel\u00f3 Bennasar\nAcad\u00e8mics d\u2019honor\n 2003 - Excm. Sr. Santiago Grisolia Garc\u00eda, Premi Pr\u00edncep d\u2019Ast\u00faries \n 2007 - Excm. Sr. Ciril Rozman, Premi Jaime I\nAcad\u00e8mics numeraris\nM. I. Sra. Juana M. Rom\u00e1n Pi\u00f1ana\nM. I. Sr. Josep Tom\u00e0s Monserrat\nM. I. Sr. Bartomeu Anguera Sans\u00f3\nM. I. Sr. Bartomeu Nadal Moncadas\nM. I. Sr. Alfonso Ballesteros Fern\u00e1ndez\nM. I. Sr. Ferran Tolosa i Caban\u00ed\nExcm. Sr. Maci\u00e0 Tom\u00e0s Salv\u00e0\nM. I. Sra. Joana M. Sureda Trujillo\nM. I. Sr. Joan Buades Rein\u00e9s\nM. I. Sr. Jos\u00e9 L. Olea Vallejo\nM. I. Sr. Pere Riutord Sbert\nM. I. Sr. Joan Besalduch Vidal \nM. I. Sr. F\u00e8lix Grases Freixedas\nM. I. Sr. Antoni Ca\u00f1ellas Trobat\nM. I. Sr. Josep Francesc Forteza Albert\u00ed\nM. I. Sr. Jordi Ib\u00e1\u00f1ez Juv\u00e9\nM. I. Sr. Joan March Noguera\nM. I. Sr. \u00c1ngel Arturo L\u00f3pez Gonz\u00e1lez\nM. I. Sra. Pilar Roca Salom\nM. I. Sr. Javier Cort\u00e9s Bordoy\nM. I. Sr. Llu\u00eds Masmiquel Comas\nM. I. Sr. Sebasti\u00e0 Cresp\u00ed Rotger\nM. I. Sra. Ant\u00f2nia Barcel\u00f3 Bennassar\nM. I. Sr. Javier Garau Alemany\nM. I. Sr. Jordi Reina Prieto\nM. I. Sr. Joan M. Benejam Gual\nM. I. Sr. Claudio Rub\u00e9n Mirasso Santos\nAcad\u00e8mics supernumeraris\nM.I. Sr. \u00c0lvar Agust\u00ed Garc\u00eda-Navarro \nM.I. Sra. Marta Emma Couce Matovelle\nAcad\u00e8mics em\u00e8rits\nM.I. Sr. Arnau Casellas BernatProtectors de la Reial Acad\u00e8mia\nBanca March\nConselleria de Presid\u00e8ncia\nASISA\nConselleria de Salut\nCol\u00b7legi Oficial de Metges de les Illes Balears\nFundaci\u00f3 Patronat Cient\u00edfic del Col\u00b7legi de Metges de les Illes Balears\nBenefactors de la Reial Acad\u00e8mia  \nSalut i For\u00e7a\nPatrocinadors de la Reial Acad\u00e8mia\nCl\u00ednica Rotger\nMetges Rossell\u00f3\nGrup Hospitalari Quir\u00f3nsalud\nCol\u00b7legi Oficial d\u2019Infermeria de les Illes Balears\nAssociaci\u00f3 Espanyola contra el C\u00e0ncer a les Illes Balears\nCol\u00b7legi Oficial de Farmac\u00e8utics de Balears\nEscola Universit\u00e0ria ADEMAwww.ramib.org www.medicinabalear.orgMEDICINA BALEARACADEMIC  JOURNAL  \nOF HEALTH  SCIENCES", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}